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Abstract 
 
Congenital cardiovascular malformations (CCVM) are the most common human birth 
defects, occurring in up to 1% of newborn infants.  Many cell populations are required 
for correct cardiovascular development, including the neural crest cells (NCC).  NCCs 
migrate from the dorsal neural tube into the pharyngeal arches and contribute to the 
asymmetric remodelling of the pharyngeal arch arteries (PAA).  A subset of NCCs 
continue to migrate into the outflow tract (OFT) of the heart, and aid in the septation 
of the OFT into the aorta and pulmonary trunk.   Tcfap2a, which encodes the murine 
transcription factor AP-2α, is highly expressed within NCCs and the pharyngeal surface 
ectoderm (PSE), and mutations in this gene causes CCVM affecting the OFT, PAAs and 
the formation of the interventricular septum.   
This thesis investigates the tissue-specific requirements of Tcfap2a in cardiovascular 
development and the mechanisms of PAA malformation.  Conditional deletion of 
Tcfap2a from NCCs resulted in a limited prevalence of CCVM, which was not increased 
by altering the genetic background or simultaneous deletion from the PSE.  However, 
Tcfap2a expression within both the NCCs and PSE is required in craniofacial and 
thymus development.  Immunohistochemical analysis in Tcfap2a-null embryos 
suggests that Tcfap2a is required in the formation of the PAAs, in addition to a possible 
role in their remodelling.  Quantitative PCR analysis was used to investigate potential 
transcriptional targets of AP-2α within the pharyngeal arch region and we propose that 
Dlx5 is regulated by AP-2α in a pathway independent of endothelin signalling.  A study 
investigating the potential interaction between these genes is presented here. 
This thesis presents further insights into the genetic networks regulating the formation 
of the PAAs, OFT and interventricular septum of the heart.  We also highlight issues 
associated with the use of transgenic mouse models and the effect of genetic 
background in the study of cardiovascular development. 
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Chapter 1. Introduction 
1.1. Heart development 
The heart is one of the first organs to develop within vertebrates, and begins 
functioning during the fourth week of human development.  The organ develops from 
two populations of cells in the splanchnic mesoderm, which migrate anteriorly and 
fuse at the midline to form a linear heart tube.  The heart tube then undergoes a 
complex remodelling process to form the mature mammalian heart.  Disruptions to 
this process can result in congenital defects which affect the ability of the heart to 
function correctly.  It is estimated that between 0.5 and 39.5% of spontaneous 
terminations during pregnancy may be due to heart developmental deficiencies.  In 
addition, approximately 1% of infants are born with a congenital cardiovascular 
malformation (CCVM) (Hoffman, 1995). 
1.1.1. Basic heart development in mice 
The heart is the first organ to form during murine development.  It begins at 
embryonic day (e) 7.0 with the formation of the primary heart fields from the 
splanchnic mesoderm, and is completed at approximately e15.5 with the remodelling 
of the aortic arch arteries and the outflow tract (OFT). 
The cardiac precursor cells are specified from the splanchnic mesoderm shortly after 
gastrulation in response to bone morphogenetic protein (BMP) signals from the 
endoderm.  These mesodermal cells form two primary heart fields (Figure 1.1a), which 
migrate anteriorly and fuse at the ventral midline forming the cardiac crescent (e7.5) 
(Figure 1.1b). By e8.0 a beating linear heart tube has formed (Figure 1.1c), composed 
of an endocardial tube surrounded by a layer of myocardial cells, with an intervening 
layer of extracellular matrix termed ‘cardiac jelly’.  The segments which will form the 
major structures of the mature heart are already visible at this stage.  At the anterior 
end, the aortic sac connects the conotruncus (primitive OFT) to the pharyngeal arch 
arteries (PAAs).  These arteries join the OFT to the dorsal aortae, and later remodel 
into the vessels of the mature aortic arch.  At the posterior end, the vitelline veins 
drain blood from the yolk sac into the sinus venosus.  The ventricular and atrial 
chambers fall in the intermediate region, and join the inflow region (vitelline veins and 
Introduction 
2 
 
sinus venosus) to the outflow region (conotruncus and aortic sac) (reviewed in 
Bruneau, 2008; High and Epstein, 2008; Srivastava and Olson, 2000).  
 
Figure 1.1: Normal heart development in the mouse.  
The heart begins as two primary heart fields (a) which merge at the ventral midline to form the cardiac crescent (b).  
By e8.0 the linear heart tube has formed and the segments which will form the structures of the mature heart are 
visible (c).  The linear tube loops (d) and the atrioventricular (AV) canal forms, separating the atria from the 
ventricles (e).  The endocardial cushions, which will develop into the major valves of the heart form within the OFT 
and AV canal (f).  At e9.5 ventricular trabeculation occurs by the invasion of cardiomyocytes (g).  The OFT undergoes 
septation and the PAAs are remodelled (h) to form the final aortic arch arteries of the mature heart (i). (Figure taken 
from High and Epstein, 2008). 
The heart tube undergoes a rightward cardiac looping event, initiated by the 
ballooning of the cardiac chamber segments (e8.5) (Figure 1.1d).  Further cardiac 
progenitor cells, derived from the pharyngeal mesoderm are added to the linear heart 
tube at the conotruncus (Mjaatvedt et al., 2001).  This population, termed the second 
heart field (SHF), is multipotent and contributes to the OFT, right ventricle and both 
atria.  The atrioventricular (AV) canal, which separates the atrial and ventricular 
segments, forms in response to TBX2 repression of chamber-specific genes (Figure 
1.1e).  The endocardial layer, separated from the myocardium by the cardiac jelly, 
receives signals from the myocardial cells, which induces an epithelial-to-mesenchymal 
transition (EMT) of a number of endocardial cells.  This process activates pathways 
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within the endocardium, which allows cells to dissociate from the epithelium and 
invade the cardiac jelly.  These cells form the endocardial cushions within the AV canal 
and OFT (Figure 1.1f), which will later form the mitral, tricuspid, pulmonary and aortic 
valves.   
Ventricular trabeculation begins at around e9.5 (Figure 1.1g).  This requires the 
cardiomyocytes to proliferate inwards, producing the ‘finger-like’ projections which 
invade the ventricular lumen.  It is thought that the trabeculae provide a surface for 
rapid oxygen diffusion to occur, before the coronary arteries form (Breckenridge et al., 
2007).  This process is not well understood, but is likely to involve signalling of 
paracrine factors, originating in the epicardium.  Molecules such as retinoic acid and 
erythropoietin are implicated in initiating mitosis in the myocytes, and are therefore 
candidates for inducing the inward proliferation required for ventricular trabeculation 
(Stuckmann et al., 2003).  BMP10 is also expected to play a role in this process, as 
mutations in this gene result in abnormal ventricular trabeculation, likely caused by a 
decrease in proliferation at e9.0-9.5 (Chen et al., 2004). 
At e11.5-12.0, the caudal PAAs begin remodelling to form the asymmetrical aortic arch 
arteries of the mature heart (Figure 1.1h-i).  The OFT becomes septated to form the 
pulmonary trunk and the aorta.  These processes will be described in detail later (see 
sections 1.2.3 and 1.3.2). 
1.1.2.  Addition of cells to the linear heart tube 
Following the formation of the linear heart tube, the heart receives further cellular 
contributions from other sources:  the SHF, the neural crest cells (NCCs) and the 
proepicardium. 
The SHF originates from a region of pharyngeal mesoderm anterior to the primary 
heart-forming fields that produce the linear heart tube.  The cells of the SHF begin 
migrating into the linear heart tube at e8.0 of murine development, through two 
regions which remain connected to the splanchnic mesenchyme of the dorsal body 
wall.  At the anterior end, these cells enter through the aortic sac and at the posterior 
end they enter at the dorsal mesocardium (Cai et al., 2003).    
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Figure 1.2: Addition of cells to the linear heart tube. 
(a) Double whole mount in situ hybridisation demonstrates two distinct populations contributing to the primitive 
heart.  MLC2a expression (orange) marks the primary heart field, while Isl1 expression (green) marks the SHF (Image 
adapted from Cai et al., 2003).  (b-d) Addition of cells from the proepicardium (Images adapted from von Gise and 
Pu, 2012).  (b) Whole mount photograph of an e9.5 embryo. The proepicardium (PE, red arrow) is situated by the 
sinus venosus.  (c) Sagittal section through an e9.5 embryo demonstrating the position of the proepicardium (red 
arrow). Blue staining represents lineage tracing of Nkx2.5-positive cells.  (d) Left panel: Transverse section through 
an e15.5 heart demonstrates a monolayer of epicardial cells (green) over the heart.  Right panel:  Magnified view of 
the dashed box in the left panel.  Epicardial cells undergo EMT to become EPDCs which migrate into the 
myocardium and give rise to a number of cells types.  (e) NCC contribution to the developing PAAs and outflow 
tract.  NCCs migrate from the dorsal neural tube, between the otocyst and the third somite.  These cells surround 
the PAAs, forming the smooth muscle lining of these vessels, and then continue to migrate to the outflow tract 
where they initiate the septation of the aorticopulmonary region (Image taken from Hutson and Kirby, 2007). A, 
atrium; V, ventricle; PE, proepicardium. 
Islet1 (Isl1) is expressed from e7.0 in a population of cells anterior to the primary heart 
field, and was therefore proposed as a marker of the SHF.  Indeed, double in situ 
hybridisation of Isl1 with an early marker of differentiated cardiomyocytes, atrial 
myosin light chain 2 (MLC2a), demonstrates the mutually exclusive expression of these 
markers (Figure 1.2a).  As these cells enter the linear heart tube, they differentiate into 
cardiac precursors and downregulate Isl1 expression, likely indicating that Isl1 
expression is required to maintain the undifferentiated state of these cells.   Isl1-
expressing cells give rise to the OFT, most of the cells of the right ventricle and the 
atria, and a small number of cells of the left ventricle, while the primary heart field 
contributes the majority of cells of the right ventricle.  Loss of Isl1 expression in these 
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cells affects proliferation, migration and survival of these cells, and a loss of those 
portions of the heart derived from Isl1-expressing cells (Cai et al., 2003). 
The proepicardium, situated near the sinus venosus (Figure 1.2b-c), is a source of 
extracardiac mesenchyme, which produces the majority of the epicardium of the 
heart.  The cells migrate from the proepicardium as multicellular aggregates, which 
adhere to the myocardium and flatten.  The flattened aggregates fuse together to form 
the primitive epicardium.  The epicardium then extends by migration from the 
periphery (Komiyama et al., 1987).  EMT of a subset of epicardial cells results in the 
formation of epicardial-derived cells (EPDCs) which migrate into the underlying 
myocardium and form connective tissue and the endothelium and smooth muscle cells 
(SMCs) of the coronary arteries (Figure 1.2d) (Reviewed in von Gise and Pu, 2012). 
A further extracardiac population required in the development of the heart is the 
NCCs.  This multipotent population of cells delaminates from the neural tube, 
undergoes EMT and migrates towards the heart.  The NCCs populate the caudal 
pharyngeal arches (PAs) (see section 1.2.1 below) and differentiate into SMCs which 
line the PAAs.  A sub-population of these cells continue to migrate into the OFT where 
they form part of the aorticopulmonary septation complex required in the septation of 
the OFT into the aorta and the pulmonary trunk (Figure 1.2e) (Reviewed in Hutson and 
Kirby, 2007).  The NCCs will form a major focus of this thesis and therefore will be 
discussed in greater detail later (see section 1.3). 
1.1.3.  Congenital cardiovascular malformations 
A CCVM is defined as a structural defect of the heart or associated vessels, which 
severely affects cardiac function (Mitchell et al., 1971).  Figure 1.3 summarises the 
types of defects that can occur during cardiovascular development and the prevalence 
per 1000 live births (shown in brackets).  The most common form of CCVM is bicuspid 
aortic valve (BAV), which is caused by the fusion of two leaflets of the tricuspid valve of 
the aorta and results in regurgitation of blood from the aorta back into the ventricle.  
This mild phenotype is often asymptomatic at birth and in childhood, but is thought to 
predispose an affected individual to more severe heart disease in later life (Tadros et 
al., 2009; Siu and Silversides, 2010).  
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The next most common CCVM is a ventricular septal defect (VSD), which occurs to 
varying degrees in around 3.5 per one thousand live births.  A VSD is the failure in the 
formation of the interventricular septum which separates the two ventricles.   Small 
VSDs, along with atrial septal defects (ASDs) and small patent ductus arteriosus (PDA) 
are considered the least severe CCVMs, and usually close naturally or do not cause 
problems to the patient (Hoffman et al., 2004). 
The most severe forms of CCVM include double outlet right ventricle (DORV), 
persistent truncus arteriosus (PTA), transposition of the great arteries (TGA), tetralogy 
of Fallot (TOF), atrioventricular septal defects (AVSDs) and large VSDs.  These occur 
collectively at a rate of around 2.5-3 per thousand live births and cause infants to 
become seriously ill within the immediate postnatal period, or soon after (Hoffman et 
al., 2004).  Each of these defects put additional strain on the heart of the patient by 
allowing the mixing of oxygenated and deoxygenated blood.  DORV is a condition in 
which both the aorta and pulmonary trunk arise from the right ventricle.  In live born 
infants this defect is often accompanied by a VSD in order to allow oxygenated blood 
from the left side of the heart to reach the aorta and be pumped out into systemic 
flow.  PTA is a continuation of a more primitive state of OFT development, in which the 
early OFT, then termed the truncus arteriosus, has not yet septated into the aorta and 
the pulmonary trunk.  TGA is another defect of OFT formation in which the major 
arteries become aligned incorrectly, so that the aorta arises from the right ventricle 
and the pulmonary trunk arises from the left ventricle.  TOF is a collection of four 
cardiovascular defects:  a large VSD, an overriding aorta (OA) which arises from a 
central position directly above the VSD, right ventricular hypertrophy and pulmonary 
stenosis.  An AVSD is the failure of the formation of both the atrial and ventricular 
septum. 
In addition to the defects of the OFT and interventricular septum many defects 
affecting the aortic arch arteries can also occur.  The most severe of which is 
interruption of the aortic arch (IAA) which prevents the blood from passing from the 
aorta into systemic flow.  Other malformations may be mostly asymptomatic such as 
anomalous right subclavian artery (A-RSA).  This results in the right subclavian artery 
(RSA) passing behind the oesophagus, putting pressure on the oesophagus.  This 
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presents in patients as a difficulty in swallowing (dysphagia), but is often asymptomatic 
(Erami et al., 2013). 
 
Figure 1.3: Congenital cardiovascular malformations and incidence. 
Diagram of the heart, showing a number of regions affected by CCVM.  The incidence of each defect in newborn 
infants per thousand live births is shown in brackets.  DORV, double-outlet right ventricle; TGA, transposition of the 
great arteries;  PTA, persistent truncus arteriosus;  IAA, interrupted aortic arch; PDA, patent ductus arteriosus;  PS, 
pulmonary stenosis;  TOF, tetralogy of Fallot;  BAV, bicuspid aortic valve; VSD, ventricular septal defect;  AVSD, 
atrioventricular septal defect; ASD, atrial septal defect.  (Modified from Bruneau, 2008). 
1.2. Pharyngeal arch artery development 
1.2.1. The pharyngeal arches 
The PAs are transient structures which contribute to the skeleton, musculature, 
ligaments and glands of the body.  There are five PAs which form during embryonic 
development numbered 1-4 and 6.  The fifth PA never fully forms and does not carry a 
vessel in mammals and is therefore generally excluded.  Each PA is composed of four 
tissue types: ectoderm, endoderm, mesoderm and NCC-derived mesenchyme (Figure 
1.4).  The mesoderm and NCC-derived mesenchyme form the bulk of the PA tissue and 
are required to support the PAAs which develop within.  The NCCs also contribute 
SMCs to the tunica media layer of the vessels.  The pharyngeal ectoderm covers the 
PAs externally, and forms invaginations between the PAs named pharyngeal clefts.  
The endoderm forms the inner lining of the PAs and also forms invaginations which 
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meet with the pharyngeal clefts, termed pharyngeal pouches (reviewed in Graham and 
Smith, 2001; Lindsay, 2001; Grevellec and Tucker, 2010). 
  
Figure 1.4: The structure of the embryonic pharyngeal arch system. 
(a)  Cartoon of the pharyngeal arches.  Five pharyngeal arches form during embryonic development (1-4 and 6).    
(b) Coronal section through the PAs.  Each arch consists of mesoderm (beige) and NC-derived mesenchyme (red), 
surrounded by ectoderm (green) and endoderm (blue).   The pharyngeal pouches are formed from the endoderm 
between each PA (arrows).  Each PA contains a single vessel. (Image taken from Lindsay, 2001). 
1.2.2. The pharyngeal pouches 
The pharyngeal pouches, as described above, form at the point where the pharyngeal 
endoderm meets the ectoderm, between the arches (arrows, Figure 1.4b).  The third 
pharyngeal pouch gives rise to the developing thymus and inferior parathyroid gland, 
the fourth pharyngeal pouch gives rise to the superior parathyroid gland and the 
ultimobranchial body (required in calcium homeostasis) (reviewed in Grevellec and 
Tucker, 2010). 
Although the development of these structures does not directly affect the developing 
cardiovascular system, many syndromes which have abnormalities of the PAAs also 
show abnormal development of these structures, presumably due to an overall 
disruption in the development of the PA system.  Therefore, it is also useful to 
understand the formation of these tissues.  
The formation of the thymus and parathyroid glands begins at e11.5 with the 
migration of endodermal cells of the third pharyngeal pouch into the underlying NCC-
derived mesenchyme on either side of the pharynx.  These cells then begin to express 
Foxn1, a marker of differentiated thymic tissue.  It is likely that signals of the Wnt, BMP 
Introduction 
9 
 
and sonic hedgehog pathways are involved in the initiation and maintenance of Foxn1 
expression, and in the regulation of the size of the thymic rudiments (reviewed in 
Boehm, 2008).  As the thymus/parathyroid primordia develop they begin to detach 
from the ectoderm.  By e12 the remaining connections to the ectoderm are lost 
through apoptosis and the primordia are able to begin migration to their final location 
above the heart.  By e13.0 the thymus and parathyroids are beginning to separate 
(reviewed in Manley and Blackburn, 2003). 
There is much controversy over which pharyngeal lineages are responsible for each 
layer of tissue in the final thymus.  Although it is well established that the endoderm 
plays a key role in the thymic epithelia, with the surrounding capsule being contributed 
by the NCC-derived mesenchyme, many others propose a ‘dual-origin’ of the thymic 
epithelia.  The dual-origin model suggests that the internal medullary epithelium is 
derived from the endoderm, while the surrounding cortex epithelial cells originate 
within the ectoderm of the pharyngeal cleft (Reviewed in Manley and Blackburn, 
2003). 
1.2.3. Pharyngeal arch arteries 
The PAAs form within the PAs, as bilaterally paired vessels connecting the aortic sac to 
the paired dorsal aortae at mid-embryogenesis (Figure 1.5a).  Each artery arises from a 
single PA and is surrounded by an endothelial wall, formed from pharyngeal 
mesoderm, and SMCs and connective tissue, derived from NCC-derived mesenchyme 
(Graham and Smith, 2001; Kirby, 1987). 
These vessels later undergo a complex remodelling process to develop into the aortic 
arch and associated vessels of the mature mammalian heart (Figure 1.5b).  The 
processes by which the vessels both form and remodel are not fully understood; 
however, what is currently known will be discussed here. 
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Figure 1.5: Pharyngeal arch artery development.   
The PAAs begin as a symmetrical structure (a) consisting of 5 pairs of arteries, which are remodelled into the mature 
aortic arch (b).  pa, pulmonary artery; RSA, right subclavian artery; RCC, right common carotid artery; BC, 
brachiocephalic trunk; LCC, left common carotid artery; AoA, aortic arch; LSA, left subclavian artery; DA, ductus 
arteriosus. 
1.2.3.1. Formation 
In 2002, Hiruma et al. characterised the development of the PAAs using a vascular 
casting technique, at various stages throughout murine development.  Formation of 
the PAAs begins at e8.5-9.0 (12 somite stage) of murine development with the 
formation of the first PAAs.  The first PAAs develop as a loop between the bilaterally 
paired dorsal and ventral aortae (Figure 1.6a). By the 15 somite stage (early e9.0-9.5), 
the second PAAs have begun to sprout from the dorsal and ventral aortae, with the 
vessel becoming fully lumenised by the 16 somite stage (Figure 1.6b).  The third PAAs 
appear as a thin network within the caudal part of the second pharyngeal pouch, 
connecting the dorsal and ventral aortae, by early e9.5-10.0 (22 somite stage).  By mid 
e9.5-10.0 (24-26 somites) the first, second and third PAAs are clearly visible.  The first 
PAAs begin to reduce in diameter, while the second PAA is at its greatest diameter 
(Figure 1.6c).  
From the 27-29 somite stage (late e9.5-10.0) the fourth PAAs appear, although thin, 
and the first PAAs begin to regress (Figure 1.6d).  The second PAAs regress from e10.0 
(31-34 somites) (Figure 1.6e).  At this stage the sixth PAAs are becoming apparent.  The 
sixth PAA increases to a size similar to the third and fourth PAAs and by e10.5-11.0 the 
bilaterally symmetrical PAA system is fully-formed and well-developed (Figure 1.6f) 
(Hiruma et al., 2002).  At this time the paired dorsal aortae can be divided into three 
segments – α, β and γ.  The α-segment forms the region from the bifurcation of the 
paired vessels to the base of the sixth PAAs.  The β-segment forms the region between 
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the fourth and sixth PAAs and the γ-segment (also known as the carotid duct) form the 
region between the third and fourth PAAs (Figure 1.6f). 
 
Figure 1.6: Development of the bilaterally symmetrical pharyngeal arch artery system. 
(a) The first PAA (PAA1) forms as a loop between the dorsal and ventral aortae by the 12 somite (s) stage. (b) The 
second PAA (PAA2) is lumenised by the 16 somite stage.  (c)  By the 24-26 somite stage the first, second and third 
(PAA3) are fully formed.  (d) The fourth PAA (PAA4) begins to form at the 27-29 somite stage and the first PAA 
begins to regress.  (e) By 31-34 somites the first and second PAAs have fully regressed and the sixth PAA (PAA6) is 
beginning to form.  (f)  PAA formation is completed between e10.5 – e11.0.  The third, fourth and sixth PAAs appear 
to be of equal size and three segments of the dorsal aortae (α, β and γ) can be distinguished. s, somite; pa, 
pulmonary artery. 
There are two schools of thought on the mechanisms by which the PAAs form: 
angiogenesis and vasculogenesis.  Angiogenesis is the process by which new vessels 
form from previously established vessels.  Whereas, in a vasculogenesis model new 
vessels arise by the aggregation of nascent angioblast to form a string of endothelial 
cells, independently of other vessels. This endothelial string then joins to a pre-existing 
vessel before becoming lumenised to form the vessel.  This mechanism is responsible 
for the formation of the primitive vasculature of the early embryo.  Vessel formation 
then tends towards an angiogenic process, once the major vascular network has been 
established.  The development of the PAAs lies in a somewhat grey area between 
these two processes, leading to much debate over how the vessels are produced 
(Anderson et al., 2008; Li et al., 2012).  
Although the method of vascular casting has proven invaluable in demonstrating the 
timings of PAA formation, this technique is unable to identify the mechanisms of their 
Introduction 
12 
 
development.  Vascular filling methods, such as the resin casting used by Hiruma et al. 
(2002), often suggest that the PAAs develop by an angiogenic mechanism, as they rely 
on the vessel being patent in order to take up the resin.  Therefore, authors often 
describe the PAAs as forming from the dorsal aorta via angiogenesis, when in reality 
they are observing the luminisation of the vessels from each end.  Studies of the 
formation of the pulmonary vasculature has demonstrated that the use of polymer 
casting is only able to detect patent vessels (Anderson-Berry et al., 2005). This study 
used three techniques to investigate the development of the pulmonary vasculature in 
chicken embryos: vascular filling, histology and immunohistochemistry.  Their results 
clearly demonstrate that neither histology, nor vascular filling methods were sensitive 
enough to identify vessels forming by vasculogenesis.  However, the use of 
immunohistochemistry to detect the vascular endothelial growth factor (VEGF) and its 
receptor Flk-1 were able to identify coalescing angioblasts as expected during 
vasculogenesis.  
Furthermore, recent work using immunohistochemistry of endothelial markers 
indicates that PAA formation occurs via vasculogenesis (Li et al., 2012).  This work 
demonstrates the aggregation of endothelial cells into a string, which later lumenises 
to form a patent PAA.  In addition, confocal imaging of transgenic zebrafish embryos 
has yielded similar results.  A fluorescent reporter driven by the zebrafish flk1 
promoter was used to visualise aortic arch development.  The vessels were found to 
form from a cluster of endothelial cells between the dorsal and ventral aortae, which 
then grew out to join these vessels, followed by luminisation (Anderson et al., 2008).   
1.2.3.2. Remodelling 
Once the PAAs have completed their formation at e11.0 they almost immediately 
begin remodelling to form the aortic arch of the mature heart (Figure 1.5b).  The first 
and second PAAs regress into capillary beds and do not contribute to the final 
structure of the aortic arch.  The third PAAs form the left and right common carotid 
arteries (LCC, RCC).  The left fourth PAA forms part of the arch of the aorta between 
the LCC and left subclavian artery (LSA), and the right fourth arch artery forms the 
proximal region of the RSA.  The sixth right PAA regresses and the sixth left forms the 
ductus arteriosus.  The remodelling of the PAAs requires a complex array of cellular 
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processes, such as apoptosis, proliferation and differentiation, as well as other factors 
such as the rate of blood flow through the arteries (haemodynamics).  
By e11.5-12.0 the proximal part of the aortic sac has septated into the aorta and 
pulmonary trunk and the pulmonary arteries begin to shift along the sixth PAAs to the 
site where the pulmonary trunk joins (Hiruma et al., 2002) (Figure 1.7a).  The OFT 
undergoes a 90° clockwise rotation, causing the sixth right PAA to lengthen and 
decrease in diameter.  The reduced diameter of this vessel is thought to restrict the 
blood flow through the artery, which then leads to the regression of the vessel.  This, 
in turn, reduces the blood flow through the α-segment of the right dorsal aorta, and 
this vessel often regresses immediately after the right sixth PAA (Yashiro et al., 2007).  
Hiruma et al. (2002) report that the regression of the sixth right PAA begins at e11.5, 
closely followed by the loss of the right dorsal aorta by e12.5.  At this time, the left and 
right carotid ducts, the γ-segments of the dorsal aortae, also begin to reduce in size 
and have fully regressed by e12.5 (Figure 1.7b) (Hiruma et al., 2002).  By e13.0 the α-
segment of the right dorsal aorta has completely regressed (Figure 1.7c).  The left 
fourth PAA now forms the aortic arch and the right horn of the aortic sac has become 
the brachiocephalic trunk.  By e15.0 the remodelling process is complete (Figure 1.7d).  
The fourth right PAA forms the proximal portion of the RSA, which arises from the 
brachiocephalic trunk, and the right seventh intersegmental artery forms the distal 
portion.  The sixth left PAA forms the ductus arteriosus and the left intersegmental 
artery has become the LSA. 
Apoptosis is an important process in forming the asymmetric structure of the aortic 
arch.  Molin et al. (2002) demonstrated that apoptosis begins in the mesenchyme 
surrounding the right dorsal aorta and right sixth PAAs immediately before the vessels 
regress.  Apoptosis within the media of the vessel becomes more prominent as the 
vessel thins into a strand of SMCs before completely regressing.  In addition, work in a 
rat model has also indicated an increased level of apoptosis surrounding the carotid 
ducts before they begin to regress (Molin et al., 2004).   
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Figure 1.7: Pharyngeal arch artery remodelling. 
(a) PAA remodelling begins at e11.5. The distal portion of the aortic sac becomes septated into the aorta (Ao) and 
pulmonary trunk (PT).   The right sixth PAA and the γ-segment (carotid duct, CD) of the dorsal aorta on both sides 
begin to regress.  The seventh intersegmental arteries, which will form the subclavian arteries, are now visible.  (b) 
By e12.5 the carotid ducts and right sixth PAAs have completely regressed and the right α-segment of the dorsal 
aorta becomes very thin.  (c) By e13.5 the α-segment of the right dorsal aorta has completely regressed.  The right 
horn of the aortic sac forms the brachiocephalic trunk.  (d) By e15.5 PAA remodelling is complete.  Ao, aorta; PT, 
pulmonary trunk; CD, carotid duct;  BC, brachiocephalic trunk; RSA, right subclavian artery; LSA, left subclavian 
artery; RCC, right common carotid artery;  LCC, left common carotid artery; AoA, aortic arch; DA, ductus arteriosus. 
1.2.3.3. Pharyngeal arch artery defects 
The development of the PAAs is a very complex procedure, requiring the orchestration 
of many genes and processes in order to achieve the correct final aortic arch 
configuration.  Therefore, it is unsurprising that perturbing these processes in any way 
can result in serious PAA malformations.  Defects of the PAAs can develop either 
during the formation of the vessels (primary defect) or during the remodelling of the 
vessels into the mature aortic arch (secondary).   
The most commonly identified defects appear to affect the fourth PAAs.  Defects of 
the fourth left PAA are much more severe than defects affecting the development of 
the right fourth PAA.  In the normal condition, the left fourth PAA provides the 
segment of the aortic arch, which lies between the LSA and the LCC.  Absence of the 
left fourth PAA results in IAA type B (IAA-B), which prevents the blood from the 
ascending aorta entering the dorsal aorta and therefore, systemic flow (Figure 1.8a).  
Embryos carrying this malformation are often able to survive until birth and for a 
number of hours afterwards, as the ductus arteriosus provides blood to the dorsal 
aorta.  However, shortly after birth the ductus arteriosus closes, preventing blood 
entering the systemic flow and resulting in death.   
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Figure 1.8: Defects of the left fourth PAAs. 
Loss of the left fourth PAA results in two possible defects.  (a)  Loss of the left fourth PAA, with all remaining 
structures developing normally, results in an interruption between the LCC and LSA (IAA-B).  (b)  Loss of the left 
fourth PAA, accompanied by the persistence of the left carotid duct, results a cAoA in which the persistent carotid 
duct forms the connection between the ventral and dorsal aortae.   
Another defect which can result from the absence of the fourth left PAA is a cervical 
aortic arch (cAoA).  The left carotid duct persists in the absence of the fourth left PAA 
to produce an aortic arch which arises from the LCC at a more distal position (Figure 
1.8b). 
Defects of the right fourth PAA are often asymptomatic.  In the normal condition the 
RSA is formed by the fourth right PAA and the seventh intersegmental artery, 
connected by the β-segment of the right dorsal aorta.  The loss of the fourth right PAA 
can result in three altered routes for the formation of the RSA, as first described by 
Kutsche and van Mierop in 1984.  This work investigated the anomalous origin of the 
RSA in infants with IAA-B, under the assumption that RSA defects primarily occur when 
the fourth PAAs are bilaterally absent. This study found that the most common route is 
an A-RSA, in which the RSA forms in a retroesophageal position.  In this case the α-
segment of the right dorsal aorta aberrantly persists, and passes behind the 
oesophagus to form the connection between the aortic arch and the seventh 
intersegmental artery (Kutsche and Van Mierop, 1984) (Figure 1.9a).  
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Figure 1.9: Defects of the right fourth PAAs. 
Loss of the right fourth PAA results in three possible routes for RSA development.  (a) Loss of the right fourth PAA 
accompanied by the persistence of the right α-segment of the dorsal aorta results in an A-RSA.  (b)  Loss of the right 
fourth right PAA accompanied by persistence of the right carotid duct results in CORSA in which the RSA arise from 
the RCC at a cervical position.  (c)  Loss of the right fourth PAA accompanied by the persistence of the right sixth 
PAA results in an I-LSA, in which the RSA arises from the pulmonary artery. 
The next most common route for the RSA was arising from a more cervical position 
along the brachiocephalic trunk, at the point where the RCC bifurcates into the internal 
and external common carotid arteries.  From here the vessel descends into the right 
arm.  This defect occurs when the right carotid duct persists and joins the seventh 
intersegmental artery to the brachiocephalic trunk.  This defect is known as cervical 
origin of the RSA (CORSA) due to the position in which the RSA arises (Figure 1.9b).  
The final and least common route for the RSA is arising from the pulmonary artery.  In 
this system the right sixth PAA fails to regress and joins the seventh intersegmental 
artery to the blood flow from the aortic sac (Kutsche and Van Mierop, 1984) (Figure 
1.9c).  This study demonstrated that in the presence of IAA that two thirds (66%) of 
infants also carried RSA defects. 
The PAAs pass through two main phases of development before reaching the final 
aortic arch configuration.  These two phases, as described above, are formation and 
remodelling; and perturbation of the normal developmental pathways at either of 
these stages can cause severe disruptions to the correct formation of the aortic arch.  
During the formation stages, reduced aggregation of endothelial cells to form the 
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initial endothelial tube of the vessel, reduced NCC migration to the PAs or NCC 
differentiation into SMCs may all contribute to PAA defects.  Later, in the remodelling 
stages, apoptosis and haemodynamic changes are the key to correct development, and 
aberrant patterns of apoptosis within the vessel walls may lead to abnormal regression 
or persistence of specific segments of the aortic arch. 
1.3. Neural crest cells 
A major event in the development of the heart involves the migration of the NCCs into 
the PAs and OFT.  The neural crest (NC) is a transient structure, which assembles 
between the surface ectoderm and the neural tube of the embryo as these two 
structures contact each other.  The concentrations of BMPs in the interacting tissues 
are crucial to the initiation of NC formation: the neural plate contains much lower 
levels of this paracrine factor than the ectoderm and the NC forms at intermediate 
concentrations.  NCCs are a pluripotent population, which migrate from the neural 
tube to multiple areas of the body, where they differentiate and contribute to various 
structures.  The fate of each cell is defined by the position of the cell along the 
anterior/posterior axis of the developing embryo and the region to which it migrates 
(reviewed in Hutson and Kirby, 2003; Snider et al., 2007).   
The NC is vital for cardiovascular development, and disruptions of this cell type are 
thought to be responsible for a number of congenital cardiac abnormalities.  Following 
the formation of the NC, the cells undergo EMT before migrating to their required 
locations.  Epithelium is composed of polarised cells, joined at adherens junctions 
consisting of E-cadherin, catenins and actin rings, and tight junctions.  During EMT, 
EMT-inducing genes, such as Sox9, Foxd3 and Snail, are activated and E-cadherin is 
targeted for degradation, resulting in a loss of polarisation.  The basement membrane 
is broken down and the cytoskeleton of the cell is rearranged to allow the NCCs to 
delaminate from the neural tube (Acloque et al., 2009). 
The cardiac NCCs migrate from the dorsal neural tube to the PAs, where they 
differentiate into SMCs investing the tunica media of the PAAs.  A sub-population 
continues to migrate into the OFT.  Once in the OFT the condensed mesenchyme 
migrates inwards initiating the formation of the aorticopulmonary septum, separating 
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the aorta from the pulmonary trunk (reviewed in Hutson and Kirby, 2003; Snider et al., 
2007). 
1.3.1. Pharyngeal arch arteries 
Lineage tracing experiments in mice have been used to identify the route of the NCCs 
to the heart (Jiang et al., 2000).  NCCs infiltrate the PAs, and by e9.5 were found within 
the PA mesenchyme, but not in the endoderm, ectoderm or vascular endothelium.  
The presence of the NCCs in the walls of the ductus arteriosus, ascending aorta, LCC 
and RCC arteries was also demonstrated at e15.5.  However, the dorsal aortae and 
pulmonary trunk are devoid of NCCs at this time.  In the adult mouse, NCC-derivatives 
remain in the vessel wall of the PAA-derivatives: the aortic arch, LCC, RCC, the 
brachiocephalic trunk and the proximal portions of the LSA and RSA.  The distal regions 
of the subclavian arteries, which are derived from the seventh intersegmental vessels 
do not carry any NCCs (Jiang et al., 2000).   
This work is in-keeping with two previous studies, which propose a NCC-origin of the 
SMCs surrounding these vessels in the chicken embryo (Topouzis and Majesky, 1996; 
Bergwerff et al., 1998).  These studies demonstrate that the ascending aorta, LCC, RCC, 
ductus arteriosus and the proximal LSA and RSA are surrounded by NCC-derived SMCs 
after the remodelling process.  The authors also demonstrate a sharp boundary 
between the NCC-derived SMC of the fourth and sixth PAA, with the mesodermally-
derived SMCs of the dorsal aorta.  However, the carotid ducts show some NCC 
contribution to their SMCs (Bergwerff et al., 1998). 
The NCCs are important in the stabilisation of the vessels, required for remodelling.  
This is due to their differentiation into SMCs, which then secrete extracellular matrix 
(ECM) proteins, which are also required in the stabilisation of the arteries (Waldo et 
al., 1996).  
The processes by which NCCs differentiate into SMCs are not well understood, 
however, many genes have been implicated as playing a cell-autonomous role within 
the NCCs for correct migration, survival and differentiation to SMCs.  For sexample, 
NCC-specific deletion of the histone deacetylase 3  gene (Hdac3) reduces the amount 
of SMCs and the expression of the Notch receptor Jagged-1, surrounding the fourth 
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PAAs, resulting in hypoplasia or interruption of the aortic arch at later stages (Singh et 
al., 2011).  Additionally, defective SMC differentiation is seen in the Df1 heterozygotes, 
a mouse model of the 22q11 deletion syndrome (22q11DS) in humans (Lindsay and 
Baldini, 2001).  The authors demonstrated normal migration of the NCCs and 
comparable levels of apoptosis to control mice in these mutants. 
1.3.2. Outflow tract development 
The majority of work on understanding the role of NCCs in OFT septation has been 
carried out in quail-chicken chimeras.  The OFT is separated by the aorticopulmonary 
septal complex into the aorta and pulmonary trunk.  The aorticopulmonary septal 
complex consists of condensed NC-derived mesenchyme (mostly derived from the 
fourth PA (Phillips et al., 1987)), which forms an inverted ‘U’ shape within the aortic 
sac, separating the aorta and pulmonary trunk.  Septation proceeds caudally towards 
the ventricles in a spiral pattern, separating the great vessels and causing their lumens 
to rotate around each other.  OFT septation is completed by the fusion of the septum 
with the endocardial cushions of the AV canal and the interventricular septum (Waldo 
et al., 1998).  
OFT septation in the mouse is thought to occur in much the same way, as 
demonstrated by NC lineage tracing experiments.  At e9.5, the NCCs begin to infiltrate 
the OFT of the heart, and by e11.5 are involved in the formation of the 
aorticopulmonary septum complex (Jiang et al., 2000).   
1.3.3.  Cardiac neural crest ablation phenotype 
Much of our understanding of the role of the NCCs in cardiovascular development 
comes from studies in which the NCCs have been ablated, and the effects of losing the 
NCCs examined.  The majority of this work has been carried out in the chicken embryo 
due to the easy access to the neural tube; however, more recently new strategies for 
NCC-ablation in mouse have come into practise. 
1.3.3.1. Chicken 
Although the formation of the heart in the chicken is very similar to that of the mouse, 
the development of the aortic arch arteries varies somewhat.  The chicken develops a 
right-sided aortic arch, with two brachiocephalic arteries and a ductus arteriosus on 
each side. The third PAAs of the chicken produce a brachiocephalic artery on either 
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side, which gives rise to a subclavian artery and a common carotid artery.  The right 
fourth PAA gives rise to the arch of the aorta, while the left fourth PAA regresses.  The 
distal portion of each sixth vessel forms the bilateral ductus arteriosi (Bergwerff et al., 
1998).  
Initial studies using quail-chicken chimeras indicated that the NCCs between the 
otocyst and the caudal boundary of somite 3 are required to migrate through the PAs, 
and into the OFT of the heart.  This population of NCCs became known as the ‘cardiac’ 
NCCs for this reason (Kirby et al., 1985).  Therefore, early studies investigated the 
ablation of this region, either bilaterally or unilaterally, and identified high proportions 
of embryos with VSD and PTA.  In addition, smaller deletions – ablating only a single 
somite region unilaterally – also uncovered further, less severe OFT defects such as 
DORV and OA, which were grouped together in many of the subsequent studies as 
dextroposed aorta (DPA).  It was also found that bilateral deletion of a region 
encompassing two somites (somites 1-2 or 2-3)  resulted in 100% penetrance of PTA 
and VSD, while unilateral deletion of the same regions also gives rise to DORV in 40% 
cases.   Additionally, bilateral deletion of the NCCs associated with somite 1 results in 
100% DORV, while the penetrance of VSD was reduced to 80% (Besson et al., 1986).  
Although this study was  very small (n=5) in comparison to many other NCC-ablation 
experiments, it lead to the suggestion that DORV was caused by a small unilateral 
lesion of a single somite within the cardiac NC region, or a larger ablation in the pre-
otic, or ‘non-cardiac’ NC.  PTA, on the other-hand, was proposed to result from larger 
deletions of the cardiac NCCs – either encompassing a single somite bilaterally, or 
multiple somites unilaterally or bilaterally (Kirby, 1987).  
As discussed above the septation of the OFT involves the cardiac NCCs and it is, 
therefore,  quite clear that the removal of this important population of cells, or even a 
large proportion of these cells results in the aorticopulmonary septation complex being 
unable to septate the OFT.  However, in the DPA phenotype, OFT septation occurs 
normally, but the vessels do not align properly with the correct ventricles.  Insight into 
the role of the NCCs in this process came from the identification that the OFT of NCC-
ablated embryos was shortened (Yelbuz et al., 2002).  This group examined the 
incorporation of the cells of the SHF into the OFT myocardium and found a significant 
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reduction within those embryos that underwent NCC-ablation.  This suggests that the 
SHF cells are important in the elongation of the OFT in order for correct looping and 
alignment with the ventricles to occur.  It is likely that the NCCs are required in this 
region to secrete signalling molecules which attract the SHF cells into the OFT (Yelbuz 
et al., 2002).  It has also been suggested that DPA and VSDs are the result of a 
haemodynamic effect, as these also occur with ablations of the non-cardiac NCCs 
(Kirby, 1987). 
In addition to the high prevalence of intracardiac and OFT anomalies found in NCC-
ablated embryos, there is also a high incidence of PAA defects including persistent left 
fourth PAA and absence or anomalous origin of the subclavian arteries.  The highest 
rate of CCVM occurs when the NCC-ablation covers the region of NCCs destined for the 
fourth PA (somites 1-2), with 95.2% embryos having some form of cardiac anomaly.  
Ablation of the somite 1-3 region, which also encompasses the NCCs which will 
migrate to the sixth PAs, resulted in 100% penetrance of CCVM.  Hypoplasia or aplasia 
of the third, fourth and sixth PAAs also occur most frequently in these embryos.  
Interestingly, defects of the sixth PAA were not present when NCCs destined for this 
arch alone were ablated.  In most cases, where a defect of the fourth right PAA was 
observed, the vessel was absent and an OFT defect was also observed.  In a number of 
cases the fourth left PAA persisted to act as a substitute aortic arch.   In other cases 
only remnants of this vessel were observed (Nishibatake et al., 1987). 
It was later demonstrated using quail embryos that the NCCs are not required in the 
formation of these vessels, but in their stabilisation.  Waldo et al. (1996) demonstrated 
that the NCCs are required to separate the developing vessel from the endoderm of 
the PA, but that this process occurs once the vessel has already begun to lumenise.  
The ablation of the NCCs causes a reduction in the size of the developing PA and also 
results in a misshapen vessel, which remains in contact with the endoderm, and in 
some cases the ectoderm, throughout the entire length of the PA.  The loss of the NCC-
derived ectomesenchymal sheath surrounding the third PAA resulted in asymmetry of 
these vessels, with a hypoplastic or collapsed third vessel occurring on one side while 
the other side was unusually large.  These defects occur prior to the formation of the 
tunica media by the NCCs, which suggests that the NCCs are also required to stabilise 
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the vessels before differentiating into SMCs, in order to support the vessel as blood 
flow increases.  This supporting role may involve the deposition of an elastic ECM by 
these cells (Waldo et al., 1996). 
Additionally, a number of NCC-ablated embryos also presented with extracardiac 
malformations including thoracic wall defects, hyoid and mandibular defects, 
exencephaly and microphthalmia.  However, some of these defects are observed in 
sham-operated embryos at lower frequencies, and may therefore be partially 
attributed to the experimental procedure (Kirby et al., 1985; Besson et al., 1986; 
Nishibatake et al., 1987). 
Although NCC-ablation in chicken embryos has proved invaluable to our understanding 
of the role of NCCs in development, and in particular cardiovascular morphogenesis,  
the development of the heart in the chicken and in mammals varies, particularly in the 
formation of the aortic arch arteries.  Therefore, the work already carried out in the 
chicken embryos should also be validated in the mouse.  However, this is more difficult 
due to the in utero development of the mammalian embryo. 
1.3.3.2.   Mouse 
The first study investigating NC ablation was carried out by inducing toxicity in those 
cells of the NC lineage (Porras and Brown, 2008).  This study utilised NC-specific 
expression of the herpes simplex virus type 1 thymidine kinase (TK) suicide gene, 
which relies on the administration of the prodrug ganciclovir (GCV) in order to induce 
toxicity.  TK expression causes susceptibility to GCV, which prevents the incorporation 
of guanosine residues into elongating DNA. Cells which are incapable of DNA synthesis 
undergo apoptosis.  This therefore results in cell death, only in those cells having 
expressed TK and also receiving GCV.    
GCV was administered to 3 groups, each with a different regimen.  One group received 
a single injection at e7.5, which resulted in ablation of the cranial NCCs, but not the 
cardiac NCCs, as TK is not activated within that population at this time.  The second 
group received two doses, at e7.5 and e8.5.  The final group received an additional 
dose at e9.5.  Of those in the single dose group, 52% developed normally, while the 
remaining 48% had VSDs.  In addition, 10% also had DORV, and 19% had an OA.  
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Administration of a second dose at e8.5 resulted in only 32% embryos with normal 
cardiovascular development.  Of those embryos with abnormal heart development 
20% had DORV, 20% OA, 8% PTA and a further 20% had a VSD only.  In addition, 
approximately 35% of embryos also had a PAA abnormality, including IAA, A-RSA and 
right aortic arch (RAA).  In the final group, which received three injections of GCV, no 
embryos had normal cardiovascular development.  75% of these embryos had PTA, 
10% OA and 15% DORV.  In addition, all embryos of this group also had a PAA defect 
(Porras and Brown, 2008). 
Another study of NCC-ablation in mouse used the diphtheria toxin fragment A (DTA) to 
induce toxicity in NCCs by interfering with RNA translation machinery and causing the 
cell to apoptose.  Mouse mutants had 100% penetrance of PTA, although there was 
variability in the number of leaflets within the valve.  Additionally, a number of PAA 
malformations were identified in e10.5 mutant embryos.  The authors failed to 
describe these defects in detail, but indicate that a number of embryos display 
aberrant regression of vessels required in the final aortic arch structure, while other 
vessels that would normally regress were persistent (Olaopa et al., 2011). 
1.3.4. Signalling between NCCs and other cell types 
The survival and the migration of the NCCs into the PAs is affected by signalling 
molecules originating from the surrounding tissues.  The first step in the migration of 
the NCCs is their delamination from the neural tube, caused by repulsive semaphorin 
signalling from the neural tube.  Signalling from the pharyngeal ectoderm then attracts 
the NCCs into the PAs.  From here they are drawn to the developing OFT by signals 
originating in the SHF-derived myocardium, where they participate in the formation of 
the aorticopulmonary septum.  Any disruptions to the signalling pathways required in 
the migration and survival of the NCCs can cause severe cardiovascular defects. 
1.3.4.1. Second Heart Field 
The NCCs require signalling cues to migrate into the cardiac OFT.  These signals 
originate from the SHF-derived myocardium of the OFT and are received by the NCCs 
within the PAs, causing them to migrate into the OFT and initiate the formation of the 
aorticopulmonary septum.   
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Semaphorin3C (Sema3C) signals have been shown to attract NCCs and aid in their 
migration, as demonstrated by in vitro migration assays (Toyofuku et al., 2008).  In 
addition, Sema3C is expressed within the myocardium of the proximal OFT and the PA 
mesenchyme at e10.5, with expression also becoming evident in the aorticopulmonary 
septation complex by e12.5 (Feiner et al., 2001).  During this time the NCCs express the 
semaphorin co-receptor PlexinA2 (Brown et al., 2001), suggesting an involvement of 
semaphorin signalling in NCC migration to the OFT.   
Further evidence for the role of semaphorins in NCC migration comes from Sema3C 
mutant mice.  75% of Sema3C null mice exhibit PTA, accompanied by a single 
semilunar valve with 4 cusps and a VSD (Feiner et al., 2001).  This phenotype is 
characteristic of NCC-ablation in chicken and mouse embryos (see section 1.3.3), 
strengthening the link between Sema3C expression in the OFT and infiltration of NCCs 
into this region. 
Work in chicken embryos suggests that the semaphorin receptor PlexinA2, expressed 
by NCCs, is responsible for receiving repulsive signals.  Sema6A and Sema6B secreted 
from the neural tube are thought to cause the NCCs to delaminate from the neural 
tube and migrate away from this area.  Additionally, these authors demonstrate that 
PlexinD2, in a heterodimeric complex with neuropilin-1, receive the SHF-derived 
Sema3C signals, which attract the NCCs to the OFT (Toyofuku et al., 2008).  This work 
demonstrates the multitude of heterodimer receptors that are used in semaphorin 
signalling and that the outcome of this signalling can differ depending on both the 
signalling molecule and the combination of co-receptors involved.  As the NC-derived 
dorsal root ganglia remain unaffected in the Sema3C mutant mice, it has also been 
suggested that an as yet unidentified cardiac NCC-specific Sema3C co-receptor may 
exist within these cells (Brown et al., 2001). 
1.3.4.2. Pharyngeal Surface Ectoderm 
The pharyngeal surface ectoderm (PSE) produces signals which affect the NCCs as they 
migrate through the PAs.   The signalling pathways so far identified include FGFs, 
endothelins and sonic hedgehog.  Fgf8 has been identified as the main component of 
the FGF family that is involved in signalling from the pharyngeal ectoderm to the NCCs.  
Fgf8 is expressed in the pharyngeal ectoderm and endoderm, and hypomorphic 
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mutations in the gene results in 100% penetrance of ASD and VSD.  OFT defects, such 
as DORV and PTA, and PAA defects such as IAA and abnormalities of the RSA are also 
observed with lower penetrance (Abu-Issa et al., 2002).  The PAA defects are 
attributed to the loss or hypoplasia of the fourth PAAs as a result of disruptions to the 
NCCs.  The authors demonstrate apoptosis of the NCCs within the PAs (Abu-Issa et al., 
2002), which could reduce the stability of the PAAs, causing aberrant regression of 
these vessels.  
The Fgf8 receptors, FGFR1 and FGFR3, are expressed within the NCCs and are thought 
to be required in NCC migration.  Plating NCCs onto Fgf8 in vitro, increased their 
migratory capacity, while inhibition of FGFR1 both in vitro and in vivo reduced 
migration (Sato et al., 2011), indicating that this pathway may be required in NCC 
migration and survival within the PAs. 
The Fgf8 signal required in NCC migration to the PAs originates from the pharyngeal 
ectoderm.  Tissue-specific removal of Fgf8 from the ectoderm, phenocopies the fourth 
PAA defects seen in hypomorphs, suggesting that the pharyngeal ectoderm-derived 
Fgf8 is required in fourth PAA formation and development (Macatee et al., 2003).   
A further signalling pathway, thought to mediate interactions between the pharyngeal 
ectoderm and the NCCs, is the endothelin pathway.  The Edn-1 gene which encodes 
endothelin-1 (ET-1) is expressed within the surface ectoderm and paraxial mesoderm 
of the PAs, while the endothelin receptor (ETA) is expressed within the NCCs 
(Yanagisawa et al., 1998a; Clouthier et al., 1998).  Mutations disrupting these genes 
result in PAA defects, such as IAA and absent RSA.  In addition, many mutants have 
VSDs and OFT defects, such as OA, DORV, PTA and TGA (Kurihara et al., 1995; Clouthier 
et al., 1998; Yanagisawa et al., 1998a). As these mutations do not affect the formation 
of the vessels, it is likely that the observed defects are due to reduced proliferation or 
differentiation of the NCCs or increased apoptosis, although the exact mechanism has 
not yet been described.  This would reduce the number of NCCs within the PAs which 
results in reduced mesenchymal support for the vessels, and therefore aberrant 
regression of the vessel. 
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This work therefore demonstrates the importance of signalling between the surface 
ectoderm and other surrounding tissues to the NCCs.  Loss of any element of these 
signalling pathways inhibits correct NCC development. 
1.4. AP-2α 
Activator protein 2α (AP-2α) was the first characterised member of the AP-2 family of 
transcription factors, which also consists of AP-2β, -γ,-δ and – ε (see Table 1-1 for a 
summary of AP-2 family genes in mice, humans and zebrafish). These proteins are 
localised to the nucleus where they activate specific genes, resulting in the increased 
proliferation and decreased differentiation of the cells (Pfisterer et al., 2002).  In the 
mouse, AP-2α, -β and –γ are co-expressed during embryonic development in the limb 
and facial mesenchyme, the trophectoderm, the peripheral nervous system and the 
NCCs (Mitchell et al., 1991; Moser et al., 1995; Chazaud et al., 1996). 
Table 1-1: Summary of AP-2 family members in mice, humans and zebrafish. 
Gene name Species No. of exons Chromosome 
AP-2α 
Tcfap2a Mouse 7 13 
TFAP2A Human 7 6 
tfap2a Zebrafish 7 24 
AP-2β 
Tcfap2b Mouse 7 1 
TFAP2B Human 7 6 
tfap2b Zebrafish 7 20 
AP-2γ 
Tcfap2c Mouse 7 2 
TFAP2C Human 7 20 
tfap2c Zebrafish 7 6 
AP-2δ 
Tcfap2d Mouse 8 1 
TFAP2D Human 8 6 
tfap2d Zebrafish 8 20 
AP-2ε 
Tcfap2e Mouse 7 4 
TFAP2E Human 7 1 
tfap2e Zebrafish 6 19 
 
Introduction 
27 
 
AP-2α was discovered in 1987 (Mitchell et al., 1987), and was later found to be 
associated with the development of multiple organs such as the kidneys, heart and 
eyes, in addition to limb and skeletal development.   A homozygous deletion of the 
murine AP-2α gene (Tcfap2a) results in severe craniofacial defects, thoracic wall 
defects and neural tube closure defects.  In addition, defects in the development of the 
kidneys, cranial ganglia and skeleton were also observed (Schorle et al., 1996; Zhang et 
al., 1996).  A wide range of cardiovascular defects have also been identified (Brewer et 
al., 2002).  These include OFT defects, such as DORV, PTA and occasionally cases of 
TOF.  In addition, PAA defects such as A-RSA, IAA-B, right dorsal aorta, pulmonary 
stenosis and pulmonary atresia, were also observed. 
1.4.1. AP-2α structure 
AP-2α is a 48 kilo Dalton (kDa) transcription factor, which was first identified due to its 
association with viral and cellular enhancer elements (Mitchell et al., 1987).  The gene 
consists of seven exons, spanning 18 kb of genomic DNA.  The protein consists of three 
major motifs: a transactivation domain, a basic region and a helix-span-helix motif 
(Williams and Tjian, 1991a; Williams and Tjian, 1991b) (Figure 1.10).  The basic region 
and helix-span-helix domains are responsible for the DNA binding and dimerisation 
abilities of the transcription factor. 
 
Figure 1.10: The structure of the Tcfap2a gene and AP-2α protein. 
(a) The Tcfap2a gene consists of seven exons.  The structural domains of the protein contributed by each exon are 
indicated above. (b) The AP-2α protein is composed of three main domains. The transactivation domain is involved 
in the binding of coactivator molecules.  The basic region forms the DNA-binding domain of the protein. The 
dimerisation domain is composed by two α-helices separated by a short span of amino acids. 
1.4.1.1.  Transactivation domain 
The transactivation domain of AP-2α consists of a proline and glutamine rich region 
within the N-terminal half of the protein, encoded entirely by exon 2 of the genomic 
sequence (Williams and Tjian, 1991a; Wankhade et al., 2000).  This region is 
responsible for recruiting coactivators to the protein in order to induce transcriptional 
activation.  
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1.4.1.2.  DNA binding and dimerisation domains 
The DNA binding and dimerisation domains consist of a basic helix-span-helix (bHSH) 
motif, formed by a 200 amino acid region at the C-terminus of the protein.  The basic 
region is rich in positively charged amino acids and is responsible for the DNA binding 
activity of the transcription factor.  The following HSH motif is composed of two 
amphipathic α-helices, separated by a span of around 80 amino acids, which is 
required for both dimerisation and DNA binding of the protein.  The amphipathic 
nature of the helices causes the hydrophobic and hydrophilic residues to be orientated 
on opposing sides of the structure, therefore aiding in dimer formation.  The HSH motif 
is unique to members of the AP-2 family of transcription factors.   It differs from other 
motifs such as the helix-turn-helix and helix-loop-helix motifs in the number of 
residues separating the two α-helices (Williams and Tjian, 1991b).  This structure is 
similar to the design of other DNA-binding and dimerisation motifs known as leucine 
zippers, which are found within many transcription factors.  The leucine zipper motif is 
comprised of a helix with leucine residues spanning out from one face of the helix.  
Proteins containing this motif interact with each other through these leucine residues 
by forming a coiled-coil structure around each other.  In these transcription factors, a 
string of basic amino acids is found directly adjacent to this helix and both regions are 
required for the DNA-binding activity of the dimer (Abel and Maniatis, 1989; Jones, 
1990).  It is suggested that the bHSH motif in AP-2α function in much the same way.   
Deletions within the basic region of AP-2α result in a protein which was able to 
dimerise with wild type AP-2α, but unable to bind DNA to stimulate transcription or 
form a homodimer, while mutations within the HSH domain result in a protein which is 
unable to dimerise or bind DNA (Williams and Tjian, 1991b). 
1.4.2. AP-2α function 
The transcription factor AP-2α has been linked with multiple cellular processes such as 
apoptosis and proliferation and has been found to be important in the development of 
many structures throughout the embryo.   The role of this protein in cell death and 
proliferation has made it a target in many studies of cancer and it has found to be both 
repressive and inductive in different types of cancer.  
The AP-2α recognition site, found within many viral and cellular enhancer elements, is 
a dyad repeat with the consensus sequence 5’ – GN4GGG – 3’ (Williams and Tjian, 
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1991a).  AP-2α is also capable of binding to various G/C rich regions with differing 
affinities (Eckert et al., 2005).  The repetition of this binding sequence on the 
complementary strand is consistent with AP-2α binding DNA as a dimer (Williams and 
Tjian, 1991a).  This binding sequence is also found in the promoter region of the 
TFAP2A gene (at position -622 with respect to the ATG), suggesting this gene is 
positively regulated by its own product, or other AP-2 family members.  It has also 
been suggested that the first exon of the gene is capable of negative regulation in the 
protein, as deletion of the first 51 amino acids resulted in transcriptional upregulation 
of the gene (Bauer et al., 1994). 
1.4.2.1. AP-2α in neural crest cells 
The role of the transcription factor AP-2α in the NCCs of mammals has not been fully 
elucidated.  In mice, the loss of Tcfap2a impacts on many derivatives of the NCCs, such 
as pigmentation, neurofilament development, the formation of multiple craniofacial 
bones and the fusion of the neural tube (Zhang et al., 1996).  This is also true of 
zebrafish mutations in the AP-2α gene (tfap2a), which causes reduced pigmentation at 
the 24 hours post fertilisation (hpf) stage and reduction in the size and organisation of 
the craniofacial bones and cartilaginous elements (Knight et al., 2003; Knight et al., 
2004). 
Work on the role of AP-2α in Xenopus laevis has identified a potential role in the 
induction of the NC from the surrounding ectoderm and epidermis (Luo et al., 2002; 
Luo et al., 2003; de Croze et al., 2011).  Morpholino-mediated knockdown of AP-2α 
followed by in situ hybridisation has demonstrated the reduced expression of both 
neural plate border (NB) specifying genes (e.g., Msx1, Pax3, Zic1 and Hairy2) and NC 
specifying genes (e.g., FoxD3, Sox10, Sox9 and Snail2/Slug).  Furthermore, these 
embryos show an expansion of the neural plate marker Sox2 expression domain, 
demonstrating that the failure of NB specification results in the tissue being specified 
as neural plate instead.  Treatment of neuralised ectoderm (treated with either noggin 
or chordin) with AP-2α RNA, was sufficient to induce the full complement of NB 
specifying genes and rescue NC formation.  It was also shown that the neuralisation of 
these tissues causes the repression of neural plate markers Sox2 and Otx2.  AP-2α gain 
of function at mid-neurula (stages 12-14 in Xenopus) demonstrated activation of NC-
specifying genes, without further expansion of the neural border, therefore suggesting  
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a second role of AP-2α in NC-specification, independent of its role in NB-specification 
(Luo et al., 2003; de Croze et al., 2011). 
As AP-2α plays such an important role in the formation of the neural crest in Xenopus, 
it has been proposed that the phenotype in AP-2α mutant mice may be the result of  
loss of NC-specification, rather than reduced migration or differentiation of the 
specified NC (Luo et al., 2003).  However, both Zhang et al. (1996) and Schorle et al. 
(1996), have demonstrated the normal migration of NCCs in Tcfap2a-/- mouse 
embryos, therefore, indicating the role of AP-2α in the mammalian NC differs from 
that of Xenopus.  Furthermore, work on a zebrafish mutant of tfap2a (lockjaw, low) 
demonstrates that many of the NB and NC-specifier genes (Pax3, Sox9b, Snail2/slug 
and Foxd3) showing reduced expression in the Xenopus knockdown model are only 
marginally affected, if at all, in zebrafish (Knight et al., 2003).  At later, mid-migratory, 
stages (14-18 hpf, 12 somites) the expression of Sox9b becomes severely reduced, 
while other NC-markers remain unaffected.  By 26 hpf, genes associated with 
melanocyte precursors, dopachome tautomerase (dct) and kit, are severely reduced in 
the post-otic NCCs.  Additionally, the cranial ganglia, sympathetic neurons and NC-
derived enteric neurons are all disrupted in low mutants at 72 hpf.  The authors 
demonstrate, through fluorescent dye fate-mapping, that the NCCs are able to migrate 
to the PAs, but show a 3-9-fold increase in apoptosis in mutant embryos, suggesting 
that tfap2a is required in the survival, rather than specification of a subset of NCCs 
(Knight et al., 2003). 
Additionally, the specification and migration of NCCs appears unaffected in Tcfap2a 
mutant mice, where the path of the migrating NC has been followed using HNK-1 
staining and a Wnt1 promoter driving expression of LacZ.  However, increased 
apoptosis again appears to be a clear consequence of the loss of Tcfap2a, with 
elevations in cell death being seen in the trigeminal ganglia and first PA at e9.0-9.5, 
and in the facial region at e12.5 (Schorle et al., 1996; Zhang et al., 1996). 
1.4.2.2. AP-2α in cancer and disease 
AP-2α is an important transcription factor associated with activation and repression of 
many genes. Disruption of the human TFAP2A gene has been implicated in many 
cancers, including melanomas (Huang et al., 1998) and breast carcinomas (Bosher et 
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al., 1995).  AP-2α was elevated in a number of mammary cell lines overexpressing the 
oncogene ErbB2, and was found to bind directly to the ErbB2 promoter by DNA 
fingerprinting (Bosher et al., 1995).   AP-2α upregulation was also found to synchronise 
with c-KIT activation in a number of human melanoma lines.  In addition, loss of AP-2α 
expression correlated with a loss of c-KIT activation (Huang et al., 1998).  c-KIT is 
known to activate downstream signalling pathways such as the PI3 kinase and MAP 
kinase pathways, which result in an increase in proliferation (Joensuu and Dimitrijevic, 
2001).  Luciferase assays demonstrated the specific and dose-dependent upregulation 
of c-KIT by AP-2α, with a loss of this regulation in the presence of a dominant negative 
AP-2 protein (Huang et al., 1998).   
A further link between AP-2α and cancer comes from its role in the regulation of p21, a 
cell-cycle exit protein involved in terminal differentiation.  AP-2α was found to directly 
bind to the p21 promoter and is capable of activating the gene through this site. 
Furthermore, mutagenesis of the AP-2α binding site inhibited transcription of p21 
(Zeng et al., 1997), implicating AP-2α in the regulation of cell growth and in the 
activation of terminal differentiation. 
In addition, AP-2α is capable of negatively regulating the oncogene c-myc, which is 
involved in various types of cancers.  Wild type AP-2α can competitively inhibit c-myc 
function by binding to AP-2 binding sequences which overlap with the myc response 
element on many target genes.  It is also capable of directly interacting with the DNA 
binding and dimerisation domains of the myc proteins via its own bHSH motif, 
impairing the DNA binding of the myc/max heterodimer to target genes (Gaubatz et 
al., 1995).  Furthermore, AP-2α and another AP-2 family member, AP-2β have been 
shown to inhibit c-myc-induced apoptosis in culture (Moser et al., 1997a). 
Angiogenesis is an important process in tumourigenesis as it generates a blood supply 
to support the tumour which allows it to survive and grow.  An important gene in this 
process is VEGF (Leung et al., 1989).  AP-2α has been implicated in transforming 
growth factor (TGF)-α-mediated regulation of VEGF, through luciferase and gel-shift 
assays (Gille et al., 1997).  
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In the later stages of cancer, as a tumour proceeds from benign to malignant, a 
number of protease genes become reactivated and are secreted from the cancer cells 
in order to break down the ECM.  This breakdown of the ECM, including the basement 
membrane, allows the metastatic cells to migrate to other areas of the body.  These 
proteases are also secreted to allow the metastatic cells access to new tissues of the 
body.  Studies have implicated AP-2α in the regulation of this process through 
activation of matrix metalloproteinase (MMP)-2 (Frisch and Morisaki, 1990) and 
inhibition of the ECM protein Aggrecan (Tuli et al., 2002). 
Overall, the work described above implicates AP-2α in the activation of proliferation 
and both positive and negative regulation of apoptotic pathways in addition to the 
inhibition of ECM deposition and activation of ECM degradation.  This infers that AP-2α 
may play a role as both a tumour suppressor and an oncogene, dependent on the type 
of cancer under investigation.   
1.4.2.3. The role of transcriptional targets in cardiovascular development 
Although the majority of studies investigating the transcriptional targets of AP-2α have 
intended to understand its role in cancer progression and development, many of the 
processes involved can be transferred to cardiovascular development.  This work has 
identified significant involvement of AP-2α in basic cellular processes such as 
proliferation, apoptosis and differentiation, which play major roles in cardiovascular 
development.  Additionally, many of the target genes discussed above have additional 
roles in cardiovascular development.   
For example, VEGF and ErbB2, both of which are regulated by AP-2α (Bosher et al., 
1995; Gille et al., 1997), are involved in ventricular trabeculation.  ErbB2 is also 
required in the development of the endocardial cushions of the OFT and AV canal 
(Camenisch et al., 2002).  VEGF is pivotal in both angiogenesis and vasculogenesis, and 
is therefore integral to the formation of the vasculature of the developing embryo.  
Deletion of 2 of 3 VEGF isoforms in mice results in severe malformations of the PAAs, 
including IAA, double aortic arch and persistence of the carotid duct segments of the 
dorsal aorta, which ordinarily regress during development.  In addition, TOF was also 
observed in mutants only expressing the VEGF120 isoform.  Those mutants expressing 
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only VEGF164 developed normally, suggesting this is the dominant isoform in 
cardiovascular development (Stalmans et al., 2003). 
It is therefore likely, as with many other cases in cancer, that mutations within TFAP2A 
in cancer cause a reactivation of early developmental pathways, many of which may be 
actively involved in cardiovascular development.   
1.4.3. Coactivation 
The transcriptional activation of target genes by AP-2α requires coactivator proteins.  
A number of coactivators have been implicated in the activation of AP-2 family 
members including two members of the CBP/p300 interacting transactivators with 
glutamic acid(E)/aspartic acid (D)-rich carboxy-terminal domain (CITED) family, Cited-2 
and Cited-4  (Bamforth et al., 2001) and Poly-(ADP-ribose) polymerase-1 (PARP-1) 
(Kannan et al., 1999). 
1.4.3.1. Cited2 
Although there are multiple coactivator proteins capable of regulating AP-2α function 
most work has been carried out on the interaction of Cited2 with AP-2α.  Cited2 is a 
ubiquitously-expressed, non-DNA binding transcription factor. Deficiencies in the 
mouse Cited2 gene result in multiple cardiovascular defects, in addition to 
exencephaly, adrenal agenesis and abnormalities of the cranial ganglia.  These 
embryos die during development, or soon after birth (Bamforth et al., 2001). 
Cardiac defects in Cited2-/- embryos included ASD, VSD, OA, DORV, PTA and RAA 
(Bamforth et al., 2001).  Cited2 deficiency has also been shown to cause left-right 
patterning defects, such as cardiac looping defects and right isomerism on a C57BL/6J 
background.  This phenotype was rescued on a mixed background, indicating the 
importance of genetic background on the penetrance of the phenotype (Bamforth et 
al., 2004) .  Further investigation of these laterality defects indicated a mechanism in 
which Cited2 acts upstream of Pitx2, an important gene in the determination of the 
left-right axis in mammals, to activate correct cardiovascular development (Bamforth 
et al., 2004; Ryan et al., 1998; Kitamura et al., 1999). 
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CITED2 mutations have also been implicated in human CCVM.  Seven mutations were 
identified only in patients with CCVM, three of which clustered within the serine-
glycine-rich junction (SRJ) of the protein, suggesting a possible hotspot for CITED2 
mutations.  Cardiovascular defects observed in patients with CITED2 mutations were 
TOF, VSD, ASD, situs inversus, TGA and abnormal pulmonary venous return.  These 
defects are somewhat similar to that seen in the Cited2-/- mouse model. Also, the role 
of Cited2 in left-right patterning may explain the situs inversus observed in patients 
(Sperling et al., 2005). 
1.4.3.2. CBP/p300 
Cited2 recruits the coactivators CBP/p300 to AP-2α in order to activate transcription.  
CBP and p300 are ubiquitously expressed and exhibit histone acetyl transferase (HAT) 
activity, which is involved in histone modification and also capable of acetylating 
transcription factors in order to modulate their functions (Kouzarides, 2000).  
Deletions of these proteins can result in cardiac, skeletal and neural tube closure 
defects (Yao et al., 1998; Oike et al., 1999).  Functional studies have demonstrated that 
the Cited2 and p300/CBP complex bind to the transactivation domain of AP-2α, 
activating the transcriptional activity of the protein in a dose-dependent manner 
(Braganca et al., 2003; Bamforth et al., 2001).  It has also been shown that p300 is 
capable of interacting with AP-2α independent of Cited2; however, this interaction 
alone is not sufficient to activate transcription, suggesting that this may be a secondary 
interaction required to stabilise the co-activation complex.  Removal of the HAT 
domain from p300 inhibits this interaction, without affecting the DNA binding ability of 
AP-2α, indicating that the HAT domain of p300 is not required to modulate 
transcription factor function in this instance  (Braganca et al., 2003).  Cited2 deficiency 
prevents activation of AP-2α, however, this can be rescued by ectopic expression of 
Cited2 (Bamforth et al., 2001) further indicating the requirement for this protein in AP-
2α activation.  
1.4.4. AP-2α in development 
Tcfap2a is frequently used as a marker of NCCs during their migration.  It is also 
expressed in the developing kidney, the retina, the progress zone of the limb bud and 
the surface ectoderm (Brewer et al., 2002).  AP-2α is also required in the melanocytes 
in mice and zebrafish (Knight et al., 2003; Brewer et al., 2004). 
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In the mouse expression of Tcfap2a begins at e8.5 in the surface ectoderm and 
presumptive cranial NCCs, from the midbrain to the start of the hindbrain. By e9.5, 
expression was observed in the post-migratory NCCs that form the mesenchyme of 
PAs 1-3 and the pharyngeal ectoderm of these arches, but not the endoderm or 
vascular epithelium.  Expression was also seen in the presumptive NCCs invading 
between the pharynx and distal OFT (Brewer et al., 2002).  At e10.5, expression was 
reduced in the first and second arch mesenchyme, however strong expression was 
seen in the surface ectoderm of these and more caudal arches.  Expression was also 
observed in the distal OFT.  By e11.5 expression becomes reduced throughout the 
embryo. 
Tcfap2a-/- mice display a number of defects, affecting craniofacial morphogenesis, limb 
development, neural tube closure and cardiac development (Figure 1.11) (Schorle et 
al., 1996; Zhang et al., 1996; Brewer et al., 2002).  These defects affect the viability of 
the mouse post-parturition, and mutant embryos generally die at or before birth, as a 
result of these congenital defects.  The most notable external characteristics of the 
phenotype are the severe craniofacial defects: absence of the eyes and mouth, and 
defects affecting the frontonasal process.  In addition, these embryos also present with 
anencephaly, in which the forebrain region of the neural tube is open, the forebrain is 
absent, and the remaining brain regions are exposed; and thoraco-abdominoschisis, in 
which the ventral body wall is absent, causing the thoracic and abdominal organs to be 
exposed.  Defects were also seen in limb development, resulting in the absence of the 
radius in the mature forelimb.  This is consistent with Tcfap2a expression in the 
developing limb bud.  Closer examination of these embryos indicated that the heart 
and kidneys were hypoplastic (Schorle et al., 1996; Zhang et al., 1996). 
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Figure 1.11: External phenotype of Tcfap2a
-/-
 mutant embryo at e15.5. 
(a) Tcfap2a mutant allele used to generate Tcfap2a
-/-
 mutant embryos.  An IRES-LacZ cassette was inserted into 
exon 7, generating a null allele. (b) Control (Tcfap2a
+/-
) and (c) mutant (Tcfap2a
-/-
) embryos, stained with X-gal. 
Tcfap2a
-/-
 mutant embryos have an open neural tube, craniofacial malformations and failed closure of the ventral 
body wall, resulting in the organs being exposed. h, heart. (Figure a based on information from Brewer et al., 2002; 
figures b and c taken from Brewer et al., 2002). 
1.4.4.1. AP-2α in cardiovascular development 
The cardiovascular abnormalities observed include a VSD in all embryos examined and 
OFT defects, such as DORV in a large proportion of embryos, and PTA in a minority.  In 
two embryos with DORV the VSD was sub-aortic and the embryos also showed signs of 
pulmonary atresia/stenosis and therefore were proposed by the authors to more 
accurately fit the criteria for TOF. In addition, a small number of embryos (5/15) also 
showed defects of the PAAs, including A-RSA, IAA-B and right dorsal aorta (Brewer et 
al., 2002).  Many of these cardiovascular defects are reminiscent of the malformations 
seen in studies of NCC ablation in both mouse and chicken models (see section 1.3.3).  
In addition, ventral body wall defects and exencephaly were also observed in a small 
proportion of NCC-ablation embryos. 
1.4.4.2. NCC-specific deletion of Tcfap2a 
Despite the similarities between NCC-ablation embryos and the phenotypes described 
for Tcfap2a-/- mouse embryos, the migration of the NCCs in the global knock-out 
occurs normally (Schorle et al., 1996; Zhang et al., 1996).  A conditional deletion of 
Tcfap2a from the NCCs resulted in a severe reduction of the Tcfap2a-/- phenotype.  The 
defects of neural tube closure were seen at much lower frequencies (6/39, ~15%) in 
these mutants, and no CCVM was described.  Most embryos with a NCC-specific 
deletion failed to thrive post-parturition, however, some were able to survive to 
Introduction 
37 
 
adulthood.  Perinatal death was attributed to cleft palate, causing respiratory 
problems and an inability to feed (Brewer et al., 2004). 
1.4.5. Other AP-2α mutations 
In addition to the multitude of defects observed in the mouse model as described 
above, a number of mutations have also been identified in other organisms and 
suggest a conserved function of the transcription factor AP-2α during development in 
these organisms.  
1.4.5.1. Humans 
Mutations in the human TFAP2A gene have been found to cause branchio-oculo facial 
syndrome (BOFS).  This disease is characterised by a branchial (or cutaneous) defect, 
abnormalities of the eyes and a distinct facial phenotype, and exhibits autosomal 
dominant inheritance (Milunsky et al., 2011). 
Many individuals with BOFS also present with cleft lip (cL), with or without cleft palate 
(cP), prematurely grey hair, kidney anomalies and mild mental retardation (reviewed in 
Milunsky et al., 2011).   In addition, an ectopically placed ‘dermal’ thymus has been 
described in a number of patients.  This is a phenotype caused by the ectopic 
placement of the thymic rudiments, which results in tumour-like skin lesions on the 
neck of the patients.  Upon excision of this tissue, it was identified that it was 
functional thymus tissue (Barr et al., 1989; Bennaceur et al., 1998; Drut and Galliani, 
2003).  It has been estimated that the incidence of this defect in BOFS is approximately 
30%, although in many case studies the presence or absence of the defect was not 
addressed (Lin et al., 2009; Milunsky et al., 2011). 
One study, analysing 37 BOFS patients at various ages, revealed a range of intellectual 
developmental anomalies, multiple incidences of partial syndactyly and a single case of 
congenital heart malformation in the form of an anomalous pulmonary venous return 
and an ASD (Gestri et al., 2009).  Two further patients have also been described with 
CCVM: another ASD (Milunsky et al., 2011) and one with signs of TOF (Reiber et al., 
2010).   Although the incidence of CCVM observed in BOFS patients is low, it is also of 
note that echocardiography is only performed in those patients suspected of 
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cardiovascular problems (approximately half).  Therefore, the actual prevalence of 
CCVM in these patients may be higher (Milunsky et al., 2011). 
BOFS is caused by mutations in the TFAP2A gene, many of which cluster in exons 4 and 
5, which encode parts of the DNA binding and dimerisation domains (Milunsky et al., 
2008; Milunsky et al., 2011).  It has therefore been suggested that the observed 
phenotypes may be due to the production of a dominant negative (DN) protein, 
capable of binding other isoforms of the AP-2 family and inhibiting their function.  
However, three cases (a father and his 2 children) were described with a heterozygous 
whole gene deletion (Gestri et al., 2009), suggesting that the molecular mechanisms of 
the disease are more complex than first thought. 
Additionally TFAP2A has been associated with the negative regulation of the T-box 
gene, TBX20, expression of which is increased in atrial and ventricular biopsies of 
patients with TOF.  The TBX20 promoter was found to contain AP-2 binding sites and 
its transcription was reduced in a luciferase assay when constructs encoding TFAP2A or 
TFAP2C were co-transfected (Hammer et al., 2008).  The TOF phenotype has also been 
observed in Tcfap2a-null mice (Brewer et al., 2002), suggesting conservation of 
function between species.   
1.4.5.2. Zebrafish 
Expression of tfap2a is first seen at 8 hpf in the non-neural ectoderm.  By 12 hpf 
expression has extended into the cardiac NC progenitors.  From 18 hpf expression is 
found in the pronephric duct, and by 24 hpf expression has spread to the NC-derived 
mesenchyme and ectoderm of PAs.  At 36 hpf tfap2a expression has extended to the 
optic tectum, the mid brain and hindbrain.  By 52 hpf expression is also observed in the 
retina, the lateral line of the organs, and the pectoral fins (Knight et al., 2003; Knight et 
al., 2005).  
A number of mutations in zebrafish, generated by a forward genetic screening 
approach, have been found to cause craniofacial defects and absent or aberrant PA 
cartilage formation.  Two of these lines, lockjaw (low) and mont blanc (mob) are the 
result of mutations in tfap2a (Neuhauss et al., 1996; Schilling et al., 1996; Knight et al., 
2003; Barrallo-Gimeno et al., 2004). Craniofacial defects in these lines include a ventral 
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protrusion of the jaw and the failure of the mesodermal and NC-derived trabeculae to 
fuse correctly to form the ethmoid plate.  This phenotype is analogous to a cleft palate 
in mammals, which is observed in NC-specific inactivation of murine AP-2α (Brewer et 
al., 2004) and in patients with BOFS (Lin et al., 2009; Milunsky et al., 2011).  Other 
elements of the phenotype include defects in the positioning of the cartilage derived 
from the first arch.  The derivatives of the second arch are also affected by mutation in 
tfap2a.  Both the hyosymplectic and ceratohyal cartilages, which derive from this arch 
are reduced and fuse to the cartilage of the first arch.  The more posterior 
ceratobranchial cartilages, which arise from the caudal arches (3-6) are severely 
reduced and disorganised (Neuhauss et al., 1996; Schilling et al., 1996; Barrallo-
Gimeno et al., 2004; Knight et al., 2003; Knight et al., 2005). 
Studies of tfap2a mutant zebrafish have also shown the presence of pericardial 
oedema, indicative of cardiovascular defects (O'Brien et al., 2004).  Some deficiencies 
in the development of the aortic arch has been observed in tfap2a mutants, however,  
the phenotype has not been studied further, and therefore revealed nothing regarding 
the impact of this upon normal cardiovascular development (Knight et al., 2003). 
1.5. Preliminary data 
Brewer et al. (2002) have demonstrated the fully penetrant cardiovascular defects 
observed in Tcfap2a-/- mutant embryos on a black swiss background.  In addition, this 
group also investigated a conditional deletion of Tcfap2a from the NCCs, but failed to 
identify any cardiovascular defects in these mutant embryos (Brewer et al., 2004).   
Work in our group, examining Tcfap2a-/- mutant embryos on a congenic C57BL/6J 
background has also revealed a fully penetrant cardiovascular phenotype affecting the 
formation of the interventricular septum, OFT and the PAAs.  In addition, a conditional 
deletion of Tcfap2a from the NCCs, on this genetic background, also indicated a 
number of defects affecting these regions.  As this work forms the basis for much of 
the work within this thesis, this preliminary data will be presented here. 
1.5.1. Tcfap2a-/- embryos  
Preliminary work in our group (Dr Simon Bamforth) utilised the Tcfap2a-null allele 
created by Brewer et al. (2002).  Mice were crossed onto a C57BL/6J background, to 
Introduction 
40 
 
limit the effect of genetic modifiers which would confound results, and the phenotypes 
of homozygous mutants were examined.  
A number of cardiovascular defects were observed in these mutant embryos including 
VSDs, OFT defects (DORV, TGA and OA) and PAA defects (IAA-B, A-RSA, CORSA and 
cAoA), which were not seen in control embryos (Figure 1.12).  Overall, each embryo 
had an OFT defect and VSD, as described previously (Brewer et al., 2002).  In addition, 
each embryo also presented with a PAA malformation.  This is a dramatic increase  in 
prevalence compared to the PAA malformation observed previously (33% PAA 
defects).  The increase in the penetrance of PAA defects in this dataset is likely due to 
the change in genetic background.  These results indicate a 100% penetrance of CCVM 
in the Tcfap2a-/- embryos examined here, on a ~95% C57BL/6J background.   
 
Figure 1.12: 3D reconstructions of cardiovascular phenotypes in Tcfap2a
-/-
 mutant embryos. 
Cardiovascular phenotypes of control (Tcfap2a
+/+
) and mutant (Tcfap2a
-/-
) embryos.  (a) Ventral view of control 
embryo heart showing normal development of the cardiovascular system.  (b) Ventral view of a mutant embryo 
with VSD, OA, CORSA and cAoA.  (c) Mutant embryo with RAA, TGA and VSD.  (d) Mutant embryo with VSD, DORV 
and CORSA.  (e) Dorsal view of a control embryo showing normal cardiovascular development.  (e) Dorsal view of a 
mutant embryo with A-RSA and IAA. Scale bar = 500 μm.  Images provided by Dr Simon Bamforth.  RCC, right 
common carotid artery; RSA, right subclavian artery; Ao, aorta; Tr, trachea; LCC, left common carotid artery; LSA, 
left subclavian artery; PT, pulmonary trunk; dAo, dorsal aorta; RV, right ventricle; LV, left ventricle. 
1.5.2. NCC-specific deletion of Tcfap2a 
As the work above demonstrates, changing the genetic background in the Tcfap2a-/- 
mutant embryos resulted in an increase in the penetrance of CCVM.  Therefore, our 
group chose to investigate how the change in genetic background could affect the 
prevalence of CCVM in the conditional deletion from the NCCs.   
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Examination of mutant embryos on a 72.55% C57BL/6J background identified neural 
tube defects and a number of cardiovascular defects.  Exencephaly was observed in 
45% (4/9) of mutant embryos (Figure 1.13e).  Cardiovascular defects in the form of 
VSD (Figure 1.13f-g), TGA (Figure 1.13g) and A-RSA (Figure 1.13h) were observed in 
55% (5/9) of mutant embryos.  
 
Figure 1.13: Preliminary data suggests a Wnt1cre-mediated deletion of Tcfap2a results in severe CCVM. 
Control (Tcfap2a
+/f
 or Tcfap2a
+/f
;Wnt1cre) (a-d) and mutant (Tcfap2a
f/-
;Wnt1cre) (e-h) embryos on a 72.55% 
C57BL/6J background were collected at e15.5.  Externally control embryos were phenotypically normal (a), whereas 
mutant embryos often had exencephaly (Ex) and oedema (Ed) along the spine (e).  Examination by MRI revealed 
VSD in a number of mutants (f) that were not observed in controls (b).  3D reconstructions were created from the 
MRI datasets for controls (c, d) and mutants (g, h) and further defects such as TGA (g) and A-RSA (h) were identified. 
Scale bar = 500 μm.  Figure provided by Dr Simon Bamforth.  
1.6. Aims and objectives 
AP-2α is required in the mouse for correct development of many structures, and for 
perinatal life.  Deletions of this gene have been found to cause severe craniofacial 
malformations and cardiovascular defects, which result in death at, or before, birth 
(Zhang et al., 1996; Brewer et al., 2002).  However, the precise role of AP-2α in the 
pathways required for development is yet to be defined.  Tcfap2a-/- mutant embryos 
exhibit a cardiovascular phenotype similar to that seen in NCC ablation experiments 
(Brewer et al., 2002) (see section 1.5.1), while a NCC-specific conditional deletion of 
Tcfap2a showed no cardiovascular phenotype (Brewer et al., 2004).   
However, further work in our group has indicated that Tcfap2a is important in PAA 
formation on a C57BL/6J background.  In addition, it appears that upon breeding to a 
C57BL/6J background a proportion of the CCVM can be recapitulated through 
conditional deletion from the NCCs. 
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The aims of this thesis are as follows: 
1) To investigate the role of Tcfap2a within the NCCs on a congenic C57BL/6J 
background. 
2) To investigate the role of genetic background in the variation of CCVM 
observed. 
3) To investigate the role of Tcfap2a in PAA formation and remodelling 
4) To investigate potential transcriptional targets of Tcfap2a in cardiovascular and 
PAA development. 
1.6.1. The role of Tcfap2a in NCCs on a congenic C57BL/6J background 
Our preliminary work indicates that genetic background is an important factor in the 
penetrance of CCVM in Tcfap2a mutant embryos.  We have demonstrated a number of 
PAA malformations in mutant embryos with a NCC-specific deletion of Tcfap2a on a 
72% C57BL/6J background.  In addition, a fully penetrant cardiovascular phenotype, 
including PAA malformations, was also identified in Tcfap2a-/- mutant embryos on a 
congenic C57BL/6J background.   
This chapter, therefore, aims to investigate the NCC-specific deletion of Tcfap2a on a 
congenic C57BL/6J background, to determine the level of CCVM observed in these 
mutant (Tcfap2af/-;Wnt1cre) embryos.  In addition, we also aim to investigate any 
changes in NCC behaviour that may occur in the Tcfap2a-null embryos, using lineage 
tracing techniques.   
1.6.2. The role of genetic background in CCVM observed in Tcfap2a mutants 
The genetic background appears to be important in the penetrance of PAA 
malformation in Tcfap2a-/- embryos, and in CCVM in general in the NCC-specific 
deletion of Tcfap2a.  We aim to further investigate how changes in genetic background 
can affect the penetrance of cardiovascular and PAA malformation in Tcfap2a mutants. 
1.6.3. Tcfap2a in PAA formation and remodelling 
The preliminary data presented above indicates an increase in the prevalence of PAA 
malformation on a congenic C57BL/6J background compared to that previously 
observed by Brewer et al. (2002).  Therefore, I aim to exploit this fully penetrant 
phenotype in order to investigate the role that Tcfap2a plays in PAA development and 
the molecular processes that are disrupted when Tcfap2a is removed. 
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1.6.4. Tcfap2a transcriptional targets in PAA development 
Although a number of genes have been suggested to be regulated by Tcfap2a, the 
majority of these targets have been suggested based on the role of Tcfap2a in cancer 
progression.  However, a number of these target genes have roles in basic cellular 
processes, such as proliferation and apoptosis.  Therefore, I aim to investigate the 
differential expression of these target genes in the Tcfap2a wild type and null PA 
region.  In addition, potential transcriptional targets will be further investigated to 
validate the differential expression, by investigating the expression of related genes 
and genetic interaction experiments. 
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Chapter 2. Materials and Methods 
All reagents were purchased from Sigma Aldrich, unless otherwise stated. 
2.1. General reagents 
Many reagents were common to multiple protocols and were used throughout the 
work contained within this thesis.  These general reagents are listed here.  Other 
reagents which were specific to individual protocols are listed with the appropriate 
section below.  
2.1.1. Phosphate buffered saline 
Phosphate buffered saline (PBS) was prepared from tablets (Oxoid, BR0014).  10 
tablets were dissolved in 1 litre of distilled water (dH2O) and autoclaved before use. 
2.1.2. RNase-free PBS 
1 litre PBS was prepared as described above.  This was then treated with 0.1% volume 
per volume (v/v) diethyl pyrocarbonate (DEPC) overnight and then autoclaved. 
2.1.3. Paraformaldehyde 
Fixation of all embryos was carried out in 4% weight per volume (w/v) 
paraformaldehyde (PFA) dissolved in DEPC-PBS with 7.5 mM sodium hydroxide 
(NaOH), unless otherwise stated. 
2.2. Mouse lines 
Throughout this study we used a number of mouse lines in the generation of mutant 
and control embryos between the ages of e7.5 and e15.5.  Embryonic age was 
calculated based on the assumption that embryos were e0.5 at noon on the day of 
detection of the copulatory plug.  All adult mice were kept in a 12-hour light/dark 
cycle.  Wild type mice were purchased from Jackson Laboratories. 
2.2.1. Tcfap2aLacZ  
The Tcfap2a-null allele, generated by the insertion of an internal ribosome entry site 
(IRES)-LacZ cassette into the coding sequence of this gene (Brewer et al., 2002), was a 
gift from Prof. Trevor Williams (University of Colorado School of Medicine).  This allele 
interrupts the final exon (exon 7) of the gene, causing a disruption of the DNA binding 
and dimerisation domains which are essential for AP-2α function.  In addition, the 
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inclusion of the IRES-LacZ cassette into the gene allows the translation of β-
galactosidase, under the control of the Tcfap2a promoter.  In the presence of the 
substrate 5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-gal), those tissues 
expressing β-galactosidase will be stained blue, therefore also allowing the expression 
pattern of the gene to be monitored (see section 2.6). 
The Tcfap2aLacZ allele, from here on referred to as the Tcfap2a-null allele was crossed 
to wild type C57BL/6J mice for several generations in order to generate heterozygotes 
(Tcfap2a+/-) on a congenic background.  Heterozygotes were then crossed together in 
timed matings to generate homozygous null (Tcfap2a-/-) embryos for downstream 
analysis. 
2.2.2. Tcfap2aflox  
To further examine the importance of Tcfap2a in cardiovascular development, a 
conditional allele, Tcfap2aflox, was also utilised.  This mouse was also given to us by 
Prof. Trevor Williams.  This allele includes two loxP sites inserted by homologous 
recombination upstream of exon 5 and downstream of exon 6 (Brewer et al., 2004).  In 
the presence of Cre recombinase, the loxP sites undergo recombination to remove the 
intervening exons.  
2.2.3. Cre lines 
In addition to the Tcfap2a alleles described above, a number of cre lines were also 
used to produce conditional deletions of Tcfap2a.  These cre lines are listed in Table 
2-1.   
Table 2-1: Expression domains of Cre lines used in this project compared to Tcfap2a. 
Expression 
domains 
Tcfap2a Wnt1cre Nkx2.5cre Foxg1cre PGKcre Sox2cre 
SHF       
Myocardium       
Ectoderm       
Endoderm       
Mesoderm       
NCCs       
Reference(s) Brewer et 
al., 2002 
Danielian 
et al., 1998 
Moses et 
al., 2001 
Hebert and 
McConnell, 
2000 
Lallemand et 
al., 1998 
Hayashi et 
al., 2002 
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2.2.3.1. Wnt1cre  
Cre recombinase under the control of a Wnt1 enhancer (Wnt1cre; Danielian et al., 
1998) was used for conditional deletion of Tcfap2a from the NCCs.  This cre line was 
created by random integration of the transgene into the genome.  Wnt-1 expression 
begins from e8.0, within the midbrain, and extends into the hindbrain and forebrain by 
e8.5.  Expression continues in the derivatives of the cranial NC, with expression in the 
mesenchyme of the PAs observed from e9.25 (Echelard et al., 1994).  Activation of a 
reporter construct activated by Wnt1cre-mediated recombination was observed from 
e8.5 (Danielian et al., 1998). 
2.2.3.2. Nkx2.5cre 
Nkx2.5cre is a ‘knock-in’ cre line, in which the Cre cDNA has been inserted directly into 
exon 2 of the Nkx2.5 locus.  This allows cre expression to be controlled directly by the 
endogenous gene; however, it results in the disruption of one allele of Nkx2.5, 
therefore reducing this gene to heterozygosity.  This cre line is expressed within the 
cardiac crescent from e7.5.  Expression continues in the myocardium during looping 
(e8.5-e9.0) and is also expressed in the ectoderm of the developing first PA from this 
time (Moses et al., 2001). Nkx2.5cre was used to remove Tcfap2a from the PSE. 
2.2.3.3. Foxg1cre 
Foxg1cre is also a knock-in allele.  This drives expression of cre from e8.5, within the 
anterior tip of the head folds and the underlying ectoderm. By e9.5, expression is 
observed in the PSE and by e10.5 throughout the foregut region (Hebert and 
McConnell, 2000).  Therefore, this construct will remove Tcfap2a in the surface 
ectoderm of the PA region.  
2.2.3.4. PGKcre 
The PGKcre transgene was generated by cloning the PGK-1 promoter upstream of the 
Cre gene and introduced by microinjection (Lallemand et al., 1998).  The transgenic 
construct was incorporated into the genome by random integration.  Expression of this 
transgene is ubiquitous and will overlap with Tcfap2a in all tissues.  The PGK-1 locus 
becomes active from e3.5 (McBurney et al., 1994), therefore, recombination of the 
Tcfap2a locus should occur long before endogenous Tcfap2a expression begins at e8.5 
(Brewer et al., 2002). 
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2.2.3.5. Sox2cre 
The Sox2cre transgene was generated by the insertion of the Cre gene downstream of 
a 12.5 kb Sox2 promoter sequence (Hayashi et al., 2002). The transgene was 
microinjected into mouse pronuclei and was incorporated into the mouse genome by 
random integration.  Expression of the Sox2cre was confirmed from e6.5 in all cells of 
the epiblast, but was excluded from extra-embryonic tissues.  Therefore, this Cre line 
will conditionally delete Tcfap2a from all embryonic tissues, prior to activation of the 
Tcfap2a promoter. 
2.2.4. Reporter lines 
The expression pattern of Wnt1cre was examined using either a LacZ or enhanced 
yellow fluorescent protein (EYFP) construct introduced into the Rosa26 locus (R26RLacZ 
(Soriano, 1999), R26REYFP (Srinivas et al., 2001)).  These constructs contain a 
transcriptional stop sequence flanked by loxP sites, which is removed in the presence 
of Cre recombinase, therefore, allowing the expression of the LacZ and EYFP constructs 
in these tissues.  The expression patterns of the Cre lines may then be visualised by X-
gal staining for the expression of the LacZ construct (see section 2.6) in the R26RLacZ 
allele.  Alternatively, recombination in R26REYFP embryos was visualised using 
fluorescence immunohistochemistry on sectioned embryos (see section 2.5.5). 
2.2.5. Dlx5-CreERT2 
In order to investigate the potential genetic interaction between Tcfap2a and Dlx5, 
Dlx5 Cre-ERT2 mice were purchased from Jackson laboratories (#010705).  
Homologous recombination was used to introduce the CreER cDNA at the translation 
initiation site of the Dlx5 gene (Taniguchi et al., 2011).  This strain is, therefore, 
heterozygous for Dlx5 and may be used in the generation of compound heterozygotes 
by breeding with Tcfap2a+/- mice.  In this thesis, the Dlx5 Cre-ER mouse is used only as 
a null allele of Dlx5 and will, therefore, be referred to as Dlx5- from here on. 
2.2.6. Calculating genetic background 
Throughout this thesis all mice were maintained on a C57BL/6J background.   The 
genetic background of all mice used was between 93-99%.  The genetic background of 
each embryo used in this work was calculated as the average of the genetic 
backgrounds of both parents.  The genetic background of wild type mice was assumed 
to be 100% C57BL/6J.  The genetic background of mice obtained from other groups, 
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which had been inbred onto a C57BL/6J background for numerous generations was 
presumed to be 99% C57BL/6J. 
2.3. Genotyping 
2.3.1. DNA extraction 
DNA extraction of sample tissues was carried out using proteinase K digestion.    The 
lysis buffer was prepared by diluting proteinase K to a final concentration of 600 µg/ml 
in proteinase K buffer (50 mM potassium chloride (KCl), 1.5mM magnesium chloride 
(MgCl2), 10 mM Trizma base (tris) pH 8.5, 0.45% v/v Igepal® CA-630, 0.45% v/v Tween-
20).   This was added to the samples and incubated at 56°C for 2 hours, or until the 
sample had completely lysed.  The samples were vortexed intermittently to ensure 
complete breakdown of the tissues and release of the DNA.  Proteinase K was heat 
inactivated by incubating at 95°C for 10 minutes. The lysed sample was centrifuged at 
full speed for 1 minute to collect any debris and stored at 4°C until use. 
The volume of lysis buffer prepared was dependant on the tissue to be lysed.  For 
weaned mice, an ear punch was collected and lysed in 150 µl lysis buffer.  For 
genotyping embryos at mid-embryogenesis (e8.0-11.5), the yolk sac was collected and 
lysis buffer volume was dependant on the size of the sample (see Table 2-2).  For the 
genotyping of late-gestation embryos (e14.5-15.5) the left forelimb was collected for 
lysis.   
Table 2-2: Volume of lysis buffer used in DNA extraction of various samples. 
Sample to be lysed Volume of lysis buffer 
e7.5 extra-embryonic material 15 μl 
e8.0 yolk sac 25 μl 
e8.5 yolk sac 30 µl 
e9.5 yolk sac 50 µl 
e10.5 yolk sac 100 µl 
e11.5 yolk sac 200 µl 
e14.5/15.5 forelimb 400 µl 
ear notch 150 µl 
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2.3.2. Polymerase chain reaction 
Genotyping was carried out using the polymerase chain reaction (PCR) to identify the 
presence or absence of the gene of interest.  All primers were designed by Dr Simon 
Bamforth or the lab responsible for generating the mouse strain and all PCR 
programmes have been optimised previously. 
PCR reactions were carried out using GoTaq polymerase (Promega) and the associated 
buffer with the following reaction conditions: 1 unit GoTaq polymerase, 1x GoTaq 
reaction buffer (contains 1.5 mM MgCl2), 0.25mM each deoxyribonucleotide 
triphosphate (dNTP) (Fisher), 0.5 µM forward primer, 0.5 µM reverse primer and 2 µl 
cell lysate prepared as above (section 2.3.1).   
Samples were then incubated in a thermocycler for 35 cycles.  The exact programme 
used for each primer pair was dependant on the size of the amplification product and 
the annealing temperature of the primers. 
2.3.3. Gel electrophoresis 
PCR products were analysed by gel electrophoresis.  1% w/v agarose (Lonza) was 
added to tris-acetic acid-ethylenediaminetetraacetic acid (EDTA) buffer (TAE) (40mM 
tris, 20mM acetic acid, 1mM EDTA) and heated to dissolve.  Once the agarose solution 
had cooled, ethidium bromide (EtBr) was added to a final concentration of 0.5µg/ml. 
The agarose was poured into a cast and allowed to set before adding the PCR samples.  
PCR products were run alongside a GeneRuler™ 100 bp or 1 kb DNA ladder (Fisher 
Scientific) at 100 volts (V) for 30-60 minutes, until the bands had fully resolved.  The 
gel was then imaged under UV light. 
2.4. Embryo dissection 
For those embryos collected at mid-gestation (e8.5-11.5), the general dissection 
procedure is described here; however, some applications required variations of this 
protocol.  These variations are given in the descriptions of these applications.  For 
embryos at late gestation the dissection procedure is described later (see section 
2.7.1). Pregnant dams were sacrificed by cervical dislocation, and the uterus was 
removed and submersed in ice-cold PBS.  Deciduates were removed from the uterus 
using vannas scissors and forceps (InterFocus).  The yolk sac was removed and retained 
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for genotyping.  Embryos were fixed in 4% PFA, unless otherwise stated.  Fixation was 
carried out overnight for embryos aged e9.5-11.5 and for a minimum of 4 days for 
e15.5 embryos. 
2.5. Histology 
2.5.1. Wax embedding 
Fixed embryos were briefly rinsed in PBS then dehydrated through a series of ethanol 
solutions at room temperature.  Embryos were cleared in Histoclear (National 
Diagnostics, #HS-200), then a 1:1 solution of Histoclear:paraffin wax (VWR) at 60°C, 
before embedding in paraffin wax.  The incubation times varied with the age of the 
embryos and are shown in Table 2-3. 
Table 2-3: Dehydration and processing protocol for the wax embedding of fixed embryos. 
 E9.5 E10.5 E11.5 E14.5 E15.5 
50% Ethanol 30 minutes 30 minutes 1 hour 3 hours 3 hours 
70% Ethanol x2  30 minutes 
30 minutes 
30 minutes 
30 minutes 
1 hour 
1 hour 
3 hours 
3 hours 
3 hours 
3 hours 
95% Ethanol 30 minutes 30 minutes 1 hour 3 hours 3 hours 
100% Ethanol 
x2  
30 minutes 
30 minutes 
30 minutes 
1 hour 
1 hour 
1 hour 
3 hours 
Overnight 
3 hours 
Overnight 
Histoclear x2  10 minutes 
10 minutes 
15 minutes 
15 minutes 
20 minutes 
20 minutes 
20 minutes 
20 minutes 
30 minutes 
30 minutes 
Histoclear/wax  15 minutes 20 minutes 20 minutes 1 hour 1 hour 
Wax x3/4  
(Heated: 60°C) 
20 minutes 
20 minutes 
20 minutes 
30 minutes 
30 minutes 
30 minutes 
40 minutes 
40 minutes 
40 minutes 
1 hour 
1 hour 
1 hour 
1 hour 
1 hour 
1 hour 
1 hour 
1 hour 
 
2.5.2. Sectioning 
Embedded embryos were sectioned using a Leica RM 2235 microtome.  Sections were 
cut at 8µm. For embryos at e9.5-11.5 embryos, were embedded in a coronal 
orientation and sections were stretched using a water bath at 37°C and collected on a 
glass microscope slide (VWR).  Slides were dried for a few minutes on a hot plate 
(37°C) then transferred to a slide oven at 40°C for overnight drying. For embryos aged 
e14.5-15.5 embryos were embedded in a transverse orientation.  Sections were 
stretched by placing onto a slide coated with water and heating on a hot plate, until all 
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water had evaporated.  Once dry, slides were transferred to the 40°C oven overnight 
to dry, to ensure sections were firmly adhered prior to staining. 
2.5.3. Haematoxylin and eosin staining 
Haematoxylin and eosin staining was used to identify any morphological changes 
within embryos.  Haematoxylin stains the cell nuclei purple, while eosin stains the 
cytoplasm pink.   
Slides were submersed in Histoclear twice for 10 minutes each to remove wax from 
the sections.  The sections were then incubated in 100% ethanol twice for 3 minutes, 
followed by rehydration through 90%, 70% and 50% ethanol solutions, and then 
washed in dH2O for 2 minutes each.  The sections were then stained in Harris’ 
haematoxylin solution for 10 minutes.  Excess haematoxylin was washed away with 
running water for 5 minutes, then slides were dipped in an acid alcohol solution (1% 
v/v hydrochloric acid (HCl), 70% ethanol) to remove the stain from all tissues except 
the nucleus and returned to the running water for a further 5 minutes.  The slides were 
then incubated in eosin (Fisher Scientific) for 5 minutes, rinsed in running water and 
dehydrated by dipping in 50%, 70% and 90% ethanol.  The slides were then transferred 
to 100% ethanol for 3 minutes, twice, and incubated twice in Histoclear for 10 
minutes.  Slides were mounted in Histomount (National Diagnostics) and dried 
overnight.  Sections were imaged using a Zeiss Axioplan2 microscope and associated 
software. 
2.5.4. Slide immunohistochemistry 
Immunohistochemistry for platelet endothelial cell adhesion molecule-1 (PECAM-1; 
CD-31) was carried out on coronal sections of mutant and heterozygous embryos at 
stages e9.5, e10.5 and e11.5.  Embryos were dissected as described above (section 2.4) 
and fixed in zinc fixative (BD Pharmingen) overnight.  Embryos were embedded in 
paraffin wax and sectioned as described above (sections 2.5.1 and 2.5.2). 
Slides were de-waxed in Histoclear, twice for 10 minutes each, followed by rehydration 
through an ethanol series (2 x 100%, 90%, 70%, 50%), for 2 minutes in each solution.  
Slides were equilibrated in PBS solution for 5 minutes, then incubated in 3% v/v 
hydrogen peroxide (H2O2) for 5 minutes.  Slides were rinsed in dH2O and Tris-buffered 
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saline with Triton-X 100 (TBS-TX; 100mM Tris-HCl, pH 7.5, 150mM sodium chloride 
(NaCl), 0.5% v/v Triton-X 100), followed by blocking in 10% v/v foetal bovine serum 
(FBS) in TBS-TX for 30 minutes. 
The primary antibody, purified rat anti-mouse CD-31 (# 553370, BD Pharmingen) was 
prepared at a 1:50 dilution (final concentration of 0.01 µg/µl) in 2% FBS in TBS-Tx.  100 
µl was applied to each slide, and covered with a parafilm coverslip, then incubated at 
4°C in a humidified chamber overnight. 
Following overnight incubation in primary antibody, the slides were washed in TBS-Tx 
then incubated for 1 hour in a humidified chamber at room temperature, in 
biotinylated rabbit anti-rat secondary antibody (Dako), prepared at 1:300 dilution in 
2% FBS/TBS-Tx.  The avidin-biotin (AB) complex (Vector) was prepared by the addition 
of 1 drop each of solutions A and B to 5ml of 50 mM Tris HCl, pH 7.5.  Slides were 
washed in TBS-Tx, before the application of the AB complex .  Following a 30 minute 
incubation with the AB complex, slides were washed again in TBS-Tx, then incubated in 
filtered 3,3’-diaminobenzidine (DAB) solution, prepared according to manufacturer’s 
instructions for 30 minutes, or until brown staining developed.  The reaction was 
stopped by placing the slides in PBS and the slides were then counterstained with 
methyl green (0.5% w/v methyl green, 0.1M sodium acetate pH 4.2), rinsed in dH2O 
and butanol, washed in Histoclear (twice for 10 minutes each) and mounted in 
Histomount.  Slides were imaged using a Zeiss Axioplan2 microscope.   
2.5.5. Slide immunofluorescence 
Embryos were collected at e10.5 and e11.5, fixed in 4% PFA, dehydrated through an 
ethanol series, embedded in paraffin wax in a coronal orientation and sectioned, as 
described above (sections 2.5.1 and 2.5.2).  Slides were de-waxed in Histoclear for 5 
minutes twice, then rehydrated through an ethanol series for 2 minutes in each 
solution and equilibrated in PBS.  Antigen retrieval was performed using 0.01M citrate 
buffer (pH 6), heating in the microwave for 10 minutes and cooling at room 
temperature for 10 minutes then under running water for a further 10 minutes. For 
AP-2α immunofluorescence carried out by Kathleen Allinson, slides were immersed in 
citrate buffer in a pressure cooker at 80 kilo Pascals (kPa) for 5 minutes, followed by 
cooling as described above. The slides were then washed in PBS three times for 5 
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minutes each, before blocking in a 10% FCS in PBS solution.  100 µl of primary antibody 
in 2% FCS/PBS was added at the dilutions shown in Table 2-4.  Each slide was covered 
with a parafilm coverslip and incubated overnight at 4°C in a humidifying chamber. 
Primary antibody was removed by washing three times in PBS for 5 minutes each.  The 
slides were then incubated in secondary antibodies diluted in 2% FCS/PBS for 1 hour at 
room temperature, in a humidified chamber.  The secondary antibody corresponding 
to each primary antibody, and the dilution used are shown in Table 2-4. 
Primary antibody Concentration Secondary antibody Concentration 
Chicken anti-GFP 
(Abcam, ab13970) 
1:100 Alexafluor 488 goat 
anti-chicken IgG 
(Invitrogen, A11039) 
1:200 
Mouse anti-α-smooth 
muscle actin (Sigma, 
A5228) 
1:400 Alexafluor 594 donkey 
anti-mouse IgG 
(Invitrogen, A21203) 
1:200 
Mouse anti-AP-2α (3B5, 
santa cruz biotechnology  
sc-12726) 
1:50 Alexafluor 594 donkey 
anti-mouse IgG 
(Invitrogen, A21203) 
1:200 
Cleaved Caspase3 
(Asp175) antibody 
(9661, Cell Signalling 
Technology) 
1:300 Alexafluor 594 donkey 
anti-mouse IgG 
(Invitrogen, A21203) 
1:200 
Anti-phospho-Histone 
H3 (Ser10) antibody (06-
570, Millipore) 
1:500 Alexafluor 594 donkey 
anti-mouse IgG 
(Invitrogen, A21203) 
1:200 
 
Slides were then washed three times in PBS for 5 minutes each before mounting in 
Vectashield with 4',6-diamidino-2-phenylindole (DAPI) (Vector laboratories LTD, 
H1500).  Slides were analysed on a Zeiss Axioimager microscope, using the associated 
software. 
2.5.6. Cell counting 
Cell counting was performed on images of sections stained using the 
immunofluorescence technique described above (section 2.5.5).  All cell counts were 
performed using ImageJ software (available from http://rsbweb.nih.gov/ij/) using the 
cell counter feature.  Data was analysed in Microsoft Excel (Microsoft) to obtain 
average cell counts for each embryo and statistical analysis in the form of a student’s  
Table 2-4 : Primary and secondary antibody concentrations used for immunofluorescence. 
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t-test was carried using the Prism 6 statistical package (available from 
http://www.GraphPad.com). 
2.5.6.1. Apoptosis and proliferation 
The apoptotic and proliferative index was calculated for the fourth PA only.  Three 
control and three mutant embryos were examined for each process, with 1-3 images 
of the left and right fourth PAs being counted in each case.  Images were cropped to 
230 μm x 230 μm squares with the centre of the fourth PAA at the centre point of the 
image.  Cell counts were obtained for the total number of cells, ectodermal cells, 
endodermal cells, NCCs (marked with anti-GFP antibody) and other cell types 
(endothelium and mesoderm).  The average cell count for each of these tissues in each 
embryo was calculated, as was the average for each tissue in both the left and right 
fourth PA.  These averages were compared and used in statistical analysis.   
2.5.6.2. NCC density 
To determine the density of cells within the fourth PA, three 100 μm x 100 μm squares 
were taken from each image analysed for apoptosis and proliferation (see section 
2.5.6.1).  The total number of cells and the number of NCCs within each image was 
counted and the average cell count for each image determined.  The average number 
of cells for each PA (left and right) and the total number of cells for each embryo was 
then calculated and used for comparison and statistical analysis. 
2.6. β-galactosidase staining 
For whole mount β-galactosidase staining, transgenic mice were collected at e8.5-
e10.5.  Embryos were dissected in ice-cold PBS and lightly fixed in 0.2% v/v 
glutaraldehyde, 2 mM MgCl2, 0.1 M phosphate buffer (77.4 mM sodium phosphate 
dibasic (Na2HPO4), 22.6 mM sodium phosphate monobasic (NaH2PO4), pH 7.3) for 20 
minutes at room temperature.  Embryos were washed in a detergent rinse (2 mM 
MgCl2, 0.01% w/v sodium deoxycholate, 0.02% Igepal® CA-630, in 0.1 M phosphate 
buffer, pH 7.3) three times for 15 minutes each then the X-gal staining solution was 
added (0.1% w/v X-Gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 
mM MgCl2, 0.02% Igepal® CA-630, 0.01% sodium deoxycholate, 0.02 M Tris pH 7.3).  
Embryos were incubated in the staining solution in the dark, at room temperature 
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overnight with agitation.  The following day, the staining solution was removed and 
embryos were rinsed in PBS several times before photographing. 
2.7. Magnetic resonance imaging 
Magnetic resonance imaging (MRI) was carried out on e15.5 embryos to identify 
morphological changes as an alternative to haematoxylin and eosin staining. 
2.7.1. Dissection and processing 
Embryos at e15.5 were collected and dissected in Hanks’ balanced salt solution with 
5mM EDTA, warmed to 37°C.  The dissection procedure was performed on a heated 
mat to ensure that solutions and embryos were kept warm at all times.  Embryos were 
dissected from the uterus, then the yolk sac was removed and discarded.  The 
umbilical vessels were cut and embryos were allowed to bleed out.  Care was taken to 
ensure that any clots were removed immediately to allow the embryos to bleed out 
fully, as the presence of blood limits the contrast in MRI scans.  Embryos were washed 
twice in PBS, then the left forelimb was removed for genotyping and to allow easy 
identification of the left side of the embryo in analysis of the MRI images obtained.  
Slits were made in the skin beneath the forelimbs to allow sufficient penetration of the 
fixative.  The embryos were then fixed in 4% PFA containing 4 µl/ml Magnevist® 
(gadopentetate dimeglumine, Gd-DTPA) for a minimum of 4 days at 4°C before loading 
into the MRI tube. 
2.7.2. MRI tube preparation 
MRI tubes were prepared as described previously (Bamforth et al., 2012b).  The MRI 
tube consists of a nuclear magnetic resonance tube (outer diameter 28mm; 
Fluorochem, UK) containing a teflon disk attached to a nylon rod to allow the embryos 
to be removed from the tube after scanning. 
32 embryos (8 layers, 4 embryos per layer) were loaded into the MRI tube by 
embedding in agarose (1% agarose w/v in dH2O, heated to dissolve) containing the 
contrast reagent Magnevist® (4µl/ml).  The tube was sealed with a lid and parafilm to 
prevent the agarose from drying out and shipped on ice packs to Oxford for scanning. 
MRI scanning was carried out by Dr Jurgen Schneider (University of Oxford) and the 
embryos and images collected as a series of tagged image format (.tiff) files.    
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2.7.3. MRI data analysis and 3D reconstructions 
The collected .tiff stacks can be analysed through AMIRA software (FEI Visualization 
Science Group).  The voxel size used was: x-25.4, y-25.4, z-24.4.  The .tiff stack for each 
layer of the MRI tube was opened separately and a transverse view through the 
embryos was analysed, using the removed left forelimb for orientation purposes.  
Once all embryos had been analysed for gross morphological changes, 3D 
reconstructions were produced.  
The .tiff stack was cropped to include only the region of interest for the reconstruction, 
in order to minimise the file size.  The labelling tools within the program were then 
used to label each structure of the heart for reconstruction.  The hue, saturation and 
value levels for the colours used for each structure are shown in Table 2-5.   
Table 2-5: Hue, saturation and value levels of all colours used in MRI reconstructions. 
Structure Hue Saturation Value 
Aorta and aortic arch arteries 0.000 0.895 0.859 
Pulmonary arteries/ ductus arteriosus 0.549 0.585 0.965 
Trachea 0.376 0.161 0.949 
Left ventricular lumen 0.041 0.804 0.800 
Right ventricular lumen 0.667 0.506 1.000 
Exterior surface of the heart 0.500 0.127 0.800 
Background 0.611 0.000 0.000 
Outside surface of the embryo 0.111 0.514 1.000 
 
A 3D model of each structure may then be produced using the ‘SurfaceGen’ option 
with unconstrained smoothing.  The unconstrained smoothing option allows us to 
create a 3D representation only. 
2.8. Cloning 
2.8.1. Restriction enzyme digest 
All restriction enzymes, buffers and bovine serum albumen (BSA) were obtained from 
New England Biolabs.  1 μg plasmid DNA was digested in a 20 μl reaction mix 
containing: 20 units of restriction enzyme, 1x enzyme buffer, 1x BSA.  The digestion 
mix was incubated at 37°C for 2 hours. 
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2.8.2. PCR purification 
Purification of PCR and restriction digest reactions was carried out using a QIAquick 
PCR purification kit (QIAGEN), according to the manufacturer’s instructions.  Briefly, 
the sample to be purified was diluted in 5 volumes of the supplied buffer PB and then 
added to a QIAquick spin column and centrifuged at full speed to allow the DNA to 
adhere to the column surface.  The column was washed by adding buffer PE, 
containing ethanol, and centrifuged again at full speed.  The column was centrifuged a 
final time to ensure all of buffer PE had been removed then transferred to a fresh 
microcentrifuge tube for collection.  The sample was eluted in 30 µl of buffer EB.  To 
confirm the size of the purified sample, 5µl  was added to 1 µl of 6x loading dye 
(Fermentas) for gel electrophoresis (see section 2.3.3). 
2.8.3. NanoDrop spectrophotometry 
Quantification of DNA samples was carried out using a NanoDrop spectrophotometer 
(Thermo Scientific).  The NanoDrop channels were blanked using elution buffer and 1 
μl of each sample was loaded onto the pedestals.  Quantifications were given in ng/μl 
and quality was judged based on the absorbance at 260 nm divided by absorbance at 
280 nm (260/280 value).  A 260/280 value of 1.8 is considered high quality DNA.   
2.8.4. Luria Bertani broth and Agar plate preparation 
Luria Bertani (LB) broth was prepared with 171 mM NaCl, 1% w/v Tryptone (Oxoid) and 
0.5% w/v yeast extract (Fisher) in dH2O and autoclaved. 
Agar plates were prepared by the addition of 1.5% w/v of Agar (Fisher) to LB broth and 
autoclaving.  Agar was then cooled to 50°C and ampicillin was added to a final 
concentration of 50 μg/ml.  The agar was then poured into petri dishes (20-25 ml per 
dish) and allowed to set in the presence of a flame. 
2.8.5. Transformation 
Transformations were carried out using Subcloning Efficiency™ DH5α™ chemically 
competent Escherichia coli (E. coli) (Invitrogen) according to the manufacturer’s 
instructions.  1-10 ng of plasmid DNA was added to a 30 µl aliquot of competent cells 
and gently mixed, then incubated on ice for 30 minutes. Competent cells were heat-
shocked for 20 seconds in a 42°C water bath to encourage uptake of the plasmid DNA, 
then returned to ice for a further 2 minutes.  LB broth was preheated to 37°C and 970 
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µl was added to each vial of competent cells.  The competent cells were then 
incubated at 37°C in a thermomixer for 60 minutes with agitation.  The cells were then 
centrifuged at 3,000 x g for 10 minutes.  The pellet was resuspended in 100 μl LB broth 
and then spread onto an agar plate and incubated at 37°C for 16 hours.  After this time 
plates were stored at 4°C. 
2.8.6. Miniprep of plasmid DNA 
For miniprep of plasmid DNA, overnight cultures were prepared by inoculating 5ml of 
LB media containing ampicillin (50 μg/ml), with a single colony picked from an agar 
plate.  Cultures were incubated at 37°C for 16 hours with agitation.  The cultures were 
pelleted by centrifugation at 6,000 x g for 5 minutes at 4°C.  The miniprep protocol was 
then carried out using a QIAprep Spin Miniprep kit (QIAGEN) according to the 
manufacturer’s instructions.  Briefly, samples were resuspended in 250 μl buffer P1, 
lysed in buffer P2 and then neutralised by the addition of buffer N3.  The sample was 
centrifuged at 17,000 x g for 10 minutes to pellet cell debris and the supernatant was 
applied to a QIAprep spin column and centrifuged for 1 minute to allow binding of the 
plasmid DNA.  The DNA was washed in buffer PB, then buffer PE, with centrifugation 
for 1 minute after each step.  Plasmid DNA was eluted in 30 μl buffer EB.    
2.8.7. Midiprep of plasmid DNA 
Following transformation of competent E. coli cells and overnight incubation as 
described in 2.8.5 above, starter cultures were set up by inoculating 1ml of LB media 
containing 50 µg/ml of ampicillin with a single colony.  Starter cultures were incubated 
at 37°C for 8 hours with agitation.  Overnight cultures were then prepared in large 
flasks with a volume of 50 ml LB media containing 50 µg/ml of ampicillin.  100 µl of 
starter culture was added to each overnight culture, which were then incubated at 
37°C for a further 16 hours, with agitation. 
Cultures were transferred from flasks into 50 ml centrifuge tubes and centrifuged at 
6,000 x g for 15 minutes at 4°C.  The DNA was then extracted using a QIAGEN plasmid 
midi kit (QIAGEN), using the manufacturers recommended procedures.  Briefly, the 
supernatant was discarded and the pellet was resuspended in buffer P1.  The cells 
were lysed in buffer P2 for 5 minutes.  Chilled neutralisation buffer (buffer P3) was 
added and the samples were then incubated on ice for 15 minutes.  The samples were 
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transferred to a polypropylene centrifuge tube and centrifuged at 20,000 x g for 30 
minutes at 4°C in a Sorvall Evolution RC Superspeed centrifuge. The supernatant was 
immediately removed and centrifuged again at 20,000 x g at 4°C for 15 minutes to 
remove further particulate material.  The supernatant was then added to a supplied 
QIAGEN-tip 100, equilibrated using buffer QBT, and allowed to drain.  The column was 
washed twice with buffer QC and allowed to drain fully.   The plasmid DNA was then 
eluted in 5 ml of buffer QF.  The DNA was precipitated by the addition of 0.7 volumes 
of isopropanol and centrifuged at 15,000 x g for 30 minutes at 4°C.  The pellet was 
washed in 70% ethanol and centrifuged for a further 10 minutes at 15,000 x g at 4°C.  
The pellet was air-dried and redissolved in 100 µl Tris-EDTA (TE) buffer (10 mM Tris pH 
8.0, 1 mM EDTA) and stored at -20°C. 
The concentration of the plasmid DNA was determined by analysis on a NanoDrop 
spectrophotometer (see section 2.8.3). 
2.8.8. DNA sequencing 
Sequencing was performed to confirm that the correct plasmid DNA had been 
amplified.  A 20μl volume containing between 30-100 ng/μl of plasmid DNA was sent 
to GATC biotech for sequence analysis.  The sequence was returned in FASTA format 
and was analysed using a basic local alignment search tool (BLAST) (available online at: 
http://blast.ncbi.nlm.nih.gov/) to compare to all known sequences across the murine 
genome.  
2.9. Whole mount in situ hybridisation 
2.9.1. Probe preparation 
Plasmid probes were gifts from Prof. Giovanni Levi (Dlx5) and Dr. Albert Basson (Fgf8). 
Plasmids were digested using the appropriate enzyme (Table 2-6) as described above 
(see section 2.8.1).  Digested plasmid DNA was purified using a PCR purification 
method (see section 2.8.2), then quantified by spectrophotometry using a NanoDrop 
(see section 2.8.3). 
Probes were labelled using a digoxygenin (DIG) RNA labelling kit (Roche) as follows: 1 
μg linearised plasmid, 1x NTP labelling mix, 1x transcription buffer, 20 units of RNase 
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inhibitor, 40 units of polymerase (T7 or T3 (Roche) as in Table 2-6) in DEPC-H2O. The 
reaction was incubated at 37°C for 2 hours. 
Table 2-6:  Restriction enzymes and RNA polymerases used in the preparation of WISH probes. 
Probe Enzyme for linearisation RNA Polymerase 
Fgf8 antisense BamHI T7 
Fgf8 sense KpnI T3 
Dlx5 antisense EcoRI T7 
Dlx5 sense KpnI T3 
 
The probe was extracted using lithium chloride (LiCl), with the addition of 250 μl of ice-
cold 100% ethanol, 80 μl of DEPC-TE and 10 μl of 4M LiCl. The reaction was then 
incubated at -80°C for 2 hours or -20°C overnight. 
Following this incubation the samples were centrifuged at full speed for 30 minutes at 
4°C. The supernatant was removed and the pellet dried for 5-10 minutes at room 
temperature.  The probe was dissolved in 100 μl DEPC-TE and 40 units of RNase 
inhibitor (Thermo Scientific) added, then stored at -80°C.   
Probes were tested by electrophoresis on a 1% agarose gel with a 5 μl aliquot of probe 
mixed with 1 μl of loading dye and ran at 200V for 15 minutes.  The high voltage allows 
the sample to run with minimal degradation of the RNA.  
2.9.2. Embryo collection 
Embryos were dissected at e9.5 as described above (see section 2.4), in ice-cold DEPC-
PBS.  All tools and equipment were treated with RNase Away (Fisher) to remove all 
traces of RNases that may degrade the RNA of interest.  Embryos were fixed in 4% 
DEPC-PFA overnight, then rinsed in DEPC-PBS and dehydrated through a methanol 
series: 25%, 50%, 75% and 100% for 5 minutes each.  The embryos were then stored at 
-20°C until required. 
2.9.3. Whole mount in situ hybridisation 
Three wild type (Tcfap2a+/+) and three mutant (Tcfap2a-/-) embryos at e9.5 (19-25s) 
were used to investigate the expression patterns of both Dlx5 and Fgf8.  Embryos were 
transferred to an RNase-free netwell filter (Corning) in a 12-well plate containing 100% 
methanol.  Embryos were then rehydrated through 75%, 50% and 25% methanol 
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diluted in DEPC-PBT (DEPC-PBS containing 0.1% Tween-20, sterile filtered) and washed 
twice in DEPC-PBT.  The embryos were then bleached in 6% H2O2 for 1 hour at room 
temperature.  H2O2 was removed and embryos were rinsed in DEPC-PBT, three times, 
then treated with 10 µg/ml proteinase K for 15 minutes at room temperature.  The 
enzyme reaction was stopped by washing in 2 mg/ml glycine and washing twice in 
DEPC-PBT.  The embryos were fixed (0.2% glutaraldehyde, 4% PFA) for 20 minutes at 
room temperature and then rinsed in DEPC-PBT twice, then transferred to cryovials 
(thermo scientific) for hybridisation. 
1ml of pre-hybridisation solution (50% v/v formamide, 5 x saline-sodium citrate 
solution (SSC) pH6, 0.1% Tween-20, 50 µg/ml heparin in DEPC-H2O) was added to each 
vial and incubated at 70°C for 1 hour.  The probe was diluted in hybridisation solution 
(50% formamide, 5x SSC pH6, 0.1% Tween-20, 50 µg/ml heparin, 50 µg/ml yeast 
transfer RNA (tRNA), 100 µg/ml salmon sperm DNA in DEPC-H2O) and denatured at 
100°C for 5 minutes .  The pre-hybridisation solution was removed from the embryos 
and replace with hybridisation solution containing the correct probe and incubated 
overnight at 70°C with agitation in a hybridisation oven.   
The following day, the hybridisation solution was removed and replaced with pre-
warmed solution I (50% formamide, 4 x SSC, 1% w/v sodium dodecyl sulphate (SDS)).  
Embryos were washed twice, for 30 minutes each in solution I at 70°C.  Embryos were 
then washed in a preheated 1:1 mixture of solution I:solution II (0.5M NaCl, 100 mM 
Tris pH 7.5, 0.1% Tween-20) for 10 minutes at 70°C, then washed a further 3 times in 
solution II for 5 minutes each at room temperature.  Embryos were treated with 100 
µg/ml RNaseA, diluted in solution II, twice for 30 minutes each at 37°C.  Embryos were 
then washed in solution II at room temperate for 5 minutes, then in solution III (50% 
formamide, 4xSSC, 0.2% SDS) for a further 5 minutes at room temperature. The 
embryos were incubated twice for 30 minutes each in solution III at 65°C, then washed 
3 times in Tris-buffered saline with Tween-20 (TBST) (50mM Tris pH 7.5, 150mM NaCl, 
0.05% Tween-20).  Embryos were transferred to glass vials for all subsequent steps. 
Embryos were blocked in 10% FBS, diluted in TBST for 2.5 hours at room temperature.  
The blocking solution was removed and replaced with 0.5µl/ml Anti-Digoxigenin-AP 
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Fab fragments (Roche) diluted in 1% FBS/TBST and embryos were incubated overnight 
at 4°C.   
The antibody was removed and embryos were rinsed in TBST 3 times for 5 minutes 
each, then washed 5 times in TBST for 1 hour each with gentle agitation.  Embryos 
were incubated in the final TBST overnight at 4°C. TBST was removed and embryos 
were washed 5 times for 10 minutes each in NTT solution (100 mM NaCl, 100 mM Tris 
pH9.5, 0.1% Tween-20).  Embryos were then incubated in developing solution (20 
µl/ml NBT/BCIP (Roche) in NTT) in the dark at room temperature to allow staining to 
develop.  Once the development reaction was complete the embryos were washed in 
NTT twice for 10 minutes at room temperature, followed by a 10 minute wash in PBT 
pH 5.5 to stop the staining reaction and whiten embryos.  Embryos were fixed in 0.1% 
glutaraldehyde in 4% PFA for 1 hour, then rinsed in PBS and photographed. 
2.9.4. Sectioning 
Embryos were sectioned following the whole mount in situ hybridisation (WISH) 
protocol by dehydrating through an ethanol series, embedding in wax and sectioning 
at 8 µm as described in section 2.5.  Sections were counterstained in eosin only using 
the following method.  Slides were de-waxed in Histoclear twice for 5 minutes each, 
washed in 100% ethanol twice for 1.5 minutes each, then rehydrated through an 
ethanol series of 90%, 70% and 50% ethanol for 1 minute each.  Slides were washed in 
dH2O for 1 minute then incubated in 1% eosin for 5 minutes.  Following staining the 
slides were rinsed in running water to remove excess eosin then dehydrated through 
50%, 70% and 90% ethanol, by dipping three times in each solution.  The sections were 
incubated in 100% ethanol twice for 1.5 minutes then cleared in Histoclear twice for 5 
minutes each before mounting in Histomount. 
2.10. Pharyngeal arch dissections for quantitative PCR 
2.10.1. Dissection 
The pharyngeal arch region of both wild type (Tcfap2a+/+) and mutant (Tcfap2a-/-) 
embryos at e9.5 (18-25 somites) were collected for qPCR analysis.  The embryos were 
collected in DEPC-PBS and kept on ice until dissected.  Each embryo was removed from 
the deciduate and the yolk sac, with the yolk sac being collected for genotyping.  A 27 
gauge (G) needle was used to remove the PA region by cutting above the first PA and 
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below the heart (see Figure 2.1).  The remainder of the embryo was discarded.  The PA 
sample was collected in a sterile pasteur pipette and transferred to an RNase-free 
1.5ml microcentrifuge tube, with any excess PBS being removed.  The sample was 
immediately flash frozen in liquid nitrogen and stored at -80°C until RNA was 
extracted. 
 
Figure 2.1:  Dissection of the pharyngeal arch region in e9.5 embryos. 
(a) e9.5 mutant embryo extracted from yolk sac.  The lines indicate the region which was excised for RNA 
extraction.  (b)  The excised region. Scale bars = 1mm (a), 500 μm (b). 
2.10.2. RNA extraction 
500μl of TRIzol® reagent (Invitrogen) was added to each PA sample and incubated for 5 
minutes to allow the nucleoprotein complex to dissociate.  Homogenization was 
carried out by passing the sample through a 27G needle several times.  0.2 volumes of 
chloroform were added and the sample was shaken vigorously by hand, then 
incubated at room temperature for 2-3 minutes.  Samples were centrifuged at 12,000 x 
g for 15 minutes at 4°C to allow phase separation of the samples components.  200μl 
of the upper aqueous phase, containing nucleic acids, was transferred to a fresh tube 
and an equal volume of RNase-free 70% ethanol added.  The samples were mixed and 
then transferred to a PureLink™ RNA mini kit spin column (Life Technologies) and 
centrifuged for 15 seconds at full speed to allow binding of RNA to the column.  The 
spin column was washed once in the supplied wash buffer 1 before on-column DNaseI 
treatment to remove any genomic DNA within the sample.   
10 units of DNaseI were diluted in 1x DNase buffer in DEPC-H2O to a total volume of 80 
μl for each sample.  The DNaseI mix was added to the spin column and incubated for 
15 minutes at room temperature.  The column was then washed again in wash buffer 
1, followed by multiple washes in wash buffer 2 (contains ethanol).  RNA was eluted 
from the column in 50 µl of the supplied RNase-free water.  The quality and 
concentration of the eluted RNA was measured using a NanoDrop spectrophotometer 
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(section 2.8.3).  Quality was determined using the 260/280 value, where optimal 
quality is determined by a 260/280 value of 2.  Quality was also tested by running the 
samples on a 1% agarose gel at 200 V for 15 minutes.  Total RNA was then used to 
synthesise complementary DNA (cDNA). 
2.10.3. cDNA synthesis 
cDNA synthesis was carried out using the High Capacity cDNA reverse transcription kit 
(Life Technologies).  A 40 µl cDNA synthesis reaction contained: 500 ng RNA, 1 x 
Reverse transcriptase buffer, 1 mM each dNTP, 1 x random primers and 100 units 
reverse transcriptase.   The cDNA synthesis reaction was carried out in a thermocycler 
with the following cycling conditions:  25˚C for 10 minutes, 37˚C for 2 hours, 85˚C for 5 
minutes, 4˚C for 10 minutes.  Synthesised cDNA was stored at -20°C until required. 
2.10.4. Primer design 
All qPCR primers were designed using the NCBI Primer-BLAST tool (available at: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast), using the following parameters: 
PCR product size 50-150 bp 
Primer melting temperature (Tm) Min: 57°C, Max: 70°C, Optimum: 60°C 
Max Tm difference  1°C between primers 
Exon junction span Primer must span an exon-exon junction 
Database Refseq RNA (refseq_rna) 
Organism Mus musculus (taxid: 10090) 
Splice variant handling Allow primer to amplify mRNA splice 
variants 
 
An accession number for each gene was obtained from the NCBI nucleotide database 
(available at: http://www.ncbi.nlm.nih.gov/nuccore) and input as the PCR template 
when designing primers.  This allowed the Primer-BLAST tool to calculate the exon-
exon boundaries so that one primer from each pair was designed to span an exon-exon 
junction.  This, therefore, produced primers that were specific to the mRNA sequence 
of the gene and would be unable to bind to any contaminating genomic DNA.  Where a 
single gene produced multiple transcripts, the accession number of the longest mRNA 
sequence was selected from the database.  The splice variant handling parameter of 
the Primer-BLAST tool allowed us to design a single primer pair for binding to all 
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transcripts produced to get an overall impression of the activation of the genes 
promoter in the absence of Tcfap2a.  
Table 2-7:  Primer sequences and product sizes of all primers used in qPCR analysis. 
Gene Accession no. Primer name Sequence (5’- 3’) 
Product 
size (bp) 
Housekeeping genes 
GAPDH NM_008084 
Gapdh fw TGTGCAGTGCCAGCCTCGTC 
80 
Gapdh rev TGACCAGGCGCCCAATACGG 
Tcfap2 family genes 
Tcfap2a 
NM_011547 
NM_001122948 
AP2a Ex6 fw  CCGATCCCAATGAGCAAGTGG 
309 
AP2a Ex7 rev TGCTTTTGGCGCTGTTGTCCG 
Tcfap2b NM_009334 
Tcfap2b fw CGGCGTCCTCAGAAGAGCCAAAT 
93 
Tcfap2b rev CGCCTGCCCGCGGGTAAAT 
Tcfap2c NM_001025305 
Tcfap2c fw TCGTGGAAGGTGAAGCCGTCCA 
132 
Tcfap2c rev TCCGCGTGGCCATCTCATTCC 
Neural crest markers 
Foxd3 NM_010425 
foxd3 fw TCGAGGAAGGCTGGTGAAGTGAGG 
105 
foxd3 rev CGAACTCTTGCGGTCCTCGACG 
Dlx5 NM_010056 
dlx5 fw GGCTACCCGGCCAAGGCTTATG 
108 
dlx5 rev TTCTTTCTCTGGCTGGCTGGTGG 
Snail2 NM_011415 
Snai2 fw CGCGCTCCTTCCTGGTC 
187 
Snai2 rev GCTGCCGACGATGTCCATAC 
Heart development genes 
Ccne2 
NM_001037134  
NM_009830 
Ccne2 fw TCTGTGCATTCTAGCCATCG  
156 
Ccne2 rev ACAAAAGGCACCATCCAGTC  
Smad7 NM_001042660 
Smad7 fw 2 TCAACCCCGAGCTGGTGTGC 
80 
Smad7 rev 2 
GGAGTAAGGAGGAGGGGGAGACTCT
AG 
Tgfb2 NM_009367 
Tgfb2 fw 2 TGCTAACTTCTGTGCTGGGGCATG 
126 
Tgfb2 rev 2 TCCTGGGACACACAGCAAGGG 
Fgf8 
NM_010205 
NM_001166361
NM_001166362
NM_001166363 
Fgf8 all F AGTTCGCGGCGCAGAGACAG 
182 
Fgf8 all R GCCGGCCCTTGCGGGTAAAG 
Fgf10 NM_008002 
Fgf10 F GAAGAACGGCAAGGTCAGCGGG   
109 
Fgf10 R GTTGCTGTTGATGGCTTTGACGGC   
Chd7 NM_001081417 
Chd7 fw 2 TGCCACTAACGGGGTACAACAGC 
85 
Chd7 rev 2 TTCATCCATAAGTGCACCATATGCCC 
Rara NM_009024 
Rara fw 2 CATCCCCTCGCTTCGAGCACC 
187 
Rara rev 2 CGGAGGGGCCAGGTGGATTG 
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Gene Accession no. Primer name Sequence (5’- 3’) 
Product 
size (bp) 
Rarb NM_011243.1  
Rarb fw 2 CCGCAGCATCAGCGCGAAAG 
81 
Rarb rev 2 TGAATGAGAGGTGGCATTGATCCAGG 
Msx1 NM_010835 
Msx1 fw 2 AGCTCTGCTGCCCTATACCA 
202 
Msx1 rev 2 CTTGGCCTCTGCACCCTTAG 
Known Tcfap2a target genes 
Tbx20 
NM_194263 
NM_020496 
NM_001205085 
Tbx20 F CGCCTGCAGCCTGGAAACGA 
109 
Tbx20 R TGACACGCGGATGGTGGGGA 
ErbB2 BC046811.1 
ErbB2 fw AACTGTGGTGGGCGTCCTGTTGT 
130 
ErbB2 rev GGCACGCCTCACCTCGGTCTC 
Acan NM_007424.2 
Acan fw TACGGCGTGCGCCCATCATC 
79 
Acan rev TGGCGAAGAACACTTCCCCCTCA 
cMyc 
NM_001177353
.1 
c-Myc fw CCAGGCTCCGGGGAGGGAATTTT 
143 
c-Myc rev CGTCGTGGCTGTCGGGGTTTC 
cKit 
NM_001122733
.1 
c-kit fw CGGCACGGTGGAGTGTAAGGC 
103 
c-kit rev AGTGTGGGCCTGGATTTGCTCTTTG 
MMP-2 NM_008610.2 
MMP2 fw ACGTCACTCCGCTGCGCTTTT 
83 
MMP2 rev ATCTCCATGCTCCCAGCGTCCA 
VEGF-A 
NM_001025250 
NM_009505 
NM_001025257 
Vegfa fw1 CCAGGCTGCACCCACGACAG 
171 
Vegfa rev1 CGCATCAGCGGCACACAGGA 
Sox10 NM_011437.1 
Sox10 fw TCACTACAAGAGTGCCCACCTGGA 
134 
Sox10 rev GCAGCTCTGTCTTTGGGGTGGTT 
Cited2 NM_010828.3  
Cited2 fw 2 GAGCCCGCCTTCGGTGTTCC 
158 
Cited2rev 2 GGCTCGGGAACTGCCCCATG 
Dlx family genes 
Dlx1 NM_010053.1 
Dlx1 fw TCGGTCAGCAGCCACGCGTCCA 
113 
Dlx1 rev CTCTTCTCGGAGTCCGCCCCTGGGT 
Dlx2 NM_010054.2 
Dlx2 fw GGGCCTCACCCAAACTCAGGTCAA 
90 
Dlx2 rev TCGGTGGGTATCTCGCCGCT 
Dlx3 NM_010055.3 
Dlx3 fw TTGCCTGCCCAGGACCCAGT 
96 
Dlx3 rev CGTTCGCGGCTTTCGGACCT 
Dlx4 NM_007867.4 
Dlx4 fw GCCACCCCCGGTCCTATTCC 
150 
Dlx4 rev GTGCCAGCTTCTCTGATTCTGCTTC 
Dlx5 NM_010056.2 
Dlx5 fw3 CCAGCCAGCCAGAGAAAGAAGTGG 
150 
Dlx5 rev3 GCAGGGCGAGGTACTGAGTCTTCT 
Dlx6 NM_010057.2  
Dlx6 fw GCGGGGACGACACAGATCAACAAAA 
135 
Dlx6 rev AGCGATGGTTTAAAGCCTGGAGCTG 
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Gene Accession no. Primer name Sequence (5’- 3’) 
Product 
size (bp) 
Upstream activators of Dlx5 
Edn1 NM_010104 
Edn1 fw AGACCCCGCAGGTCCAAGCG 
106 
Edn1 rev CGACGCGCTCGGGAGTGTTGA 
ECE-1 NM_199307.2 
ECE1 fw GCCGCCCATGGTGAACGCTT 
106 
ECE1 rev CAAGGCGTTGGGTGAAGAGCGG 
Ednra NM_010332.2 
Ednra fw TGTGGACAGGTACAGAGCAGTGGC 
134 
Ednra rev CGAAGCCGATTGCTTCCGGGAT 
Gnaq NM_008139.5 
Gnaq fw ACCGTGTAGCCGACCCTTCCT 
132 
Gnaq rev GGCCCCCTACATCGACCATTCTGA 
Gna11 NM_010301.3 
Gna11 fw ACAATGAGAACCGCATGGAGGAGA 
142 
Gna11 rev TCGACCAAGTGTGAGTGCAGGA 
Gnas NM_201618.1 
Gnas fw GGTGGCCAGCAGCAGCTACA 
113 
Gnas rev TGGTGCGCAGCCATCTGTTGT 
Gnai 
 
NM_010305.1 
 
Gnai fw CCATGGGCTGCACATTGAGCG 
132 
Gnai rev ATTCCCCAGCACCCAGCAGC 
Downstream targets of Dlx5 
Cyp26a1 NM_007811.2 
Cyp26a1 fw TGGTGCTTCAGCGGAGGAAGTTT 
121 
Cyp26a1 rev ATGCGCCGCACATTATCCGC 
Cyp26b1 
variant1 
NM_175475.3 
Cyp26b1.1 fw GGGCTTGGGGCTTTGATGGCGGA 
99 
Cyp26b1.1 rev AGATTGCCTGGGGAGGCCTTGGCT 
Cyp26b1 
variant2 
NM_001177713
.1 
Cyp26b1.2 fw CCCCTTCCACCTTCTATCGGCAATC 
112 
Cyp26b1.2 rev TCCTGGCACCCCTCGGAGAA 
Cyp26c1 
NM_001105201
.1 
Cyp26c1 fw TCGGCAACGGCGTAAGGTCC 
75 
Cyp26c1 rev CCCTGCAACCGTGGCACGAA 
Hand1 NM_008213 
Hand1 fw 2 CGGAAAAGGGAGTTGCCTCAGCAG 
83 
Hand1 rev2 CCGGTGCGCCCTTTAATCCTCTTC 
Hand2 NM_010402 
Hand2 fw CCAGCTACATCGCCTACCTC 
163 
Hand2 rev TTCTTGTCGTTGCTGCTCAC 
Isl1 NM_021459 
Isl1 F TGCCACCTAGCCACAGCACC 
158 
Isl1 R TGCCGCAACCAACACACAGGG 
Gbx2 NM_010262 
Gbx2 F GAGGCGGCAACTTCGACAAAGCC 
190 
Gbx2 R TCCTCCTTGCCCTTCGGGTCATC 
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2.10.5. Quantitative PCR 
2.10.5.1. Sample preparation 
cDNA samples, prepared as above, were diluted 1:4 in dH2O.  Diluted samples were 
vortexed to ensure thorough mixing of the samples and briefly centrifuged.  2 µl of 
diluted cDNA was used in each quantitative PCR (qPCR) reaction. 
2.10.5.2. Primer preparation 
Primer stocks (Sigma) were diluted to a final concentration of 10 µM for use in the 
qPCR reactions.  Each 10 µM primer mix was prepared with 10 µl forward primer, 10 µl 
reverse primer and 80 µl dH2O.  1 µl of primer mix was added to an individual qPCR 
reaction.  Tcfap2b primers were diluted to 5 µM using 5 µl forward primer, 5 µl reverse 
primer and 90 µl dH2O, with 1 µl of primer mix being used in an individual reaction. 
2.10.5.3. qPCR reactions 
All qPCR reactions were performed on a 7900HT Fast Real-Time PCR system (Applied 
Biosystems) using SYBR®Green JumpStart™ Taq Ready Mix™ (Sigma).  Each 10 µl 
reaction contained: 1 x SYBR Green mix, 1 x internal reference dye (Rox), 1 µM forward 
primer, 1 µM reverse primer and 2 µl diluted cDNA. Each reaction was carried out in 
triplicate on a 384-well plate (Greiner).  The plate was centrifuged to collect all 
components of the reaction together in a Sorvall Evolution RC Superspeed centrifuge, 
using the SH-3000 rotor, for 4 minutes at 4,000 x g and 4°C.  The plate was then 
inserted into the 7900 HT machine and the qPCR reaction was run using the 
programme shown in Table 2-8. 
Table 2-8:  qPCR programme used on the 7900 HT machine. 
Temperature Time  
95 °C 15:00   
95 °C 00:30  
39 
cycles 
 
60 °C 00:30  
72 °C 00:30  
79.5 °C 00:10 Data collection point 
68 °C 00:10  Data collection point 
99°C 00:10  Data collection point 
 
2.10.6. Analysis 
Data was analysed by the comparative cycle threshold (Ct) method using Microsoft 
Excel (Microsoft) (Schmittgen and Livak, 2008) and also the data analysis for real-time 
PCR (DART-PCR) excel spreadsheet method to ensure primer efficiencies were 
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comparable between target genes and sample groups (mutants vs controls) (Peirson et 
al., 2003). 
2.10.6.1. Comparative Ct method 
The comparative Ct method of analysis requires data to be extracted in the form of Ct 
values.  This is the number of reaction cycles required for level of fluorescence within 
each individual reaction to reach the threshold level set prior to the start of the 
reaction.  Any Ct values within a triplicate which fell outside of 0.5 Ct values of each 
other were discarded as outliers and analysis was carried out with only two values.   
Firstly, the average Ct value of the triplicate was calculated for each sample.  This was 
then normalised to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), by 
subtracting the average Ct for GAPDH for each sample from the average Ct for the 
target gene of that sample.  The ΔCt of each normalised value was calculated by 2 
raised to the power of the negative of the normalised value: 
                                               
This calculation is based upon the assumption of a 100% efficiency of the PCR reaction 
which would produce two copies of the gene at each cycle.  The average ΔCt value for 
each sample group (control and mutant) was then calculated.  The fold change in gene 
expression was calculated by dividing the ΔCt value of both control and mutant groups 
for each gene by the average ΔCt value for the control group.  This allowed the value 
for all control groups to be maintained at 1 and all changes in expression in the mutant 
groups to be plotted relative to wild type expression.  All data analysis and graphs 
were carried out using Microsoft Excel.  Standard deviations were calculated using the 
raw ΔCt values for all samples and all genes for both groups and standard error was 
used for error bars on the graphs.  The data was imported into the Prism 6 statistics 
package and statistical significance was calculated using a student’s t-test. 
2.10.6.2. DART-PCR 
The use of the comparative Ct method described above assumes that efficiency of any 
PCR reaction is 100% and produces two copies of the target DNA per cycle of the 
reaction.  However, an efficiency between 90-110% is generally considered acceptable 
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for using the comparative Ct method of analysis.  The DART-PCR method (Peirson et 
al., 2003) was used to calculate primer efficiencies for each target gene and the 
housekeeping gene GAPDH.  This method uses the raw fluorescence data (ΔRn values) 
from the qPCR reaction to calculate how many copies of the target gene product are 
produced per cycle. The ΔRn value is calculated by normalising the fluorescence 
emission intensity of the reporter dye to that of the Rox dye and then subtracting the 
baseline level of fluorescence observed in the initial cycles of PCR when there is very 
limited change in fluorescence levels.  The ΔRn values for each well were input into the 
DART-PCR spreadsheet and the primer efficiencies for both wild type and mutant 
groups were calculated and compared to ensure that the fold change calculated by the 
comparative Ct method was reliable and not the product of changes in the primer 
efficiency between these groups.   
2.11. Reverse transcription PCR 
Reverse transcription (RT)-PCR uses end point PCR on cDNA samples.  All components 
of the RT-PCR reaction are as outlined in section 2.3.2 above, with the exception of 
DNA, which was replaced with varying volumes of cDNA.  RNA extraction, cDNA 
synthesis and primer design were carried out as described above (see section 2.10), 
however regions of interest were specified for each primer pair designed to Tcfap2a. 
2.11.1. PGKcre and Sox2cre 
This method was used to investigate the transcripts produced by both PGKcre and 
Sox2cre-mediated deletions of Tcfap2a.  Embryos were collected at e9.5 and stored for 
RNA extraction (see section 2.10.2).  The primers used in the analysis of the PGKcre 
mutant embryos were GAPDH, Tcfap2a, Tcfap2a floxed and Tcfap2a common shown in 
Table 2-9.   The Tcfap2a primers used in the qPCR analysis were initially used to 
investigate the wild type transcripts produced in the embryos.  The Tcfap2a floxed 
primers bind either side of the floxed region and are therefore used to examine if this 
region has been successfully recombined in these mutants.  The Tcfap2a common 
primers were designed to bind to all transcripts of Tcfap2a, including all splice variants 
and both mutant alleles.  Analysis of Sox2cre mutant embryos used Tcfap2a floxed and 
GAPDH primers only. 
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2 µg of total RNA from each sample was used to synthesise cDNA.  The cDNA was then 
diluted 1:10 and 2 μl were used in the RT-PCR reactions. 
2.11.2. Wnt1cre 
To investigate the recombination of Tcfap2a by Wnt1cre embryos were collected at 
e7.5, e8.0 and e8.5 for RT-PCR analysis.   The primer pairs used in this analysis are 
shown in Table 2-9.  The Tcfap2a floxed and common primers described above (see 
section 2.11.1) were used to examine Tcfap2a expression.  Expression of Wnt1cre was 
examined using primers designed to the Cre cDNA construct.  As these primers will 
bind both genomic DNA (gDNA) and cDNA a set of primers designed to Cited2 which 
will also bind to gDNA  were included in the analysis to exclude the possibility of gDNA 
contamination.  Any gDNA contamination in these samples would result in a 636 bp 
band in addition to the 158 bp band observed for cDNA samples. 
Table 2-9: Sequences and product sizes of primers used in RT-PCR reactions. 
Gene Primer name Sequence (5’-3’) Product size (bp) 
GAPDH 
Gapdh fw TGTGCAGTGCCAGCCTCGTC 
80 
Gapdh rev TGACCAGGCGCCCAATACGG 
Tcfap2a 
AP2a Ex6 fw  CCGATCCCAATGAGCAAGTGG 
309 
AP2a Ex7 rev TGCTTTTGGCGCTGTTGTCCG 
Tcfap2a  
floxed 
Tcfap2a ex3/4 fw TTAAGAAAGGCCCCGTGTCCCTG Wild type – 663 
Recombined - 402 Tcfap2a ex7 rev TAACCGCTGCACACACCGCC 
Tcfap2a 
common 
Tcfap2a ex3/4 fw TTAAGAAAGGCCCCGTGTCCCTG 
102 
Tcfap2a ex 4 rev CGTTGGGGTTTACCACGCCAC 
Cre 
S1X-A GCATAACCAGTGAAACAGCATTGCTG 
280 
S1X-B GGACATGTTCAGGGATCGCCAGGCG 
Cited2 
Cited2 fw 2 GAGCCCGCCTTCGGTGTTCC 158 
(636 – gDNA) Cited2 rev 2 GGCTCGGGAACTGCCCCATG 
 
Four Wnt1cre positive and four Wnt1cre negative embryo samples were used at each 
stage.  RNA extraction and cDNA synthesis was carried as described above (see section 
2.10.5), with a few exceptions.  The RNA from e7.5 embryos was eluted in 15 µl RNase-
free water and 200 ng total RNA was used in a 20 µl cDNA synthesis reaction.  2 µl of 
cDNA was used in each RT-PCR reaction.   For embryos at e8.0, RNA was eluted in 20 μl 
RNase-free water and 200 ng total RNA was used in a 20 μl cDNA synthesis reaction. 
For embryos at e8.5, RNA was eluted in 25 µl RNase-free water and 250 ng were used 
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in a 20 µl cDNA synthesis reaction.  cDNA was diluted 1:2, and 2 µl were used in each 
RT-PCR reaction.   
2.12. Western blotting 
2.12.1. Sample collection 
Embryos from a timed mating of Tcfap2a+/f;PGKcre x Tcfap2af/f  animals were collected 
at e10.5.  Embryos were dissected in ice-cold PBS.  Mutant embryos 
(Tcfap2af/f;PGKcre) could be identified by an open neural tube at this stage.  All 
embryos were flash frozen in liquid nitrogen and stored at -80°C until use.  Yolk sacs 
were collected for genotyping.   
2.12.2.  Sample lysis 
Whole e10.5 embryos were lysed in 300 μl  of 1 x Laemmli buffer (2% SDS, 5% v/v β-
mercaptoethanol (Merck), 10% glycerol, 0.05% w/v bromophenol blue (SLS), 62.5 mM 
Tris pH 6.8).  The tissue was homogenised by passing through a 19G syringe several 
times, followed by passing through a 21G needle several times.  Each sample was then 
heated at 95°C to denature the proteins within the sample for 5 minutes, followed by a 
5 minutes centrifugation at full speed.   
2.12.3. Polyacrylamide gel electrophoresis 
Commercially available pre-cast gels (Mini-PROTEAN TGX Precast Gels, 10%; Bio-Rad) 
were used in all experiments to minimise variation between experiments. 10 µl of each 
sample was loaded into a well, and 9 µl of a protein standard (Life technologies) was 
run alongside for comparison.  Samples were electrophoresed in a tank containing 1x 
running buffer (25mM Tris, 190 mM glycine 0.1% SDS, pH 8.3) at 180 V for 35 minutes 
or until the migration front had reached the end of the gel.   
2.12.4. Protein transfer 
A polyvinyl difluoride (PVDF) membrane was activated by immersion in 100% 
methanol for 30 seconds, then rinsed in dH2O for 5 minutes and equilibrated in ice-
cold transfer buffer (48 mM Tris, 39 mM glycine, 0.04% SDS, 20% methanol) for 20 
minutes prior to transfer.  Once the polyacrylamide gel had run completely it was 
removed from the plastic cast and placed onto the membrane.  The gel and membrane 
were clamped together between with 2 sheets of blotting paper and a sponge on 
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either side and blotted at 100 V for 1 hour at 4°C.  The transfer buffer was gently 
agitated with a magnetic flea throughout. 
To ensure efficient transfer, proteins were visualised on the membrane using a 
ponceau staining technique.  The membrane was removed from the transfer cassette 
and re-activated in methanol for 30 seconds.  The membrane was then stained with 
ponceau staining solution (0.1% w/v ponceau-S, 5% v/v acetic acid) for 5 minutes and 
rinsed in 5% acetic acid to clear any background staining.  The staining solution was 
then removed by rinsing several times in TBST (50 mM Tris, 150 mM NaCl, 0.1% 
Tween-20, pH 7.6). 
2.12.5. Blocking and immunodetection 
The membrane was blocked in 5% w/v milk powder, diluted in TBST, for 1 hour at 
room temperature with gentle agitation.   The primary antibody, anti AP-2α (3B5, 
santa cruz biotechnology, sc-12726) was diluted 1:1000 in 5% milk/TBST blocking 
solution and incubated overnight at 4°C with gentle agitation.  The following day the 
primary antibody was removed and the membrane washed 4 times in 5% milk/TBST 
for 10 minutes each then replaced with secondary antibody (polyclonal goat anti-
mouse immunoglobulins/horse radish peroxidise, P0447) diluted 1:10,000 in 5% 
milk/TBST and incubated for 1 hour at room temperature.  The membrane was washed 
a further 4 times in 5% milk/TBST then 4 times in TBST. 
2.12.6. Development 
For detection of the bound secondary antibody the SuperSignal West Dura Substrate 
(Thermo Scientific) was used.  Solutions A and B were mixed in equal ratios and 2 ml 
were added to the membrane and incubated for 5 minutes.  Excess substrate was 
drained from the membrane and the membrane wrapped in plastic and exposed to a 
sheet of X-ray film (Amersham Hyperfilm ECL, GE healthcare).  The exposed film was 
then developed. 
2.12.7. Bioinformatics 
In order to determine the outcome of the mutations within the Tcfap2aLacZ and 
Tcfap2afloxed alleles on the protein produced, a bioinformatics approach was taken.   
The cDNA sequence was obtained from Ensembl (available online at: 
http://www.ensembl.org/index.html) as was the coding sequence of each exon 
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individually.  The sequence of the recombined allele was recreated based on 
information from Brewer et al. (2004) and input into the GENESCAN web server 
(available online at: http://genes.mit.edu/GENSCAN.html) to determine if the removal 
of exons 5 and 6 had resulted a change in the position of the exon-intron boundaries.  
The protein sequence retrieved from GENESCAN was compared to the wild type 
protein sequence using a multiple sequence alignment tool (available online at: 
http://www.ebi.ac.uk/Tools/msa/clustalo).  The ProtParam tool (available at: 
http://web.expasy.org/protparam) was also used to predict the size of any protein 
product that may be produced from this transcript. 
2.13. India ink injections 
To investigate the formation of the PAAs, embryos were collected at e10.5 (32-39s) for 
india ink injections.  Dissections were carried out in ice-cold PBS as described above 
(section 2.4).  The embryo was transferred to a petri dish containing 1% agarose (made 
up in dH2O) and submersed in PBS.  Embryos were pinned to the agarose from their 
right side, with one pin through the head and a further pin holding the tail in place, to 
expose the heart.  India ink (pelikan, diluted 1:1 in dH2O) was then injected into the 
left ventricle using a mouth pipette (Sigma) and a pulled glass pipette.  The ink was 
forced into the PAAs by the pumping of the embryo heart.  Images of the embryos 
from both right and left sides were taken for analysis.
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Chapter 3. Investigating the role of Tcfap2a in the neural crest 
cells 
3.1. Introduction 
The preliminary data presented in the introduction chapter described the severe 
cardiovascular malformations observed in Tcfap2a-/- mutant mice on a C57BL/6J 
background (see section 1.5.2).  The data obtained from a NCC-specific deletion of 
Tcfap2a on a 72.55% C57BL/6J background was also presented.  This work indicated an 
increase in the levels of CCVM in comparison to that previously described (Brewer et 
al., 2002; Brewer et al., 2004).   This chapter will investigate the penetrance of CCVM 
in a conditional deletion from the NCCs on a congenic C57BL/6J background.  We also 
aim to further investigate the role that the genetic background has on the penetrance 
of the phenotype seen with the NCC-specific deletion of Tcfap2a, as variation between 
our data and that of Brewer et al. (2004), may be attributed to modifier loci on the 
altered genetic background affecting the observed phenotype.    
3.1.1. Requirement of NCCs in PAA and heart development 
The NCCs play important roles in the development of the mammalian heart.  They 
migrate from the dorsal neural tube, through the caudal PAs and into the OFT.  Once in 
the OFT, the NCCs are involved in the formation of the aorticopulmonary septation 
complex and in the septation of the interventricular septum.  NCCs remaining in the 
PAs surround the PAAs and differentiate into the SMCs of the tunica media.  The SMCs 
here are important in the ability of the vessel to withstand haemodynamic pressure as 
blood circulation begins, and also in supporting the PAAs during the subsequent 
remodelling stages (Kirby and Waldo, 1990; Hutson and Kirby, 2003).  Reduction in 
NCCs, due to defective migration or cell death, or failure to differentiate into SMCs are 
key components in the development of PAA defects in many animal models (Lindsay 
and Baldini, 2001; Abu-Issa et al., 2002; Calmont et al., 2009) . 
3.1.2. Cre/loxP recombination  
First described in 1992, the Cre/loxP recombination system has been extensively used 
throughout developmental biology (Lakso et al., 1992; Orban et al., 1992).  This 
technique utilises the enzyme cre recombinase, produced by the bacteriophage P1, 
which acts on short sequences termed ‘loxP sites’.  The enzyme causes recombination 
between two such sites, removing intervening sequences.  These loxP sites can be 
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introduced into specific regions of a gene of interest to cause inactivation, by removal 
of important regions required for the function of the gene product.  Alternatively, 
insertion of a floxed (flanked by loxP sites) ‘stop’ sequence upstream of a gene of 
interest, can be used to inactivate a gene in all tissues but that under investigation.  
The expression of the cre recombinase gene can be directed by the promoter of 
another gene (Figure 3.1a), allowing specific spatial and temporal activation of the cre 
enzyme, which therefore results in tissue-specific activation/inactivation of the gene of 
interest. 
 
Figure 3.1: Tissue-specific deletion of Tcfap2a. 
(a) A tissue-specific promoter drives the expression of the Cre recombinase gene, allowing recombination in only 
the desired tissues.  (b) The structure of the floxed allele of Tcfap2a. The loxP sites (solid arrowheads) flank exons 5 
and 6. (c) Cre-mediated recombination of the loxP sites removes exons 5 and 6. (d) A male heterozygous for Tcfap2a 
and carrying Cre driven by a tissue-specific promoter (Tcfap2a
+/-
;Cre) was crossed to a female homozygous for the 
floxed Tcfap2a allele (Tcfap2a
f/f
) to generate offspring which were heterozygous for Tcfap2a in all tissues, and are 
null in those tissues expressing cre (Tcfap2a
f/-
;Cre).  Embryos which were wild type in all tissues except those 
expressing Cre (Tcfap2a
+/f
;Cre) were used as controls. 
A floxed allele of Tcfap2a was generated by insertion of loxP sites within introns 4 and 
6 of the Tcfap2a gene (Brewer et al., 2004) (Figure 3.1b).  Cre-mediated recombination 
between these sites results in the excision of exons 5 and 6 (Figure 3.1c), removing a 
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large portion of the basic region, important in DNA binding, and much of the HSH 
region of the dimerisation domain. 
To generate tissue-specific deletions of Tcfap2a, the floxed allele was used in 
combination with the Tcfap2a-null allele.  A cre-positive male heterozygous for 
Tcfap2a was crossed to a female homozygous for the floxed allele (Figure 3.1d) to 
generate mutant (Tcfap2af/-;Cre) and control (Tcfap2a+/f;Cre) embryos.   
In this study, we aimed to investigate the conditional deletion of Tcfap2a from the 
NCCs on a congenic C57BL/6J background.  In addition, Tcfap2a is highly expressed 
within the PSE.  We were, therefore, also interested in the role of Tcfap2a in this 
tissue.  To investigate these tissues we used Wnt1cre to remove Tcfap2a from the 
NCCs and both Foxg1cre and Nkx2.5cre were used to inactivate the gene in the PSE. 
3.1.2.1. Wnt1cre 
Wnt1cre (Danielian et al., 1998) was used to inactivate Tcfap2a within the NCCs.  The 
Wnt1 promoter becomes active at e8.0 with expression restricted to the midbrain.  By 
e8.5, expression has extended caudally into the hindbrain and extended into the 
forebrain (Echelard et al., 1994).  The Wnt1cre transgene was generated by the 
insertion of the Cre cDNA downstream of the Wnt1 promoter, therefore allowing 
Wnt1-driven activation of Cre in all NCCs.  The transgene was electroporated into 
embryonic stem cells, allowing random integration of the construct.  A line carrying a 
single construct was used to generate the Wnt1cre transgenic mouse strain.  The 
expression of the Wnt1cre transgene was confirmed using a lineage tracing mouse 
strain and demonstrated that recombination had taken place within the midbrain by 
e8.5, less than 12 hours after the activation of the Wnt1 promoter (Danielian et al., 
1998). 
3.1.2.2. Nkx2.5cre 
The Nkx2.5cre line was generated by introducing the Cre cDNA directly into the Nkx2.5 
locus by homologous recombination, producing a knock-in allele.  The Nkx2.5 
promoter drives expression of Cre in the myocardium and the ectoderm and 
endoderm of the PAs, by e9.5 (Moses et al., 2001). As Tcfap2a is not expressed within 
Investigating the role of Tcfap2a in the neural crest cells 
78 
 
the myocardium or endoderm (Brewer et al., 2002), Nkx2.5cre can be used to disrupt 
Tcfap2a specifically within the PSE.  
3.1.2.3. Foxg1cre 
The Foxg1cre construct, like Nkx2.5cre, was also generated by homologous 
recombination into the Foxg1 locus.  Expression of Cre begins at e8.5 in the tip of the 
head folds and in the underlying ectoderm, the anterior neural ridge (ANR).  By e8.75 
expression has extended into the ectoderm that will come to cover the PAs.  LacZ 
expression is seen in the PSE at e9.5 and extends into the foregut by e10.5 (Hebert and 
McConnell, 2000). 
3.1.2.4. Wnt1cre-mediated deletions of Tcfap2a 
Previously published data suggests that the deletion of Tcfap2a from the NCCs in mice 
on a black swiss background results in no cardiovascular anomalies (Brewer et al., 
2004).  However, 43% of these mutants died before postnatal day (P) 1, due to inability 
to feed and respiratory distress.  This was attributed to a cleft secondary palate, and 
embryos examined at e16.5 demonstrated that the palatal shelves elevate normally, 
but fail to elongate and fuse at the midline.  Interestingly, a milder phenotype, in 
which incomplete fusion of the palatal shelves occurred, was also described in a 
number of mutants.  These mutants survived in the immediate postnatal period, but 
failed to thrive, and died or were euthanized by P4 (Brewer et al., 2004). 
3.1.3. Genetic dissection in cardiovascular development 
Genetic dissection is often used in models of cardiovascular development in an 
attempt to decipher which expression domains are responsible for each element of the 
phenotype.  In some cases this can be a relatively simple task, in which a single Cre line 
is required to recapitulate the CCVM phenotype of the null mouse.  However, in some 
cases it is not possible to dissect the individual expression domains of a gene, either 
due to the lack of specific cre lines, the complex genetic interactions between multiple 
tissue-types, or the gene of interest being expressed earlier than the cre lines available 
for that tissue.  A number of cases in which genetic dissection has been used to 
investigate cardiovascular development, with variable outcomes are discussed below. 
Gbx2-/- embryos have 39-50% incidence of heart defects, mostly affecting the 
development of the fourth PAAs, and a low incidence of OFT defects such as DORV and 
Investigating the role of Tcfap2a in the neural crest cells 
79 
 
OA (Byrd and Meyers, 2005; Calmont et al., 2009).  These defects have been attributed 
to disruptions of NCC migration into the PAAs at e9-9.5.  However, as Gbx2 is not 
expressed within the NCCs, the authors propose that Gbx2 is important within the 
pharyngeal epithelia for the activation of signalling pathways required in NCC 
migration into the arches (Byrd and Meyers, 2005).  Conditional deletion of Gbx2 from 
the PSE, using AP-2α-IRESCre, resulted in a comparable level of fourth PAA defects to 
that seen in Gbx2-/- embryos, when examined at e10.5 by ink injection, suggesting that 
ectodermal expression of Gbx2 is key to the NCC migration defects observed in Gbx2-/- 
embryos.  The authors also demonstrate that these defects are the result of 
disruptions of the Slit/Robo pathway, involved in migration of the NCCs to the PAs 
(Calmont et al., 2009). 
Deciphering the tissue-specific requirements of Tbx1 has proven much more difficult, 
however.  The phenotype produced in Tbx1-/- embryos affects many areas of the 
embryos, including the OFT, interventricular septum, PAAs, thymus, parathyroids, ears 
and craniofacial development (reviewed in Lindsay, 2001; Scambler, 2010).  As Tbx1 is 
widely-expressed throughout the PA tissues and the SHF it is possible that each 
expression domain may contribute to different aspects of the phenotype.  Additionally, 
haploinsufficiency of Tbx1 results in thymus defects and hypoplasia of the fourth PAAs, 
adding to the difficulties associated with conditional removal of this gene.  Therefore, a 
series of cre lines have been used to investigate the tissue-specific requirements of 
Tbx1, both in the context of null and heterozygous embryos. 
Mutant embryos with a homozygous deletion in the endothelium and myocardium 
(using Tie2cre and αMHCcre, respectively) yielded no additional defects to those 
observed in Tbx1+/- embryos.  However, conditional homozygotes using Nkx2.5cre, 
which is expressed within the pharyngeal endoderm, ectoderm and mesoderm in 
addition to the SHF, resulted in full recapitulation of the OFT defects and VSD observed 
in Tbx1-/- mutants.  The authors describe a reduced and disorganised SMC layer 
surrounding the OFT in these mutants and propose that the reduced proliferative 
activity in the SHF is responsible (Xu et al., 2004). 
Further evidence that mesodermal expression of Tbx1 is important for correct  for OFT 
morphogenesis comes from crosses with MesP1cre, which is expressed in all 
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mesodermal derivatives including the endothelium.  Conditional homozygotes in 
MesP1cre-expressing tissues exhibit 100% penetrance of PTA, VSD and PAA 
malformations.  In addition, the segmentation of the pharynx is disrupted, resulting in 
the loss of the caudal PAs.  Further defects affecting the migration of the NCCs into the 
PAs, disruptions of the NC-derived cranial ganglia and reduced proliferation of the PA 
mesenchyme, were also observed.  
Reactivation of Tbx1 within the mesoderm of mutant embryos was achieved through 
the introduction of a neomycin cassette, flanked by LoxP sites into the Tbx1 locus.   
Null embryos, which were homozygous for this allele were produced and Mesp1cre 
was used to remove the neomycin cassette and reactivate mesodermal expression.  
This rescued the OFT and VSD phenotypes, but not the fourth PAA defects, suggesting 
other tissues are required in this malformation (Zhang et al., 2006).   
In order to address the tissue-specific requirements of Tbx1 in PAA morphogenesis, a 
similar array of cre lines were used to produce conditional heterozygous embryos.  
Conditional deletions within the endothelium (Tie2cre) and mesoderm (MesP1cre and 
Nkx2.5cre) yielded no PAA malformations.  However, removing Tbx1 from the SHF, 
mesoderm, ectoderm and endoderm using Foxg1cre resulted in 42% fourth PAA 
hypoplasia.  Fgf15cre, which is also expressed within the pharyngeal endoderm and 
ectoderm, was also used and PAA malformations were observed in 55% conditional 
heterozygotes, an almost complete recapitulation of the 60% penetrance of fourth 
PAA malformations observed in this genetic background. This suggests that Tbx1 
expression within the pharyngeal epithelia is required for correct PAA morphogenesis 
(Zhang et al., 2005).   
Further evidence for the role of epithelial expression of Tbx1 in PAA development 
comes from conditional heterozygotes within the PSE (using AP-2α-IREScre), which 
resulted in 76% fourth PAA defects at e10.5,  suggesting that the PSE is a major tissue 
for Tbx1 expression in correct morphogenesis of the PAAs (Randall et al., 2009).   
In conclusion, mesodermal expression of Tbx1 is required for proliferation in OFT 
morphogenesis and in correct fusion of the interventricular septum, while biallelic 
expression within the ectoderm is required in the development of the fourth PAA.  In 
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addition the fourth PAA malformations within the MesP1cre mutants are likely to be 
the result of the loss of segmentation of the pharynx in these mutants, rather than 
suggesting a role of Tbx1 in the mesoderm for PAA morphogenesis. 
Despite a number of successes and the significant amount of knowledge gained from 
the use of cre lines to genetically dissect genes required for cardiovascular 
development, it is not always possible to understand the tissue-specific requirements 
of a gene of interest.  An example of this is the genetic dissection of the AP-2 
coactivator gene Cited2.  Cited2-null mutations result in a number of cardiovascular 
defects including ASD, VSD, AVSD, DORV and PTA, with PAA defects such as IAA and 
RAA (Bamforth et al., 2001).  In addition, defects in left-right patterning were also 
observed on an altered genetic background (Bamforth et al., 2004).  Therefore, a series 
of genetic dissection experiments were designed in order to investigate the tissue-
specific requirements for this gene.  Removal of Cited2 from the NCCs, using Wnt1cre, 
resulted in defects of the NCC-derived cranial ganglia in approximately 80% embryos, 
although no defects in NCC-migration were observed.  Deletions in the mesoderm, 
using Mesp1Cre and TCre, resulted in cardiac septal defects in 16% and 21% embryos, 
respectively, with an additional 7% (1/14) of embryos having a left-right patterning 
defect and 71%  with adrenal agenesis in the TCre mutants.  Removal of Cited2 from 
the entire epiblast using Sox2cre, however resulted in VSD and adrenal agenesis in all 
mutant embryos and cardiac laterality defects in 60% embryos.  The authors conclude 
that Cited2 is required in the epiblast during early stages of development for correct 
left-right patterning, with a secondary requirement in the mesoderm for cardiac 
septation (MacDonald et al., 2008). 
The examples presented above demonstrate both the advantages and disadvantages 
associated with the investigation of conditional mutants.  Although in some cases the 
defects observed in null-mutants are relatively simple and the required tissues can be 
readily identified (e.g. Gbx2), other genes with more complex phenotypes require vast 
numbers of cre lines in order to infer which tissues are most important (e.g. Tbx1).  In 
addition, for some genes (Cited2) it is not possible to distinguish between individual 
expression domains with currently available cre lines. 
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3.1.4. Effect of Genetic Background in Mice 
The global deletion of Tcfap2a results in a fully penetrant cardiovascular phenotype, 
affecting the OFT, interventricular septum and PAAs.  Both VSDs and OFT defects have 
been previously described in this model, however, the prevalence of PAA 
abnormalities was limited (Brewer et al., 2002).  The preliminary data described in the 
introduction chapter (see section 1.5.2) demonstrates full penetrance of PAA defects 
on a C57BL/6J background, which may be attributed to the change in genetic 
background. 
Genetic background is a very important element in the phenotype of any mouse 
mutation and has been found in many cases to severely affect the manifestation of 
mutations in a gene of interest.  In most cases modifying loci are mutated in specific 
backgrounds, and are phenotypically silent.  It is only in the presence of another 
mutation, usually an experimentally-induced mutation in a gene of interest, that the 
effect of the modifying gene is visible.  
The modifying gene generally has a function relevant to the phenotype which is being 
observed by the mutation in the gene which it is said to be modifying.  Therefore, 
genes which modify the phenotype of a mutation in another gene are likely to be 
involved in similar processes or pathways to the gene of interest.  However, in many 
cases the modifying gene is unknown, or multiple genes may be modifying the same 
phenotype generating greater variability.   
3.1.5. Aims of chapter 
The aim of this chapter is to investigate the role of Tcfap2a in the NCCs in the 
developing mouse cardiovascular system on a congenic C57BL/6J background.  
Previous work on Tcfap2a-/- embryos (Brewer et al., 2002) demonstrates a fully 
penetrant cardiovascular phenotype consisting of a VSD and a malformation of the 
OFT, with limited prevalence of PAA defects.  Further work by this group using a NC-
specific cre line, Wnt1cre, has suggested that Tcfap2a is not required within the NCCs 
for correct cardiovascular development (Brewer et al., 2004).  However, our work on 
Tcfap2a-/- embryos demonstrates an increase in PAA defects (100% penetrant) to that 
seen by Brewer et al. (2002) on this altered background.  In addition, preliminary data 
investigating Tcfap2af/-;Wnt1cre mutant embryos demonstrates 55% penetrance of 
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CCVM.  Therefore, we wanted to examine the NC-specific deletion on this congenic 
C57BL/6J background to determine if the change in genetic background has had an 
effect on the NCCs.  We also aim to investigate the role of the genetic background on 
the penetrance of the observed defects.  Additionally, the role of another Tcfap2a-
expressing tissue, the PSE, in modulating the phenotype will also be explored. 
3.2. Results 
3.2.1. Cleft palate in Tcfap2af/-;Wnt1cre embryos (72.55% C57BL/6J) 
The study by Brewer et al. (2004) demonstrated that Tcfap2af/-;Wnt1cre mutants die in 
the immediate postnatal period, or soon after due to a cleft secondary palate.  We, 
therefore, examined the Tcfap2af/-;Wnt1cre mutant embryos presented in the 
preliminary data (see section 1.5.2) for the presence of cleft palate.  Of the 9 mutant 
embryos examined 3 were aged e14.5.  During normal development the palatal 
shelves have elevated, elongated and begun fusion at this stage (Bush and Jiang, 
2012).  However, of 3 mutants and 1 control examined at this stage, all embryos 
showed failed elevation of the palatal shelves.  This suggests a possible developmental 
delay in these embryos and they were excluded from further analysis.   
 
Figure 3.2: Palate development in Tcfap2a
f/-
;Wnt1cre mutants. 
Wild type (a) embryos show complete formation of the secondary palate, with the palatal shelves (ps) fused at the 
midline. 5/6 mutant embryos show normal palatal development (b), however, in one mutant the palatal shelves 
failed to fuse. T, tongue; ps, palatal shelves; cP, cleft palate; MES, midline epithelial seam.  Scale bar = 2mm. (n=6) 
Of the remaining e15.5 mutant embryos examined 5/6 showed normal palate 
development (Figure 3.2a-b).  A single mutant embryo showed a failure in the fusion of 
the palatal shelves (Figure 3.2c).  All embryos examined at this stage show evidence of 
the midline epithelial seam (MES), which would usually be apparent in only the most 
anterior regions.  However, at e15.0 the MES is visible throughout the palate, again 
suggesting a mild developmental delay in these embryos, possibly due to differences in 
genetic background. 
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Overall, of the 6 Tcfap2af/-;Wnt1cre embryos examined at e15.5, only 1 (16.67%) 
showed any sign of cleft palate, indicating a significant reduction from that observed 
by Brewer et al., (2004). 
3.2.2. Wnt1cre-mediated deletions of Tcfap2a 
3.2.2.1. Expression patterns of Tcfap2a and Wnt1cre 
To ensure efficient recombination between LoxP sites in the Wnt1cre mutants, we first 
chose to examine the expression pattern of both Tcfap2a and the Wnt1cre construct 
to confirm that Wnt1cre is active before the onset of Tcfap2a expression.  Wnt1cre 
activation was examined using the R26RLacZ reporter construct (see section 2.2.4) 
(Soriano, 1999).   These transgenic mice allow for fate mapping of all cells in which 
Wnt1cre becomes activated.   To determine the expression pattern of Tcfap2a we used 
the LacZ cassette knocked-in to the gene in the creation of the null allele.   
Embryos were collected at e8.5-e10.5 and stained using the substrate X-gal to identify 
β-galactosidase activity.  At early e8.5 (4-5 somites) a low level of Tcfap2a expression 
was apparent in a thin region of the midbrain (Figure 3.3a).  At this stage, Wnt1cre 
expression is prominent throughout the midbrain region (Figure 3.3b).  By e9.5 (22-24 
somites), Tcfap2a expression can be seen throughout the first and second PAs and 
expression is becoming evident in the region where the caudal PAs (3-6) will develop 
(Figure 3.3c).  Wnt1cre is strongly expressed throughout the head, and in both PAs and 
in the area that will give rise to the caudal PAs, at this stage (Figure 3.3d).  At e10.5 
Tcfap2a expression continues within the PAs.  Expression is also visible in the limb 
buds at this stage (Figure 3.3e).  At this time, Wnt1cre expression is visible throughout 
the head and PAs and extends along the dorsal midline into the tail (Figure 3.3f).   
This demonstrates that the Wnt1 promoter is active prior to e8.5, allowing the removal 
of the transcriptional stop sequence of the R26RLacZ reporter construct, so that β-
galactosidase can be produced.  The expression of Wnt1cre begins before Tcfap2a at 
all stages, suggesting that efficient recombination of the Tcfap2aflox allele by Wnt1cre 
would be possible, prior to the activation of the Tcfap2a promoter.   
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Figure 3.3: Comparison of the expression patterns of Tcfap2a and Wnt1cre during early development. 
(a)  Expression of Tcfap2a begins at e8.5 (5 somites) in a thin region of the midbrain. Scale bar = 500 μm.  (b) At the 
same stage, Cre recombinase is active throughout the entire midbrain, with a sharp boundary between the 
midbrain and hindbrain.  (c)  By e9.5, expression of Tcfap2a has extended into the craniofacial region, throughout 
pharyngeal arches 1 and 2 and is beginning to be expressed in region which will come to form pharyngeal arches 3-
6.  Scale bar = 1mm. (d) Wnt1cre has been expressed throughout the entire head and within pharyngeal arches 1, 2 
and 3-6.  (e) At e10.5, Tcfap2a expression in the head is more restricted to the frontonasal region, and expression 
continues throughout the pharyngeal arches.  LacZ expression is also visible in the limb buds.  Scale bar = 2mm. (f) 
At this stage, Wnt1cre expression has extended along the dorsal midline through the trunk region and into the tail.  
Expression of these genes in the heart (h) is restricted to the NCCs of the OFT at the stages examined. 
3.2.2.2. Wnt1cre-mediated deletion of Tcfap2a on a 94% C57BL/6J background 
Both strains of mice (Tcfap2af/f and Tcfap2a+/-;Wnt1cre) were bred onto a C57BL/6J 
background for several generations, until the background reached approximately 94% 
C57BL/6J.  Embryos were collected at e15.5, a stage at which cardiovascular 
development is complete.  Examination of the dissected embryos revealed a reduction 
in the penetrance of exencephaly from that seen in the preliminary data.  The majority 
of mutant embryos were indistinguishable from wild type animals in appearance, 
however, a small percentage showed an external phenotype.  Exencephaly was 
observed in 5.26% (1/19) of Tcfap2af/-;Wnt1cre mutants examined (Figure 3.4b).  A 
further 21% (4/19) of embryos showed a slight spinal curvature (Figure 3.4b), while the 
remaining embryos were wild type in appearance (Figure 3.4c).  
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Embryos were examined by MRI.  The aligned .tiff stacks generated by this method 
were analysed with AMIRA software and used to create 3D representations of the 
observed cardiovascular phenotype (Figure 3.5).  CCVM was observed in only 10.53% 
(2/19) of the examined mutant embryos.  One embryo had a VSD and A-RSA (Figure 
3.5c-d).  Another embryo had a vascular ring (VR), which arises from the dorsal aorta 
passes behind the oesophagus, as an A-RSA would, however, this vessel joins to the 
ascending aorta.  This would produce a completed ring, however, the aortic arch in this 
embryo contains an interruption and therefore, the VR is the only connection from the 
ascending aorta to the systemic blood flow (Figure 3.5e-f).  The RSA forms normally in 
this embryo. 
 
Figure 3.4: External phenotype of 94% C57BL/6J background Tcfap2a
f/-
;Wnt1cre mutant embryos.  
Tcfap2a
+/f
;Wnt1cre  control embryos (a) show a normal external phenotype.  One Tcfap2a
-/f
;Wnt1cre mutant 
embryo had exencephaly (b), all other mutants appear as controls (c). Scale bar = 2 mm. (n = 19). 
Histological analysis allows for a much higher resolution image than that provided by 
MRI analysis, and was therefore used to confirm the defects seen in the MRI data and 
to identify any subtle defects which could not be identified by MRI.  The A-RSA in the 
first embryo was confirmed and can clearly be seen in the histological images as a 
protrusion from the dorsal aorta (Figure 3.6h).  The VR was also confirmed.  The series 
of sections in Figure 3.6 (i-l) show a vessel protruding from the dAo, much like the A-
RSA in Figure 3.6 (h).  This vessel then passes behind the oesophagus, and joins the 
ascending aorta.  The brachiocephalic trunk, giving rise to the RSA and the RCC artery, 
develops normally from this vessel (seen in higher sections). 
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Figure 3.5: Limited CCVM phenotype in 94% C57BL/6J background Tcfap2a
f/-
;Wnt1cre mutant embryos. 
3D reconstructions of MRI data for Tcfap2a
f/+
;Wnt1cre control (a-b) and Tcfap2a
f/-
;Wnt1cre mutant hearts (c-f), 
from ventral (a, c, e) and dorsal (b ,d, f) views.  One mutant had a VSD with an A-RSA (c-d).  The other mutant had a 
IAA-B, with a VR joining the ascending aorta (Ao) to the systemic blood flow (e-f).  Scale bar = 500 μm. (n = 19).  RCC, 
right common carotid artery; RSA, right subclavian artery; Ao, aorta; Tr, trachea; LCC, left common carotid artery; 
LSA, left subclavian artery; PT, pulmonary trunk; dAo, dorsal aorta; RV, right ventricle; LV, left ventricle. 
 
Figure 3.6: Histological analysis of CCVM in 94% C57BL/6J Tcfap2a
f/-
;Wnt1cre mutants. 
Haematoxylin and eosin-stained sections of Tcfap2a
f/+
;Wnt1cre control (a-f) and Tcfap2a
f/-
;Wnt1cre mutant (g-l) 
embryos.  The mutant embryos are the same as those in the 3D reconstructions shown in Figure 3.5.  In normal 
development an interventricular septum forms between the left and right ventricles (a).  However, in one mutant 
embryo, a small interruption of this septum was seen, resulting in a VSD (b).  Additionally, this embryo was also 
seen to have an A-RSA, with the right subclavian artery arising directly from the dorsal aorta (dAo) (h) instead of the 
brachiocephalic trunk (b).  The remaining images are serial sections.  In normal development, the pulmonary trunk 
arises from the right ventricle (RV) and forms the ductus arteriosus (DA) joining the dAo.  The ascending aorta then 
joins to the dAo forming the aortic arch (AoA), which later gives rise to the left common carotid (LCC) artery and the 
brachiocephalic trunk (BC) (the base of both the right common carotid and the right subclavian arteries).  In the 
mutant embryo (i-l) a vascular ring (VR) arises from the dAo (i), passes behind the oesophagus (j-k) and joins to the 
ascending aorta (l). Scale bar = 500 μm. (n = 19). 
 
Figure 3.7: Identifying cleft palate in 94% C57BL/6J background Tcfap2a
f/-
;Wnt1cre mutants. 
Normal fusion of the palatal shelves as inTcfap2a
+/f
;Wnt1cre controls (a) was observed in 58% Tcfap2a
f/-
;Wnt1cre 
mutant embryos (b).  The remaining mutants had varying severities of phenotype, such as a failure in the fusion of 
the shelves (c), failure of the shelves to elongate (d) and failed elevation of one palatal shelf (e). Scale bar = 2mm.  
(n = 19). 
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This MRI dataset was also used to investigate the prevalence of cleft palate in these 
mutants.  It was found that the majority (11/19, 58%) of mutant embryos had a fully 
formed palate as seen in controls (Figure 3.7a-b).  In 10.5% (2/19) of mutant embryos 
examined the palatal shelves had elevated and elongated, but had failed to fuse at the 
midline (Figure 3.7c), while in another embryo the shelves had failed to elongate (1/19, 
5.26%) (Figure 3.7d).  A final class of cleft palate, which affected over 25% of mutant 
embryos (5/19, 26.3%), showed a failure in the elevation of the left palatal shelf, with 
the right palatal shelf being unaffected.  Overall, 42% (8/19) of the embryos examined 
showed some malformation of the secondary palate. 
To summarise, Tcfap2af/-;Wnt1cre mutant embryos on the high (94%) C57BL/6J 
background have a very low penetrance of CCVM (10.53%).  Preliminary work on the 
Wnt1cre deletion of Tcfap2a revealed 55% penetrance of CCVM on a 72.55% C57BL/6J 
background.  However, inbreeding further onto C57BL/6J (94%) has reduced the 
penetrance of defects.  Therefore, altering the genetic background has affected the 
penetrance of CCVM in this line. 
3.2.2.3. Wnt1cre-mediated deletion of Tcfap2a on a 72% C57BL/6J background 
To further investigate the role of the genetic background in these mice, we attempted 
to recapitulate the penetrance of CCVM seen previously in the NCC-specific deletions, 
by outbreeding the Tcfap2a+/-;Wnt1cre strain onto a CD1 background (Figure 3.8).  
Offspring from this cross would have a genetic background of approximately 50% 
C57BL/6J;50% CD1.  Tcfap2a+/-;Wnt1cre male offspring were then crossed with 
Tcfap2af/f females (97% C57BL/6J).  The embryos generated from these timed matings, 
therefore, had a genetic background which was approximately 75% C57BL/6J; 25% 
CD1.   
This genetic background is similar to that used in the preliminary work (72.55% 
C57BL/6J), and we hypothesised that this background would increase the penetrance 
of CCVM to a level similar to that seen previously.  40% (4/10) of the mutants 
examined presented with exencephaly (Figure 3.9b), a pronounced increase in 
comparison to those embryos on the 94% C57BL/6J background, and more similar to 
that seen previously on the 72% C57BL/6J background (4/9, 45%).  However, these 
mutant embryos were found to have no obvious cardiovascular malformations; 
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although one embryo had an unusual origin of the brachiocephalic trunk, arising 
directly from the ascending aorta (Figure 3.9h-l).   
 
Figure 3.8:  Breeding strategy for the generation of Tcfap2a
f/-
;Wnt1cre mutant and Tcfap2a
+/f
;Wnt1cre control 
embryos on a 72.5% C57BL/6J background. 
The Tcfap2a
+/-
;Wnt1cre male of 95.6% C57BL/6J background was bred to wild-type CD1 females.   Offspring from 
this cross would be of a 47.8% C57BL/6J background.  A male of genotype Tcfap2a
+/-
;Wnt1cre from these litters was 
used in timed matings with Tcfap2a
f/f
 females from the congenic background.  All resulting embryos of these 
matings were 72.5% C57BL/6J background.  Other genotypes were produced in these crosses, but only those used 
in subsequent crosses or collected at embryonic stages for analysis are shown.   
 
Figure 3.9: Outbreeding Tcfap2a
f/-
;Wnt1cre  mutants to 75% C57BL/6J resulted in no CCVM.   
Control (a) and mutant (b) embryos were collected at e15.5.  4/10 (40%) mutants were found to show exencephaly 
(b).  Serial sections of control (c-g) and mutant (h-j) embryos demonstrate that cardiovascular development in 
mutants occurs as in controls. One embryo had an aberrant origin of the brachiocephalic trunk (BC) (j). Scale bar =  
2mm (a, b), 500 μm (c-l) (n=10). 
As described above (see section 3.2.1), defects in the formation of the secondary 
palate were seen previously in Tcfap2af/-;Wnt1cre mutant embryos at e15.5.  We 
therefore investigated the formation of the palate in these mutants.  Of 9 embryos 
examined for CCVM, 3 were excluded due to developmental delay (aged e14.5).  The 6 
remaining mutants were analysed and compared to controls (Figure 3.10a). 33.33% 
(2/6) of embryos showed complete fusion of the palatal shelves (Figure 3.10b) as seen 
in controls.  One embryo (16.67%) showed complete elongation of the palatal shelves, 
without fusion (Figure 3.10c), while 33.33% (2/6) showed incomplete elongation 
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(Figure 3.10d).  In a further embryo (16.67%) the palatal shelf on the right had 
elevated, while the left shelf failed to do so (Figure 3.10e). 
 
Figure 3.10:  Identifying cleft palate in 72.46% C57BL/6J background Tcfap2a
f/-
;Wnt1cre mutants. 
(a) Tcfap2a
f/+
;Wnt1cre  control embryo with correct fusion of the palatal shelves.  2/6 Tcfap2a
f/-
;Wnt1cre mutants 
also had complete fusion of the palatal shelves (b).  One mutant embryos showed failed fusion of the palatal shelves 
(c), in two other mutants the palatal shelves had failed to elongate (d) and in another the left palatal shelf failed to 
elevate (e). Scale bar = 500 μm (n=10). 
3.2.2.4. Summary and conclusions from Tcfap2af/-;Wnt1cre mutants 
We have shown that the penetrance of CCVM in the NC-specific deletion of Tcfap2a is 
dependent on the genetic background.  As summarised in Table 3-1, on the 72.55% 
C57BL/6J background there was a relatively high incidence of exencephaly and CCVM, 
but with low incidence of cleft palate.  On the more congenic (94%) C57BL/6J 
background, the prevalence of both exencephaly and CCVM was reduced, while cleft 
palate is seen more often.  In those embryos outbred to CD1 animals, the rate of 
exencephaly has increased closer to that seen in the original 72.55% C57BL/6J 
background, however CCVM had disappeared entirely, and the prevalence of cleft 
palate was higher than either of the previous crosses.   
Table 3-1: Summary of phenotypes for Tcfap2a
f/-
;Wnt1cre embryos on altered genetic backgrounds. 
% C57BL/6J 72.55% 94% 72.46% 
Other background Mixed/129 Mixed/129 CD1 
Exencephaly 45% 5.26% 40% 
Cleft palate 16.67% 42.1% 66.66% 
CCVM 55% 10.53% 0% 
Phenotype TGA, A-RSA, VSD A-RSA, VSD, VR No CCVM 
Full descriptions See sections 
1.5.2 and 3.2.1 
See section 
3.2.2.2 
See section 
3.2.2.3 
 
The reduced penetrance of CCVM in the NCC-specific deletion of Tcfap2a on a 94% 
C57BL/6J background is striking as on this background the global knockout showed 
100% penetrance of VSD, OFT defects and fourth PAA defect.  These defects are similar 
to those seen in NCC ablation in chicken embryos (Kirby, 1993), however, NCC-specific 
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loss of Tcfap2a yielded very low incidences of CCVM.  This suggests that complex 
mechanisms of NCC patterning and regulation are in place which require signals from 
outside of the NC for NC development, and may indicate a further cell non-
autonomous role of AP-2α on the NC. 
3.2.3. Tcfap2a deletion from neural crest cells and surface ectoderm 
As Tcfap2a is highly expressed in both the NCCs and the PSE, we wanted to investigate 
the possibility that the CCVM seen in the global knockout are the result of the removal 
of Tcfap2a from both tissues. 
Previous work by our group has shown that Tcfap2a deletion using the ectodermally 
expressed cre lines, Foxg1cre and Nkx2.5cre, results in fully penetrant craniofacial 
defects.  However, cardiovascular defects were seen only in very low numbers of these 
mutant embryos (Dr. Simon Bamforth, unpublished data).  Therefore, as deletion from 
neither tissue individually can recapitulate the CCVM seen in the global mutants, we 
wanted to investigate the possibility that Tcfap2a is required in both tissues for correct 
cardiovascular development.  
3.2.3.1. Breeding strategy 
In order to investigate the role of Tcfap2a in both the NCCs and the PSE, complex cre 
lines, carrying both the NCC-specific Wnt1cre and one of the PSE-specific cre lines (PSE-
cre) were generated (Figure 3.11).  This was done by breeding Tcfap2a+/-;Wnt1cre mice 
with Tcfap2a wild type mice carrying the PSE-cre of interest (Tcfap2a+/+;PSE-cre).  Once 
a complex cre male (Tcfap2a+/-;Wnt1cre;PSE-cre) was created, he was bred with 
Tcfap2a floxed females to generate embryos with a conditional deletion of Tcfap2a in 
both the NCCs and the surface ectoderm of the PAs.  Embryos with a tissue-specific 
deletion of Tcfap2a in either the NCCs or the PSE (Tcfap2af/-;Wnt1cre or Tcfap2af/-;PSE-
cre) were used as controls to demonstrate that neither deletion alone gives fully 
penetrant CCVM. 
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Figure 3.11: Breeding strategy for the generation of complex cre lines. 
Tcfap2a
+/-
;Wnt1cre stud male was bred with Tcfap2a
+/+
 females carrying a cre line expressed in the pharyngeal 
surface ectoderm (PSE-cre), either Foxg1cre or  Nkx2.5cre.  Male offspring of the genotype Tcfap2a
+/-
;Wnt1cre;PSE-
cre were crossed to Tcfap2a
f/f
 females and embryos were collected at e15.5.  Mutant embryos had a tissue-specific 
deletion of Tcfap2a in both the NCCs and PSE (Tcfap2a
+/-
;Wnt1cre;PSE-cre). Embryos with Tcfap2a deleted from 
only one of these tissues (Tcfap2a
f/-
;Wnt1cre or Tcfap2a
f/-
;PSE-cre) were used as controls. 
3.2.3.2. Wnt1cre;Nkx2.5cre x Tcfap2a (97% C57BL/6J) 
Nkx2.5 is most commonly known of as a cardiomyocyte-specific marker.  However, the 
cre line is also known to be expressed within the surface ectoderm of the PAs, and it is 
here that the expression domain overlaps with that of Tcfap2a.  Previous work by our 
group on Tcfap2af/-;Nkx2.5cre mutant embryos demonstrated a low level of CCVM 
(14%) in these embryos (Dr Simon Bamforth, unpublished data).  A NCC-specific 
deletion using Wnt1cre, as discussed earlier, causes 10.53% penetrance of CCVM.   
 
Figure 3.12: PSE-deletion of Tcfap2a by Nkx2.5cre results in lower jaw clefting. 
(a) All Tcfap2a
f/-
;Wnt1cre embryos show normal development of the craniofacial region.  (b) Embryos carrying a 
tissue-specific deletion of Tcfap2a by Nkx2.5cre (either Tcfap2a
f/-
;Wnt1cre;Nkx2.5cre or Tcfap2a
f/-
;Nkx2.5cre) 
exhibit a craniofacial defect, caused by the failed fusion of the lower jaw at the midline.  Scale bar = 2 mm. (n=6). 
Tcfap2af/-;Wnt1cre;Nkx2.5cre mutant embryos were collected at e15.5.  Tcfap2af/-
;Wnt1cre or Tcfap2af/-;Nkx2.5cre littermates were used as controls.  All Tcfap2af/-
;Wnt1cre;Nkx2.5cre  mutant and Tcfap2af/-;Nkx2.5cre control embryos show a mid-
facial clefting in the lower jaw (Figure 3.12).  However, histological examination of 
these embryos revealed no CCVM in any of the 6 mutants examined.   
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3.2.3.3.  Wnt1cre;Foxg1cre x Tcfap2a (95.7% C57BL/6J) 
Foxg1cre is also expressed in the surface ectoderm covering the PAs (Hebert and 
McConnell, 2000) and can be used in conjunction with Wnt1cre to remove Tcfap2a 
from both the PSE and NCCs.   
A craniofacial defect affecting the frontonasal region was observed in all embryos of 
the genotypes Tcfap2af/-;Wnt1cre;Foxg1cre or Tcfap2af/-;Foxg1cre (Figure 3.13a-b).  In 
addition 33% (2/6) of Tcfap2af/-;Foxg1cre;Wnt1cre embryos also presented with 
exencephaly (Figure 3.13, ex) as previously seen in the NC-specific deletion of Tcfap2a.  
This is also slightly higher level than seen in the NCC only conditional deletions of 
Tcfap2a (5.26%).   
 
Figure 3.13: PSE-deletion of Tcfap2a by Foxg1cre results in frontonasal defects. 
(a) Tcfap2a
+/f
;Wnt1cre controls had normal craniofacial development.  (b) All embryos with a PSE-deletion using 
Foxg1cre (Tcfap2a
f/-
;Foxg1cre or Tcfap2a
f/-
;Wnt1cre;Foxg1cre) develop a defect affecting the frontonasal region (FN 
defect).  Some Tcfap2a
f/-
;Wnt1cre; Foxg1cre embryos developed exencephaly (ex) in addition to the frontonasal 
defect. Scale bars = 2 mm (n=6 ,Tcfap2a
f/-
;Wnt1cre; 5, Tcfap2a
f/-
;Foxg1cre; 6, Tcfap2a
f/-
;Wnt1cre;Foxg1cre). 
Mutant and control embryos were sectioned and stained with haematoxylin and eosin 
and examined for cardiovascular defects.   No cardiovascular defects were observed in 
either the Tcfap2af/-;Foxg1cre control or the Tcfap2af/-;Foxg1cre;Wnt1cre mutant 
embryos.  However, an A-RSA was identified in a Tcfap2af/-;Wnt1cre control.  
Interestingly, anomalies relating to the thymus were also observed in these sections 
(Figure 3.14, Table 3-2).   
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In normal development, the two thymic rudiments develop from the third pharyngeal 
pouch endoderm and migrate downwards into their final position above the heart, as 
seen in the Tcfap2af/-;Wnt1cre controls (Figure 3.14a).  However, in the Tcfap2af/-
;Foxg1cre controls, only a single thymic rudiment migrates to this location.  In 80% 
(4/5) of the embryos examined, the remaining thymic rudiment is on the left, with the 
right thymic rudiment being absent or ectopically placed.  In 20% (1/5) of embryos the 
thymic rudiment had a central location.  The removal of Tcfap2a from the NCCs in 
combination with the PSE exacerbated this phenotype further.  Tcfap2af/-
;Foxg1cre;Wnt1cre embryos showed a reduced number in which the right thymic 
rudiment was absent (2/6, 33.33%), but an increase in the number in which the 
rudiment was placed centrally (2/6, 33.33%).  Additionally, a further 2/6 (33.33%) 
embryos were found to have no thymic rudiments present at this location, suggesting 
a complete failure of the thymic rudiments to migrate in these embryos.  
 
Figure 3.14: Absent thymus in embryos with a PSE deletion of Tcfap2a using Foxg1cre. 
At e15.5 two thymic rudiments can be seen at the level of the brachiocephalic trunk in transverse sections.  Thymus 
development is normal in Tcfap2a
f/-
;Wnt1cre embryos (a).  In embryos with a PSE-deletion using Foxg1cre, only one 
thymic rudiment is visible in the correct position, either on the left (b) or in a central location (c).  Tcfap2a
f/-
;Wnt1cre;Foxg1cre mutants also show these phenotypes (d-e), however, some mutants had no thymic rudiment (f). 
Th, thymic rudiment.  Scale bar = 500 μm. (n = 6, Tcfap2a
f.-
;Wnt1cre; 5, Tcfap2a
f/-
;Foxg1cre; 6, Tcfap2a
f/-
;Foxg1cre;Wnt1cre).  
Table 3-2: Prevalence of thymus defects in Tcfap2a
f/-
;Foxg1cre and Tcfap2a
f/-
;Foxg1cre;Wnt1cre mutants.  
  Tcfap2af/-;Foxg1cre  
(n=5) 
 Tcfap2af/-;Foxg1cre;Wnt1cre  
(n=6) 
 No. Percentage No. Percentage 
Absent left 0 0 0 0 
Absent right 4 80 2 33.33 
Central 1 20 2 33.33 
Both absent 0 0 2 33.33 
Investigating the role of Tcfap2a in the neural crest cells 
95 
 
In summary, all embryos with a PSE-deletion using Foxg1cre (Tcfap2af/-;Foxg1cre and 
Tcfap2af/-;Foxg1cre;Wnt1cre) exhibit a frontonasal defect and absent thymus.  
Tcfap2af/-;Foxg1cre;Wnt1cre mutant embryos also displayed exencephaly and an 
exacerbation of the absent thymus phenotype, with 33.33% (2/6) of embryos having 
bilaterally absent thymic rudiments.  Of all the embryos examined, only a single 
embryo showed signs of CCVM, however this was in a Tcfap2af/-;Wnt1cre control 
(Table 3-3). 
Table 3-3: Summary of defects observed in Tcfap2a
f/-
;Wnt1cre;Foxg1cre mutant embryos and controls. 
 
Those embryos with absent thymic rudiments (Tcfap2af/-;Foxg1cre or Tcfap2af/-
;Foxg1cre;Wnt1cre) were re-examined to determine if the thymic rudiment was 
ectopically placed.  It was found that the thymic rudiment appeared higher up in the 
embryo towards the head.  In higher sections the thymic rudiment became misshapen 
and protruded from the skin.   
3D reconstruction of Tcfap2af/-;Foxg1cre embryos imaged by MRI were made to 
determine the position of the protruding thymic rudiment from the skin.  We found 
that the thymic rudiment protruded from the ‘neck’ region of the embryo (Figure 
3.15).  
Genotype n FN defects Exencephaly Absent thymus CCVM 
defects Unilateral Bilateral 
Tcfap2af/-;Foxg1cre 5 100% 0% 100% 0% 0% 
Tcfap2af/-;Wnt1cre 6 0% 0% 0% 0% 16%  
(1, A-RSA) 
Tcfap2af/-
;Foxg1cre;Wnt1cre 
6 100%   33.33%  
(2) 
66.67% 
(4)  
33.33% 
(2) 
0% 
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Figure 3.15:  3D reconstruction of the ectopic thymus defect in Tcfap2a
f/-
;Foxg1cre mutant embryos. 
(a) A ventral view of the reconstructions demonstrates the frontonasal defect (Fn) observed in all Tcfap2a
f/-
;Foxg1cre mutant embryos. (b) A side view of the reconstruction demonstrates that the thymus arises from an 
ectopic position in the neck.  Scale bar = 2mm.  
3.3. Discussion 
This chapter aimed to investigate the importance of Tcfap2a within the NCCs in the 
development of the mouse cardiovascular system in C57BL/6J mice.  The preliminary 
data collected suggested that AP-2α was important in the NCCs for the development of 
the OFT, PAAs and interventricular septum.  However, further examination on a 
congenic C57BL/6J background showed limited penetrance of this phenotype.  We 
therefore went on to examine the effect of changing the genetic background in 
embryos with a NCC-specific deletion.  This resulted in complete absence of CCVM, 
despite the appearance of an external phenotype (exencephaly was observed in 40% 
of embryos outbred to a CD1 background).  To investigate the potential 
communication between the Tcfap2a-expressing tissues within the PAs (NCC-derived 
pharyngeal mesenchyme and PSE), we also carried out tissue-specific removal of 
Tcfap2a from both tissues simultaneously.   Although this appeared to affect the 
development of other tissues (thymus and craniofacial region), no CCVM was observed 
in any of these complex mutant crosses.   
3.3.1. Genetic Background 
As described earlier in this chapter (see section 3.1.4), the genetic background of a 
mouse model can be highly influential in any phenotype resulting from genetic 
modification.  These modifier loci are variations which arise in a specific strain of mice 
and persist in that background due to the lack of selective pressures.  Modifier loci 
usually lay dormant until another gene in the same or related pathway is mutated.  
The modifier then becomes apparent in the manifestation of the phenotype.     
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The results shown here suggest that genetic background is important in the 
penetrance of the phenotype seen in Tcfap2a mutant mice.  In the preliminary study, 
on a mixed background (72.55% C57BL/6J), an external phenotype was observed in 
45% of mutants, and cardiovascular defects were seen in 55% of mutants.  When these 
mice were inbred further onto a C57BL/6J background (94% C57BL/6J) the previously 
observed defects diminished considerably, to only 5.26% mutants with the external 
phenotype (exencephaly) and 10.53% with a CCVM.  Following outbreeding of these 
mice onto a CD-1 background (75% C57BL/6J) the penetrance of exencephaly 
increased to 40%, however, there was no CCVM in these mutants.  This suggests that 
the background of these mice is important in determining the presence or absence of 
an external phenotype and of CCVM in these crosses.  For example, it is possible that a 
modifier locus which is required in the fusion of the neural tube is affected on a CD1 
background, whereas, modifier loci involved in the role of Tcfap2a within the NCCs for 
cardiovascular development, are likely found on a mixed/129 background. 
Work in many groups has demonstrated that variation of the genetic background in 
mice with Tcfap2a mutations cause alterations to the phenotype.  Kohlbecker et al. 
(2002), demonstrated a variable penetrance of exencephaly in Tcfap2a heterozygotes 
(Tcfap2a+/-).  These mice were crossed from a 129/Sv strain to 129/Ola and collected at 
e13.5. At this stage 14% of heterozygous embryos showed exencephaly.  However, this 
phenotype was no longer observed when the mice were bred to the Balb/c strain, 
suggesting that there may be modifier genes on the 129/Ola strain which affect the 
closure of the neural tube (Kohlbecker et al., 2002).  It is noteworthy that exencephaly 
was not observed in any of the heterozygotes examined here.   
Furthermore, an effect of genetic background has also been described in mutant mice 
of both the AP-2 coactivator, Cited2, and another AP-2 family member Tcfap2b.  
Cited2-/- embryos inbred onto C57BL/6J displayed an increased penetrance of left/right 
patterning defects compared to that seen on the mixed background (Bamforth et al., 
2004).  Additionally, mice with a homozygous deletion of Tcfap2b on a mixed 
129S1/C57BL/6J background die at P1-2, from polycystic kidney disease (Moser et al., 
1997a).  Whereas, breeding these mice onto a 129P2 background allowed mutant 
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embryos to survive up to 2 weeks of age, before dying from hypocalcaemia and 
polycystic kidneys (Moser et al., 2003).   
3.3.1.1. Effect of genetic background in Tcfap2af/-;Foxg1cre mutants 
Interestingly, our study of PSE deletions of Tcfap2a is not the first.  Brewer et al.(2004), 
also used Foxg1cre to delete Tcfap2a from the surface ectoderm, and found a 
substantially different phenotype.  The Tcfap2af/-;Foxg1cre mutants presented in this 
chapter show a fully penetrant frontonasal defect.  However, the same cross 
performed by Brewer et al.(2004), on a mixed 129/Black swiss background, presented 
with varying severities of ventral body wall defects.  Some embryos showed only a mild 
exaggeration of an umbilical hernia, usually observed at e15.5, while others showed 
full omphalocele, reminiscent of that seen in Tcfap2a-/- embryos.   
As both the Tcfap2a-null and Tcfap2aflox alleles used in this work are the same as those 
used by Brewer et al. (2004) the differences between the phenotype of these mutants 
are likely caused by changes in the genetic background.  It is possible, that this altered 
genetic background causes changes in the expression pattern of Foxg1, which results 
in an alteration in the regions from which Tcfap2a is removed. This has been 
previously demonstrated for the strain (Hebert and McConnell, 2000). It is also 
possible that on an altered genetic background, the function of Tcfap2a is changed in 
such a way that removal from the PSE in one strain prevents fusion of the craniofacial 
processes, but in another background causes defects in the formation of the ventral 
body wall.  A further possibility is that there are modifiers present on each genetic 
background that affect the presentation of each phenotype. 
An extreme example of the effect of genetic background on an observed phenotype 
can be seen in mice with mutations of the EGF receptor (EGFR).  On a CF-1 background 
these mice die at the peri-implantation stage (before e6.5), whereas on a 129/Sv 
background these embryos implanted into the uterine wall normally, but were unable 
to survive past mid-gestation (e12.5).  Furthermore, outbreeding onto a CD-1 
background allowed these mutants to survive for up to 18 days post-parturition.   The 
authors attribute this to modifying loci within each genetic background (Threadgill et 
al., 1995).  
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3.3.2. Cleft palate in Tcfap2af/-;Wnt1cre mutants 
Brewer et al. (2004) previously described the conditional knockout of Tcfap2a in the 
NCCs, using Wnt1cre.  The authors observed a number (17/39, 43%) of Tcfap2af/-
;Wnt1cre neonates with insufficient elongation of the palatal shelves, resulting in a 
cleft palate.  A further 7 mutants failed to thrive due to a milder cleft palate phenotype 
(Brewer et al., 2004).  We, therefore, examined the mutant embryos in our study for 
the presence of cleft palate.  In the original study (72% C57BL/6J background), a single 
embryo with a mild form of cleft palate was found.  Further breeding of these mice 
onto the C57BL/6J background increased the penetrance of cleft palate to 40% of all 
mutants examined.  There was also an increase in the range of defects observed, with 
the most prevalent defect being the failure of the left palatal shelf to elevate.  
Additionally, outcrossing these mutants onto a CD1 background caused a further 
increase in the penetrance of cleft palate, with 66.66% of all mutants examined having 
a cleft palate (Table 3-4).  Although the size of each study varies quite considerably, it 
does appear that there is an overall increase in the frequency and severity of the cleft 
palate phenotype across the three studies.  
Table 3-4: Summary of palate phenotypes in Tcfap2a
f/-
;Wnt1cre mutants. 
 Genetic background of Tcfap2af/-;Wnt1cre mutants 
72% C57BL/6J (mixed) 94% C57BL/6J 72% C57BL/6J (CD1) 
Phenotype n=5 % n = 19 % n=6 % 
Normal palate 4 80 11 57.9 2 33.3 
Failed fusion 1 20 2 10.5 1 16.6 
Failed elongation - - 1 5.2 2 33.3 
Failed elevation 
(left) 
- - 5 26.3 1 16.6 
Total 1 20% 8 40% 4 66.66% 
 
It is interesting to note that in those embryos that show signs of failed elevation of the 
palatal shelves, only the left shelf was affected, with the right shelf elevating correctly.  
This phenotype was observed in 6 mutant embryos across two genetic backgrounds 
and suggests that the loss of Tcfap2a from the NCCs has a more severe effect on the 
left side of the embryo in relation to palate formation.  It is also interesting to note 
that this phenotype was observed most frequently in those mutants on the congenic 
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C57BL/6J background.  This suggests potential modifiers in this background that 
predispose these mutants to this apparently more severe clefting phenotype. 
It should be clarified that although the failed elevation of the palate appears to be a 
more severe phenotype, Brewer et al .(2004) demonstrated even mutants with a mild 
phenotype, such as partial failure in fusion, were unable to survive after P0, therefore, 
it is likely that any form of palatal clefting in these mutants would result in postnatal 
lethality. 
3.3.3. Ectopic thymus in Tcfap2af/-;Foxg1cre mutants 
The thymus develops from two thymic rudiments, derived from the PA endoderm, 
which migrate to a position just above the heart and fuse at the midline.  Ectopic 
thymus was identified in all Tcfap2af/-;Foxg1cre mutants examined.  This phenotype 
was further exacerbated in the Tcfap2af/-;Foxg1cre;Wnt1cre double mutants, in which 
2 of these embryos (33.33%) show no thymic rudiment present in the normal position.  
This suggests that there is an additive effect of Tcfap2a being removed from both 
these tissues simultaneously.  The absent thymic rudiment was found to be ectopically 
placed and protruding from the neck.   
There is much controversy over the role of the ectoderm in the formation of the 
thymus (reviewed in Manley and Blackburn, 2003). A dual-origin model for thymus 
development suggests that the distinct components of the thymus are derived from 
different tissues, with the cortical epithelium forming from the PA ectoderm and the 
medullary epithelium arising from the endoderm.  However, many others suggest that 
the thymus arises solely from the endoderm of the pharyngeal pouch, with no 
contribution from the ectoderm.  It is, therefore, interesting to note that Tcfap2a is not 
expressed within the pharyngeal endoderm, but is found within the ectoderm and NC-
derived mesenchyme of the PAs (Brewer et al., 2002).  This may align with the dual-
origin model, suggesting that Tcfap2a expression may be important within the PSE, in 
order for the PSE to form the cortical epithelium.  However, although we did not 
investigate the structure and function of the thymus in our mutants, the thymus 
appears to be of normal size, suggesting that no component tissue is absent.  
Therefore, we postulate a role of Tcfap2a in the detachment of the thymic rudiment 
from the surface ectoderm and pharynx, which allows the thymic rudiments to migrate 
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to their final positions.  It has been suggested that apoptosis is required for the 
endodermal pouch tissue to detach from the ectoderm and begin migration.  As AP-2α 
has also been implicated in apoptosis, it is possible that AP-2α-mediated apoptosis is 
required to separate the naive thymic rudiment from the PSE. In the absence of 
Tcfap2a within the surface ectoderm, this detachment may not be possible, resulting 
in the thymus remaining attached to the ectoderm.  As the embryo and the ectopically 
placed thymic rudiment grow, the new position of the thymic tissue may result in it 
being displaced by other developing structures.  Therefore, the thymic rudiment 
becomes misshapen and protrudes externally.   
The additive effect caused by the deletion of Tcfap2a in both the NCCs (Wnt1cre) and 
the ectoderm (Foxg1cre) suggests that Tcfap2a in the NCCs is also important in the 
development of the thymus.  During development, the nascent thymic rudiment 
becomes surrounded by a layer of NCCs shortly after its formation from the interacting 
tissues of the pharyngeal pouch/cleft (Jiang et al., 2000).  This may therefore help to 
explain the additive effect caused by the loss of Tcfap2a from both tissues.   
It is particularly interesting that a similar ectopic thymus phenotype to that described 
here has also been observed in patients with BOFS, caused by mutations in TFAP2A in 
human patients.  In these patients the ectopic thymus is suggested to derive from the 
dermal layer of the skin in the neck and is therefore often described as a ‘dermal 
thymus’.  This particular phenotype appears to be unique to BOFS patients, and 
therefore to TFAP2A mutations.  This therefore, suggests that the Tcfap2af/-;Foxg1cre 
mouse may be a unique model for further examination of this phenotype and 
determination of the molecular causes that result in the defect.  It is also interesting to 
note that a number of ectodermal abnormalities are frequently described in BOFS 
patients, including hypodontia, prematurely grey hair and dysplastic nails (Milunsky et 
al., 2008; Gestri et al., 2009; Milunsky et al., 2011). 
The ectopic thymus in these patients is described, in clinical literature, as a ‘tumour’, 
or a ‘scar-like lesion’, which on resection of the tissue is found to be functional thymus 
tissue.  The ectopic thymus in BOFS patients is often found on the right side of the 
neck, but most commonly appears bilaterally (Rizzo et al., 1995; Bennaceur et al., 
1998; Hiraumi et al., 2001; Drut and Galliani, 2003; Hiroshi et al., 2006).  This is 
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interesting as the Tcfap2af/-;Foxg1cre mutant mice  most commonly show absence of 
the right thymic rudiment at the correct position, suggesting possibly conserved roles. 
3.3.4. Craniofacial development in PSE-deletions of Tcfap2a 
Nkx2.5cre and Foxg1cre were both used in this study to remove Tcfap2a from the 
surface ectoderm in conjunction with a Wnt1cre-mediated deletion from the NCCs.  
However, despite covering highly similar expression domains, each cre line gave 
different non-cardiac phenotypes.  Foxg1cre-mediated deletion of Tcfap2a resulted in 
a craniofacial defect affecting the upper jaw and nasal region, with additional defects 
affecting the development of the thymic rudiments.  The Nkx2.5cre-mediated deletion 
resulted in a lower jaw phenotype, which appeared to be the result of a failed fusion at 
the midline.   
The vertebrate face forms from the frontonasal prominence, the lateral nasal 
prominence and the maxillary and mandibular components of the first PA (Figure 3.16 
a-d).  The frontonasal prominence goes on to form the philtrum of the lower lip and 
the primary palate.  The lateral nasal prominence becomes the sides of the nose.  The 
dorsal component of the first PA (the maxilla) gives rise to the sides of the middle and 
lower face and the secondary palate, while the ventral component (the mandible) 
forms the lower jaw.  In the Foxg1cre-mediated deletion of Tcfap2a, the observed 
frontonasal defect appears to be caused by the failure of the frontonasal process to 
fuse with the maxillary component of the first PA.  Whereas in the Nkx2.5cre mutants 
the defect is caused by a failed fusion of the mandibular components.   
It is possible that this discrepancy between craniofacial defects is due to the slight 
differences in the expression patterns of the two cre lines within the maxillary and 
mandibular components of the first PA.  It appears, from the literature, that Nkx2.5cre 
is expressed throughout the ectoderm of the mandibular component of the first PA, 
but not in the maxilla (Figure 3.16e).  However, Foxg1cre appears to be expressed 
more strongly within the ectoderm of the maxillary component of first PA (Figure 
3.16f).  Therefore, Tcfap2a expression is required in the ectoderm of each of these first 
PA components in order for fusion to occur.   
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Figure 3.16: Craniofacial development in mouse embryos. 
(a-d)  The craniofacial region develops from three regions.  The median nasal prominence (red) forms the primary 
palate, the philtrum and the middle of the nose.  The lateral nasal prominence (blue) gives rise to the sides of the 
nose.  The maxillomandibular prominence forms the lower jaw, the sides of middle and lower face and the 
secondary palate.  (Figure taken from Helms et al., 2005).  (e) Lineage trace of Nkx2.5cre-expressing cells in an e9.5 
embryo.  Expression is observed in mandibular component of the first PA (md), with some expression in the maxilla 
(mx).  Expression is also observed throughout the heart. (Figure taken from Moses et al., 2001).   (f)  Lineage trace of 
Foxg1cre-expressing cells in an e9.5 embryo. Expression is observed in the maxillary component of the first PA (mx) 
with some expression in the mandibular component (md).  Expression is also observed in the optic vesicle (opv) and 
the otic vesicle (ov). (FIgure taken from Hebert and McConnell, 2000).  md, mandible; mx, maxilla; CV, Common 
ventricle. 
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Interestingly, the loss of fusion of the frontonasal prominence with the maxilla, as seen 
in the Foxg1cre mutants, is a cause of cleft lip, a phenotype which is highly prevalent in 
patients with TFAP2A mutations.  Additionally, BOFS patients often have a dermal 
thymus, similar to the ectopic thymus phenotype also observed in Foxg1cre-mediated 
deletions of Tcfap2a.  Therefore, it is plausible that BOFS is caused by mutations of 
TFAP2A, which are only manifesting in some tissues.  
Defects affecting the development of the thymus were only identified in the Foxg1cre 
mutants, again suggesting differences between the expression of the PSEcre lines used 
in this study.  It is possible that this is also due to differences in the expression patterns 
of these cre lines.  However, as the thymic rudiments are derived from the third 
pharyngeal pouch endoderm, rather than any component of the first PA, it may be due 
to differences in the timing of expression of each cre line.  Foxg1cre expression begins 
at e8.75, before the ectoderm has come to cover the PAs (Hebert and McConnell, 
2000).  Nkx2.5cre expression, however, is not observed in the pharyngeal ectoderm 
until e9.5 (Moses et al., 2001).  It is therefore possible that Tcfap2a is required within 
the surface ectoderm at some point before the expression of Nkx2.5cre begins, for 
correct thymus development. 
3.4. Conclusions 
The work presented in this chapter demonstrates that the role of Tcfap2a in 
cardiovascular development is very complex.  The genetic dissection method used here 
has allowed us to identify the regions of Tcfap2a expression which are important in 
particular elements of the Tcfap2a phenotype.  For example,  it is clear that Tcfap2a 
deletion from the NCCs are important in correct fusion of the neural plates to form the 
neural tube, as Wnt1cre-specific deletion results in exencephaly with variable 
penetrance in these mutants.  Also, Tcfap2a-deletion from the surface ectoderm 
results in the loss, or ectopic placement, of a single thymic rudiment.  This, therefore, 
demonstrates a requirement for Tcfap2a in the PSE at this time.  As the loss of the 
thymic rudiment was not observed in the Nkx2.5cre deletion this suggests that there is 
a narrow window between activation of these two cre lines, during which Tcfap2a is 
crucial in this tissue for thymic development.  It would be interesting to investigate if 
loss of Tcfap2a in this tissue at an even earlier time-point would eradicate thymic 
development entirely.   
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In addition the loss of both thymic rudiments in some of the Foxg1cre;Wnt1cre double 
mutant embryos suggests that there may be a Tcfap2a-mediated interaction between 
the NCCs and surface ectoderm, which is required in thymus development.  However, 
this phenotype had a lower penetrance than the single thymic rudiment loss seen in 
the Foxg1cre only deleted embryos, therefore suggesting that other factors are at 
work.   
3.5. Further work 
The histological staining of the Tcfap2af/-;Foxg1cre;Wnt1cre embryos demonstrates 
that the thymic rudiments have failed to migrate into their final position, remaining in 
a cervical position and protruding from the neck region.  Furthermore, this phenotype 
appears closely related to the ectopic thymus defect observed in BOFS patients.  
However, during this study we were unable to confirm that the structure observed by 
histology was indeed the thymus.  A good experimental test for this would be to use a 
marker of the developing thymus to stain the tissue.  One such marker is Foxn1.  Foxn1 
is expressed in the thymic primordia and continues to be expressed throughout 
development and at least up to e14.5 (Manley and Blackburn, 2003; Boehm, 2008; 
Okubo et al., 2011).  Therefore staining using an anti-Foxn1 antibody would 
demonstrate that the observed tissue is of thymic origin.  However, although a number 
of Foxn1 antibodies are commercially available, no account of their use in 
immunohistochemical procedures was identified within the literature.  An alternative 
method would be to use slide in situ hybridisation on these  specimens to confirm the 
thymic origin of the tissue.  This has been performed for identifying ectopically placed 
thymic rudiments within mouse samples on many occasions.  However, these samples 
were not prepared in an RNase-free environment, therefore, further embryos would 
need to be collected for this analysis. 
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Chapter 4. Recapitulating the Tcfap2a-/- phenotype using the 
Tcfap2aflox line 
4.1. Introduction 
In the previous chapter we attempted to genetically dissect the function of Tcfap2a by 
conditional deletion from the NCCs and the PSE.  We identified low penetrance of 
CCVM in the NCC-deleted mutants, which was not increased by simultaneous removal 
from the NCCs and PSE.  Furthermore, it appears that the phenotype is dependent on 
genetic background.  In this chapter we will attempt to recapitulate both the external 
phenotype and the cardiovascular defects of the Tcfap2a-/- global mutants using 
ubiquitously expressed cre lines.  This will allow us to understand the low penetrance 
of CCVM observed in the conditional deletions described in the previous chapter.   
4.1.1. Ubiquitously-expressed cre lines 
Ubiquitously expressed cre lines, which are expressed in all tissues of the embryo, are 
very useful tools.  They are often used in the validation of a newly generated floxed 
allele.  Efficient recombination is likely to result in the recapitulation of the phenotype 
generated by a null allele.  These lines are also often used to create a null line, by the 
deletion of the floxed region throughout the entire embryo.  Heterozygotes carrying 
one wild type allele and one floxed-deleted allele may then be interbred to generate a 
null mutant.  The ubiquitously expressed cre lines which will be used in this chapter are 
discussed below. 
4.1.1.1. PGKcre 
3-phosphoglycerate kinase (PGK) is an important enzyme in the glycolytic pathway and 
is therefore, expressed throughout all tissues of an organism.  The Pgk-1 gene in 
mouse becomes active at e3.5 within the inner cell mass of the blastocyst, with 
additional expression in the trophectoderm in some embryos examined.  By e7.5, 
expression is observed throughout all embryonic tissues, with particularly strong 
expression in the ectoderm.  This pattern of expression is maintained at e8.5, with less 
intense expression within the trophectoderm being visible (McBurney et al., 1994).   
The PGKcre transgene was generated by the introduction of a cre cDNA downstream of 
the Pgk-1 promoter.  This construct was then introduced into pronuclei by 
microinjection, and allowed to randomly integrate into the genome. The efficiency of 
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cre-mediated recombination by this transgenic strain was then tested using southern 
blotting to indicate the loss of intervening sequences between two loxP sites.  Efficient 
recombination was determined for multiple tissues, including the brain, kidneys, heart 
and liver (Lallemand et al., 1998).   
As with many cre lines, PGKcre is already active in the early stages of oogenesis and 
therefore, the cre recombinase protein may be passed from mother to offspring within 
the cytoplasm of the oocyte, a phenomenon termed ‘maternal transmission’.  
Consequently, all offspring of a PGKcre-positive female will carry the enzyme, and 
recombination between flox sites, transmitted from the male, occurs at the zygote 
stage (Lallemand et al., 1998). 
4.1.1.2. Sox2cre 
Sox2cre is an epiblast-specific cre line, which initiates recombination of LoxP sites 
within all cells of the embryo proper and excludes the extraembryonic ectoderm.  The 
Sox2cre transgene uses a 12.5 kb portion of Sox2 enhancer/promoter region to drive 
the expression of cre recombinase within the epiblast cells.  Validation using the 
R26RLacZ reporter construct demonstrated that Sox2cre is able to efficiently recombine 
LoxP sites throughout the embryo by e6.5 of mouse development.  In addition, 
recombination also occurred within the epiblast derivatives of the extraembryonic 
ectoderm, including the yolk sac mesoderm and the amnion, while primitive endoderm 
derivatives, such as the visceral endoderm, do not undergo recombination.  By e7.5 
expression was evident in all three germ layers of the embryo and the epiblast-derived 
extraembryonic tissues, including the allantois, the amnion and the yolk sac mesoderm 
(Hayashi et al., 2002).   
Further validation using a sonic hedgehog (Shh) conditional allele demonstrated that 
Sox2cre was capable of recapitulating the null phenotype.  Comparisons to Mox2cre 
(MORE) demonstrated that recombination with Sox2cre is more efficient, with MORE 
giving 33% of embryos with a milder phenotype, pertaining to incomplete 
recombination.  It was also demonstrated that Sox2cre is activated earlier than MORE 
(Hayashi et al., 2002). 
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This group went on to show that Sox2cre, like PGKcre, is inherited within the female 
germline, and is therefore transmitted to all offspring irrespective of their own 
genotype.  As such, Sox2cre females mated to males carrying the R26RLacZ construct 
produced litters in which β-galactosidase was activated in all embryos.  Also, timed 
matings between a Sox2cre female and males homozygous for a conditional allele of 
Smoothened yielded 50% offspring with a null phenotype, instead of the expected 
25%.  Maternal expression of the cre, however, does result in efficient recombination 
in the early embryo (Hayashi et al., 2003; Vincent and Robertson, 2003).   
4.1.2. Tcfap2a mutant alleles 
As described in the introduction chapter, Tcfap2a is composed of 7 exons, which 
contribute to 3 functional domains within the resulting protein.  The transactivation 
domain encoded by exon 2 is the binding site for co-factors, which regulate the 
transcriptional activity of AP-2α.  The DNA binding domain, consisting of a large 
number of basic amino acid residues, is encoded by portions of exons 4 and 5, while 
the helix-span-helix dimerisation domain is produced from the remaining segments of 
exon 5 and exons 6 and 7 (Williams and Tjian, 1991a; Williams and Tjian, 1991b) 
(Figure 4.1a).   
The conditional allele used in the previous chapter was constructed by the addition of 
loxP sites flanking exons 5 and 6, which would therefore result in the removal of a 
large portion of both the DNA binding domain and the dimerisation domain of the 
protein (Figure 4.1c).  The Tcfap2aLacZ null allele was produced by replacing all but a 
single nucleotide of exon 7 with an IRES-LacZ cassette.  This disrupts the dimerisation 
domain of the protein by removing much of the span region and the entire second α-
helix (Figure 4.1b). 
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Figure 4.1: Structure of Tcfap2a alleles utilised in this thesis. 
(a)  Wild type Tcfap2a consists of 7 exons. The functional domain of the protein encoded by each exon is indicated 
above.  (b) Tcfap2a-null allele.  Exon 7, encoding a portion of the span domain and the second helix, has been 
removed and replaced with an IRES-LacZ cassette, producing a null allele.  (c) Conditional (Tcfap2a
flox
) allele.  Exons 
5 and 6 are flanked by LoxP sites (black triangles) (top panel), which are recombined in the presence of Cre 
recombinase (bottom panel). Numbers refer to exon number. 
The function of each structural domain of the protein was determined through the use 
of in vitro assays assessing the consequences of a number of large deletions 
throughout the gene (Figure 4.2).  DNA binding abilities were examined using an 
electrophoretic mobility shift assay (EMSA), while cross-linking or co-
immunoprecipitation (co-IP) was used to investigate the dimerisation ability of each 
mutant construct.  Mutations situated within exons 1-3 or the start of exon 4, were 
found to result in a protein which was capable of dimerisation and DNA binding, but 
had a reduced capacity to activate transcription.  Mutations in the latter half of exon 4 
or the start of exon 5, the regions which encode the basic DNA binding domain, results 
in a loss of DNA binding ability despite the protein being able to dimerise.  Mutations 
within either of the α-helices causes the protein to lose the both dimerisation and DNA 
binding ability.  Finally, mutations in the span region between the α-helices prevent 
the formation of homodimers, but allow heterodimer formation and DNA binding 
(Williams and Tjian, 1991a; Williams and Tjian, 1991b).   
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Figure 4.2: Functional consequences of deletions within AP-2α. 
AP-2α contains a transactivation domain, a proline-rich basic domain and a helix-span-helix dimerisation domain.  
The functional consequences of mutations in these domains are indicated below.  (Based on work by Williams and 
Tjian, 1991a; Williams and Tjian, 1991b) 
Taking all of this information into consideration, it is therefore likely that any protein 
products of both the conditional and the null alleles will be non-functional, due to the 
disruption of large portions of the dimerisation domain, which will likely also result in 
an inability of the proteins to bind to DNA. 
4.1.3.  Aims of chapter 
Tcfap2a expression is widespread throughout embryonic development, however, only 
two areas of Tcfap2a expression are likely to be involved in cardiovascular 
development, as discussed in the previous chapter.  Deletion of Tcfap2a within the 
NCCs alone resulted in a low penetrance of cardiovascular defects (10.53%).  In 
addition, deletion of Tcfap2a from both the NCCs and the PSE resulted in no CCVM.   
We, therefore, wanted to understand the reasons for the low penetrance of 
cardiovascular defects in these conditional mutants.  There are three possible 
explanations for this.  The first is that Tcfap2a is not required within either the PSE or 
the NCCs for correct cardiovascular development.  This, however, seems unlikely due 
to the importance of these tissues in PAA formation and remodelling and the high 
penetrance of PAA malformations in Tcfap2a-/- embryos.  A second possibility is that 
these cre lines were not expressed at the appropriate time to allow efficient 
recombination of the Tcfap2aflox allele. 
A further possibility is that the Tcfap2aflox allele is unable to recapitulate the 
phenotypes observed in the Tcfap2a-/- mutant embryos.  As discussed above, the 
Tcfap2a-null and Tcfap2aflox alleles vary in the exons which are disrupted.  Therefore, it 
is possible that these differences affect the presentation of the phenotype in some 
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way.  In this chapter, we will use a series of ubiquitously expressed cre lines in order to 
investigate the effect of these differences.  In addition, this approach will allow us to 
understand the effect that the timing of the deletion has on the phenotype observed.  
All mutant embryos examined within this chapter have a genetic background of 97-
98.3% C57BL/6J. 
4.2. Results 
4.2.1. Tcfap2af/f;PGKcre (97.22% C57BL/6J) 
In order to investigate the consequences of a PGKcre-mediated deletion of Tcfap2a we 
first required a male of the genotype Tcfap2a+/-;PGKcre.  However, after several rounds 
of breeding yielded unsuccessful results, we generated an alternative breeding 
strategy as shown in Figure 4.3.  A PGKcre-positive male was crossed to a female 
homozygous for the Tcfap2aflox allele in order to generate a stud male of the genotype 
Tcfap2a+/f;PGKcre.  The floxed allele will undergo cre-mediated recombination so that 
the male is heterozygous for Tcfap2a in all tissues expressing PGKcre. This male was 
then crossed to further Tcfap2af/f females in timed matings to generate offspring with 
a ubiquitous deletion of Tcfap2a. 
 
Figure 4.3: Breeding strategy for the generation of Tcfap2a
f/f
;PGKcre mutant embryos. 
A Tcfap2a
+/+
;PGKcre male was crossed to Tcfap2a
f/f
 females to generate a Tcfap2a
+/f
;PGKcre stud male.  The stud 
male was then further bred to Tcfap2a
f/f
 females to generate Tcfap2a
f/f
;PGKcre mutant and Tcfap2a
+/f
;PGKcre 
control embryos for MRI analysis. 
4.2.1.1. External phenotype  
Mutant (Tcfap2af/f;PGKcre) and control (Tcfap2a+/f;PGKcre) embryos were collected at 
e15.5.  The external phenotype (Figure 4.4 b-d) clearly recapitulates the Tcfap2a-/- 
phenotype (Figure 1.11) and also displays variability, as was previously observed in the 
Tcfap2a-/- embryos (Dr Simon Bamforth, unpublished observations).  
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Figure 4.4: External phenotype in Tcfap2a
f/f
;PGKcre mutant embryos. 
(a)  Tcfap2a
+/f
;PGKcre control embryo.  (b-d)  Tcfap2a
f/f
;PGKcre mutant embryos exhibit a variable phenotype, 
similar to that seen in Tcfap2a
-/-
 mutant embryos.  Scale bar = 2mm. (n=10). 
4.2.1.2. Cardiovascular phenotype 
The Tcfap2a-/- embryos presented with 100% penetrance of cardiovascular defects, 
characterised by a VSD, an OFT defect (TGA, OA or DORV) and defects of the fourth 
PAA derivatives (IAA, cAoA, CORSA, A-RSA).  Therefore, the cardiovascular phenotype 
of the Tcfap2af/f;PGKcre mutant embryos was examined to confirm that these embryos 
showed full recapitulation of the Tcfap2a-/- mutant phenotype.  Mutant and control 
embryos were examined by MRI, and 3D reconstructions were created.  The results are 
summarised in Table 4-1. 
The penetrance of fourth PAA defects in these mutants was very similar to that seen in 
the previous Tcfap2a-/- mutant embryos, with 50% (5/10) of mutant embryos having a 
defect affecting the left fourth PAA and 100% mutants having a right fourth PAA 
defect.  The defects of the left fourth PAA included 20% (2/10) IAA-B, 20% cAoA and 
10% hypoplastic aortic arch (hypoAoA, 1/10).  The most common defect affecting the 
fourth right PAA was CORSA (70%, 7/10), with only 30% (3/10) of mutants with an A-
RSA.   
However, the remaining defects which were observed at 100% penetrance in the 
Tcfap2a-/- mutants appeared at very low levels in these mutants.  Only 50% (5/10) of 
mutant embryos were found to have a VSD.  In addition, the number and variety of 
OFT defects was also reduced.  OA was found in 20% (2/10) of mutant embryos 
examined and the penetrance of DORV observed was also reduced to 20% (2/10).  No 
TGA was observed in any of these mutant embryos. 
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Table 4-1: Prevalence of CCVM in Tcfap2a
f/f
;PGKcre mutant embryos at e15.5 compared to Tcfap2a
-/-
 embryos. 
CCVM Prevalence 
(n=10) 
Summary Prevalence in 
Tcfap2a-/-  
Summary for 
Tcfap2a-/- 
VSD 50% VSD – 50% 100% VSD – 100% 
OA 20% 
OFT defects - 
40% 
30% 
OFT defects – 
100% 
DORV 20% 20% 
TGA 0% 50% 
IAA 20% 
Left 4th PAA 
defects – 50% 
30% 
Left 4th PAA 
defects – 50% 
cAoA 20% 20% 
Hypo AoA 10% 0% 
A-RSA 30% Right 4th PAA 
defects – 100% 
40% Right 4th PAA 
defects – 90% CORSA 70% 50% 
RAA 0% No defects 
observed 
10% RAA with I-LSA 
– 10% I-LSA 0% 10% 
 
Overall, of the 10 Tcfap2af/f;PGKcre mutant embryos examined, only 40% (4/10) 
exhibited the full phenotype as seen in the global deletion mutants (Figure 4.5c). A 
further 50% (5/10) of the mutant embryos presented only with defects of the PAA 
derivatives; with the ventricular septum and OFT being unaffected (Figure 4.5d-e).  In 
addition, a single embryo was identified with a VSD and PAA defects, but with no OFT 
defect, suggesting that all three elements of the phenotype occur independently and 
that the VSD and OFT defects are not linked, with one being secondary to the other. 
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Figure 4.5: Deletion of Tcfap2a with PGKcre causes reduced penetrance of CCVM as compared to Tcfap2a
-/-
 
embryos.   
(a, b) Control embryos from a ventral (a) and dorsal (b) orientation, showing normal development of the heart and 
aortic arch.  Mutant embryos (c-f) show variable penetrance of the Tcfap2a-null CCVM phenotype.  (c) Full 
phenotype consisting of a VSD, and OFT malformation (DORV) and defects of the derivatives of the fourth PAAs 
(IAA, CORSA).  (d, e) Defects of the fourth PAAs only (A-RSA) from ventral (d) and dorsal (e) view. (f) VSD and fourth 
PAA defects (A-RSA and hypo AoA).  RV, right ventricle; LV, left ventricle; Ao, aorta; PT, pulmonary trunk; RCC, right 
common carotid artery; LCC, left common carotid artery; RSA, right subclavian artery; LSA, left subclavian artery; Tr, 
trachea; dAo, dorsal aorta. Scale bar = 500 μm. (n=10). 
Due to the poor resolution of the MRI images, embryos were also analysed by 
haematoxylin and eosin staining to identify more subtle defects and to confirm the 
defects identified by MRI analysis (Figure 4.6). 
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Figure 4.6: Histological sections confirm Tcfap2a
f/f
;PGKcre phenotypes observed by MRI.   
(a-c, g-i) Tcfap2a
+/f
;PGKcre control embryos show normal cardiovascular development.  (d-f, j-l) Tcfap2a
f/f
;PGKcre 
mutant embryos with a variety of defects:  (d) A-RSA, (e) VSD with OA, (f) DORV (j) hypoAoA, (k) IAA, (l) CORSA. BC, 
brachiocephalic trunk.  Scale bar = 500 μm. (n=10). 
4.2.1.3. Transcript analysis 
As the levels of CCVM in the Tcfap2af/f;PGKcre mutants is variable we wanted to 
investigate if there was variable recombination efficiency between embryos from this 
cross.  We collected Tcfap2af/f;PGKcre mutants at e9.5, a stage at which Tcfap2a is very 
strongly expressed, for RT-PCR analysis.   
RNA was extracted from 2 wild type (Tcfap2a+/f), 1 heterozygous (Tcfap2a+/f;PGKcre) 
and 4 mutant (Tcfap2af/f;PGKcre) littermate embryos and used to synthesise cDNA for 
subsequent RT-PCR analysis.  Samples from Tcfap2a+/- intercrosses were also used as 
controls and for comparison of the Tcfap2a expression levels: wild type (Tcfap2a+/+), 
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heterozygous (Tcfap2a+/-) and mutant (Tcfap2a-/-) embryos.  Strong expression of 
Tcfap2a was seen in both the Tcfap2a+/+ and Tcfap2a+/- samples, with the Tcfap2a-/- 
lane being entirely devoid of any gene expression (Figure 4.7).  Similar expression was 
seen for the PGKcre conditional deletion embryos with the wild type (Tcfap2a+/f) and 
heterozygote (Tcfap2a+/f;PGKcre) samples showing strong expression.   
 
Figure 4.7: RT-PCR of Tcfap2a expression in Tcfap2a
f/f
;PGKcre mutant embryos 
(a)  Tcfap2a expression in Tcfap2a control and mutant embryos.  No Tcfap2a expression is observed in Tcfap2a
-/-
 or 
Tcfap2a
f/f
;PGKcre mutant embryos. (b)  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was also 
examined as a loading control. 
The expression analysis described above was designed to investigate the expression of 
wild type Tcfap2a only.  The primers used bind within exon 6 (removed in the 
recombined conditional allele) and exon 7 (removed from the null allele) and therefore 
will not bind to transcripts produced from either mutant allele.  To determine if the 
floxed allele can produce a functional transcript, primers were designed within exons 4 
and 7, which span the deleted region.  These primers will generate a band of 663 bp in 
samples in which the floxed region remains, and a band of 402 bp in samples in which 
cre-mediated recombination has excised the sequence between the LoxP sites.  RNA 
was collected from Tcfap2af/f;PGKcre mutants and Tcfap2a+/f controls and cDNA 
synthesised for use in the RT-PCR reactions.  A Tcfap2a-null (Tcfap2a-/-) sample was 
used as a negative control to demonstrate that no functional transcript was produced 
in these mutants.   
In control samples we observed a single band of approximately 663 bp, which relates 
to the wild type transcript.  In mutant samples a single band of approximately 402 bp 
was observed. This indicates that PGKcre has induced efficient recombination of the 
Tcfap2aflox allele in these mutant embryos.  As expected the Tcfap2a-/- negative control 
showed no product (Figure 4.8). 
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A further set of primers, binding within exons 3 and 4 and common to all Tcfap2a 
alleles, were used to determine if a transcript is also produced from the Tcfap2a-null 
allele.  A 102 bp band was found in all samples at similar levels (Figure 4.8), indicating 
that a transcript is produced from each of the alleles. 
 
Figure 4.8: PGKcre-mediated recombination of Tcfap2a
flox
 allele. 
(a) RT-PCR of control (Tcfap2a
+/f
) and mutant (Tcfap2a
f/f
;PGKcre) samples demonstrates efficient recombination 
between LoxP sites only in mutant samples.  (b)  RT-PCR using primers within exons 3 and 4 demonstrates that all 
samples contain a Tcfap2a transcript, even those of Tcfap2a-null embryos. 
4.2.1.4. Protein analysis 
As shown above, the recombined conditional allele is capable of producing a transcript 
which is not degraded and therefore could be translated into a protein with impaired 
function, which may account for the inability to completely recapitulate the Tcfap2a-/-
CCVM phenotype using this allele.  Therefore, we chose to investigate the changes in 
the protein sequence of the mutant allele using a bioinformatics approach. 
First the coding sequence of each mutant allele was determined in order to infer the 
changes caused by the mutations.  As described by Brewer et al. (2002) the insertion of 
the LacZ cassette into the null allele results in the loss of all but a single nucleotide of 
exon 7.  As exon 7 has been shown to be important in DNA binding and dimerisation  
(Williams and Tjian, 1991a; Williams and Tjian, 1991b) (Figure 4.2) it is predicted that 
this allele will not produce a functional protein. The floxed allele contains loxP sites 
inserted into the introns flanking exons 5 and 6 (Brewer et al., 2004).  These exons also 
form part of the DNA binding and dimerisation domains and are therefore important 
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for the function of the protein (Williams and Tjian, 1991a; Williams and Tjian, 1991b) 
(Figure 4.2).   
To confirm that the insertion of the loxP sites did not alter the exon-intron boundaries 
of the conditional allele the genomic DNA sequence for Tcfap2a was obtained from the 
Ensembl database and loxP sequences were inserted at the appropriate positions.  The 
sequences between the two loxP sites was removed and the coding sequence was 
input into the GENESCAN web server.  This server generated the amino acid sequence 
of the recombined transcript, which was compared to the wild type protein using a 
multiple sequence alignment tool.  This revealed that the removal of exons 5 and 6 did 
not disrupt the open reading frame, but simply removed the amino acids coded for by 
these exons (Figure 4.9).  Therefore, if a protein were to be produced from this allele, 
it would contain the same sequence as the wild type protein but without the portions 
of the sequence contributed by these exons.  
  
Figure 4.9: Multiple sequence alignment of wild type and recombined protein sequences. 
Multiple sequence alignment reveals that the removal of exons 5 and 6 does not disrupt the open reading frame of 
the protein. *, conserved residue; :, residues have similar properties. 
Exons 5 and 6 contribute to the DNA binding domain, the first α-helix and a portion of 
the span domain.  In the absence of these exons, the resultant protein would contain a 
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transactivation domain, some of the DNA binding domain, a portion of the span and 
the final α-helix.  It is therefore possible that the recombined allele may produce a 
protein with some reduced function, which may cause the incomplete recapitulation of 
the Tcfap2a-null phenotype.   
Therefore, we chose to investigate if the cre-recombined allele was capable of 
producing a protein product using western blotting.  Wild type AP-2α has a molecular 
weight of 48 kDa.  The removal of 87 amino acids in the cre-recombined allele will 
reduce the size of any resulting protein.  Protein prediction software was used to 
predict the molecular weight of the protein produced from the Tcfap2aflox allele.  The 
molecular weight of this mutant protein would be 38.4 kDa 
Heterozygous (Tcfap2a+/f;PGKcre) and mutant (Tcfap2af/f;PGKcre) embryos were 
collected at e10.5 and lysed in denaturing conditions. Samples were run on a gel, 
transferred to a PVDF membrane and then detected using an anti-AP-2α antibody, 
which detects an antigen at the N-terminus of the protein.  A 50 kDa band 
corresponding to wild type AP-2α was identified in the heterozygous controls (Figure 
4.10), but absent from the mutant samples.  Furthermore, no band corresponding to 
the predicted 38.4 kDa mutant protein was observed in the Tcfap2af/f;PGKcre mutant 
samples.  The membrane was stripped and re-probed for γ-tubulin to control for 
difference in loading quantities. 
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Figure 4.10: PGKcre-mediated recombination of the Tcfap2a conditional allele is unable to produce a protein 
product. 
Western blot analysis of control (Tcfap2a
+/f
) and mutant (Tcfap2a
f/f
;PGKcre) embryos demonstrates the presence of 
wild type AP-2α  (50kDa band) in control samples, which is not found in mutant samples.  No further protein 
product relating to the recombined transcript is observed.  The additional band at 60 kDa is due to non-specific 
binding of the antibody.  A γ-tubulin antibody was used as a loading control. 
We conclude that the deletion of exons 5 and 6 results in a non-functional protein, 
which is therefore degraded, and unable to cause the reduction in phenotype 
observed in the Tcfap2af/f;PGKcre mutant embryos. 
4.2.2. Tcfap2af/-;PGKcre mutants (97.2% C57BL/6J) 
After further rounds of breeding we were able to generate a stud male of genotype 
Tcfap2a+/-;PGKcre for timed matings with Tcfap2af/f females, through a breeding 
strategy similar to that described for the Wnt1cre male in the previous chapter. This 
will allow the results to be directly comparable.  Embryos from this cross were 
collected at e15.5 and displayed an external phenotype identical to that of both 
Tcfap2a-/- and Tcfap2af/f;PGKcre mutant embryos examined previously.   These 
embryos were examined by MRI for the presence of cardiovascular defects and 3D 
reconstructions were generated.   
Of the 10 mutants examined 7 carried a VSD.  7 mutants also had OFT defects in the 
form of DORV.  Although these phenotypes overlapped in most cases (6/7), one 
mutant had a VSD with no OFT defect, and a further embryo with DORV had a fully 
formed interventricular septum.  No other OFT defects were observed in this dataset. 
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Figure 4.11: 3D reconstructions of the cardiovascular phenotypes in Tcfap2a
f/-
;PGKcre mutant embryos. 
(a) control, (b) mutant with full phenotype (CORSA, IAA,VSD, DORV), (c) mutant with full phenotype (RAA and I-LSA, 
DORV, VSD), (d) OFT + PAA defects (CORSA, IAA, DORV), (e) VSD + PAA defects (VSD, CORSA, cAoA), (f) PAA defects 
only (CORSA, cAoA).  Scale bar = 600 μm. (n=10). 
Defects of the fourth left PAA were observed in 50% (5/10) of embryos.  The most 
common of these defects was a cAoA, seen in 40% (4/10) embryos.  Another embryo 
had an IAA.  An RAA was also observed in 10% (1/10) of mutant embryos in this case.  
This defect was accompanied by an isolated left subclavian artery (I-LSA).  CORSA was 
the only defect affecting the fourth right PAA in these embryos.  This was observed in 
90% (9/10) of embryos examined.  These defects are summarised in Table 4-2 below. 
Table 4-2: Prevalence of CCVM in Tcfap2a
f/-
;PGKcre mutant embryos at e15.5 compared to Tcfap2a
-/-
 embryos. 
CCVM Prevalence 
(n=10) 
Summary Prevalence in 
Tcfap2a-/-  
Summary for 
Tcfap2a-/- 
VSD 70% VSD – 70% 100% VSD – 100% 
OA 0% 
OFT defects - 
70% 
30% 
OFT defects – 
100% 
DORV 70% 20% 
TGA 0% 50% 
IAA 10% 
Left 4th PAA 
defects – 50% 
30% 
Left 4th PAA 
defects – 50% 
cAoA 40% 20% 
Hypo AoA 0% 0% 
A-RSA 0% Right 4th PAA 
defects – 90% 
40% Right 4th PAA 
defects – 90% CORSA 90% 50% 
RAA 10% RAA with I-LSA 
– 10% 
10% RAA with I-LSA 
– 10% I-LSA 10% 10% 
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Overall, these embryos had a slightly higher penetrance of VSD than that seen in the 
Tcfap2af/f;PGKcre mutant embryos (70% vs. 60%).  An increased incidence of OFT 
defects was also observed, however, there was also a decrease in the range of OFT 
defects.  In the previous Tcfap2af/f;PGKcre mutants, 40% of embryos had an OFT 
defect, which consisted of two cases of DORV and two incidences of OA.  In this cross, 
we now see 70% incidence of OFT defects in the form of DORV only.  Further, the 
variety of defects affecting the fourth PAAs is altered.  In the previous PGKcre mutants 
we saw 50% left PAA defects (IAA, cAoA, hypoAoA) and 100% right fourth PAA defects 
(A-RSA, CORSA).   In contrast, although in this cross we saw similar numbers of each 
PAA defect (50% left PAA, 90% right PAA) there were no incidences of A-RSA observed 
in these mutants, nor were there any cases of hypoplastic aortic arch. 
4.2.3. Sox2cre (97.68% C57BL/6J) 
As PGKcre deletion of Tcfap2a failed to recapitulate the phenotype observed in the 
global knockouts we chose to attempt to recapitulate the phenotype using a further 
ubiquitously expressed cre line, Sox2cre.  Due to the difficulties we encountered in 
generating Tcfap2a+/-;PGKcre stud males above, we employed two different breeding 
strategies in order to obtain either a Tcfap2a+/-;Sox2cre or Tcfap2a+/f;Sox2cre stud 
male.  Once generated, these males were crossed to Tcfap2af/f females in order to 
generate mutant embryos with a ubiquitous deletion of Tcfap2a.  
4.2.3.1. Evidence of linkage between Sox2cre and Tcfap2a 
Embryos from both breeding strategies were collected at e15.5 and their phenotypes 
and genotypes analysed.  It became immediately apparent that there was a reduction 
in the number of mutant embryos collected in both crosses, compared to the expected 
mendelian ratios (see Table 4-3).  As Tcfap2a-/- mutant embryos are able to survive to 
birth (Schorle et al., 1996; Zhang et al., 1996; Brewer et al., 2002), this suggested that 
the loss of mutants is likely to be due to the Sox2cre transgene in these embryos.  In 
addition, there was a reduction in the number of embryos of a ‘wild type’ (Tcfap2a+/f) 
genotype obtained, suggesting that there may be genetic linkage between the Sox2cre 
transgene and the Tcfap2a locus. 
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Table 4-3: Frequency of each genotype obtained in breeding for a Sox2cre stud male. 
Tcfap2a
+/-
;Sox2cre male Tcfap2a
+/f
;Sox2cre male   
Genotypes no. (%) Genotypes no. (%) Total Expected 
Tcfap2a
+/f 
16 (12.9%) Tcfap2a
+/f 
3 (16.7%) 19 (13.4%) 25% 
Tcfap2a
f/- 
50 (40.3%) Tcfap2a
f/f 
6 (33.3%) 56 (39.4%) 25% 
Tcfap2a
+/f
;Sox2cre 53 (42.7%) Tcfap2a
+/f
;Sox2cre 7 (38.9% 60 (42.25%) 25% 
Tcfap2a
f/-
;Sox2cre   5 (4%) Tcfap2a
f/f
;Sox2cre 2 (11.1%) 7   (4.9%) 25% 
Total 124 Total 18 142  
 
The Sox2cre mouse is a transgenic line generated by random integration of the Sox2cre 
transgene into the genome at an undefined genetic locus. As this line was generated 
using wild type mice, if the transgene is in close proximity to the Tcfap2a locus then it 
will be linked to a wild type allele (Figure 4.12a).  When a Sox2cre positive animal is 
bred with a Tcfap2a+/- mouse, both the Sox2cre transgene and the Tcfap2a-null allele 
will be transmitted to offspring equally, resulting in genotypes of the expected 
Mendelian ratios (Figure 4.12a).  When the Tcfap2a+/-;Sox2cre male is then crossed to 
a Tcfap2af/f female, the Sox2cre transgene will co-segregate most often with the wild 
type allele (Figure 4.12b).  Therefore, a recombination event during gametogenesis is 
required in order for the Sox2cre transgene to segregated with the Tcfap2a-null allele, 
producing the recombinant wild type (Tcfap2a+/f) and mutant (Tcfap2af/-;Sox2cre) 
genotypes (Figure 4.12c). 
A simple calculation can be used to calculate the genetic distance between the two loci 
in terms of centimorgans (cM).  This distance is calculated based on the rate of 
recombination between the two loci.  A total of 26 recombinant genotypes were 
obtained from a total of 142 embryos.  Therefore, the recombination frequency is 
18.3%, indicating that the distance between the two loci is 18.3 cM.  
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Figure 4.12: Segregation of allele in the breeding strategy designed to generate a Sox2cre stud male. 
(a) Breeding a Sox2cre-positive male to a Tcfap2a
+/-
 female results in the generation of four different genotypes.  In 
each genotype the Sox2cre transgene is linked to a wild type allele of Tcfap2a.  (b)  Breeding Tcfap2a
+/-
;Sox2cre 
offspring from the cross in (a) with a Tcfap2a
f/f
 results in only two possible genotypes of offspring. (c)  If 
recombination occurs in the region between the Tcfap2a locus and the insertion site of the Sox2cre  transgene then 
Sox2cre may be linked to the Tcfap2a-null allele.  This will then result in the recombinant genotypes shown. 
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4.2.3.2. Breeding strategy 
In order to generate enough mutant embryos for analysis of cardiovascular 
development we chose to generate a ‘recombinant’ male of the genotype 
Tcfap2a+/f;Sox2cre, in which the Tcfap2aflox allele and Sox2cre transgene occur on the 
same chromosome.  To generate this, a non-recombinant Tcfap2a+/f;Sox2cre male was 
crossed to wild type C57BL/6J females.  Any male offspring of this cross with the 
genotype Tcfap2a+/f;Sox2cre will be a recombinant and has inherited both the 
Tcfap2aflox allele and the Sox2cre transgene from the male (Figure 4.13).   
Using this breeding strategy we were able to generate enough Tcfap2af/f;Sox2cre 
mutant embryos to analyse the cardiovascular phenotype by MRI.  Further evidence of 
linkage between the Tcfap2a locus and the Sox2cre transgene was provided in the 
generation of these mutant embryos.  The genotypes previously considered to be 
recombinant (Tcfap2a+/f and Tcfap2af/f;Sox2cre) were now obtained at much higher 
frequencies, similar to the frequencies previously seen with the non-recombinant 
genotypes (Tcfap2af/f and Tcfap2a+/f;Sox2cre).  In addition those genotypes previously 
regarded as non-recombinant were now obtained at similar frequencies to the 
previously regarded as recombinant genotypes. 
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Figure 4.13: Breeding strategy for the generation of Tcfap2a
f/f
;Sox2cre mutant embryos. 
(a) A Tcfap2a
+/f
;Sox2cre male was crossed to wild type C57BL/6J females.  Due to the presumed linkage between the 
Tcfap2a locus and the Sox2cre transgene the majority of offspring from this cross will be of non-recombinant 
genotypes, as shown here.  (b)  If recombination occurs in (a) the Sox2cre transgene will be linked to the Tcfap2a
f
 
allele, resulting in the recombinant genotypes shown.  (c)  Using recombinant male offspring of the genotype 
Tcfap2a
+/f
;Sox2cre generated in (b), we can cross with Tcfap2a
f/f
 females to produce offspring of the genotype 
Tcfap2a
f/f
;Sox2cre. 
4.2.3.3. External phenotype 
Embryos were collected at e15.5 and examined for external malformations.  The 
phenotypes observed in these mutant embryos conform to the external phenotype of 
Tcfap2a-/- mutant embryos (Figure 4.14). 
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Figure 4.14: The external phenotype of Tcfap2a
f/f
;Sox2cre mutant embryos phenocopies Tcfap2a
-/-
 mutant 
embryos. 
(a) Control (Tcfap2a
+/f
;Sox2cre) embryo with normal external phenotype.  (b-d) Mutant (Tcfap2a
f/f
;Sox2cre) 
embryos with variable external malformations, which phenocopy Tcfap2a
-/-
 mutant embryos.  Scale bar = 2mm. 
(n=11). 
4.2.3.4. Cardiovascular phenotype 
Tcfap2af/-;Sox2cre mutant embryos were examined at e15.5 by MRI analysis.  The 
phenotype of the Tcfap2a-/- mutants was not fully recapitulated in these mutant 
embryos.  Of the 11 mutant embryos examined only 4 displayed the full CCVM 
phenotype seen in the Tcfap2a-/- mutants (Figure 4.15c-e).  Other embryos carried 
variations of the full Tcfap2a-/- phenotype, including VSD with OFT malformation (1/11, 
9.09%) (Figure 4.15f), VSD and PAA malformations (2/11, 18.18%), OFT defect and PAA 
malformations (1/11, 9.09%) (Figure 4.15g) and PAA malformations only (1/11, 9.09%) 
(Figure 4.15i).  In addition, 2 of the mutant embryos had no CCVM at all (Figure 4.15j). 
The most common OFT defect was OA, which occurred in 36.36% embryos (4/11), 
while DORV was seen in only 18.18% (2/11) of mutant embryos.  TGA was not 
observed in any of the mutants in this dataset.  The most common PAA malformation 
in this group was CORSA, which occurred in 45.45% (5/11) of mutant embryos.  IAA 
(18.18%, 2/11), A-RSA (9.09%, 1/11) and cAoA (9.09%, 1/11) were also found in a small 
number of mutant embryos.  A single embryo with a RAA was also identified.  
Interestingly, this RAA arose from a more cervical position along the brachiocephalic 
trunk suggesting a bilateral absence of the fourth PAAs, with persistence of the right 
carotid duct to connect the ascending aorta to the dorsal aorta.  The penetrance of 
these defects is summarised in Table 4-4. 
   
 
Figure 4.15: 3D reconstructions of the cardiovascular phenotype of Tcfap2a
f/f
;Sox2cre mutant embryos. 
(a-b) Ventral (a) and dorsal (b) views of a control (Tcfap2a
+/f
;Soxcre) embryo heart with normal cardiovascular development. (b-g) Mutant (Tcfap2a
f/f
;Sox2cre) embryos with various cardiovascular 
malformations: (c-d) Ventral (c) and dorsal (d) views of an embryo with the full phenotype consisting of a VSD,  OFT defect (OA) and a PAA malformation (A-RSA);  (e) Ventral view of an embryo with 
the full phenotype consisting of a RAA which appears at a more cervical position (cervical RAA, cRAA), a VSD and OA; (f) mutant embryo with VSD and OFT malformations (OA) only; (g) mutant 
embryo with a VSD and PAA malformations (IAA) only; (h) a mutant embryo with malformations of the OFT (DORV) and PAAs (IAA, CORSA) only; (i) a mutant embryo with defects of the PAAs (CORSA) 
only; (j) mutant embryo with no cardiovascular defects.  Scale bar = 500 μm. (n=11). 
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Table 4-4: Prevalence of CCVM in Tcfap2a
f/f
;Sox2cre mutant embryos at e15.5 compared to Tcfap2a
-/-
 embryos. 
CCVM Prevalence 
(n=11) 
Summary Prevalence in 
Tcfap2a-/-  
Summary for 
Tcfap2a-/- 
VSD 54.54% VSD – 54.54% 100% VSD – 100% 
OA 36.36% 
OFT defects - 
54.54% 
30% 
OFT defects – 
100% 
DORV 18.18% 20% 
TGA 0% 50% 
IAA 18.18% 
Left 4th PAA 
defects – 27.27% 
30% 
Left 4th PAA 
defects – 50% 
cAoA 9.09% 20% 
HypoAoA 0% 0% 
A-RSA 9.09% Right 4th PAA 
defects – 54.54% 
40% Right 4th PAA 
defects – 90% CORSA 45.45% 50% 
RAA 9.09% 
RAA only – 9.09% 
10% RAA with I-LSA 
– 10% I-LSA 0% 10% 
 
4.2.3.5. Transcript analysis 
To exclude the possibility that Sox2cre does not cause efficient recombination between 
the loxP sites within the Tcfap2aflox allele, embryos were collected at e9.5 for RT-PCR 
analysis.  Whole RNA was extracted from these embryos and used to synthesise cDNA 
which was used in RT-PCR reactions.  Using primers that span the floxed region we 
were able to determine that successful recombination of the loxP sites has occurred by 
e9.5 in Tcfap2af/f;Sox2cre mutant embryos, and no wild type transcripts were observed 
(Figure 4.16).  We have already demonstrated that this recombined transcript is not 
translated to produce a protein product (see section 4.2.1.4). 
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Figure 4.16: RT-PCR demonstrates efficient recombination of the Tcfap2a
flox
 allele by Sox2cre. 
Top panel:  Tcfap2a expression was investigated using primers spanning the floxed region and demonstrates a large 
(~663 bp) band in control (Tcfap2a
+/f
;Sox2cre) embryos, corresponding to the wild type transcript.  In mutant 
embryos (Tcfap2a
f/f
;Sox2cre) a smaller band (~402 bp) was observed, corresponding to the product of a recombined 
allele. 
4.2.4. Tcfap2a+/Δ x Tcfap2a+/Δ (98.28% C57BL/6J) 
The use of both PGKcre and Sox2cre failed to recapitulate the phenotype observed in 
the Tcfap2a-/- embryos.  The Tcfap2af/f;PGKcre and Tcfap2af/f;Sox2cre mutants differ 
from the Tcfap2a-/- mutants both in the timings of deletion and the exons which are 
removed by each mutation.  To investigate if these factors were affecting the 
phenotype observed we generated Tcfap2aΔ/Δ mutants (where Δ or ‘del’ refers to the 
deletion of the recombined allele) by the intercrossing of mice with recombined alleles 
of Tcfap2aflox (recombined by Sox2cre) (Figure 4.17).  The Tcfap2a+/f;Sox2cre stud male 
generated by the breeding strategy described above (see 4.2.3.2) was used to produce 
both male and female offspring of the genotype Tcfap2a+/Δ.  These offspring were then 
intercrossed to generateTcfap2aΔ/Δ mutant embryos. 
4.2.4.1. External phenotype 
Embryos were collected at e15.5 for MRI analysis.  The external phenotype resembled 
that of the Tcfap2a-null mutant embryos and the other crosses described within this 
chapter (Figure 4.18). 
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Figure 4.17: Breeding strategy for the generation of Tcfap2a
Δ/Δ
 mutant embryos. 
A Tcfap2a
+/f
;Sox2cre male was crossed to wild type females to generate Tcfap2a
+/Δ
 mice in which the Tcfap2a
flox
 
allele has been recombined by Sox2cre.  Tcfap2a
+/Δ
 mice were intercrossed to generate Tcfap2a
Δ/Δ
 mutant embryos. 
 
 
Figure 4.18:  The external phenotype of Tcfap2a
Δ/Δ
 mutant embryos recapitulates the phenotype of Tcfap2a
-/-
 
mutant embryos. 
(a)  Control (Tcfap2a
+/Δ
) embryo showing a normal external phenotype. (b-d) Mutant (Tcfap2a
Δ/Δ
) embryos showing 
variable external malformations.  Scale bar = 2mm. (n=12). 
4.2.4.2. Cardiovascular phenotype 
Mutant embryos from timed matings of Tcfap2a+/Δ parents were collected at e15.5 for 
MRI analysis.  As with the Tcfap2af/f;Sox2cre mutant embryos, these mutant embryos 
failed to recapitulate the cardiovascular phenotype observed with Tcfap2a-/- mutant 
embryos.  Of the 12 mutant embryos examined only 3 (25%) had the full phenotype 
associated with Tcfap2a-null embryos (Figure 4.19b).  A further 7 embryos (58.33%) 
had only PAA malformations (Figure 4.19d, f) and two further embryos (16.67%) had a 
VSD and OFT defect in the absence of PAA malformations (Figure 4.19c).   
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Figure 4.19: 3D reconstructions of the cardiovascular malformations observed in Tcfap2a
Δ/Δ
 mutant embryos. 
(a) A ventral view of a control (Tcfap2a
+/Δ
) embryo showing normal cardiovascular development. (b-d) Ventral views 
of mutant (Tcfap2a
Δ/Δ
) embryos with a variety of cardiovascular phenotypes: (b) A mutant embryo with the full 
phenotype of cardiovascular malformations consisting of a VSD, an OFT defect (DORV) and PAA malformations 
(IAA);  (c) A mutant embryo with a VSD  and OFT defect (OA) only; (d) a mutant embryo with PAA malformations 
only (CORSA).  (e) A dorsal view of a control embryo with normal cardiovascular development. (f) A dorsal view of a 
mutant embryo with PAA malformations only (A-RSA). Scale bar = 500 μm.  (n=12). 
A VSD was observed in 41.67% (5/12) of mutant embryos.  The observed OFT defects 
were OA and DORV, which occurred in 25% (3/12) and 16.67% (2/12) of mutant 
embryos respectively, and always in the presence of a VSD.  PAA malformations 
occurred more commonly on the right (75%, 9/12) than the left (8.33%, 1/12), with the 
most common defect being CORSA (58.33%, 7/12).  A-RSA (16.67%, 2/12) and IAA 
(8.33%, 1/12) occurred less often in these mutant embryos.  None of these mutant 
embryos exhibited normal cardiovascular development (Table 4-5). 
 
Table 4-5: Prevalence of CCVM in Tcfap2a
Δ/Δ
 mutant embryos at e15.5 compared to Tcfap2a
-/-
 embryos. 
CCVM Prevalence 
(n=9) 
Summary Prevalence in 
Tcfap2a-/-  
Summary for 
Tcfap2a-/- 
VSD 41.66% VSD – 41.66% 100% VSD – 100% 
OA 25% 
OFT defects – 
41.66% 
30% 
OFT defects – 
100% 
DORV 16.67% 20% 
TGA 0% 50% 
IAA 8.33% 
Left 4th PAA 
defects –8.33% 
30% 
Left 4th PAA 
defects – 50% 
cAoA 0% 20% 
Hypo AoA 0% 0% 
A-RSA 16.66% Right 4th PAA 
defects – 75% 
40% Right 4th PAA 
defects – 90% CORSA 58.33% 50% 
RAA 0% No defects 
observed 
10% RAA with I-LSA – 
10% I-LSA 0% 10% 
 Recapitulating the Tcfap2a-/- phenotype using the Tcfap2aflox line 
133 
 
4.2.5. Tcfap2a and Wnt1cre expression analysis 
The data collected from the above experiments demonstrates that the CCVM observed 
in Tcfap2a-/- mutant embryos cannot be fully recapitulated using the Tcfap2aflox allele.  
However, the penetrance of CCVM observed in the NCC-specific conditional deletion 
was much lower than that observed here.  We, therefore, wanted to investigate the 
timing of Tcfap2a and Wnt1cre expression to confirm the ability of this cre line to fully 
recombine the Tcfap2aflox allele, before the Tcfap2a locus becomes active. 
Embryos were collected at e7.5, e8.0 and e8.5 for analysis by RT-PCR.  RNA was 
extracted from the samples and cDNA synthesis was carried out for use in RT-PCR 
reactions.  Four cre-positive and four cre-negative samples were examined at each 
stage.  To investigate the temporal expression of Wnt1cre within our embryos we used 
primers designed to bind within the Cre cDNA sequence of the expressed transcript.  
As these primers were not specific to the transcript and will also bind to genomic DNA, 
we used another primer pair, binding to Cited2, in order to distinguish between cDNA 
and genomic DNA contamination. These primers bind within exons 1 and 2 of the 
Cited2 gene, and span a small intervening intron.  Therefore, in the presence of 
genomic DNA contamination these primers will produce an additional larger band.  To 
investigate Tcfap2a expression in these embryos we used primers spanning the floxed 
region (described in sections 4.2.1.3 and 4.2.3.5 above).  This allowed us to determine 
both the timing of normal Tcfap2a activation, and whether the Cre transcript has been 
translated into a functional enzyme and induced recombination within the Tcfap2aflox 
allele.  GAPDH was used as a housekeeping gene. 
At e7.5, neither Tcfap2a nor Wnt1cre are expressed, however, low levels of GAPDH 
expression were observed (Figure 4.20).  By e8.0, expression of Wnt1cre is visible in 
cre-positive samples only.  This product relates to the mRNA transcript, not the Cre 
cDNA within the genome, as the Cited2 primers demonstrate that there is no 
contaminating genomic DNA within these samples.  Expression of Tcfap2a is also 
observed at this stage and two bands, pertaining to the wild type and recombined 
transcript, were found in cre-positive sample 1.  However, cre-positive sample 2 shows 
low levels of Wnt1cre expression in addition to only a single, wild type band for 
Tcfap2a.  Although this result was only observed in a single sample, the sample in 
question was generated from an embryo of a younger age than the other samples (1 
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somite stage, compared to 3-4 somite stage embryos used for other samples).  
Therefore, it is possible that in this sample the Tcfap2a locus is already active, while 
the Cre transcript is still being translated.  If this were the case it would allow some 
wild type Tcfap2a transcripts, and therefore wild type AP-2α protein, to be produced 
before the conditional removal of exons 5 and 6.  By e8.5 Wnt1cre expression is 
reduced and both wild type and recombined bands are observed for Tcfap2a.  
 
Figure 4.20: RT-PCR analysis of the temporal expression patterns of Tcfap2a and the Wnt1cre transgene. 
Expression of Tcfap2a and the Wnt1cre transgene was examined at e7.5 (left), e8.0 (middle) and e8.5 (right).  Top 
panel: Expression of Wnt1cre transgene.  Second panel: Expression of Tcfap2a wild type (663 bp) and recombined 
(402 bp) transcripts. Third panel: Expression of Cited2 was examined to control for gDNA contamination. Bottom 
panel: Expression of GAPDH was examined as an internal control. Four cre-positive and four cre-negative samples 
were examined at each stage, representative images shown. 
4.3. Discussion 
In the previous chapter, we demonstrated the low penetrance of CCVM associated 
with conditional deletion from the NCCs, and the complete lack of CCVM in embryos 
with a conditional deletion from the NCCs and PSE.  In this chapter we attempted to 
understand the reasons for this low penetrance. Tcfap2a is strongly expressed 
between e8.5 and e11.5 in various tissues of the developing mouse embryo.  However, 
expression within tissues contributing to the developing cardiovascular system is 
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restricted to the NCCs and the PSE.  Therefore, it is possible that the inability to 
recapitulate the cardiovascular defects observed in Tcfap2a-/- embryos in these crosses 
is the result of some intrinsic problems in the Tcfap2aflox allele used here, or in the 
timings of expression of the tissue-specific cre lines examined in the previous chapter.    
Therefore, to address these questions, a series of ubiquitously expressed cre lines, 
which are expressed early in embryonic development, were used. 
4.3.1. CCVM is not secondary to external malformations 
Tcfap2a-/- embryos exhibit a very severe external phenotype characterised by 
anencephaly, a ventral body wall defect and severe craniofacial malformation (Schorle 
et al., 1996; Zhang et al., 1996; Brewer et al., 2002).  Each of these phenotypes may 
cause alterations to the haemodynamics of the developing embryo or allow the 
developing organs to be exposed to the external environment.  It is therefore possible 
that the cardiovascular defects observed in Tcfap2a-/- mutant embryos are the result of 
the severe external malformations observed.  As a very limited number of CCVMs were 
identified in the tissue-specific mutants, it is possible that the inability to recapitulate 
the cardiovascular phenotype was a result of the low penetrance of external 
phenotypes observed in these embryos. 
PGK is a glycolytic enzyme and is therefore expected to be expressed at different levels 
in various tissues, owing to their different metabolic requirements (McBurney et al., 
1994).  Examination of the mutant embryos collected revealed very similar external 
phenotype to that seen in the Tcfap2a-/- mutant embryos. However, MRI analysis of 
these embryos demonstrated that there were variations in the levels of CCVM 
observed in mutant embryos, despite the similarities between external phenotypes. 
This, therefore, suggests that the presence of CCVM is independent of the external 
malformations observed. Four different breeding strategies were employed 
throughout this chapter.  Of the embryos examined under these four breeding 
strategies, less than half (39.5%, 17/43) had the full cardiovascular phenotype of the 
Tcfap2a-/- embryos described in the preliminary data (see section 1.5.1).  Of those 
embryos failing to adhere to the full phenotype many different combinations of these 
defects were observed (Table 4-6).  Approximately one third of mutant embryos (35%, 
15/43) had only a PAA malformation.  The remaining embryos had a variety of 
combinations of the phenotypes which occurred at low penetrance.  Interestingly, 
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across the 4 different breeding strategies employed within this chapter, there were no 
cases in which either VSD or OFT defects occurred alone.  In addition, these two 
phenotypes were found together in 46.5% (20/43) of mutant embryos.  This indicates 
that these two elements of the phenotype may be linked by a common mechanism of 
development.  However, less than 15% (13.95%, 6/43) of mutant embryos had only 
one of these phenotypes, in the presence of a PAA malformation.  This suggests that 
the correct alignment of the OFT may be dependent on the formation of the 
interventricular septum or that the septation of the ventricles relies on correct OFT 
alignment.  It has been previously suggested that in Tbx1 mutant embryos the VSD 
phenotype is the result of PTA, in that the abnormal aorticopulmonary septum is 
unable to fuse to the forming interventricular septum (Arnold et al., 2006).  Although 
in our data the aorticopulmonary septum forms, but is simply misaligned, it is possible 
the phenotypes result from a similar mechanism.  Additionally, NCC ablation in chicken 
embryos has also demonstrated that DORV and OA often occur in the presence of a 
VSD (Nishibatake et al., 1987). 
 
Table 4-6:  Summary of the variety of CCVM observed in each mutant genotype examined in this chapter. 
Genotype Tcfap2af/f; 
PGKcre 
Tcfap2af/-; 
PGKcre 
Tcfap2af/f; 
Sox2cre 
Tcfap2aΔ/Δ Total 
Full phenotype* 4 (40%) 6 (60%) 4 (36.36%) 3 (25%) 17 (39.5%) 
OFT and PAA 
defects 
- 1 (10%) 1 (9.09%) - 2 (4.65%) 
VSD and OFT 
defects 
- - 1 (9.09%) 2 (16.67%) 3 (7%) 
VSD and PAA 
defects 
1 (10%) 1 (10%) 2 (18.18%) - 4 (9.3%) 
PAA defects 
only 
5 (50%) 2 (20%) 1 (9.09%) 7 (58.33%) 15 (35%) 
No CCVM - - 2 (18.18%) - 2 (4.65%) 
All numbers given above indicate the total number of embryos with each phenotype, with percentages given in 
brackets. 
* The full phenotype is defined as a VSD, an OFT defect and a PAA malformation and was observed at 100% 
penetrance in Tcfap2a
-/-
 mutant embryos. 
In addition, analysis of Tcfap2af/f;Sox2cre mutant embryos revealed two embryos with 
normal cardiovascular development despite severe external malformations.  Therefore 
it appears that the external malformations do not cause the cardiovascular phenotypes 
observed and that these phenotypes also occur independently.  Further, one of the 
embryos from the Tcfap2aΔ/Δ dataset, which had a PAA defect, also exhibited a mild 
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ventral wall defect in comparison to other mutant embryos (see Figure 4.18b).  This 
suggests that the external phenotype is completely independent of the cardiovascular 
phenotype. 
4.3.2. The Tcfap2aflox conditional allele 
The Tcfap2aflox allele was generated by the insertion of loxP sites within introns 4 and 6 
of the Tcfap2a gene.  In the presence of cre this results in the excision of exons 5 and 
6.  The work presented in this chapter demonstrates that both PGKcre and Sox2cre are 
able to successfully recombine the Tcfap2aflox allele throughout the embryo by e9.5.  
However, western blotting revealed that this transcript failed to produce a functional 
protein by e10.5, therefore suggesting that any protein product from this allele is 
rapidly degraded and is therefore unlikely to be involved in any transcriptional 
processes. 
The Tcfap2a-null allele was produced by the disruption of exon 7 of the Tcfap2a gene.  
We demonstrate in this chapter that the disruption of this exon does not prevent the 
production of a transcript; however, the ability of this transcript to be translated into 
protein was not investigated.  Any protein resulting from this transcript would contain 
only approximately half of the dimerisation domain of the protein and is, therefore 
unlikely to be functional (Figure 4.21b).  Sequence alignment of wild type and 
recombined transcripts revealed that any protein produced from the recombined 
allele would result in the removal of a portion of the basic DNA binding domain and 
the first helix and part of the span region of the dimerisation domain (Figure 4.21c).  
However, this transcript is not translated into a protein product. 
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Figure 4.21: The structure of AP-2α protein products of the Tcfap2a alleles examined in this thesis. 
(a)The structure of wild type AP-2α protein with the structural domains indicated.  The regions disrupted by the 
conditional and null alleles are indicated below.  (b)  The structure of the protein product of the null allele.  The 
insertion of a LacZ cassette into exon 7 removes part of the span region and the second helix of the dimerisation 
domain. (c) The structure of the protein product of the recombined conditional allele.  Recombination between loxP 
sites results in removal of part of the basic DNA binding domain in addition to the first helix and part of the span 
region of the dimerisation domain. 
Two previous Tcfap2a-null alleles have been produced to investigate the role of this 
gene in development (Schorle et al., 1996; Zhang et al., 1996).  These null alleles varied 
from that produced by Brewer et al. (2002) in the positions of the mutations.  Schorle 
et al. (1996) disrupted Tcfap2a by replacing exon 5 with a neomycin cassette, whereas 
Zhang et al. (1996) removed exon 6 and the first 3 nucleotides of exon 7 by a similar 
technique.  Both mutations result in the same severe external phenotype observed 
here, however, these authors did not describe any cardiovascular defects in these 
mutants.  Brewer et al. (2002) examined the cardiovascular defects of both the 
Tcfap2a-null allele, used within our work, and that produced by Zhang et al. (1996) and 
demonstrated complete penetrance of VSD and OFT defects, with a lower penetrance 
of PAA malformations.  However, there were slight variations between the OFT 
phenotypes observed in each of these models.  The OFT defect in the majority of 
embryos from these two models was DORV, however, the knock-out allele produced 
by Zhang et al. (1996) also resulted in 40% (2/5) of mutants with PTA.  In addition, 60% 
(3/5) of these mutant embryos also had a malformation of the PAAs (IAA and A-RSA), 
whereas the knock-in allele created by Brewer et al. (2002) produced no mutant 
embryos with PTA and only a single mutant embryo with PAA malformations (A-RSA, 
10%, 1/10) (Brewer et al., 2002).  Although the authors do not describe the genetic 
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background of the knock-out allele it is likely that both strains were maintained on a 
black swiss background and that this is not a factor in the variation of the phenotypes 
observed.  Therefore, it is possible that the differences in the regions which are 
disrupted in the two alleles are the cause of the variations in the CCVM observed.  
4.3.3. Conditional mutations of Tcfap2a are unable to recapitulate the null 
phenotype 
Throughout this chapter a number of attempts have been made to recapitulate the 
phenotype observed in the Tcfap2a-/- mutant embryos, using various cre lines and 
breeding strategies.  However, each strategy has proven unsuccessful.  The conditional 
allele contains loxP sites within introns 4 and 6, which in the presence of Cre 
recombinase undergo recombination to excise the intervening sequence pertaining to 
exons 5 and 6.  These exons encode a major part of the DNA binding and dimerisation 
domains of AP-2α and in vitro analysis has demonstrated that both functions are lost in 
mutant transcripts with deletions within these regions (Williams and Tjian, 1991a; 
Williams and Tjian, 1991b).  It is therefore expected that upon efficient recombination 
this allele would behave as a null. 
In this chapter we have demonstrated that both PGKcre and Sox2cre are capable of 
efficient recombination of the loxP sites within the Tcfap2aflox allele by e9.5 of 
development.  In addition, western blotting analysis failed to detect a protein product 
in these mutant embryos, suggesting that this transcript is incapable of translation or 
that any protein produced is rapidly degraded.  As these embryos were collected at 
e10.5, a stage at which Tcfap2a is highly expressed, we would expect that any 
translated product would be visible in a western blot at this stage.  It therefore 
appears that the recombined conditional allele does behave as a null allele in the sense 
that it results in no functional protein product.   
However, recombination of this allele using two independent Cre lines failed to 
recapitulate the full cardiovascular phenotype observed in the global mutant embryos.  
One possibility for this discrepancy is the alteration in genetic background between the 
various lines under examination.  However, this alteration is minor and unlikely to 
cause such severe changes to the cardiovascular phenotype.  Another possibility is that 
recombination of the conditional allele within the genomic DNA is not complete by 
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e8.5, when Tcfap2a becomes active, but by e9.5 all alleles have been efficiently 
recombined.  This would allow the synthesis of some functional protein product which 
may activate downstream targets, but has degraded by e10.5 when western blot 
analysis was carried out. However, the Tcfap2aΔ/Δ mutants, produced by intercrossing 
mice which were heterozygous for a Sox2cre-recombined conditional allele, show a 
similar penetrance of cardiovascular defects to that observed in the other ubiquitously 
deleted conditional mutants.  This indicates that the reduced penetrance of 
cardiovascular defects observed in these mutant embryos are not the result of 
inefficient recombination of the cre enzyme or delayed activation of the cre gene. 
It therefore appears that the discrepancies between the two models, the conditional 
mutant and the null-mutant are the result of intrinsic differences between the two 
alleles under investigation.  The work presented within this chapter demonstrates that 
the cre-mediated recombination of the conditional allele results in no protein product.  
Therefore, it suggests that the issue lies with the Tcfap2a-null allele, used in the 
production of the global knock-out phenotype, upon which we have based our 
investigations.  This allele incorporates a LacZ cassette into exon 7 of the Tcfap2a 
locus, which contains a portion of the HSH dimerisation domain required for the 
protein function.  As discussed above, disruptions in this region result in abolishment 
of DNA binding and dimerisation activity of the resulting protein.  It is therefore 
unlikely that this protein would be able to function as a transcription factor.  It is also 
unlikely that this product can act as a conventional DN protein by dimerisation with 
the wild type protein to prevent wild type homo- or heterodimer formation and DNA 
binding activity.  However, Buettner et al. (1993) characterised an alternatively spliced 
transcript consisting of the first five exons of the human TFAP2A gene only, which 
upon translation demonstrated DN activity.  The authors demonstrate that the DN-AP-
2α is incapable of binding to DNA or forming either homo- or heterodimers and 
proposed an indirect mechanism of inhibition, potentially mediated by additional 
factors provided by nuclear extracts in their experiments (Buettner et al., 1993). These 
authors later described a mechanism of AP-2 inhibition termed ‘transcriptional self-
interference’.  In this mechanism, overexpression of AP-2α results in a decrease in 
transcriptional activation due to the sequestration of coactivator molecules.  AP-2 
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dimers bound to target genes do not receive the required coactivator molecules and 
are therefore unable to activate transcription (Kannan et al., 1994).   
We propose a similar mechanism is active in the Tcfap2a-/- mutant embryos in which 
coactivator molecules required for target gene transcription are unavailable to all 
members of the AP-2 family, resulting in downregulation of target genes of these 
transcription factors (Figure 4.22).  It is interesting to note that of the four datasets 
investigated within this chapter, the Tcfap2af/-;PGKcre mutant embryos show the 
highest penetrance of CCVM.  These mutant embryos show full recapitulation of the 
fourth PAA defects observed in Tcfap2a-/- mutant embryos and 70% penetrance of VSD 
and OFT defects.  Overall, 60% of these mutant embryos recapitulate the full 
phenotype observed in the Tcfap2a-/- embryos.  This suggests that the presence of the 
Tcfap2a-null allele is capable of modifying the phenotype in some way.  Additionally, 
several authors have reported that whole gene deletions of TFAP2A in BOFS patients 
results in a milder phenotype to that seen in patients carrying missense mutations 
affecting only a few amino acids of the protein (Milunsky et al., 2008; Gestri et al., 
2009; Milunsky et al., 2011; LeBlanc et al., 2013; Li et al., 2013). Although, the 
phenotypes observed in BOFS are the result of heterozygous mutations within TFAP2A, 
it supports our suggestion that the presence of a mutant AP-2α protein is more 
deleterious than the complete absence of this transcription factor, as we see in the 
conditional mutants. 
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Figure 4.22: Model of transcriptional self interference in Tcfap2a-null allele. 
(a)  The wild type AP-2α protein forms dimers with other wild type AP-2 proteins and binds to coactivators 
molecules in order to activate transcription of target genes.  (b)  The mutant AP-2α protein produced from the 
Tcfap2a-null allele is unlikely to form dimers with any other AP-2 proteins.  However, this protein may bind to and 
sequester coactivator molecules, preventing them from binding to wild type proteins to activate transcriptional 
targets. 
4.3.4. Disadvantages of transgenic mouse lines 
The random integration of transgenes into the murine genome creates numerous 
issues for geneticists.  Although multiple copies of a single transgene may be 
integrated at various sites, this is usually controlled for using southern blotting 
techniques to select for embryonic stem cells with only a single copy of the transgene.  
However, other issues such as the location at which the transgene integrates and how 
this location impacts the expression of the transgene, are less readily controllable and 
the exact location of many transgenes within many mouse models remains unknown.  
For example, many cre lines become expressed in altered patterns due to the 
differential regulation by surrounding elements. 
As shown in this chapter, the lack of information about the location of a transgene 
further impedes genetics research using mouse models.  We demonstrated that 
Sox2cre is likely to have integrated into mouse chromosome 13, in close proximity to 
the Tcfap2a locus (approximately 18 Mb apart).  Once it was identified that the two 
loci were in linkage disequilibrium, we were able to generate a viable breeding 
strategy in order to achieve our goals.  However, if the location at which the transgene 
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had integrated was known prior to our investigation this would have guided our 
decisions on both which Cre lines to utilise and the appropriate breeding strategy for 
the generation of mutant embryos.   
Despite these issues, the use of transgenic mouse lines remains a more viable option 
than cre lines which are ‘knocked-in’ to a locus, as many of these cre lines replace the 
gene at this locus (as is the case with the Foxg1cre and Nkx2.5cre lines used in the 
previous chapter).   This can cause further difficulties as many of the genes used due to 
their specific expression within the developing heart, also have a role in the 
development of the cardiovascular system.  This, therefore, can result in the insertion 
of the cre line acting to modify the phenotype that would potentially be observed.  In 
these cases researchers need to be careful in interpreting results that may be the 
result of a genetic interaction between the two mutated loci rather that an effect of 
the deletion of the gene of interest in a specific tissue. 
An alternative to the methodology for the generation of tissue-specific Cre lines, is to 
insert the Cre cDNA into the 3’ untranslated region of the gene.  This requires the use 
of an IRES cassette upstream of the cDNA, both of which are inserted into the gene, 
between the stop codon and the poly-adenylation signal.  This allows Cre recombinase 
activity to be modulated by the promoter of the gene of interest, but does not 
interfere with the gene product.  This technique was used in the creation of the AP-2α-
IREScre and Hoxa3-IREScre lines (Macatee et al., 2003). 
4.3.5. PAA malformations in ubiquitous deletions of the Tcfap2a conditional 
allele 
Although the conditionally null embryos described here failed to fully recapitulate the 
phenotype of the Tcfap2a-/- mutant embryos, the majority of mutant embryos do 
exhibit some form of PAA malformation. A total of 38 of the 43 mutant embryos 
(88.37%) examined in this chapter have some form of PAA malformation.  This 
suggests that the PAAs may be more sensitive to deletions of Tcfap2a than other 
elements of the phenotype.  It has previously been suggested that the PAA 
malformations of Tbx1 mutants may be more susceptible to reduced levels of this gene 
than other cardiovascular malformations and heterozygotes show a range of PAA 
malformations (Baldini, 2006).  PAA malformations in embryos in which the conditional 
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allele of Tcfap2a had been recombined using Sox2cre were much lower than those 
using PGKcre.  Another possibility is that, as the phenotype of both PGKcre mutants is 
able to recapitulate the levels of PAA malformations in the Tcfap2a-/- mutant embryos, 
this may represent differences in the expression patterns of PGKcre and Sox2cre.   
RAA has been observed twice in the mutant embryos examined within this chapter.  
This defect was also observed in one of the Tcfap2a-/- mutant embryos and was 
accompanied by an I-LSA.  It is likely that each of these malformations are also 
associated with defects of the fourth PAAs.  The loss of the left fourth PAA would 
cause the right fourth PAA to take its place, therefore resulting in a RAA.  In this case, 
the right sixth PAA would persist to form the ductus arteriosus, the embryonic vessel 
connecting the pulmonary trunk directly to the aortic arch, and the left sixth PAA 
would be expected to regress, as is normal for the right sixth PAA in the left aortic 
arch.  However, persistence of the left sixth PAA, accompanied by the loss of the 
fourth PAA on this side, could result in the left sixth PAA forming a connection 
between the pulmonary trunk and the seventh intersegmental vessel, therefore 
resulting in the I-LSA phenotype we observe here.  Interestingly, the RAA observed in 
the Tcfap2af/f;Sox2cre mutant embryo also appeared to be in a more cervical position 
than would be normally expected.  It is likely that this is due to the loss of both fourth 
PAAs, with persistence of the right carotid duct, as is normally observed in mutant 
embryos with a cervical left aortic arch.  This phenomenon has been previously 
described in mouse embryos with mutations of the endothelin signalling pathway 
(Yanagisawa et al., 1998a), therefore suggesting a possible common mechanism 
between these mutants and the defects observed in Tcfap2a-/- mutant embryos. 
4.3.6. Temporal expression of Wnt1cre  
The work presented within this chapter demonstrates that the conditional allele of 
Tcfap2a is incapable of recapitulating the phenotype observed in the Tcfap2a-/- mutant 
embryos.  However, the number of PAA defects remains very similar between the two, 
as discussed above.  Conditional deletion of Tcfap2a from the NCCs using Wnt1cre 
results in approximately 10% of mutant embryos with CCVM.  Additionally, the defects 
observed affect the formation of the PAAs (A-RSA and vascular ring observed in these 
mutants).  Therefore, it is tempting to propose that any conditional deletion is capable 
of recapitulating the majority of PAA malformations, providing that tissue is of 
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importance in the development of that structure.  In this scenario, we would propose 
that the levels of PAA malformations observed in conditional deletion from the NCCs 
were representative of the effect of the deletion of Tcfap2a from this tissue.  However, 
expression analysis presented in this chapter demonstrates that the Tcfap2a locus is 
activated prior to the Wnt1cre transgene.  Therefore, it is possible that some wild type 
transcripts and therefore, wild type AP-2α protein, are produced within the NCCs 
before the Wnt1cre transgene is translated into cre recombinase and able to 
recombine the Tcfap2aflox allele.   
The preliminary data presented in the introduction chapter demonstrated that, on an 
alternative background, conditional deletion of Tcfap2a using Wnt1cre resulted in 45% 
CCVM, affecting the ventricular septum, OFT and PAAs.  Therefore, it appears that 
altering the genetic background in these embryos may affect the time at which one or 
both of these loci are activated.  A similar phenomenon, in which the expression 
pattern of Foxg1cre is affected upon altering the genetic background of the strain, has 
been described previously (Hebert and McConnell, 2000).   
Interestingly, the work presented here may suggest that early expression of wild type 
Tcfap2a is important within the NCCs for correct formation and development of the 
PAAs.  By e8.5, the Wnt1cre transcript has been translated and is capable of inducing 
recombination within the conditional allele.  Therefore, it is likely that wild type AP-2α 
is required at e8.0 within the NCCS for PAA morphogenesis.  It has previously been 
proposed that Tbx1 expression as early as e7.5 is required for correct development of 
the PAAs.  Removal of this gene from e8.5 onwards fails to recapitulate the PAA 
malformations observed in Tbx1+/- mice (Xu et al., 2005).  It is therefore, possible that 
Tcfap2a is required at a similar time for this process.  However, the PAs have not yet 
begun to form at this stage and Tcfap2a expression is observed only within the NCCs at 
this time (Figure 3.3) (Brewer et al., 2002).  Therefore, it is likely that at this stage AP-
2α is involved in the survival of the NCCs or delamination of these cells from the neural 
tube, which then results in a reduction of the number of NCCs migrating into the PAs 
and OFT later in development. 
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4.4. Conclusions 
The work presented in this chapter demonstrates the issues relating to genetic 
dissection using mouse models.   We have identified that the Tcfap2aflox  allele is 
unable to recapitulate the CCVM found in Tcfap2a-/- mutant embryos, through the use 
of two different cre lines and a germ line deletion.  This work suggests an intrinsic 
difference between the Tcfap2a-null and Tcfap2aflox alleles, potentially through a 
mechanism of transcriptional self-interference. 
In addition, we have demonstrated the issue relating to transgenic mouse lines, both in 
their location and the alteration of expression patterns when the genetic background 
is altered.  We also conclude that the low penetrance of defects observed in the 
previous chapter are the result of both the reduced ability of the Tcfap2aflox  line to 
recapitulate the phenotype of the Tcfap2a-/- embryo and the delayed expression of the 
Wnt1cre transgene. 
4.5. Future work 
Future work will focus on investigating the functional consequences of the Tcfap2a-
null allele, to determine if this could indeed function to down regulate other AP-2 
isoforms.  Initial investigations would be to identify if a protein product is produced 
from this allele by western blotting.  Subsequent work would then investigate the 
ability of this protein to form both homo- and heterodimers, bind DNA and activate 
transcription.
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Chapter 5. Investigating the role of Tcfap2a in the development of 
the pharyngeal arch arteries 
5.1. Introduction 
5.1.1. Tcfap2a in cardiovascular development 
In 1996, two studies were published investigating the role of Tcfap2a during mouse 
embryonic development (Schorle et al., 1996; Zhang et al., 1996). These studies 
demonstrated a severely abnormal external phenotype in mutant embryos, with 
defects of the sensory organs, cranial ganglia, craniofacial development, neural tube 
and ventral body wall.  
In 2002, a further study was conducted, using a mutant allele which incorporated a 
LacZ cassette into the final exon of Tcfap2a, for the purpose of tracing Tcfap2a 
expression patterns.  Work on this model and the previous mouse created by Zhang et 
al. (1996)  identified an important role of Tcfap2a in cardiovascular development 
(Brewer et al., 2002).  It was found that Tcfap2a-/- mice show a fully penetrant 
cardiovascular phenotype, affecting the interventricular septum and OFT, with only 
33% penetrance of PAA defects.  In the majority of mutant embryos (13/15) the OFT 
defect observed was DORV, with a small number of these showing additional signs of a 
TOF phenotype, such as pulmonary atresia or stenosis.  The remaining mutant 
embryos (2/13) had PTA, leading to the suggestion that Tcfap2a is required within the 
NCCs for correct cardiovascular development (Brewer et al., 2002).     
However, in addition to VSD and OFT defects observed by these authors, our group has 
demonstrated a fully penetrant PAA malformation phenotype in Tcfap2a-/- mutants, 
when further inbred onto a C57BL/6J background (see section 1.5.1), including IAA, A-
RSA, CORSA and cAoA.  Therefore, this congenic background may be used to 
investigate the role of Tcfap2a in PAA formation and remodelling. 
5.1.2. Molecular processes of PAA development 
The PAAs begin as five pairs of bilaterally symmetrical arteries, which remodel to form 
the mature mammalian aortic arch and associated vessels (see section 1.2.3).  The 
processes through which these vessels form are still a point of controversy; however, 
studies in both mouse and zebrafish suggest that the most likely mechanism of 
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formation is vasculogenesis (Li et al., 2012; Anderson et al., 2008).  Vasculogenesis is 
the process by which new vessels form from the aggregation of nascent endothelial 
cells (angioblasts) within the PAs, which then join to form a string of endothelium.  
Once this endothelium joins the ventral aorta to the dorsal aorta it begins to lumenise 
to form a PAA.   
5.1.2.1. Vessel formation 
The formation of blood vessels can be investigated using a number of different 
markers.  The earliest known marker of the endothelial lineage is the VEGF receptor-2 
(VEGFR2), which becomes expressed within the developing extraembryonic 
vasculature by e7.0 of mouse embryonic development (Yamaguchi et al., 1993).  A 
further marker of vessel endothelium is the platelet/endothelial cell adhesion 
molecule 1 (PECAM-1 or CD31), which is expressed by differentiated endothelium.  
Once the vessel has lumenised it becomes invested with NCCs, which differentiate into 
SMCs to support the vessels during remodelling. 
5.1.2.2. Remodelling 
PAA remodelling is an important process in the development of the mature aortic arch 
structure seen in neonatal mice.  By e11.5, the formation of the bilaterally symmetrical 
PAA system, which will contribute to the mature aortic arch, is complete and the 
vessels begin to remodel.  This remodelling process results in the regression of a 
number of vessels which are not required in the final aortic arch structure, such as the 
right sixth PAA, the α-segment of the right dorsal aorta and the γ-segments of the 
dorsal aortae (carotid ducts) on both left and right sides (Hiruma et al., 2002) (see 
Figure 1.6).  An important process in this regression is apoptosis.  Apoptosis has been 
identified in the mesenchyme of the right dorsal aorta and right sixth PAA in mouse 
embryos, and surrounding the carotid ducts during development of the PAA system in 
rats (Molin et al., 2002; Molin et al., 2004). Reduced apoptosis in these sites, in Tgfb2-/- 
mutant embryos, results in a number of PAA remodelling defects.  In addition, these 
authors also suggest a mechanism in which the regression of a specific vessel is the 
result of apoptosis in the absence of proliferation, which acts as a ‘counter balance’.  
Therefore, both of these cellular processes are important in the development of 
correct PAA structure.  The authors also demonstrate an increase in the levels of 
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apoptosis within the fourth PAAs, which are found to aberrantly regress in these 
mutants (Molin et al., 2002). 
5.1.3. Aims of chapter 
The aim of this chapter is to investigate the role of Tcfap2a in the development of the 
PAAs.   MRI data from our group demonstrates a fully penetrant cardiovascular 
phenotype in Tcfap2a-/- mutant embryos, affecting the development of the 
interventricular septum, the OFT and the PAAs.  
Previous work has demonstrated the fully penetrant VSD and OFT defect phenotypes 
associated with Tcfap2a mutants (Brewer et al., 2002).  However, PAA malformations 
in these mutants were observed at very low levels (4/15, 26%). The MRI data collected 
by our group (see section 1.5.1) demonstrates a variety of defects affecting the 
development of the fourth PAAs in all embryos examined.  It is likely that the change in 
genetic background from Black Swiss, used by Brewer et al. (2002), to C57BL/6J used 
by our group has resulted in the increased penetrance of these defects in our dataset.  
We, therefore, plan to exploit the fully penetrant PAA defects in our mutants in order 
to identify the role Tcfap2a plays in the development of these vessels. 
The PAA malformations observed in Tcfap2a-/- mutant embryos may be classified as 
primary – occurring during the formation of the initial symmetrical PAA system – or 
secondary – occurring during the remodelling stages of the vessel.  In order to classify 
these defects we will examine the development of the PAAs at e10.5, when the 
bilaterally symmetrical structure is fully formed.  We will then further examine these 
defects by examining the molecular processes which contribute to the formation of 
the PAAs: endothelium development, SMC differentiation, apoptosis and proliferation.  
In addition, due to the issues we faced with the conditional deletion of Tcfap2a within 
the NCCs, we will also focus much of this work on understanding the effect that loss of 
Tcfap2a has on the NCCs in PAA development. 
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5.2. Results 
5.2.1. Histological analysis of CCVM in Tcfap2a-/- mutant embryos (93.45-
95% C57BL/6J) 
The MRI data demonstrated high numbers of CCVM in the Tcfap2a-/- mutants (see 
section 1.5.1).  However, due to the low resolution of the MRI images it was necessary 
to confirm the observed defects by histology.  Embryos were embedded in paraffin 
wax and sectioned, then stained with haematoxylin and eosin.  
Analysis of the sections confirmed the defects observed in the MRI data and 3D 
reconstructions.  All mutant embryos have a VSD (Figure 5.1g, m) and OFT defect as 
discussed above.  The most common OFT defect was DORV which was observed in 50% 
(5/10) of mutant embryos (Figure 5.1h).  A further 30% (3/10) of mutant embryos had 
an OA (Figure 5.1n), which is one of the components of TOF.  However, no other 
components of this defect were observed.  The remaining 20% (2/10) of embryos had 
a TGA (Figure 5.1i), which has not been previously described in Tcfap2a-/- mutant 
embryos.  In addition, in one mutant with DORV, the septation of the OFT was 
incomplete and therefore, could be considered as PTA. 
There were also a number of defects relating to the derivatives of the fourth PAAs.  
Defects of the left fourth PAA were identified in 50% (5/10) of mutant embryos.  Of 
these, 20% (2/10) have a cAoA (Figure 5.1j), while 30% (3/10) have an IAA (Figure 
5.1p).  In addition, defects of the fourth right PAA were also observed in 90% (9/10) of 
mutant embryos.  A-RSA was observed in 40% (4/10) of mutant embryos (Figure 5.1k, 
l) and CORSA was identified in 50% (5/10) of mutants (Figure 5.1q).  In addition, one of 
the embryos with A-RSA also had a RAA, which was accompanied by an I-LSA (Figure 
5.1r).  Overall, all examined embryos have a VSD, an OFT defect and a defect of one or 
both fourth PAAs (Table 5-1). 
  
 
 
Figure 5.1: Histological sections confirm the Tcfap2a
-/-
 phenotypes observed by MRI. 
(a-f)  Sections of a control (Tcfap2a
+/+
) embryo, showing normal cardiovascular development. (a) Normal formation of an interventricular septum (IVS) between the left and right ventricles (LV, RV).  
(b, c) Normal OFT development, with the aorta (Ao) arising from the left ventricle (b) and the pulmonary trunk arising from the right ventricle.  (d-f)  Normal PAA development.  (d) The ascending 
aorta joins the dorsal aorta (dAo) to form the aortic arch (AoA).  (e) The aortic arch then gives rise to the left common carotid artery (LCC) and the brachiocephalic trunk (BC).  (f) The brachiocephalic 
trunk bifurcates into the right common carotid artery (RCC) and the right subclavian artery (RSA).   (g-r)  Mutant (Tcfap2a
-/-
) embryos have a number of cardiovascular malformations.  (g, m) VSDs 
were observed in all mutant embryos. (h-i, n-o)  All mutant embryos have an OFT malformation: (h) DORV, (i) TGA, (n) OA, (o) DORV with incomplete septum formation (partial PTA).  (j-l, p-r)  PAA 
malformations were observed in all mutant embryos:  (j) cAoA, (k-l) A-RSA, (p) IAA, (q) CORSA, (r) RAA with I-LSA. RV, right ventricle; LV, left ventricle; IVS, interventricular septum; Ao, aorta; PT, 
pulmonary trunk; pa, pulmonary arteries; dAo, dorsal aorta; AoA, aortic arch; RSA, right subclavian artery; BC, brachiocephalic trunk; Th, thymus; LCC, left common carotid artery; RCC, right common 
carotid artery. (n=10).
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Table 5-1: Prevalence of CCVM in Tcfap2a
-/-
 mutant embryos examined by MRI and histology. 
CCVM  Prevalence 
(n=10) 
Summary 
VSD  100% VSD -100%  
OA  30% 
OFT defects – 100% 
(10/10 )  
TGA  30% 
DORV 50% 
IAA  30% Left 4th PAA defects  
50% (5/10)  cAoA 20% 
A-RSA  40% Right 4th PAA defects  
90% (9/10)  CORSA 50% 
RAA  10% 
RAA  with I-LSA -10% 
I-LSA  10% 
 
5.2.2. Early PAA development 
As demonstrated above, Tcfap2a-/- mutants on a congenic C57BL/6J background have 
an increased penetrance of fourth PAA defects to that described previously (Brewer et 
al., 2002).  In order to investigate the defects of the PAAs observed at e15.5 in  
Tcfap2a-/- embryos, we sought to understand the time at which these defects were 
arising.  PAA development occurs in two stages: formation, the development of the 
bilaterally symmetrical pairs of vessels; and remodelling, the process which moulds 
these bilaterally symmetrical vessels into the mature aortic arch configuration that we 
observe at e15.5.  If the defects observed are primary then a patent vessel will never 
form within the arch.  If the defects are secondary to this, then the bilaterally 
symmetrical vessels will develop normally by e10.5, but will fail to remodel correctly 
during later stages. 
We therefore, chose to investigate the development of the bilaterally paired vessels at 
e10.5, using India ink injections.  India ink was injected into the left ventricle of control 
(Tcfap2a+/-) and mutant (Tcfap2a-/-) embryos (97% C57BL/6J) to reveal patent vessels.  
As the heart continues to pump, it forces the ink out of the heart via the developing 
OFT and into the PAAs. The control embryos display normal PAA development from 
the 34 somite stage onwards. The first and second PAAs have regressed, and the third 
and fourth PAAs are fully formed and are approximately equal sizes, with the sixth PAA 
beginning to form at this stage (Figure 5.2a-b).  By the 37 somite stage the sixth PAAs 
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are fully formed (Figure 5.2c-d) and can be observed in all subsequent stages (Figure 
5.2e-h).   
 
Figure 5.2: PAA formation is impaired at e10.5 in Tcfap2a
-/-
 mutant embryos. 
India ink injection of e10.5 control (Tcfap2a
+/-
) (a-h) and mutant (Tcfap2a
-/-
) embryos (i-p) to investigate PAA 
formation.  (a, b) At the 34s stage the third and fourth PAA are fully formed in controls, but the formation of the 
sixth PAAs is delayed.  By the 37s stage (c, d) and in all subsequent stages (e-h), the third, fourth and sixth PAA are 
fully formed and of equal sizes.  In mutant embryos we observed a number of defects that were not observed in 
stage-matched controls including: (i) persistent second PAA, hypoplastic fourth PAA; (j) aplastic fourth PAA; (m, n) 
hypoplastic sixth PAA and abnormal branching around the fourth PAA (*), with persistent second PAA; (p) 
hypoplastic fourth PAA.  In addition, some embryos had bilaterally (k, l) or unilaterally (o) normal PAA development. 
All images were taken at the same magnification.  Scale bar = 500 μm.  (n=10). 
In mutant embryos, however, PAA formation is disrupted (Table 5-2).  We observed a 
number of embryos with aberrant persistence of the second PAAs on both the left 
(2/10, Figure 5.2n) and right sides (3/10, Figure 5.2i, m), including one embryo at 39s, 
suggesting this is not merely the product of developmental delay.  We also observed a 
high proportion of embryos with disruptions to the fourth PAAs, including both 
hypoplasia and aplasia (absence) of these vessels.  These defects occur more 
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commonly, and are more severe, on the left side, with 20% (2/10) of embryos having a 
hypoplastic left fourth PAA (Figure 5.2p) and 30% (3/10) of embryos with an aplastic 
vessel (Figure 5.2j).  Hypoplasia of the right fourth PAA was observed in 40% (4/10) of 
embryos (Figure 5.2i), with the remaining 60% developing normally.  Defects of the 
sixth PAAs were also observed in the Tcfap2a-/- embryos.  Hypoplasia of this vessel was 
observed in 40% (4/10, Figure 5.2i, m-n) of mutant embryos on both the left and right 
sides, with 30% embryos having bilaterally hypoplastic sixth PAAs.  A further 10% 
(1/10) of embryos showed aplasia of the sixth left PAA (Figure 5.2j).  In addition, a 
small number of mutant embryos showed branching of small vessels around the fourth 
PAAs.  These additional vessels occurred on both the left (3/10, 30%) and right (2/10, 
20%) sides.  One mutant embryo was also found to have completely normal PAA 
development (Figure 5.2k, l). 
Table 5-2: Summary of the PAA malformation in Tcfap2a
-/-
 mutants at e10.5. 
 Second PAAs Third PAAs Fourth PAAs Sixth PAAs 
Right Left Right Left Right Left Right Left 
Normal 7/10 8/10 10/10 10/10 6/10 5/10 6/10 5/10 
Hypoplasia - - - - 4/10 2/10 4/10 4/10 
Aplasia - - - - - 3/10 - 1/10 
Persistent 3/10 2/10 - - - - - - 
Total defects 30% 20% 0 0 40% 50% 40% 50% 
 
5.2.3. Pharyngeal arch artery formation in Tcfap2a-/- embryos (97% 
C57BL/6J) 
The data presented above demonstrates that the loss of Tcfap2a results in defective 
formation of the PAA, which contributes to the PAA malformations observed at e15.5.  
We, therefore, wanted to analyse the processes involved in PAA formation to 
understand why they were unable to form. The formation of the PAAs involves two 
main processes.  The first is the formation of an endothelial tube, which then luminises 
to form the vessel.  The second process involves the differentiation of the NCCs, within 
the PA mesenchyme, into SMCs which form the tunica media layer of the vessel to 
support it as it matures and remodels into the final aortic arch configuration. 
5.2.3.1. Formation of the PAA endothelium in Tcfap2a-/- embryos 
To visualise the formation of the endothelial layer of the PAAs, immunohistochemistry 
was used to stain coronal sections through Tcfap2a+/- control and Tcfap2a-/- mutant 
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embryos with an anti-PECAM-1 antibody.  Embryos were collected at 3 stages (e9.5, 
e10.5 and e11.5) throughout the formation process to assess the ability of the mutant 
embryos to form the initial endothelial tube. 
In control embryos at e9.5, the third PAA appears well formed and is fully invested 
with endothelium (Figure 5.3).  The fourth PA is newly formed and the PAA within is 
apparent as aggregations of PECAM-1 positive endothelial cells (Figure 5.3c, c’) or as 
small vessels budding-off from the dorsal aorta (Figure 5.3d’-f’, arrows).  Investigation 
of the mutant fourth PAAs indicates a similar pattern of PECAM-1 staining.  In some 
embryos the fourth PAA has not yet formed within the PA (Figure 5.3g’-j’), however, 
others show a vessel budding-off from the dorsal aorta (Figure 5.3k’-l’).  Therefore, it 
appears that the formation of the fourth PAA is unaffected at this time point. 
 
Figure 5.3: PECAM-1 staining of the pharyngeal arch arteries at e9.5. 
Immunohistochemistry for PECAM-1 on coronal sections through the pharyngeal arch arteries of control (Tcfap2a
+/-
) 
and mutant (Tcfap2a
-/-
) embryos at e9.5.  (a-f) The third PAAs of control embryos are well formed and invested with 
PECAM-1-positive endothelial cells.  The fourth PAAs are beginning to emerge from the dorsal aorta in these 
embryos (arrows).  (g-l)  The mutant embryos appear similar to the controls, with the fourth PAA beginning to 
emerge from the dorsal aorta in the later stage embryos (arrows).  Scale bar in a-l = 100 μm, scale bar in a’-l’ = 50 
μm. 3, third PAA; 4, fourth PAA; dAo, dorsal aorta. (n=3). 
By e10.5 (29-33 somite stage), differences between the control and mutant embryos 
may be clearly identified (Figure 5.4).  In the control embryos examined, the fourth 
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PAA had formed and fully lumenised, with a vessel diameter comparable to that of the 
third PAAs (Figure 5.4a-f).  These vessels were also clearly invested with PECAM-1 
positive endothelial cells (Figure 5.4a’-f’).  However, in mutant embryos these vessels 
were delayed in their formation, with a reduced diameter and disorganised endothelial 
cells (Figure 5.4g-l).  Although the vessel was misshapen, it is fully surrounded by 
PECAM-1 positive endothelial cells. In addition, the fourth PA in the mutant embryos is 
also reduced in size compared to that of littermate controls (Figure 5.4g’-l’).   
 
Figure 5.4: PECAM-1 staining of the pharyngeal arch arteries at e10.5. 
Immunohistochemistry for PECAM-1 on coronal sections through the pharyngeal arch arteries of control (Tcfap2a
+/-
) 
and mutant (Tcfap2a
-/-
) embryos at e10.5.  (a-f) The third and fourth PAAs of e10.5 control embryos appear fully 
invested with PECAM-1-positive endothelial cells. (a’-f’)  A higher magnification of the fourth PAA demonstrates that 
the vessel is well formed and invested with endothelium (arrows).  (g-l)  The third and fourth PAAs of mutant 
embryos.  The third PAA appears well formed and is invested with endothelial cells.  The fourth PAA endothelium 
appears disorganised.  (g’-l’)  A higher magnification of the fourth PAA demonstrates that the vessel is disorganised, 
but contains endothelial cells (arrows).  Scale bar in a-l = 50 μm, scale bar in a’-l’ =20 μm. 3, third PAA;4, fourth PAA; 
dAo, dorsal aorta. (n=3). 
By e11.5 the PAAs of control embryos are well formed and fully invested with PECAM-
1-positive endothelium (Figure 5.5a-f).  The third and fourth PAAs in mutant embryos 
are also invested with endothelium (Figure 5.5g-l).  However, in some instances the 
vessel is small and misshapen (Figure 5.5k-l, k’-l’). 
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Figure 5.5: PECAM-1 staining of the pharyngeal arch arteries at e11.5. 
Immunohistochemistry for PECAM-1 on coronal sections through the pharyngeal arch arteries of control (Tcfap2a
+/-
) 
and mutant (Tcfap2a
-/-
) embryos at e11.5.  (a-f) The third and fourth PAAs of e11.5 control embryos appear well 
formed and invested with endothelium.  (a’-f’)  Higher magnifications of the fourth PAAs in a-f.  (g-l)  The third and 
fourth PAAs of mutant embryos appear to be invested with endothelium.  (g’-l’).  Higher magnifications of the 
fourth PAAs in g-l.  Scale bar in a-l = 100 μm, scale bar in a’-l’ = 50 μm. Arrows, endothelial cells; 3, third PAA; 4, 
fourth PAA; dAo, dorsal aorta. (n=3) 
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5.2.3.2. Formation of PAA smooth muscle in Tcfap2a-/- mutant embryos 
During PAA development, the NC-derived mesenchyme of the PAs surrounds the PAAs 
and differentiates into the smooth muscle lining of the vessel.  The SMCs support the 
vessels as they remodel and also stabilise the vessels as the haemodynamic pressures 
increase.  To investigate the formation of NC-derived SMCs around the PAAs of 
Tcfap2a-/- mutant mice, we crossed Tcfap2a+/-;R26Reyfp/eyfp females to Tcfap2a+/-
;Wnt1cre males.  The presence of Wnt1cre in the NCCs will cause the translational stop 
sequence situated between the R26R promoter and the EYFP gene to be excised, 
resulting in read-through from the promoter to EYFP only in the NCCs (see section 
2.2.4).  As the R26R promoter is constitutively active, the NCCs will continue to express 
EYFP throughout development, allowing us to trace the NCC lineage in these embryos.   
Control (Tcfap2a+/-) and mutant (Tcfap2a-/-) embryos were collected at e10.5 and e11.5  
and coronal section were stained with antibodies to α- smooth muscle actin (α-SMA) 
and green fluorescent protein (GFP), which marks both GFP and YFP expressing cells.  
This allowed the identification of SMCs derived from NCC.   
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Figure 5.6: Distribution of NCC-derived smooth muscle cells in e10.5 Tcfap2a
-/-
 mutant embryos. 
NCC (green) and α-SMA (red) distribution in control (Tcfap2a
+/-
) (a-f, a’-f’) and mutant (Tcfap2a
-/-
) (g-l, g’-l’) embryos 
at e10.5.  Control embryos have a large third and fourth PAs, invested with NCCs, but limited distribution of NCC-
derived smooth muscle cells (orange) only in the third PAAs.  Mutant embryos have a reduced fourth PA in 
comparison to the third.  The fourth PA is invested with NCC, but no NCC-derived smooth muscle is observed.  Scale 
bars = 200 µm (a-l), 50 µm (a’-l’). DAPI, blue; α-SMA, red; GFP, green. (n=3). 
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Even at early e10.5 stages (33 somites) the YFP-positive NCCs have fully invested the 
PAs in the control embryos (Figure 5.6a-f).  The presence of NCC-derived SMCs is 
identified as orange staining, which was observed around the third PAAs only. No NCC-
derived SMCs are observed around the fourth PAAs in either mutants or controls at 
this stage.  Additionally, the smooth muscle surrounding the dorsal aorta is of non-NCC 
origin, as has been demonstrated previously in both mouse and chicken (Bergwerff et 
al., 1998; Jiang et al., 2000).   
The mutant embryos also displayed a similar pattern of NCC migration to that seen in 
the controls, with the NCCs infiltrating the fourth PA (Figure 5.6g-l).  As with controls, 
the fourth PAAs of the mutant embryos contain no NCC-derived SMCs.  However, NCC-
derived SMCs can be identified around the third PAAs, suggesting that Tcfap2a-
deficient NCCs are able to differentiate into SMCs to support these vessels.  In the 
mutant embryos, the fourth PAA appears reduced, compared to controls.  This 
supports the defects we see at this stage in the PECAM-1-stained mutant embryos, 
again suggesting that the vessels are failing to form before this point.  The PAs 
containing the reduced fourth PAAs also appear smaller than that of the control 
embryos in both cases.   
By e11.5, we begin to see NCC-derived SMCs surrounding the fourth PAAs in control 
embryos (Figure 5.7a-f).  However, in some embryos this expression is irregular and 
does not cover the full circumference of the vessel (Figure 5.7a’-b’, e’-f’). In mutant 
embryos, however, the presence of NCC-derived SMCs is limited (Figure 5.7g-l) and 
mostly confined to the point at which the vessel arises from the dorsal aorta (Figure 
5.7h’, i’, k’).  The remainder of the vessel is completely devoid of NCC-derived smooth 
muscle.  However, one mutant embryo had a normal left fourth PAA, with a complete 
layer of NCC-derived smooth muscle (Figure 5.7l’). 
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Figure 5.7: Distribution of NCC-derived smooth muscle cells in e11.5 Tcfap2a
-/-
 mutant embryos. 
NCC (green) and α-SMA (red) distribution in control (Tcfap2a
+/-
) (a-f, a’-f’) and mutant (Tcfap2a
-/-
) (g-l, g’-l’) embryos 
at e11.5.  NCC-derived smooth muscle cells (orange, arrows) surround the third, fourth and sixth PAAs in control 
embryos (a-f, a’-f’).  Mutant embryos appear to have comparable levels of smooth muscle cells surrounding the 
third PAAs, but reduced in the fourth PAAs (g-l).  The fourth PAA in many mutant embryos is devoid of any smooth 
muscle cells (arrowheads) (g’-k’), although a single fourth PAA appeared to be fully invested with smooth muscle 
(l’). DAPI, blue; α-SMA, red; GFP, green.  3, third PAA; 4, fourth PAA; 6, sixth PAA; dAo, dorsal aorta.  Scale bars = 
200 µm (a-l), 50 µm (a’-l’). (n=3). 
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5.2.4. Apoptosis and proliferation Tcfap2a-/- embryos 
To further understand the defects of the fourth PAAs in the Tcfap2a-/- mutants we 
chose to examine this region for changes in apoptosis and proliferation.  Embryos were 
collected at e10.5 and stained using immunohistochemistry on coronal sections.  An 
antibody to caspase3 was used to identify apoptotic cells, and phospho-histone H3 to 
detect proliferating cells.  In particular, we were interested in investigating these 
processes within the NCCs.  As shown above, the fourth PA at this stage is reduced in 
size, likely owing to a reduction in the NCC-derived mesenchyme within this structure.  
Therefore, in order to investigate this, the NCCs were again marked using the anti-GFP 
antibody, as described above.   
5.2.4.1. Apoptosis 
Examination of control embryos revealed a small number of apoptotic cells within the 
tissues of the fourth PA (ectoderm, endoderm and mesenchyme) (Figure 5.8a-f, a’-f’).  
Overall, the levels of apoptosis appeared to be consistent between each of these 
tissues.  However, in the mutant embryos, there appeared to be an increase in the 
levels of apoptosis (Figure 5.8g-l, g’-l’).  However, this was not confined to the NCCs as 
expected.  Interestingly the highest levels of apoptosis were seen in the pharyngeal 
epithelia (ectoderm and endoderm). 
In order to examine the changes in levels of apoptosis more thoroughly we employed 
cell counting techniques to quantify the amount of cell death in the tissues of the 
fourth PAs.  When the number of apoptotic cells was compared within the entire 
fourth PA, we found a non-significant increase in the levels of apoptosis in mutants 
compared to controls (Figure 5.10a).  To investigate this further, we examined the 
levels of apoptosis within each tissue of the fourth PAs.  As Tcfap2a is highly expressed 
within the NCCs we examined the levels of apoptosis within this population and found 
that, although there appears to be an increase in the number of apoptotic cells in this 
population, this change is not significant.  However, analysis of the ectoderm revealed 
an approximately 15% increase (p = 0.0429) in the number of apoptotic cells, 
suggesting that Tcfap2a in these cells is important in cell survival.  As in the NCCs, the 
loss of Tcfap2a appeared to cause an increase in the numbers of apoptotic cells within 
the endoderm, which failed to reach statistical significance.  
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To further dissect the levels of apoptosis within the fourth PA of Tcfap2a-/- mutant 
embryos we compared levels in the left and right PAs.  From the overall analysis we 
found that there was a statistically significant increase in the number of apoptotic cells 
within the fourth right PA (p = 0.0204), which was not seen in the left arch (Figure 
5.10b).  When further dissected into the individual tissue types, we again saw that the 
levels of apoptosis in the NCCs and endoderm of both arches was increased, but not 
statistically significant.   However, the ectoderm of the fourth right PA had a very 
strong, statistically significant increase in the numbers of apoptotic cells (p = 0.0013). 
5.2.4.2. Proliferation 
In order to examine the levels of proliferation within these mutant and control 
embryos, coronal sections were also stained for an antibody against phospho-histone 
H3 (Figure 5.9).  We identified that overall the levels of proliferation were variable 
between samples of the same groups.  However, there appeared to be more 
proliferation in control embryos than in mutants.  
To examine this further, we quantified the levels of proliferation within each tissue of 
the fourth arch and found that overall the levels of proliferation remained constant 
between control and mutant embryos.  When comparing the levels of proliferation 
between the composite tissues, it appears that the level of proliferation within the 
NCCs is not altered between controls and mutants (Figure 5.10c).  However, there does 
appear to be a generalised increase in the levels of proliferation within the ectoderm 
and decrease in the endoderm, neither of which were found to be statistically 
significant. 
Comparison of the levels of proliferation between the left and right fourth PAs 
confirmed that there are no statistically significant changes between controls and 
mutants in the whole arch, the NCCs or the ectoderm.  However, we identified a 
statistically significant (p = 0.0291) decrease in the levels of proliferation within the 
endoderm of the right PA (Figure 5.10d). 
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Figure 5.8: Expression of apoptosis marker in control and mutant fourth PAs at e10.5. 
Coronal sections of control (Tcfap2a
+/-
) and mutant (Tcfap2a
-/-
) embryos stained with anti-caspase3 antibody.  
Control embryos (a-f) have low levels of apoptosis in all tissues examined.  Examination of mutant embryos(g-l)  
reveals an increase in levels of apoptosis within the ectoderm of the fourth PAs. a’-l’ show higher magnifications of 
the boxed regions in a-l.  Arrows show apoptotic cells.  a’’-l’’ show only caspase3 staining and DAPI, for clarity.  ec, 
ectoderm; en, endoderm; me, mesenchyme.  Scale bars = 200 µm (a-l), 50 µm (a’-l’,a’’-l’’).  DAPI, blue; GFP, green; 
caspase 3, red. (n=3). 
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Figure 5.9: Expression of proliferation marker in control and mutant fourth PAs at e10.5. 
Coronal sections of control (Tcfap2a
+/-
) and mutant (Tcfap2a
-/-
) embryos stained with anti-phospho-histone H3 
antibody.  Control embryos (a-f) have moderate levels of proliferation in all tissues examined.  Examination of 
mutant embryos (g-l) appears to show a decrease in proliferation throughout all tissues. a’-l’ show higher 
magnifications of the boxed regions in a-l.  Arrows show proliferative cells.  a’’-l’’ show only pHH3 staining and DAPI, 
for clarity. Scale bars = 200 µm (a-l), 50 µm (a’-l’, a’’-l’’). DAPI, blue; GFP, green; pHH3, red. (n=3).
  
 
Figure 5.10: Quantification of apoptosis and proliferation within the tissue of the fourth PAs of control and mutant embryos. 
Comparison of levels of apoptosis and proliferation between control (Tcfap2a
+/-
) and mutant (Tcfap2a
-/-
) embryos at e10.5. (a) Levels of apoptosis within both fourth PAs and the individual tissues:  
the NCCs, pharyngeal ectoderm and pharyngeal endoderm.  (b) Levels of apoptosis within left and right PAs and each tissue individually. (c) Levels of proliferation within both fourth PAs and the 
individual tissues. (d) Levels of apoptosis within left and right PAs and each tissue individually.  Error bars represent standard error of the mean (S.E.M). Statistical significance calculated by a student’s 
t-test; *, p < 0.05; **, p < 0.01.
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5.2.4.3. Neural crest cell numbers 
We have identified that the fourth PAs in the mutant embryos appear smaller than 
that of the control embryos examined.  By collating the data collected from both the 
apoptosis and proliferation studies we were able to determine the total numbers of 
NCCs within each PA at e10.5.  Although there are limited numbers of NCC-derived 
SMCs surrounding the fourth PAA at this stage, it has been proposed that the NCCs 
may provide other roles in the maintenance of these vessels at this time (Waldo et al., 
1996).   
We found a statistically significant decrease in the numbers of NCC within the fourth 
PAs between controls and mutants (p = 0.0074) (Figure 5.11a).  Further, comparison of 
the left and right PAs show a generalised decrease in the numbers of NCCs in both 
arches, which reaches statistical significance only in the right PA (p = 0.0417) (Figure 
5.11b).  To confirm that the reduction of the total number of NCCs within each PA was 
not caused by a change in NCC density within the arch, we compared the density of 
total cells and NCCs within each PA.  We found that neither the cell density of the 
entire PA region (Figure 5.11c), nor of the left or right PAs individually (Figure 5.11d), 
was significantly altered in mutants compared to control embryos.  In addition, 
although on average the mutant PAs contained fewer NCCs per 100 μm2 (Figure 
5.11e), this was not significantly different.  Furthermore, the NCC density was not 
significantly different in either of the PAs individually (Figure 5.11f). 
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Figure 5.11:  NCC number and density within the fourth PAs of control and mutant embryos. 
Comparison of NCC density between control (Tcfap2a
+/-
) and mutant (Tcfap2a
-/-
) embryos. (a) Total number of NCCs 
within the fourth PA.  (b) Number of NCCs within the left and right fourth PAs.  (c) Total cell density within the 
fourth PAs.  (d) Cell density within the left and right fourth PAs. (e) NCC density within the fourth PAs.  (f) NCC 
density within the left and right PAs. Error bars represent S.E.M. Statistical significance calculated by a student’s t-
test; *, p < 0.05; **, p < 0.01. 
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5.3. Discussion 
5.3.1. CCVM in Tcfap2a-/- mutant embryos 
As discussed in the introduction, the cardiovascular defects of Tcfap2a-/- embryos have 
been explored previously, and demonstrated a fully penetrant cardiovascular 
phenotype consisting of VSDs and OFT malformations (Brewer et al., 2002).  In this 
chapter, and in the preliminary work presented in the introduction chapter (see 
section 1.5.1), we have demonstrated similar results, indicating that Tcfap2a is very 
important in the development of the OFT and interventricular septum.  The OFT 
malformations observed in our work, however, vary from that seen in the previous 
study.  Brewer et al. (2002) demonstrate a large number of mutant embryos, with 
DORV, and a small number of embryos with PTA.  Our study, however, shows a 
reduction in the number of embryos with DORV and the appearance of other defects 
including TGA and OA.  
In addition to those defects previously observed, we also identified a fully penetrant 
phenotype affecting the formation of the fourth PAAs, which were found at much 
lower levels in the previous study (Brewer et al., 2002).  Previous work on the 
cardiovascular malformations in Tcfap2a-/-  embryos on a mixed/black swiss 
background, by Brewer et al. (2002), demonstrates PAA malformations in only 33% 
(5/15) embryos, which included A-RSA and IAA.   This suggests that the prevalence of 
CCVM in Tcfap2a-/- mice changes with genetic background.  Interestingly, we also 
identified a number of PAA malformations, which were not previously described in 
Tcfap2a-/- mutant embryos, including CORSA and cAoA.  It is possible that in 
histological examination, these defects may have been overlooked.  However, the use 
of MRI and 3D reconstructions allowed us to identify these subtle defects.  Therefore, 
we have generated a model in which the PAA defects previously described in these 
embryos, can be examined thoroughly.    
5.3.2. A dual role for AP-2α in PAA morphogenesis? 
The data presented within this chapter clearly demonstrates a role for Tcfap2a in PAA 
morphogenesis.  At e15.5 Tcfap2a-/- embryos show a variety of malformations 
affecting the fourth PAAs, which are fully penetrant.  These defects most commonly 
affect the right fourth PAA (90% embryos), with the left fourth PAA being less 
commonly affected (50% embryos).   
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To further understand the role of Tcfap2a in PAA morphogenesis, mutant embryos 
were examined at e10.5 using India ink injection methods.  At this stage, the formation 
of the caudal PAAs is complete but remodelling has not yet begun.  At this time defects 
were observed in both fourth PAAs, with the left PAA being hypoplastic or aplastic in 
50% mutant embryos and the right PAA in only 40% mutant embryos (Table 5-3).  This 
suggests that the defects of the fourth left PAA in Tcfap2a-/- mutant embryos are the 
direct result of this vessel failing to form.  In addition, the remodelling defects 
associated with this arch, which result in the persistence of the left carotid duct and 
the appearance of a cAoA, occur secondarily to the abnormal formation of this vessel.   
 E10.5 E15.5 
Left fourth PAA 5/10 (50%) 5/10 (50%) 
Right fourth PAA 4/10 (40%) 9/10 (90%) 
 
The defects observed in the right fourth PAA at e10.5, however, are not consistent 
with a role for AP-2α solely in the formation of the vessel.  Between the formation of 
the vessel at e10.5 and complete development of the cardiovascular system by e15.5 
we see a two-fold increase in the number of right fourth PAA abnormalities (Table 5-3).  
Overall, this work suggests that Tcfap2a has a dual role in the development of the right 
fourth PAA:  an initial role during the formation of the vessel followed by a further role 
in the remodelling of the vessel to form the RSA. 
It is likely that the remodelling defects of the Tcfap2a-/- mutant fourth PAAs are the 
result of a NCC defect, that prevents the differentiation of these cells into smooth 
muscle, which supports the vessel throughout the remodelling process.  Indeed, at 
e11.5, we find that the majority of fourth PAAs examined were sparsely invested with 
NCC-derived smooth muscle.  It is therefore expected that these vessels would 
collapse shortly after this stage due to the increased haemodynamic pressure.   
The role of the NCCs within the PAs prior to smooth muscle differentiation is not well 
documented; however, it has been proposed that in quail embryos the NCC-derived 
mesenchyme provides support to the nascent PAA (Waldo et al., 1996).  The ablation 
of the NCCs in these embryos results in a severe reduction in the size of the PA and 
Table 5-3: Comparison between PAA abnormalities observed at e10.5 and e15.5.  
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causes significant impact on the development of the artery therein.  The vessel was 
found to become irregularly shaped and wider than normal in some regions, whilst 
hypoplastic or collapsed in others.  The authors propose that the initial formation and 
lumenisation of the vessel occurs independently of NCC involvement, however, the 
NCC-derived mesenchyme within the arch is required to maintain the correct structure 
of the PAA.  Additionally, the majority of defects in these vessels occur prior to the 
formation of the NCC-derived smooth muscle of the tunica media, suggesting that the 
NCCs may be responsible for the deposition of extracellular matrix proteins, which are 
required to support the vessel throughout its development. 
We, therefore, propose a similar scenario in the formation of the fourth PAAs in 
Tcfap2a-/- mutant embryos.  At e10.5, we observe a reduction in the number of patent 
fourth PAAs forming, in comparison to control embryos, while immunohistochemistry 
of embryos at this stage revealed a reduction in the number of NCCs within the mutant 
PAs.  Although this reduction was only found to be statistically significant in the right 
PA, the number of NCCs within the left PA was similarly reduced.  Therefore, it is 
possible that the reduction in the number of NCCs within the fourth PA at this stage is 
responsible for the loss of these vessels, due to the lack of mesenchymal support or 
deposition of extracellular matrix.   
The increased number of fourth PAA defects between e10.5 and e15.5 is intriguing, 
and suggests a specific pathway within the right PA is being disrupted in these 
embryos.  We have demonstrated that the right fourth PA has a statistically significant 
reduction in the number of NCCs and the levels of proliferation within the endoderm, 
while the levels of apoptosis within the surrounding ectoderm are significantly 
increased.  Further investigations are required to identify the effect of these defects on 
the development of the right fourth PAA, however, it is likely that these factors explain 
the remodelling defects observed within the right PAA, which are not found in the left 
PAA. 
5.3.3. Defects are specific to the fourth pharyngeal arch arteries 
The PAA defects observed in the Tcfap2a-/- embryos examined appear to be specific to 
the fourth PAA. At e10.5, we observe defects affecting the development of the second, 
fourth and sixth PAAs, however, by e15.5 only defects of the fourth PAA are observed.  
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In particular, these defects appear to affect the formation of the RSA, which is derived 
from the fourth right PAA.   Kutche and van Mierop (1984) propose three routes which 
the RSA can follow in cases where the fourth PAA fails to develop correctly.  The most 
common defect of the RSA was A-RSA, followed by CORSA and finally, in rare cases,     
I-RSA (see Figure 1.9 in introduction chapter).  In the Tcfap2a-/- mutants we observe 
both A-RSA and CORSA phenotypes, in approximately equal ratios. Although we do not 
observe any incidences of I-RSA, it is interesting to note that in the case of the single 
embryo with a RAA, the LSA arises from the pulmonary trunk.  It is therefore likely that 
this phenotype results from a similar mechanism. 
This study examined the presence of RSA malformations in human infants with an 
interruption of the aortic arch and found that two thirds (66%) of infants with an IAA 
also carried RSA defects (Kutsche and Van Mierop, 1984). Therefore, suggesting a 
common mechanism which results specifically in defects of the fourth PAAs.  However, 
in Tcfap2a-/- mutant embryos, there was a much greater incidence of RSA 
malformations than defects of the aortic arch, therefore suggesting that defects of the 
RSA are not dependent on an IAA.  Rather, it is likely that the subtle, potentially 
asymptomatic RSA defects are more readily identified in patients with a severe aortic 
arch malformation.     
It is interesting to speculate that the fourth PAAs are more susceptible to genetic insult 
that that of the other caudal PAAs.  Indeed, there are many examples in the literature 
of PAA defects as a result of fourth PAA malformations.  Of particular interest are the 
endothelin and TGFβ2 signalling pathways, which result in similar malformations to 
those observed here.  Mutation in members of the endothelin signalling pathway often 
result in the persistence of the carotid ducts in the absence of the left or right fourth 
PAAs (Yanagisawa et al., 1998a).  In addition, mutations in Tgfb2 often result in PAA 
abnormalities such as IAA, A-RSA, hypoplasia of the aortic arch and aberrant 
persistence of the right dorsal aorta (Bartram et al., 2001).  Furthermore, it has 
previously been suggested that the aberrant persistence of PAA segments, such as the 
carotid ducts (resulting in CORSA and cAoA) and the right dorsal aorta (which results in 
A-RSA) are the result of a reduction in the levels of apoptosis within the smooth 
muscle lining of these vessels (Molin et al., 2004).  Therefore, although we did not 
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investigate the levels of apoptosis within these regions, it is likely that altered levels of 
apoptosis are the cause of their persistence.  Further investigations are required to 
examine the apoptosis in this region, however, it may indicate an overall deregulation 
of basic cellular processes in Tcfap2a-/- mice. 
The CORSA phenotype has also been identified in the Df1 mouse model of 22q11DS 
(Lindsay et al., 1999), and in children with the 22q11DS mutation.  One study shows 
that the malformation was found in greater than 60% of the patients examined and 
suggest that this phenotype may be specific to the syndrome (Rauch et al., 2002). 
The failure in the correct formation of the fourth PAAs, however, may be a result of 
their natural composition.  It has been shown that these vessels have reduced α-SMA 
deposition in the tunica media layer of the vessels, leading to reduced stability of these 
arteries (Bergwerff et al., 1999).  These authors also demonstrated reduced α-SMA 
deposition in the derivatives of these vessels at later stages of development: in 
segment-B of the aortic arch and at the point where the brachiocephalic bifurcates 
into the RSA and the RCC arteries.  Therefore, it is possible that minor perturbations in 
the development of this PA are sufficient to destabilise the vessel, causing them to 
become hypoplastic or collapse.   
5.3.4. Other abnormalities of the PAAs at e10.5 
Ink injections were used to investigate how the PAA defects observed at e15.5 relate 
to the development of the early PAA system.  In control embryos at e10.5, the 
bilaterally symmetrical PAA system is fully developed and consists of three caudal PAA 
of approximately equal size.  However, at this time a number of mutant embryos were 
seen to have aberrant persistence, hypoplasia or aplasia of the second, fourth and 
sixth PAAs.   
By e15.5, defects of the second and sixth PAAs are no longer observed.  It is possible, 
therefore, that these defects are the result of developmental delay in the mutant 
embryos.   As there is no evidence for the persistence of the second PAAs into later life 
(e15.5) it is likely that the failure of these vessels to regress by e10.5 is due to a delay 
in the development of the PAA system in these mutants.  A further possibility is that 
the defects of the caudal PAAs (4 and 6) result in the persistence of the second PAAs as 
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a secondary effect, due to increasing haemodynamic pressure.  Conversely, the 
hypoplasia of the sixth PAAs may result in the persistence of the second PAAs, in order 
to maintain the blood flow from the developing heart.  Whatever the cause of these 
defects, it appears that it is corrected at some later point, allowing the second and 
sixth PAAs of the Tcfap2a-/-mutants to develop normally by e15.5. 
Defective formation of the sixth PAAs was confined to hypoplasia in the majority of 
cases.  However, a single embryo was identified at e10.5 with aplasia of the sixth left 
PAA.  This vessel contributes a major part of the ductus arteriosus to the mature aortic 
arch system, and therefore it is likely that the inability of this vessel to form would 
result in the loss of the ductus arteriosus.  In addition, this embryo also has an absent 
left fourth PAA, which may be the result of a developmental delay, as the embryo in 
question was only 34 somites.  However, it is interesting to speculate that aberrant 
loss of both the fourth and sixth PAAs on the left may be the cause of the RAA 
phenotype observed in only a single embryo of the 10 examined.  In this scenario, the 
loss of the sixth left PAA would likely result in a right-sided ductus arteriosus.  This 
would result in an increase in the levels of blood flow through the right side of the PAA 
system, which in collaboration with the loss of the fourth left PAA is likely to result in 
the formation of the RAA.  Interestingly, Yashiro et al. (2007) demonstrated that 
ligation of the left sixth PAA in wild type embryos resulted in the persistence of the 
right sixth PAA in approximately half of the embryos examined.  In addition, in those 
embryos with a patent right sixth PAA, the right dorsal aorta was often found to have a 
greater diameter than the left, indicating the importance of haemodynamics in the 
development of the PAA system.   
A further interesting finding from this work was the appearance of small branching 
vessels around the fourth PAA in mutant embryos.  These vessels were identified in 
both the left and right PAs, in 30% and 20% embryos, respectively.  It is possible that 
these vessels are the collateral channels described by Bamforth et al. (2012a), which 
connect the fourth and sixth PAA.  However, these channels were identified in wild 
type embryos from e11.5 onwards.  Our work demonstrates the presence of these 
vessels in mutant embryos at e10.5.  In addition, a similar phenotype was observed in 
Gbx2-/- mutant embryos (Calmont et al., 2009).  It is likely that these malformations are 
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a further result of the increase in blood pressure, causing new vessels to sprout in 
order to keep up with the increased blood flow. 
5.3.5. NCC migration in Tcfap2a-/- mutant embryos 
As discussed above, many of the malformations of the PAAs in Tcfap2a-/- mutant 
embryos can be attributed to defects of the NCCs.  The NCCs differentiate into the 
smooth muscle layer surrounding the PAAs, a process which we have shown to be 
disrupted in Tcfap2a-/- mutant embryos.  In addition, the NCCs are responsible for 
forming the mesenchymal tissue of the PA, which is then able to support the vessels 
during early development.  Therefore, the reduction in the number of NCCs in the PAs 
by e10.5 is likely to cause the formation defects, through reduced mesenchymal 
support of the vessels. 
Despite, the importance of the NCCs in the development of the heart and PAAs, and 
the high levels of Tcfap2a within this tissue, defects in NCC development and migration 
have not previously been described in Tcfap2a-/- mutant embryos.  In fact, examination 
of NCC migration has previously been suggested to be normal (Brewer et al., 2002; 
Zhang et al., 1996).  However, previous analysis has concentrated on the localisation of 
the NCCs.  Here, we present the first study quantifying NCCs migrating into the PA 
region, and identify that this process is disrupted in Tcfap2a-/- mutant embryos.  
Although, the reduction in the number of NCCs observed is subtle, it is possible that 
this deficit results in the defective formation and remodelling of the fourth PAAs in 
these embryos.  In addition, we have demonstrated that the levels of apoptosis and 
proliferation are not significantly disrupted in these mutant embryos, therefore, 
suggesting that the NCC deficit within the fourth PA is the result of the inability of 
NCCs to migrate into the arches, rather than loss of these cells following migration. 
5.3.6. The role of PA epithelium in PAA morphogenesis 
Overall it appears that the loss of Tcfap2a is important in cell survival and proliferation 
within the fourth PAs.  Our data demonstrates alterations in the levels of both 
apoptosis and proliferation in the epithelia of the fourth PAs.  We show a significant 
increase in the levels of apoptosis within the ectoderm of the right fourth PA at e10.5, 
accompanied by a significant decrease in the levels of proliferation within the 
endoderm of this arch.  This suggests that the remodelling of the fourth right PAA into 
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the RSA requires signals from the surrounding epithelia which help to support and 
maintain the vessel or aid in NCC differentiation into SMCs.   Although the levels of 
both cellular processes remain unaffected in the NCCs, there was a reduction in the 
numbers of NCCs within the fourth PAs at e10.5.  It is, therefore, possible that the 
changes in these cellular processes result in a decrease in the number of epithelial cells 
within the right PA.  This in turn would cause a reduction in the level of signalling from 
these tissues, which aid in the migration of the NCCs into the PAs.  It has been shown 
that signalling from the ectoderm is important in the migration of the NCCs into this 
region, and loss of this signalling results in PAA defects (see section 1.3.4.2). The 
reduced number of epithelial cells in this region may cause a reduction in the numbers 
of NCCs migrating into the area and, therefore, the number of cells available to 
differentiate into SMCs at a later time. 
5.3.7. Advantages and disadvantages of this study 
The work presented within this chapter has focussed on the formation and 
development of the PAAs in Tcfap2a-/- mutant embryos.  In order to investigate this 
process, a number of techniques were employed.  The formation of these vessels was 
investigated using ink injection, a vascular filling technique, in addition to 
immunohistochemistry.  Vascular filling methods are commonly used to identify patent 
vessels within the developing embryo, which is then used to infer if a vessel has 
formed correctly.  However, this does not accurately determine the formation of a 
vessel.  The PAAs form through the aggregation of angioblasts into an endothelial 
string, which then luminises to form a vessel.  The vascular filling methods are only 
able to investigate the lumenisation step of this process.  In this study, however, we 
have complemented this technique with the use of immunohistochemistry to 
determine if the endothelium of the vessel forms correctly.
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Chapter 6. Identification of transcriptional targets of AP-2α in 
cardiovascular development 
6.1. Introduction 
The work presented throughout this thesis demonstrates the importance of Tcfap2a in 
cardiovascular development.  However, the target genes of this transcription factor in 
cardiovascular development remain unknown.  In this chapter we will investigate the 
downstream targets of AP-2α in PAA development, in order to further understand the 
role of this transcription factor in this process. 
6.1.1. Transcriptional targets of AP-2α 
Much of the work which has deduced putative targets of AP-2α has been carried out to 
further understand the role of this transcription factor in cancer progression and 
development.  However, a number of these genes have been implicated in processes 
relevant to cardiovascular development. This work has identified significant 
involvement of AP-2α in basic cellular processes such as proliferation, apoptosis and 
differentiation, which play major roles in cardiovascular development.   
VEGF is an important gene in tumour angiogenesis and has been shown to be a 
downstream target of AP-2α in cancer (Gille et al., 1997).  This gene is pivotal in both 
angiogenesis and vasculogenesis, and is therefore integral to the formation of the 
vasculature of the developing embryo.  This suggests that downregulation of this gene 
in Tcfap2a-/- embryos may prevent PAA formation.  VEGF mutations result in severe 
malformations of the PAAs, including IAA, double aortic arch and persistence of the 
carotid duct segments of the dorsal aorta.  In addition, TOF was also observed in 
mouse embryos with mutations of the dominant VEGF164 isoform (Stalmans et al., 
2003).   Many of these phenotypes have been described in Tcfap2a-/- mutants, 
suggesting that VEGF is a viable candidate for AP-2α-mediated regulation in PAA 
development. 
MMP-2 is involved in the degradation of a number of ECM proteins (Shapiro, 1998). In 
the developing chicken embryo its expression begins in the NCCs after migration from 
the neural tube into the PAs.  It has been suggested that this expression may be 
involved in the remodelling of the PAAs (Cai et al., 2000). 
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Further, the AP-2 family has been associated with the negative regulation of the T-box 
transcription factor, TBX20 in patients with TOF.  RT-PCR of atrial and ventricular 
biopsies from patients with TOF demonstrated higher levels of TBX20 than in controls 
with VSDs, while expression of AP-2 family genes was reduced.  In addition, constructs 
of TFAP2A, -B and –C were able to downregulate TBX20 in a dose-dependent manner 
(Hammer et al., 2008).  This, therefore, suggests a role for AP-2 family genes and 
TBX20 in the presentation of TOF in patients.   
Therefore, AP-2α can be implicated in the activation of a number of genes which are 
important in cardiovascular development.  However, despite these links and the 
importance of Tcfap2a in cardiovascular development, the transcriptional targets of 
AP-2α in cardiovascular development have never been investigated. 
6.1.2. Aims of chapter 
The Tcfap2a gene encodes the transcription factor AP-2α, which has an important role 
in cardiovascular development.  We demonstrated in the previous chapter that, by 
e10.5, PAA formation is impaired in Tcfap2a-/- mice.   As discussed above, many genes 
have been suggested as downstream targets of AP-2α in cancer, some of which also 
have roles in cardiovascular development.  However, none of these genes have been 
validated as the cause of CCVM in Tcfap2a-/- mutants.   
In this chapter we aim to understand the effect of the loss of Tcfap2a at the 
transcriptional level, in order to further characterise the role of this transcription 
factor in cardiovascular development.  To do this we will examine the expression levels 
of a number of previously identified AP-2α target genes within the PA region of control 
and mutant embryos. In addition, we also aim to investigate the expression levels of a 
number of genes key to cardiovascular development, each of which contains AP-2 
binding sites within the promoter region. 
The identification of any potential downstream targets will require further validation, 
through the use of in situ hybridisation and genetic interaction studies.  This will also 
be presented here. 
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6.2. Results 
6.2.1. Transcript analysis of the pharyngeal arch region in Tcfap2a-/- 
embryos 
In order to investigate the effect of Tcfap2a deletion on the expression of potential 
target genes in the PA region, wild type (Tcfap2a+/+) and mutant (Tcfap2a-/-) embryos 
were collected at e9.5 for qPCR analysis.  This stage is immediately prior to fourth PAA 
morphogenesis (Hiruma et al., 2002) and will therefore allow us to understand the 
transcriptional changes occurring in mutant embryos at this time, in order to prevent 
correct vessel formation. The PA region was dissected and retained for RNA extraction 
(see section 2.10.1). 
A candidate gene approach was used to select target genes.  As Tcfap2a is highly 
expressed in the NCCs at the stage of interest and due to the importance of the NCCs 
during PAA development, a number of target genes were selected based on expression 
within the NCCs.  Two such genes are Tcfap2b and Tcfap2c, members of the AP-2 
family, which overlap with Tcfap2a expression patterns in the NCCs.  A number of NCC 
markers were also investigated to identify any transcriptional changes occurring in this 
population of cells at this time.  In addition, we also examined the expression levels of 
putative Tcfap2a target genes, and genes known to be involved in cardiovascular 
development, in the context of the Tcfap2a-/- PA region.   Analysis was conducted using 
the comparative Ct method, with results being normalised to the housekeeping gene 
GAPDH. 
Firstly, a qPCR reaction was performed to examine Tcfap2a expression, using primers 
that bind within exons 6 and 7.   As the null allele replaces exon 7 with a LacZ cassette, 
these primers will be unable to bind to mutant transcripts.  As expected, we found that 
Tcfap2a expression was reduced to less than 0.08% of wild type expression levels (p 
<0.0001), indicating that no wild type transcripts are produced (Figure 6.1a). 
Examination of Tcfap2b and Tcfap2c expression in Tcfap2a-/- mutant embryos 
demonstrates a marginal, but statistically significant increase in the levels of both 
genes in comparison to wild type controls (Figure 6.1a).  Tcfap2b expression was 
increased by 11% of wild type expression (p = 0.0379), while Tcfap2c was increased by 
almost 14% (13.79%, p=0.0452).  
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A number of genes associated with CCVM, which contain AP-2 binding sites within 
their promoter region, were also examined (promoter analysis carried out by Dr Simon 
Bamforth).  Some of these genes, (retinoic acid receptors α and β (Rara, Rarb)  and 
cyclin E2 (Ccne2)) appeared to be upregulated in Tcfap2a-/- mutant embryos, 
suggesting a possible repressive effect of AP-2α on these genes.  However, upon 
statistical analysis none of these were found to be significant. Other genes (Smad7, 
Chd7 and Fgf8) appear to be downregulated in Tcfap2a-/- mutant embryos.  Of these, 
only one was statistically significantly reduced in Tcfap2a-/- mutant embryos.  Fgf8 was 
reduced to approximately 78% (p = 0.0233) wild type expression in mutants (Figure 
6.1b) and therefore is a potential downstream target of AP-2α.   
Interestingly, analysis of known Tcfap2a target genes yielded no statistically significant 
changes between wild type and mutant embryos.  Three of these genes (cMyc, ErbB2 
and Acan) appeared to be marginally reduced, however, failed to reach statistical 
significance.  Sox10 appeared to be upregulated in mutant embryos.  However, the 
large error bars associated with this result, likely due to the high Ct values in the qPCR 
analysis, prevented this gene from reaching statistical significance. 
A number of known NCC markers were also examined.  As Tcfap2a is highly expressed 
in the NCCs, we wanted to examine the effects of loss of Tcfap2a on this population of 
cells as a whole. However, only one of these genes was affected in our analysis.  Dlx5 
was significantly downregulated (p = 0.0069) in Tcfap2a-/- mutant embryos, while the 
other NCC markers, Foxd3 and Snail2 show no differential expression between wild 
type and mutant samples.  This suggests that Dlx5 may be a direct target of Tcfap2a 
within the PA region. 
The qPCR analysis presented here suggests two possible downstream target genes of 
Tcfap2a in the PA region.  Fgf8 is expressed within the PSE, where it has been shown 
to be important for correct PAA development (Abu-Issa et al., 2002).  Dlx5 expression 
is activated in the post-migratory NCCs at around e9.5, and is known to be required in 
the PAs for correct craniofacial development (Acampora et al., 1999; Depew et al., 
1999). However, Dlx5 has not previously been implicated in cardiovascular 
development. 
  
 
 
Figure 6.1: Quantitative RT-PCR of potential downstream targets of AP-2α in Tcfap2a
-/-
 mutant pharyngeal arch at e9.5 relative to wild type controls. 
(a) Expression of AP-2 isoforms expressed within the murine NCCs.  (b)  Expression of genes with a known role in cardiovascular development.  The genes examined have a conserved AP-2 binding site 
within their promoter.  (c)  Expression levels of known AP-2α target genes with functions in cardiovascular development.  (d)  Expression levels of neural crest markers in mutant pharyngeal arch 
tissue.  Statistical significance determined using a student’s t-test; *, p <0.05. **, p  <0.01. ****, p <0.0001.  Error bars indicate S.E.M.
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6.2.1.1. In Situ hybridisation of candidate genes 
The qPCR analysis shown above suggests that Fgf8 and Dlx5 may be downstream 
targets of AP-2α.  Therefore, WISH was used to validate the results obtained from 
qPCR and investigate the spatial changes in expression of these genes. 
Sense and antisense probes to Fgf8 and Dlx5 were prepared by labelling with DIG.  At 
e9.5, Fgf8 expression was similar to that described previously  (Ohuchi et al., 1994).  
Expression was observed at the midbrain-hindbrain border, the future olfactory bulb, 
within the endoderm of the caudal PAs and within the first PA, in all wild type embryos 
examined (Figure 6.2a).  Examination of Tcfap2a-/- mutant embryos reveals that the 
expression pattern within the head and pharyngeal endoderm is conserved between 
wild type and mutant embryos, however, ectodermal expression within the first PA 
appears disrupted (Figure 6.2b).  Fgf8 is strongly expressed in both the maxillary and 
mandibular components of the first PA and is restricted to the ectoderm (Vitelli et al., 
2002) (Figure 6.2c).  In Tcfap2a-/- mutant embryos, however, expression in the distal 
portion of the mandibular component of the first arch is lost, and expression in the 
more proximal portion is reduced (Figure 6.2d).  Expression within the maxilla does not 
appear to be affected.  The pattern of staining in the olfactory bulb appears reduced as 
the craniofacial processes have not fused (Figure 6.2e).   
Expression of Dlx5 at e9.5 was found to be similar to that previously described 
(Acampora et al., 1999).  In wild type embryos, strong expression was identified in the 
otocyst and the PA region (Figure 6.3a) at e9.5.  Expression in Tcfap2a-/- mutant 
embryos, however, appears reduced in both regions (Figure 6.3b).  At higher 
magnifications it is apparent that Dlx5 is strongly expressed within the first and second 
PAs.  Weaker expression was also observed in the third PA and the developing fourth 
and sixth PAs (Figure 6.3c).  Mutant embryos, however, show reduced expression 
within the first and second PAs and expression in the caudal PAAs appears completely 
diminished (Figure 6.3d). 
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Figure 6.2: Fgf8 expression is reduced in the first pharyngeal ectoderm in Tcfap2a
-/-
 mutant embryos. 
WISH of Fgf8 expression in Tcfap2a
+/+
 control (panels a and c) and Tcfap2a
-/-
 mutant (panels b and d) embryos at 
e9.5.  (a) Expression of Fgf8 in wild type control embryos is observed at the border of the midbrain and hindbrain 
(arrow), in the future olfactory bulb (ob), the ectoderm of the first pharyngeal arch (PA1) and the endoderm (en) of 
the caudal PAs (PA 2-6).  (b)  Expression of Fgf8 in mutant embryos.  Expression in the midbrain/hindbrain border is 
diminished due to the open neural tube.  Expression in the first pharyngeal arch ectoderm is reduced in the mutant 
embryos.  All other expression domains remain unaffected. (c)  Higher magnification images of wild type embryos 
shown in panel a.  Strong expression is visible within the future olfactory bulb and the ectoderm of the mandibular 
(md) and maxillary (mx) components of the first pharyngeal arch.  (d)  Higher magnification images of Tcfap2a
-/-
 
mutant embryos shown in panel b.  Fgf8 expression is diminished in the distal part of the mandibular component of 
the first pharyngeal arch and is reduced in the proximal part of the mandible. Expression also appears altered in the 
future olfactory bulb.  (e) Frontal views of wild type and mutant embryos demonstrating that the change in 
expression patterns within the future olfactory bulb are the result of the failure of the craniofacial processes to 
fuse.  (f) In situ hybridisation of Fgf8 sense probe demonstrates no non-specific staining in the absence of the 
antisense probe. Scale bars = 1 mm (a-b, e-f), 500 μm (c-d). (n=3). 
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Figure 6.3: Dlx5 expression is reduced within the pharyngeal arches in Tcfap2a
-/-
 mutant embryos. 
WISH of Dlx5 expression in Tcfap2a
+/+
 control (panels a and c) and Tcfap2a
-/-
 mutant (panels b and d) embryos at 
e9.5.  (a) Control embryos showing Dlx5 expression in the otocyst (ot) and pharyngeal arches (PA) 1-6.  (b) Dlx5 
expression in Tcfap2a
-/-
 mutant embryos appears reduced in the otocyst and PAs.  (c) Higher magnification of the 
embryos in panel a.  Strong expression is observed in the first and second PAs (arrows).  Weaker expression is also 
observed in the third PA and in the forming fourth and sixth PAs (arrowheads).  (d) Higher magnification of the 
embryos in panel b.  Expression of Dlx5 in the first and second PAs appears marginally reduced (arrows, compare to 
panel c), while expression in the caudal pharyngeal arches is almost completely lost (arrowheads, compare to panel 
c).  (e)  In situ hybridisation using a Dlx5 sense probe demonstrates no non-specific binding of the probes.  Scale 
bars = 1mm (a-b, e), 500 μm (c-d).  (n=3). 
To confirm the loss of Dlx5 expression within the caudal PAs, embryos were sectioned 
in a coronal orientation (Figure 6.4).  This analysis demonstrates that Dlx5 expression 
within the first PA of wild type and mutant embryos is comparable (Figure 6.4a-b, e-f).  
However, expression within the more caudal PAs (2-4) appears strongly reduced within 
the pharyngeal mesenchyme only (Figure 6.4c-d, g-h). 
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Figure 6.4: Dlx5 expression is reduced within the caudal PAs. 
Coronal sections through Tcfap2a
+/+ 
control (a-d) and Tcfap2a
-/- 
mutant (e-h) embryos following WISH (purple 
staining) and counter-stained with eosin (pink).   Expression of Dlx5 within the first PA (PA1) appears comparable 
between controls (a-b) and mutants (e-f).  Expression within the caudal PAs (PAs 2-4) is severely reduced in mutant 
embryos.  (g-h) compared to controls (c-d).  N=3, representative images shown. Scale bars = 100 μm. PA, pharyngeal 
arch; en, endoderm; ec, ectoderm; mc, mesenchyme; m, mesoderm. (n=3). 
Fgf8 and Dlx5 were selected for further analysis as they were significantly 
downregulated in the qPCR analysis shown above.  Validation of this change in 
expression by WISH has revealed that Fgf8 expression is strongly reduced in the 
ectoderm of the mandibular component of the first PA.  However, it is unlikely that 
reduced expression of the signalling factor in this region, which is primarily involved in 
craniofacial development, would result in the severe cardiovascular malformations 
observed in Tcfap2a-/- mutant embryos.  It is likely that the reduced expression of Fgf8 
is involved in the presentation of the craniofacial phenotypes.  
Dlx5 however, shows a downregulation throughout the NCC-derived mesenchyme of 
the caudal PAs, which support the PAAs that remodel into the mature aortic arch.  This 
suggests that Dlx5 may be a target of Tcfap2a within the NCCs and reduced expression 
of this gene may result in the PAA abnormalities observed in Tcfap2a-/- mutant 
embryos. 
6.2.2. Co-localisation of Dlx5 and Tcfap2a 
The work described above demonstrates that Dlx5 is downregulated in the PA region 
of Tcfap2a-/- mutants at e9.5.  To confirm that Dlx5 may be a direct target of AP-2α, we 
wanted to confirm that both genes are expressed in the same tissues within the PA.  
AP-2α distribution was analysed by immunohistochemistry and compared to 
expression of Dlx5 in coronal WISH sections. 
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Dlx5 is strongly expressed in the mesenchyme of the first and second PAs (purple 
staining, Figure 6.5a), with all other pharyngeal tissues (endoderm, ectoderm and 
mesoderm) being devoid of staining. Expression was also observed within the 
mesenchyme of the third PA and within the presumptive fourth PA region.  Tcfap2a 
expression was identified within the pharyngeal mesenchyme of each of the PAs, and 
in the surrounding surface ectoderm (Figure 6.5b).  Therefore, both genes are 
expressed within the NCC-derived pharyngeal mesenchyme at e9.5.  The apparently 
reduced levels of expression in the more caudal PAs is likely caused by incomplete 
migration of the NCCs into these arches at this time. 
 
Figure 6.5: Colocalisation of Dlx5 and AP-2α within the pharyngeal arches at e9.5. 
Expression of Dlx5 (a) and AP-2α (b) in wild type (Tcfap2a
+/+
) e9.5 embryos. (a) Coronal sections through an embryo 
stained for Dlx5 antisense probe using WISH (purple). Sections were counterstained with eosin (pink).  Arrows 
denote expression within the NC-derived mesenchyme.  (b) Immunofluorescence on coronal sections showing the 
localisation of Tcfap2a expression (red, Tcfap2a; blue, DAPI).  Image kindly provided by Kathleen Allinson. Arrows 
denote expression within the NC-derived mesenchyme, arrowheads denote expression within the PSE.  Scale bars = 
100 μm.  PA, pharyngeal arch; en, endoderm; ec, ectoderm; mc, mesenchyme; m, mesoderm.  
6.2.3. Transcriptional activation of Dlx5 pathways 
The data presented above suggests that Dlx5 may be a direct downstream target of 
AP-2α within the NCC-derived pharyngeal mesenchyme.  To further investigate the 
nature of the potential AP-2α-mediated regulation of Dlx5, we used qPCR to examine 
the expression levels of other genes within the Dlx5 pathway. 
The members of the Dlx family are highly homologous and are found as inverted 
tandem repeats within the genome, often with shared enhancer elements between 
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the two genes (Merlo et al., 2000).  To investigate the potential role of Tcfap2a in the 
activation of all Dlx family genes, primers were designed to each of the known mouse 
paralogs of Dlx.  An additional set of primers to an alternative region of Dlx5 were also 
designed to further validate the downregulation of this gene.   
Dlx1 and Dlx2 show marginal changes in expression (84% and 91% wild type expression 
levels, respectively) in Tcfap2a-/- mutants compared to wild type controls (Figure 6.6a).  
Dlx3 and Dlx4 expression was reduced further (70% and 45% respectively), however, 
did not reach statistical significance.  Dlx5 and Dlx6, however, were both significantly 
reduced in Tcfap2a-/- mutants with expression decreased to 54% and 45%, respectively 
(p = 0.0002 and  p = 0.001).  This suggests that AP-2α regulation of the Dlx family is 
specific to Dlx5 and Dlx6.    
Expression of Dlx5 and Dlx6 is known to be controlled by the endothelin signalling 
pathway in the patterning of the first and second PAs in craniofacial development 
(Jeong et al., 2008).  The Endothelin-1 gene (Edn1), which encodes the ET-1 signalling 
molecule, and the endothelin converting enzyme (ECE-1) are expressed within the PA 
epithelium (ectoderm and endoderm) and the paraxial mesoderm of the PA. The 
converted ET-1 molecule is released from the epithelia/mesoderm and received by the 
ETA receptor (encoded by Ednra) within the PA mesenchyme.  As Tcfap2a is expressed 
within both the pharyngeal ectoderm and the NCCs it is possible that AP-2α is 
regulating Dlx5 and Dlx6 indirectly by activation of either Edn1 or ECE-1 in the 
ectoderm, or Ednra or a downstream g-protein in the mesenchyme.  To test this 
hypothesis, primers were designed to each of these genes, and qPCR analysis in wild 
type and mutant embryos carried out.   
There were no significant differences between wild type and mutant embryos in the 
expression levels of Edn1, ECE-1 or Ednra (Figure 6.6b).  Additionally, the expression 
levels of the g-proteins examined (Gnaq, Gna11, Gnas and Gnai) were also consistent 
between wild type and mutant embryos.  This suggests that AP-2α is activating Dlx5 
and Dlx6 independent of the endothelin signalling pathway, or that Tcfap2a is an 
intermediate step between the endothelin pathway and Dlx5/6. 
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Figure 6.6: Quantitative RT-PCR of genes associated with Dlx5 in Tcfap2a
-/-
 mutant pharyngeal arch at e9.5 
relative to wild type. 
(a)  Expression levels of Dlx family genes in the Tcfap2a
-/-
 mutant pharyngeal arch.  (b) Expression levels of upstream 
activators of Dlx5.  (c) Expression levels of Dlx5 downstream targets. 
Although the potential role of either Dlx5 or Dlx6 in cardiovascular development has 
never been examined, a study of Dlx5/6-/- double mutant embryos, has revealed a 
number of downstream targets, which have known roles in cardiovascular 
development, including Gbx2, Cyp26a1, Hand1 and Hand2 (Jeong et al., 2008).  Gbx2 
and Cyp26a1 are thought to be  22q11DS modifying genes based on genetic interaction 
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studies, downregulation of these genes in Tbx1-/- mice and complementary expression 
patterns (Roberts et al., 2006; Calmont et al., 2009). 
To investigate the effect of Tcfap2a loss and the reduced expression of Dlx5/6 on 
Dlx5/6 target genes, primers were designed to Hand1, Hand2, Isl1, Gbx2 and the three 
murine Cyp26 genes: Cyp26a1, Cyp26b1 and Cyp26c1.  As Cyp26b1 produces 2 
transcripts which could not be examined using a common pair of primers, primers 
were designed to each transcript individually.  These transcripts appear in the analysis 
as Cyp26b1.1 and Cyp26b1.2.   
Figure 6.6c shows the expression levels of these genes in Tcfap2a-/- mutants compared 
to wild type controls.  The majority of these genes showed only marginal changes, 
which were not statistically significant.  However, Hand2 was downregulated to 
approximately 80% of wild type expression in Tcfap2a-/- mutant embryos (p = 0.0052).  
Interestingly, Cyp26b1 variant 2 expression was increased by 50% in the mutant 
embryos, however, the high Ct values for this variant resulted in an increase in 
variability and therefore prevented this result from reaching statistical significance. 
The data presented above suggests that AP-2α is responsible for specific regulation of 
both Dlx5 and Dlx6, and that this regulation is independent of the endothelin signalling 
pathway.  In addition, most common targets of Dlx5 and Dlx6 were not found to be 
downregulated in Tcfap2a-/- embryos, despite a reduction in expression of both Dlx5 
and Dlx6 to approximately 50% of wild type expression.  However, Hand2 exhibited a 
statistically significant downregulation to 80% wild type levels. 
6.2.4. Tcfap2a x Dlx5 genetic interaction study (98.8 – 99.3% C57BL/6J) 
To investigate a potential genetic interaction between Tcfap2a and Dlx5, Tcfap2a+/- 
females were crossed to Dlx5-CreERT2 male mice, to generate compound 
heterozygotes.  This cre line was produced by direct insertion of the CreERT2 cDNA 
into the Dlx5 locus, resulting in a null allele.  Therefore, this male is heterozygous for 
Dlx5 and this genotype will be referred as Dlx5+/- throughout the remainder of this 
chapter.  
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6.2.4.1. External phenotype 
Tcfap2a+/-;Dlx5+/-  compound heterozygotes and Dlx5+/- control embryos were collected 
at e15.5 for external examination and MRI analysis of cardiovascular defects. Of 10 
Tcfap2a+/-;Dlx5+/- embryos examined only a single embryo exhibited an external 
phenotype in the form of exencephaly (Figure 6.7b).  The remaining compound 
heterozygotes and control embryos did not differ from wild type in appearance (Figure 
6.7c). 
 
Figure 6.7: External phenotype of Tcfap2a
+/-
;Dlx5
+/-
 compound heterozygotes. 
(a)  Control (Dlx5
+/-
) embryo showing normal external phenotype.  (b) Compound heterozygous embryo with 
exencephaly.  (c) Compound heterozygous embryo with normal external phenotype. Scale bar = 2mm. (n=10). 
6.2.4.2. MRI analysis 
Compound heterozygotes and control embryos were examined by MRI analysis at 
e15.5.  Examination of each of these embryos identified normal cardiovascular 
development throughout all of the embryos analysed. In addition, Dlx5-/- mutant 
embryos exhibit exencephaly and cleft palate (Acampora et al., 1999; Depew et al., 
1999).  These phenotypes have previously been described in Tcfap2a-/f;Wnt1cre 
conditional mutant embryos (see section 3.2) (Brewer et al., 2002). Therefore, the 
palate was examined in the Tcfap2a+/-;Dlx5+/- compound heterozygote and found to 
develop normally.  In addition, the development of the thymic rudiments also 
appeared normal.  Therefore, it is likely that more complex crosses will be required in 
order to fully investigate the genetic interaction of these two genes in vivo. 
6.2.5. Dlx5/6 double mutant embryos 
Investigation of the Tcfap2a+/-;Dlx5+/- compound heterozygotes did not reveal any 
cardiovascular defects.  However, both Dlx5 and Dlx6 were reduced to approximately 
50% of expression in our transcript analysis.  Therefore, it is possible that Dlx6 acts in a 
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redundant manner when Dlx5 is reduced in our compound heterozygotes.  Embryos 
were collected at e15.5 by Professor Giovanni Levi (Paris, France) and sent to us for 
analysis. 
6.2.5.1. External phenotype 
The external phenotypes of these embryos were examined and several malformations 
were identified.  The most common phenotype was a hox-like transformation of the 
lower jaw, which results in the lower jaw forming as a mirror image of the upper jaw, 
which has been previously described (Beverdam et al., 2002).  This phenotype was 
identified in 85.7% (6/7) of mutant embryos (Figure 6.8d, i).  Exencephaly was 
observed in 57.14% (4/7) of mutant embryos examined (Figure 6.8d-e).  The Dlx5/6-/- 
mutant mice have been previously described as a model for split hand-foot 
malformation (SHFM) (Merlo et al., 2002) and therefore, the hind limbs were 
examined for the presence of this phenotype.  Defects of the left hind limb were 
identified in 42.85% (3/7) of mutant embryos, and the right hind limb was also affected 
in 42.85% (3/7) of mutant embryos.  Defects of the hind limbs were identified 
bilaterally in two mutant embryos and unilaterally in two, with three others showing 
no signs of malformations of the hind limb.  The defects affecting this appendage 
varied between embryos, with some mutant embryos showing the full SHFM-like 
phenotype (Figure 6.8c, g), while others showed syndactyly of digits 2-3, with a 
reduced ‘split’ between digits 3 and 4 (Figure 6.8d, h).  Additionally, some embryos had 
a curled tail (28.57%, 2/7) (Figure 6.8d) and one embryo (14.29%) was found to have a 
protruding liver (Figure 6.8e, i) reminiscent of the ventral body wall defects in Tcfap2a 
mutant embryos.  One further embryo also had a small eye in comparison to controls 
(Figure 6.8c).
    
 
Figure 6.8: External phenotype of Dlx5/6
-/-
 double mutant embryos. 
(a)  Dlx5
+/-
 control embryo showing normal external phenotype.  (b-j)  Dlx5/6
-/-
 mutant embryos with variable malformations.  (b)  Mutant embryo with mostly normal external phenotype showing a 
mild SHFM phenotype and jaw transformation.  (c) Mutant embryo with severe SHFM phenotype and a small eye.  (d) Mutant embryo with exencephaly (ex), jaw transformation (jaw trans) and a 
curled tail.  (e) Mutant embryo with exencephaly and protruding liver.  (f)  The hind limb of a mutant embryo showing normal morphology.  (g) The hind limb of the mutant embryo shown in (b) 
showing syndactyly of digits 2 and 3 and a split between digits 3 and 4.  (h)  The hind limb of the mutant embryo in (c) showing a complete SHFM phenotype.  (i)  A frontal view of the mutant embryo 
shown in (d) demonstrating the transformation of the lower jaw.  (j)  The protruding liver of the embryos shown in (e). Scale bars = 2mm (a-e), 1 mm (f-h), 2mm (j). (n=7).
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6.2.5.2. CCVM phenotype 
Dlx5/6-/- mutant embryos were collected at e15.5 for MRI analysis.  However, two of 
the embryos were too young for MRI analysis (e14.5) and were examined by histology 
(Figure 6.9).  At this stage in the control (Dlx5/6+/-) embryo the interventricular septum 
had formed normally, separating the right and left ventricles (Figure 6.9a).  Of the two 
mutant embryos examined by this method, one had developed a normal 
interventricular septum (Figure 6.9b) while the other had a small VSD (Figure 6.9c).  
A further five mutant embryos were examined by MRI.  No cardiovascular or thymus 
defects were observed in these embryos. However, examination of the palate revealed 
a severe clefting phenotype (Figure 6.10b-f), which was not observed in control 
embryos (Figure 6.10a). 
 
Figure 6.9:  Cardiovascular phenotype of Dlx5/6
-/-
 mutant embryos. 
Ventricular septum formation in control (Dlx5/6
+/-
) and mutant (Dlx5/6
-/-
) embryos.  (a) Control embryo showing 
normal formation of the interventricular septum (IVS) between the right (RV) and left ventricles (LV).  (b) Mutant 
embryo with normal IVS formation.  (c) Mutant embryo with small VSD. Ao, aorta. Scale bar = 500 μm. (n=2). 
  
 
Figure 6.10: Palate formation in Dlx5/6
-/-
 mutant embryos. 
(a) Control (Dlx5/6
+/-
) embryos show normal palate development (P).  (b-f) Mutant (Dlx5/6
-/-
) embryos show and 
almost complete absence of palate development (*). Scale bar = 100 μm.  (n=5). 
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6.3.  Discussion 
6.3.1. Transcript analysis 
Tcfap2a encodes the transcription factor AP-2α.  Although it is clear that AP-2α is 
important for cardiovascular development, the transcriptional targets involved in this 
process are not understood.  This chapter aimed to elucidate the downstream target 
genes of AP-2α in fourth PAA morphogenesis.  
Firstly, we examined the expression of other AP-2 isoforms expressed within the NCCs.  
Both Tcfap2b and Tcfap2c encoding the transcription factors AP-2β and AP-2γ, 
respectively, are expressed within the NCCs during development (Chazaud et al., 1996; 
Moser et al., 1997b).  There is significant homology between the different members of 
the AP-2 family of transcription factors, in particular within the DNA binding basic 
region encoded by exon 5 (Oulad-Abdelghani et al., 1996).    This allows the members 
of the AP-2 family to share a consensus binding sequence, although each will bind to a 
specific sequence with variable affinities. Therefore, the increase in expression levels 
of Tcfap2b and Tcfap2c in Tcfap2a-/- PA region may suggest some functional 
redundancy between these isoforms, within the NCCs.  Interestingly, mutations of 
TFAP2B in humans (Satoda et al., 2000) and Tcfap2b in mice (Zhao et al., 2011) result 
in PDA, suggesting a role for AP-2β in cardiovascular development.  Tcfap2c-/- mice, 
however, die at e9.5 due to deficiencies in trophoblast development (Werling and 
Schorle, 2002) and therefore, no similar studies have been possible. 
Other genes were selected due to their involvement in cardiovascular development.  
The promoter regions of these genes were scanned for potential AP-2α binding sites, 
and those genes with the strongest or highest number of binding sites were selected 
for transcriptional analysis.  A number of these genes, such as Tgfb2, Chd7 and Tbx1 
have important roles in fourth PAA development (Lindsay et al., 2001; Molin et al., 
2002; Randall et al., 2009).  Tgfb2-/- mice often have CORSA or cAoA as a result of 
aberrant regression of the fourth PAAs and persistence of the carotid ducts. The 
aberrant loss of the fourth PAAs in these mutants is accompanied by an increase in 
apoptosis in the surrounding mesenchyme.  Additionally, the persistence of the right 
dorsal aorta is accompanied by a significant reduction in the levels of apoptosis 
surrounding these vessels (Molin et al., 2002).   
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A number of genes such as ErbB2, VEGF and Tbx20, which have been previously 
identified as Tcfap2a targets (Bosher et al., 1995; Gille et al., 1997; Hammer et al., 
2008) have known roles in cardiovascular development.   We therefore aimed to 
ascertain if the misregulation of these genes in the absence of Tcfap2a were likely to 
be causative of the observed phenotypes. We found very limited changes in the 
expression of any of these genes, with ErbB2 being reduced to ~70% (but not reaching 
significance) in the mutants, while VEGF and Tbx20 remained constant between 
controls and mutants.  As the role of ErbB2 during cardiovascular development is 
mostly restricted to ventricular trabeculation (Lee et al., 1995) and no trabecular 
defects are observed in Tcfap2a-/- mutants, it stands to reason that this gene would 
not be affected in our mutants.  It is therefore likely that Tcfap2a regulation of ErbB2 is 
specific to other cell and tissue types. 
6.3.2. Fgf8 as a downstream target of AP-2α 
The qPCR analysis presented in this chapter demonstrates a reduction of Fgf8 
expression to 78% of wild type expression levels within the PA region of Tcfap2a-/- 
mutant embryos.  This marginal reduction in expression levels is likely due to the 
almost complete loss of expression within the mandibular component of the first PA 
ectoderm, as demonstrated by WISH.  While, it seems that loss of expression from this 
region is not required for cardiovascular development, it may be responsible for 
elements of the craniofacial phenotype observed in Tcfap2a-/- mutant embryos.  
Additionally, our analysis has focussed on the PA region at e9.5.  However, AP-2α may 
be involved in the regulation of Fgf8 at different time points and in various regions of 
the body.   
Fgf8 hypomorphic mutants show a number of cardiovascular defects similar to that 
seen in Tcfap2a-/- mutants, such as VSDs, DORV, IAA and abnormalities of the RSA 
(Abu-Issa et al., 2002).  In addition, genetic dissection techniques have demonstrated 
that loss of Fgf8 within the pharyngeal ectoderm, recapitulates the fourth PAA 
malformations of the Fgf8 hypomorphs (Macatee et al., 2003).  Therefore, it is possible 
that the loss of Tcfap2a expression within the surface ectoderm at later stages, results 
in a reduction in Fgf8 expression in the caudal pharyngeal ectoderm.  This may then be 
involved in the PAA malformations observed in Tcfap2a-/- mutant embryos. 
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In addition, Fgf8 expression is also known to be required in limb development, another 
area which is affected in Tcfap2a-/- mutant embryos.  At e9.5, the forelimb bud is only 
just beginning to form and this region was not included in our qPCR analysis.  However, 
the work presented here suggests that Fgf8 may be a downstream target of AP-2α in 
the developing mouse embryo and it would therefore be interesting to investigate the 
effect that loss of Tcfap2a has on the expression of this gene throughout the embryo 
as a whole. 
6.3.3. Dlx5 as a downstream target of AP-2α 
Dlx5 was significantly downregulated in Tcfap2a-/- mouse embryos at a stage 
immediately before the formation of the fourth PAA and is coexpressed with Tcfap2a 
in the post-migratory NCCs of the PAs.  Although a role for Dlx5 in cardiovascular 
development has not yet been investigated, we postulated that the PAA defects 
observed in Tcfap2a-/- embryos are the result of the downregulation of Dlx5 and/or its 
downstream targets. 
Dlx5 expression begins at e8.25 in the ANR, and extends into the first PA by e9.0.  By 
e10.5 expression has extended to the NCC-derived mesenchyme of PAs 1-4.  
Additionally, Dlx5-/- embryos show varying penetrance of exencephaly (12% -28%, 
dependant on genetic background) and cleft palate (88%) (Acampora et al., 1999; 
Depew et al., 1999), both of which are observed in Wnt1cre-mediated deletions of 
Tcfap2a (see section 3.2) (Brewer et al., 2004).  This suggests that Dlx5 down 
regulation may be partially responsible for the external phenotypes in Tcfap2a 
mutants. 
We propose that Dlx5 is a direct downstream target of AP-2α within the NCCs.  Our 
analysis of Tcfap2a+/-;Dlx5+/-  compound heterozygotes revealed a single embryo with 
exencephaly.  This suggests that these genes may be involved in a similar pathway 
required for neural tube closure.  However, on some genetic backgrounds Tcfap2a+/- 
heterozygous embryos have a low penetrance of exencephaly (Kohlbecker et al., 2002) 
and therefore, the presence of the defect in Tcfap2a+/-;Dlx5+/-  embryos may be the 
result of Tcfap2a heterozygosity.  Examination of the palate and thymus, the 
development of which are affected in Tcfap2a-/- mutant embryos and conditional 
deletions from the NCCs and PSE, revealed that both structures develop normally.  
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Additionally, no cardiovascular malformations were observed in any of the compound 
heterozygote embryos examined and neonates of this genotype survive at least the 
initial postnatal period. 
Therefore, it appears that if Dlx5 is a downstream target of AP-2α, we will require 
more complex genotypes in order to identify the role in cardiovascular development.  
In addition, the high levels of homology between the members of the Dlx5 family may 
result in redundancy.  We have demonstrated, through qPCR analysis, that the 
expression levels of Dlx1-4 are not significantly affected by the loss of Tcfap2a.  
However, the expression of Dlx1 and Dlx2 appear marginally reduced, while the 
expression of Dlx3 and Dlx4 are more strongly reduced.  Therefore, it is possible that 
the loss of Tcfap2a results in an overall downregulation of the Dlx family, which 
collectively result in the external malformations observed in the Tcfap2a-/- mutant 
embryos.  In addition, our qPCR analysis revealed that both Dlx5 and Dlx6 are reduced 
to approximately 50% wild type expression levels in Tcfap2a-/- mutant embryos.  
Therefore, it is possible that Dlx6 is able to act redundantly to Dlx5 in our compound 
heterozygotes. 
In addition, Jeong et al. (2008) demonstrate that the expression of Dlx3 and Dlx4 is 
disrupted in Dlx5/6 mutant embryos.  Therefore, it is possible that the downregulation 
of the other members of the Dlx family in Tcfap2a-/-mutant embryos is due simply to 
the reduced expression levels of both Dlx5 and Dlx6. 
6.3.4. Dlx5 and Dlx6 as downstream targets of AP-2α 
Members of the Dlx gene family appear as paired clusters of genes within the genome, 
with shared enhancer elements in the intergenic region. Therefore, genes within each 
cluster (Dlx1/2, Dlx3/4 and Dlx5/6) often have similar functions and target genes and 
are therefore thought to act redundantly to each other. 
Dlx5 and Dlx6 are capable of redundancy in target gene regulation.  Jeong et al. (2008) 
performed an extensive analysis examining the regulation of downstream targets in 
Dlx5/6-/- mutant embryos.  This study focussed on genes involved in craniofacial 
development, however, a number of genes that were differentially regulated in these 
mutants are also relevant to cardiovascular development.  For example, Gbx2, Hand1 
Identification of transcriptional targets of AP-2α in cardiovascular development 
198 
 
and Hand2 were significantly downregulated in Dlx5/6-/- mutant embryos, while 
Cyp26a1 was upregulated in comparison to wild type controls (Jeong et al., 2008). 
Both Gbx2 and Cyp26a1 are thought to be modifiers of the 22q11DS phenotype 
observed in Tbx1 mutant mice.  Gbx2 mutant mice have unilateral hypoplasia/aplasia 
of the fourth PAAs as a result of defective NCC migration.  Additionally, crossing Gbx2 
heterozygotes to Tbx1 heterozygotes exacerbates the fourth PAA phenotype caused by 
Tbx1 haploinsufficiency (Calmont et al., 2009).  Cyp26a1 encodes a retinoic acid 
catabolist, which is downregulated in Tbx1+/- mice.  Further, chemical inhibition of all 
Cyp26 isoforms (Cyp26a1, Cyp26b1 and Cyp26c1), in developing chicken embryos 
phenocopy the defects observed in 22q11DS (Roberts et al., 2006).  The SHF marker 
Isl1 has also been suggested as an indirect target of Dlx5 in inner ear development 
(Sajan et al., 2011).  Although Tcfap2a is not expressed within the SHF it has recently 
been proposed that Isl1 is expressed within a small subset of NCCs which go on to 
infiltrate the cardiac OFT cushions and form the smooth muscle lining of the great 
vessels (Engleka et al., 2012).  Hand (Heart and neural crest derived)-1  and Hand2 are 
also important transcription factors in cardiovascular development (Srivastava et al., 
1997).   
The qPCR analysis presented here revealed that only Hand2 is differentially regulated 
in Tcfap2a-/- mutant embryos.  This is likely due to the incomplete knockdown of Dlx5 
and Dlx6 expression in these mutants, and suggests that Hand2 is more sensitive to the 
expression levels of Dlx5 and Dlx6 than other targets.  WISH of Hand2 expression on 
Dlx5/6-/- mutant embryos demonstrates a strong reduction in expression, however, the 
gene expression is not completely diminished (Jeong et al., 2008).  Therefore, in 
Tcfap2a-/- mutant embryos, where both Dlx5 and Dlx6  are only reduced to 50% wild 
type expression levels, it is not surprising that Hand2 levels are only modestly reduced. 
Double knock-out mice, with a deletion of both Dlx5 and Dlx6 show a homeotic 
transformation of the lower jaw, with the lower jaw being a mirror-image of the upper 
jaw (Beverdam et al., 2002).  These mice also show a split foot phenotype, in which the 
third digit fails to form correctly (Merlo et al., 2002).  Mutations in these genes have 
also shown to be linked with this phenotype in human patients SHFM (Crackower et 
al., 1996). These patients have defects in the third digit of both the hands and feet, 
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however, Dlx5/6-/- mutant mice show this phenotype only in the hind limb (Merlo et 
al., 2002).   
Defects of the hind limbs were identified in 42.85% (4/7) of the Dlx5/6-/- embryos 
examined in this chapter.  The phenotypes were variable between each mutant and 
between each limb in some mutants.  This phenomenon has been reported in cases of 
SHFM in humans (reviewed in Duijf et al., 2003).  In addition, one embryo appeared to 
have a unilateral syndactyly of digits 2 and 3.  Interestingly, this phenotype has been 
observed at low penetrance in BOFS patients with whole gene deletions of TFAP2A 
(Gestri et al., 2009; Murray et al., 2013).  Microphthalmia, the appearance of a small 
eye, was identified in a single Dlx5/6-/- mutant embryo and is often found as part of the 
BOFS phenotype and was also described in tfap2a mutant zebrafish (Gestri et al., 
2009).  Further, mental retardation, low-set ears, limb abnormalities and cleft 
lip/palate have also been described in patients with SHFM (reviewed in Duijf et al., 
2003).   Therefore, it is possible that both Dlx5 and Dlx6 are downstream targets of AP-
2α in mice, and that this regulation is conserved in humans and contributes to 
elements of the BOFS phenotype. 
SHFM has been linked to 5 different chromosomal locations and patients are 
designated as SHFM1-5, dependant on the loci affected.  SHFM1 and SHFM5 patients 
have deletions of members of the Dlx family of genes, and a number of these affected 
individual also have congenital heart defects (Elliott and Evans, 2008).  Of these 
patients, 10% of SHFM1 (affecting Dlx5/6) patients and 47% of SHFM5 (affecting 
Dlx1/2) were found to have CCVM.  These defects include a number of ASDs and VSDs, 
in addition to lower levels of TGA, PDA and total anomalous pulmonary venous return. 
6.3.5. AP-2α regulates Dlx5 and Dlx6 in an endothelin-independent manner 
Dlx5 and Dlx6 are activated by the endothelin signalling pathway within the PAs, 
through a signalling cascade which results in the activation of the I56i intergenic 
enhancer element that lies between the two genes (Park et al., 2004).  ET-1 is a 
signalling molecule secreted by the PSE and the vascular endothelium and is received 
by the ETA receptor expressed in the NCCs.   
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As Tcfap2a is expressed within the PSE and NCCs, it is possible that AP-2α may be 
regulating any one of these genes, resulting in reduced expression of both Dlx5 and 
Dlx6.  Therefore, we examined the expression of each of these genes and a small 
number of g-protein α-subunit genes (Gnaq, Gna11, Gnas and Gnai) by qPCR analysis, 
to identify any differential expression. 
We found that the endothelin signalling pathway is not disrupted in Tcfap2a-/- mutant 
embryos, suggesting that the differential expression of Dlx5/6 in Tcfap2a-/- mutant 
embryos is due to direct activation of these genes by the transcription factor AP-2α. In 
addition, it suggests a novel, endothelin-independent mechanism of activation of these 
genes.   
The endothelin pathway is important in cardiovascular development and mutations in 
any element of this pathway results in severe CCVM.  Mutations in Edn1, ECE-1 or ETA 
result in a number of cardiovascular defects affecting the development of the 
interventricular septum, the OFT and the PAAs (Kurihara et al., 1995; Clouthier et al., 
1998; Yanagisawa et al., 1998a).  In addition, the first and second PAAs and the carotid 
ducts often persisted in these mutants (Yanagisawa et al., 1998a).  The similarities 
between the phenotypes of the endothelin mutants and Tcfap2a-/- embryos suggest a 
common pathway.   
In addition, reports have also demonstrated cardiovascular defects in embryos with 
mutations of the α-subunits of the g-proteins examined here.  Simultaneous knock-
down of Gnaq and Gna11 results in mouse embryos with a common ventricle 
(Offermanns et al., 1998).  Further, analysis of downstream targets of the ETA  receptor 
in these mutants demonstrated that expression of Dlx3, Dlx6, Hand1 and Hand2 were 
almost completely lost in these mutants, while Dlx5 was not examined (Ivey et al., 
2003). 
We hypothesised that Dlx5 and Dlx6 were the common denominators that link the 
similar cardiovascular phenotypes observed between the endothelin pathway mutants 
and those of Tcfap2a-/- embryos.  However, examination of cardiovascular 
development in Tcfap2a+/-;Dlx5+/- compound heterozygotes revealed no defects.  In 
addition, no CCVM was identified in Dlx5/6-/- double mutant embryos, therefore 
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suggesting that Dlx5 and Dlx6 are not required for correct cardiovascular development.  
Severe malformations of the palate were identified in the Dlx5/6-/- mutants, however, 
suggesting that the reduced expression of these genes within the NCCs may contribute 
towards the cleft palate phenotype observed in Tcfap2af/-;Wnt1cre mutant embryos. 
6.3.6. Advantages and disadvantages of this study 
This study has been carried out to investigate the potential transcriptional targets of 
the transcription factor AP-2α in fourth PAA development.  In this study, we collected 
only the PA region of embryos to prevent any changes being diluted out by expression 
in other regions of the developing embryo.  This allowed us to focus only on the gene 
expression changes involved in PA and cardiovascular development.  This principal is 
supported by the strong reduction in Fgf8 expression within a small part of the region 
under investigation, which led to an overall reduction in expression to approximately 
80%.  It is likely that if we had produced RNA using the entire embryo, that this minor 
change would not have reached statistical significance.  The avoidance of the dilution 
of changes in gene expression levels could have been further improved by targeting 
specific tissues of Tcfap2a expression, such as the NCCs and PSE.  However, dissecting 
out these tissues alone would prove very technically difficult.  A further approach 
would be to use fluorescence-activated cell sorting (FACS) to select only tissues 
expressing the cre line of interest.  However, the genetic dissection of Tcfap2a did not 
reveal a specific tissue in which Tcfap2a was required.  In addition, these approaches 
would result in much lower levels of RNA and therefore dramatically increase the 
number of embryos required. 
The use of qPCR was chosen over microarray to allow for a more specific choice of 
candidate genes.  This approach allowed us to validate all genes as potential targets in 
advance, through literature searches and by examining the promoter regions for AP-2 
binding sites.   
A further disadvantage of this study is that the gene expression profile was examined 
only at e9.5, in order to elucidate the targets of AP-2α in fourth PAA development.  At 
this time point we identified only 2 candidates for further analysis.  However, it is 
possible that at different time points other candidate genes may have been 
differentially regulated. 
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6.4. Further work 
The work presented above suggests that Dlx5 and Dlx6 are downstream targets of the 
transcription factor AP-2α in PA and cardiovascular development.  However, this work 
is not without limitations (as discussed above).  
Disappointingly the genetic interaction study between Tcfap2a and Dlx5 did not result 
in a cardiovascular phenotype.  Therefore, it would be interesting to examine further 
crosses between these two strains to investigate their interaction.   
The expression levels of many of the Dlx family members were reduced in Tcfap2a-/- 
mutant embryos.  Therefore, it would be interesting to investigate any changes in 
expression patterns by WISH of these genes to determine if they are affected in the 
caudal PAs.  It would also be interesting to investigate the expression patterns of the 
other AP-2 family genes.  Tcfap2b and Tcfap2c were both found to be significantly 
upregulated in this analysis, potentially to compensate for the loss of Tcfap2a in a 
redundant manner.  Therefore, WISH analysis of these genes in Tcfap2a mutant 
embryo would allow us to understand where these changes take place. 
Analysis of target genes by qPCR at e9.5 yielded few potential downstream effectors of 
AP-2α.  However, this study was focussed specifically on the formation of the fourth 
PAA, which forms only one part of the Tcfap2a-/- phenotype.  Therefore, further 
investigations are required to determine the role of Tcfap2a in the formation of the 
interventricular septum and the OFT. 
 
Final Discussion 
203 
 
Chapter 7. Final Discussion 
7.1. Introduction 
Tcfap2a has an important role in cardiovascular development, and absence of this 
gene results in severe CCVM.  However, the mechanisms through which CCVM occurs 
in Tcfap2a-/-mutant mice have not yet been elucidated.  This thesis provides the first 
extensive study of the role of Tcfap2a in cardiovascular development.   
Although, we have been unable to provide definitive answers as to the function of 
Tcfap2a in cardiovascular development, we have identified a number of possible 
mechanisms which are disrupted in the absence of this gene.  Work in this thesis 
provides the first insight into defects of NCC migration within Tcfap2a mutants.  
Further, we have identified possible downstream target genes, which may be involved 
in the defects identified in the mutant embryos. 
In addition, a number of extracardiac defects, affecting craniofacial development, 
neural tube and body wall closure and the correct development of the thymic 
rudiments, have also been identified in these mutants.  Here we have provided insight 
into potential tissue-specific dysregulation of Tcfap2a in the appearance of a number 
of these defects. 
7.2. PAA malformation in Tcfap2a-/- mutant embryos 
In this thesis we describe a number of mutant embryos with malformations of the 
PAAs.  The Tcfap2a-/- mutant embryos on a congenic C57BL/6J background have a fully 
penetrant PAA phenotype, contrary to the previously published work on this model 
(Brewer et al., 2002).  In addition, the defects observed in the NCC-specific deletion of 
Tcfap2a affected the PAA system only.  Furthermore, although the ubiquitously 
expressed cre lines (PGKcre and Sox2cre) failed to fully recapitulate the phenotype 
observed in Tcfap2a-/- mutant embryos, almost 90% of these embryos showed some 
form of PAA malformation, affecting the fourth PAAs.  Therefore, it appears that, at 
least on the background examined here, Tcfap2a expression is highly important in the 
development of the PAAs.  In addition, the fourth PAAs seem to be particularly 
susceptible to genetic defects and a number of mutants have been discussed 
throughout this thesis in which the development of the fourth PAA is disrupted (Tbx1, 
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Chd7, Fgf8, En1, ECE1, Ednra, Gbx2 (Kurihara et al., 1995; Clouthier et al., 1998; 
Yanagisawa et al., 1998a; Lindsay et al., 2001; Abu-Issa et al., 2002; Byrd and Meyers, 
2005; Calmont et al., 2009; Randall et al., 2009).  It is possible that these defects are 
the result of the absence of SMCs lining a small portion of the fourth PAAs in mice 
(Bergwerff et al., 1999).  A wild type embryo is able to survive, without any 
malformations of the fourth PAAs, in spite of this absent portion of smooth muscle.  
However, in the presence of mutations of a gene which is important in the 
development of this vessel, the vessel is unable to persist and therefore collapses.  This 
theory, however, does not account for the fact that in many embryos with a mutation 
in one of these genes, the defects are visible from e10.5.  Data presented in this thesis 
demonstrates that the fourth PAA does not become invested with SMCs until later 
(approximately e11.5).  Therefore, the reduced level of smooth muscle within the 
fourth PAA cannot account for defects observed before this time.  It is likely that the 
PAA defects observed within these mutants are the result of the reduced investment 
of NCC within the PAs, which is required to support the vessel before SMC 
differentiation occurs (Waldo et al., 1996). 
This suggests that the role of Tcfap2a in PAA development lies within the NCCs, and 
that in the absence of this transcription factor, the NCCs are unable to migrate into the 
fourth PA in sufficient numbers.  However, signalling from the PSE is important in 
migration of the NCC into the PAs (see section 1.3.4.2) and it is therefore possible that 
the defective NCC migration that we observe in Tcfap2a-/-mutant embryos, is a 
consequence of the increased levels of apoptosis in the PSE, which reduces the 
number of cells and therefore the levels of signalling between the two tissues.  As Fgf8 
expression is reduced in the first PA of Tcfap2a-/- mutant embryos at e9.5, it is possible 
that this gene is also under the regulation of Tcfap2a within the PSE of the caudal 
arches at later stages.  Fgf8 hypomorphs display a number of PAA malformations 
similar to that observed in Tcfap2a-/- mutant embryos (Abu-Issa et al., 2002), which can 
be recapitulated by tissue-specific removal from the PSE (Macatee et al., 2003).  A 
further possibility is that Tcfap2a is required for cell survival.  Apoptosis was examined 
at e10.5 in these mutant embryos.  At this stage Tcfap2a is no longer expressed in the 
NCCs, but continues to be expressed within the PSE (Brewer et al., 2002).  Therefore, 
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the reduced numbers of NCCs within the fourth PA at e10.5 may be the result of 
increased cell death within this population at e9.5. 
7.3. Genetic background 
A common theme throughout this thesis is the effect of the genetic background on the 
phenotypes observed.  The change in genetic background from that used by Brewer et 
al. (2002) to that used by our group revealed an important increase in the levels of 
PAA malformations, which allowed us to examine the mechanisms resulting in these 
defects.  In addition, we have also demonstrated that the penetrance of CCVM, cP and 
neural tube defects observed in the NCC-specific mutant embryos differ, dependant on 
the genetic background of the mutant embryo. 
This phenomenon has previously been described in work on the Df1 mouse model of 
22q11DS.  This work demonstrates that approximately 50% of heterozygous embryos 
have some form of CCVM on a C57BL/6J background, which was reduced to 16% of 
embryos on 129SvEv background.  This pattern was also mirrored in the prevalence of 
thymus malformations in these mutants (Taddei et al., 2001). 
An extreme example of alterations in genetic background can be seen in mice with 
mutations of the EGFR.  On a CF-1 background these mice die at the peri-implantation 
stage (before e6.5), whereas on a 129/Sv background these embryos implanted into 
the uterine wall normally, but were unable to survive past mid-gestation (e12.5).  
Furthermore, outbreeding onto a CD-1 background allowed these mutants to survive 
for up to 18 days post parturition (Threadgill et al., 1995).  
Therefore, this work highlights the importance of using a defined genetic background 
when investigating mouse models. In addition, it is also important to accurately report 
the genetic background so that others can interpret the role of the genetic background 
more accurately.  Unfortunately, due to the time required to produce an inbred strain, 
and the increased research costs associated with this, it is not always feasible. 
7.4. Redundancy 
We have demonstrated that the Tcfap2aflox allele is unable to recapitulate the 
cardiovascular malformations observed in the Tcfap2a-/- mutant embryos, suggesting 
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that the Tcfap2a-null allele has a DN effect on the other AP-2 isoforms.  In addition, 
qPCR of the mutant PA region demonstrated a small, but statistically significant 
increase in the level of other AP-2 family genes in the absence of Tcfap2a. This 
suggests that there may be some redundancy between these isoforms.  
It has previously been proposed that the phenotypes observed upon mutation of these 
isoforms are too divergent to indicate functional redundancy (Hilger-Eversheim et al., 
2000; Eckert et al., 2005).  Embryos with mutations in Tcfap2a have severe 
morphological defects affecting limb, kidney, eye and cranial ganglia development, and 
exhibit an open neural tube and open ventral body wall in addition to severe 
craniofacial malformations and die at birth (Schorle et al., 1996; Zhang et al., 1996; 
Brewer et al., 2002).  Tcfap2b-/- embryos, however, are able to survive for up to 2 
weeks after birth, before dying from polycystic kidney disease and hypocalcaemia 
(Moser et al., 1997a; Moser et al., 2003).  Tcfap2c-null embryos die in early 
embryogenesis due to a failure of gastrulation, resulting in growth retardation by e7.5 
and embryos are reabsorbed by e9.5 (Werling and Schorle, 2002).    
However, analysis of the amino acid composition of AP-2α, -β and -γ demonstrated 
high levels of homology between the three isoforms, with the greatest protein identity 
within the basic domain and the first helix of the HSH motif (AP-2α and AP-2β - 97%, 
AP-2α and AP-2γ - 99%, AP-2β and AP-2γ – 96%) (Oulad-Abdelghani et al., 1996).  This 
high homology in the DNA binding domain suggests the proteins are capable of binding 
to and activating many of the same target genes. 
In addition, these genes also exhibit overlapping expression domains.  From e8.0 
Tcfap2b expression is observed in the lateral head mesenchyme, the neural folds and 
the extraembryonic trophoblast.  This pattern overlaps with that of early NCCs (Moser 
et al., 1997b).  At e9.0 both genes are detected in the PSE, midbrain, hindbrain and 
spinal cord.  This pattern continues at e10.0, with additional expression in the facial 
mesenchyme, dorsal root ganglia and the first PA.  From e11.0 expression of the two 
isoforms begin to diverge as Tcfap2b expression becomes more intense in the 
midbrain, Tcfap2a expression is no longer detected (Moser et al., 1997b). 
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Tcfap2c in the mouse is expressed in the neural plate, surface ectoderm and 
extraembryonic tissue at e7.5.  By e8.0-8.5 expression is also seen in the premigratory 
and migrating NCCs.  Later expression can be seen in the facial mesenchyme, surface 
ectoderm and nasal and oral epithelium.  Expression is also seen in the progress zone 
of the limb bud  (Chazaud et al., 1996).   
In zebrafish, tfap2a, is the only isoform expressed within the NCCs, however, all three 
isoforms are co-expressed within the surface ectoderm (Knight et al., 2005).  However, 
double knock-down studies have been conducted, that suggest AP-2α may act 
redundantly with AP-2β and -γ in processes such as craniofacial skeleton development 
and NCC maintenance.  Knock-down of tfap2b in low zebrafish demonstrated severe 
defects in all pharyngeal cartilages, suggesting that AP-2α and AP-2β work together 
within the PSE to induce development of the NCC-derived skeletal elements. 
Transplantation of ectoderm from wild-type embryos into these double mutant 
embryos resulted in partial rescue of the pharyngeal cartilage phenotype (Knight et al., 
2005). 
Double knock-out of tfap2a and tfap2c results in the absence of pigmentation and PA 
cartilage (Li and Cornell, 2007).  In addition, knock-down of tfap2c in low zebrafish 
demonstrated a reduction of foxd3 expression in pre-migratory NCCs, suggesting that 
tfap2a and tfap2c are required together in the maintenance of the NC (Hoffman et al., 
2007). 
In addition to the evidence of redundancy in zebrafish embryos, the phenotypes 
observed in humans with mutations in these genes also show a number of similarities.  
Human TFAP2B has been identified as the gene responsible for Char syndrome, an 
autosomal dominant disease characterised by PDA, facial malformations and 
anomalies of the fifth digit of the hand.  This disease has been found to be the result of 
the production of a DN protein product (Satoda et al., 2000). Therefore, it is possible 
that some of the phenotypes identified in these embryos, such as facial dysmorphism 
and limb abnormalities are the result of a DN effect on TFAP2A, resulting in some 
overlap between Char syndrome and BOFS.  Furthermore, a 4.5 Mb deletion 
containing TFAP2C (20q13.2-13.3) has been identified.  The patients displayed pre- and 
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postnatal growth retardation, hypotonia and facial dysmorphism (Genevieve et al., 
2005). 
Therefore, it appears that there is sufficient evidence from studies of both mouse and 
zebrafish development, in addition to phenotypic data from patients, to suggest that at 
least these three members of the AP-2 family are capable of acting  in a redundant 
manner.  In addition, the overlapping expression within the surface ectoderm and 
NCCs suggests that these three genes may function redundantly to activate the same 
target genes in PAA development. 
7.5. Branchio-oculo facial syndrome 
The tissue-specific deletions of Tcfap2a presented within this thesis demonstrate a 
number of more subtle phenotypes, which could not be identified within the Tcfap2a-/- 
mutant embryo.  These phenotypes include cleft palate, craniofacial malformations 
and thymus defects, many of which are reminiscent of BOFS. 
BOFS is a syndrome which results from TFAP2A mutations in humans.  This disease 
consists of a branchial, ocular and facial phenotype – as the name suggests – however, 
there are also a multitude of defects observed at varying degrees within these 
patients.  A number of BOFS patients present with defects affecting the development 
of the limbs, such as syndactyly, kidney abnormalities, including polycystic kidneys, and 
a small number of cardiovascular abnormalities.  Interestingly, one of these patients 
presented with TOF (Reiber et al., 2010).  In addition, Brewer et al. (2002) described 
two cases of potential TOF in Tcfap2a-/- mice.  Although, this malformation was not 
found in our work, we identified a number of embryos with VSD and OA, in the 
absence of the further phenotypes characteristic of TOF.  Furthermore,  TFAP2A has 
been associated with the regulation of TBX20 in a group of patients presenting with 
TOF (Hammer et al., 2008). TBX20 was found to be significantly upregulated in cardiac 
biopsies of TOF patients, although no mutations were seen in this gene.  TFAP2A, -B 
and –C were found to negatively regulate the TBX20 gene, and TFAP2C levels were 
significantly reduced in the cardiac biopsies of TOF patients, suggesting a possible role 
of TFAP2C in the TOF phenotype by de-regulation of TBX20. 
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Despite the strong evidence of CCVM in mouse mutants of Tcfap2a, the prevalence of 
these defects in BOFS patients is remarkably low, with only 3 reported cases of 
cardiovascular malformations to date (of approximately 100 patients).  However, it is 
likely that much of this is due to the nature of the mutations present in BOFS patients.  
CCVM is identified in all mouse embryos homozygous for a large deletion of the 
Tcfap2a gene.  The mutations in patients are heterozygous, and most commonly affect 
only a small number of nucleotides.  Therefore, it is likely that those BOFS patients 
with CCVM also have mutations at a modifying locus that further affects the 
phenotype.  Due to the severity of defects observed in Tcfap2a-/- mouse embryos, it is 
likely that an infant with homozygous mutation would be unable to survive to term, or 
would die in the immediate postnatal period.   
Furthermore, echocardiography to examine the heart is only requested by physicians 
in cases where a patient is suspected of impaired cardiac function (Milunsky et al., 
2011), therefore, the cardiovascular phenotype is unknown in approximately 50% of 
patients.  In addition, in patients with more subtle malformations, such as those 
affecting the formation of the RSA, it is unlikely that an impaired cardiac function 
would be detected.  For example, the presence of an A-RSA, which was identified in a 
number of Tcfap2a-/- and Tcfap2af/-;Wnt1cre mutant embryos in this thesis, usually 
presents as dysphagia.  It is, therefore, unlikely that echocardiography would be 
carried out in this instance, suggesting many more BOFS patients may have CCVM, 
than are currently reported in the literature. 
More commonly identified malformations in BOFS patients include cleft lip and thymus 
malformations, both of which are identified upon tissue-specific removal of Tcfap2a 
from the ectoderm using Foxg1cre.  We identified, a fully penetrant frontonasal defect 
in Tcfap2af/-;Foxg1cre mutant embryos, which is reminiscent of some of the more 
severe facial malformations in BOFS patients.  Of the 41 BOFS patients analysed by 
Milunsky et al. (2011), only 6 had no defects of the lip, while another was described 
with an abnormal philtrum.  Nine patients were identified with a complete bilateral 
cleft lip, while a further 10 patients exhibited a unilateral cleft lip.  The remaining 
patients had pseudo clefts of the lip, which are reminiscent of a badly repaired cleft lip.  
Therefore, the Tcfap2af/-;Foxg1cre mutant mice may offer a unique model for the 
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examination of  many of the facial phenotypes observed in BOFS patients.  In addition, 
a number of patients presented with cleft palate in addition to the cleft lip discussed 
above (10/41 patients analysed by Milunsky et al. (2011)).  This phenotype was 
observed at varying levels in all the embryos with a tissue-specific deletion of Tcfap2a 
from the NCCs.  This, therefore, suggests some involvement of the NCCs in the 
phenotypes described in BOFS patients.  Furthermore, as discussed in chapter 3 (see 
section 3.3.3), the thymus defects observed in the Tcfap2af/-;Foxg1cre mutant embryos 
are similar to that identified in BOFS patients, and are further exacerbated by the 
additional removal of Tcfap2a from the NCCs.  The tissue-specific deletion presented 
here, therefore, may provide a unique mouse model for the investigation of the 
phenotypes observed in BOFS patients.   
7.6. Findings in relation to initial aims 
The work presented has addressed the aims set out in the Introduction chapter, as 
follows:   
7.6.1. To investigate the role of Tcfap2a within the NCCs on a congenic 
C57BL/6J background. 
The preliminary data collected demonstrated a 55% penetrance of CCVM in Tcfap2af/-
;Wnt1cre mutant embryos, on a 72.55% C57BL/6J background.  In this thesis, we set 
out to examine these mutant embryos on a more congenic background (94% 
C57BL/6J).  We identified a reduction in the levels of CCVM observed in these 
Tcfap2af/-;Wnt1cre mutant embryos on a 94% C57BL/6J background, compared to a 
72% C57Bl/6J background.  In addition, we also identified a number of other 
phenotypes, which were affected by the change in genetic background, including cleft 
palate and exencephaly.  The prevalence of cleft palate was higher in Tcfap2af/-
;Wnt1cre on a 94% C57BL/6J (40%, compared to only 20% on a 72% C57BL/6J 
background), whereas the prevalence of exencephaly was reduced from 45% (72% 
C57BL/6J) to 5% (94% C57BL/6J).  This suggests that the role of Tcfap2a in the NCCs is 
not restricted to cardiovascular development, but also is involved in the correct 
formation and fusion of the palatal shelves and neural tube. 
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7.6.2. To investigate the role of genetic background in the variation of CCVM 
observed.   
In addition to investigating the NCC-specific deletion of Tcfap2a on a congenic 
background, we also outbred these mutant embryos to a CD1 background.  This 
allowed us to further investigate how the genetic background affects the defects 
observed in Tcfap2af/-;Wnt1cre mutant embryos.  We found no CCVM in these mutant 
embryos.  However, we identified that the phenotypes varied considerably between 
each of the backgrounds examined.  While the prevalence of CCVM in this background 
was completely diminished, the levels of cleft palate were higher than on either of the 
previously examined backgrounds (66.66%).  In addition, the rate of exencephaly in 
this background was similar to that observed in the preliminary data (40% compared to 
45% in the preliminary data).  This suggests that modifier loci are present on each of 
the three backgrounds examined, which result in altered prevalence of each of the 
phenotypes examined.  For a summary see Table 3-1. 
7.6.3. To investigate the role of Tcfap2a in PAA formation and remodelling. 
In chapter 5, we conducted a thorough examination of the PAA defects observed in 
Tcfap2a-/-embryos.  Embryos were examined between stages e9.5-11.5 to identify the 
timing and etiology of the fourth PAA defects observed at e15.5.  We determined that 
only approximately 50% of the defects of the right fourth PAA observed at e15.5 were 
the result of a primary failure in the formation of the vessels by e10.5.  In addition, we 
suggest that these primary defects are caused by the reduced number of NCCs within 
the PA region, which support the vessel as it forms.  The remaining 50% of defects of 
the right fourth PAA are likely to result from the loss of smooth muscle deposition 
around the vessels by e11.5. 
7.6.4. To investigate potential transcriptional targets of Tcfap2a in 
cardiovascular and PAA development. 
This thesis investigated transcriptional changes in a number of potential AP-2α target 
genes and identified Fgf8 and Dlx5 as putative downstream targets.  These genes were 
further investigated to identify spatial changes in expression patterns.  We propose 
that Dlx5 is a target of AP-2α in a pathway that is likely to be independent of 
endothelin-1 signalling.  We further identified that Dlx6 and the Dlx5/6 downstream 
target, Hand2, are significantly downregulated in Tcfap2a-/- mutant embryos at e9.5.  
Interbreeding of Tcfap2a+/- and Dlx5+/- mice failed to produce any relevant phenotypes, 
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however, Dlx5/6-/- mutant embryos showed a complete failure in palate formation.  
Therefore, it is possible that the cleft palate phenotype identified in Tcfap2af/-;Wnt1cre  
mutant  is related to a reduction in the expression of both Dlx5 and Dlx6 in the NCCs. 
7.7. Model of Tcfap2a function in cardiovascular development. 
For the purpose of cardiovascular development Tcfap2a is only expressed in the NCCs 
and PSE (Figure 7.1).  Therefore, the role of the protein product in regulating 
cardiovascular development is likely to lie in these tissues.  Our qPCR analysis suggests 
that AP-2α is involved in the regulation of Dlx5, Dlx6, Fgf8 and Hand2.  Of these four 
genes, only Fgf8 is expressed in the PSE, while Dlx5, Dlx6 and Hand2 are expressed 
within the NC-derived mesenchyme of the PAs.  Dlx5 and Dlx6 are activated by the 
endothelin signalling pathway, which originates from the PSE.  However, the 
expression levels of the genes involve in endothelin signalling pathway are unaffected 
in Tcfap2a-/- mutant embryos at e9.5.  Therefore, regulation of Dlx5/6 by AP-2α is likely 
to occur in the NC-derived PA mesenchyme, and be independent of Endothelin-
mediated regulation of these genes; although we cannot rule out the possibility that 
Tcfap2a is activated by Gαq/11, which then leads to activation of Dlx5/6.  In addition, 
the down regulation of Hand2 is likely due to the reduced levels of Dlx5/6 activation in 
these mutant embryos.  This does not, however, affect the expression of other Dlx5/6 
targets, such as Gbx2, Hand1 and Cyp26a1. 
In addition, our data suggests that AP-2α is capable of regulating Fgf8 in the PSE.  
Although, the WISH experiment suggests that this regulation occurs only within the 
first PA, it is likely that AP-2α is capable of activating Fgf8 expression in the more 
caudal arches at later stages.  In this case, the reduced expression of Fgf8 in the PSE 
may be a contributing factor to the reduced number of NCCs migrating into the fourth 
PA.  FGF8 signals from the PSE are received by the FGF receptors FGFR1 and FGFR3, 
within the NCCs, which then signals the cells to migrate into the PAs (see section 
1.3.4.2).  In this model, AP-2α is responsible for activating Fgf8 in the PSE. In the 
absence of AP-2α, FGF8 signals are reduced or diminished, causing a reduction in the 
numbers of NCCs migrating into the PA region.  This results in the PAAs not being 
supported during development and therefore collapsing.   
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Figure 7.1: Model of Tcfap2a function in cardiovascular development. 
In a wild type embryo, Tcfap2a is expressed and translated within both the ectoderm and NCCs of the PA region.  
The data presented within this thesis suggests that AP-2α is capable of regulating Fgf8 expression within the PSE 
and Dlx5/6 within the NCCs.  In turn, Dlx5/6 then activate a number of further downstream targets.  In addition, 
FGF8 signals to FGFR1 and FGFR3 within the NCCs and assists in the migration of the NCCs into the PA.  In Tcfap2a
-/-
 
mutant embryos, Fgf8 expression is reduced in the PSE, which is likely to result in a reduction in the levels of FGF8 
signalling to FGFR1 and FGFR3 in the NCCs.  In addition, the increase in the levels of apoptosis within the PSE is also 
likely to have an impact on Fgf8 expression levels.  Loss of AP-2α in the NCCs results in a decrease in the levels of 
Dlx5/6, which also causes a reduction in Hand2 expression, without affecting other Dlx5/6 targets.  The reduced 
signalling between FGF8 and FGFR1/3 also impacts on the migration of the NCCs into the PA region, resulting in 
fewer NCCs migrating into the PA region.  This causes the PA to be smaller and reduces the amount of support the 
PAA receives from the surrounding cells.  As a result, the PAA fails to form a patent vessel and collapses. 
7.8. Further work 
Although this thesis addresses a number of questions relating to the role of Tcfap2a in 
both cardiovascular development and craniofacial development, some further 
experiments could complement the work presented here. 
7.8.1. PAA defects in Tcfap2a-/- mutant embryos 
The work presented in this thesis suggests that the PAA defects result from a reduction 
in the number of NCCs within the PA region.  It appears that the reduction in NCC 
number is due to the increase in the levels of apoptosis within the PSE, which in turn 
would cause a reduction in the levels of signalling between the PSE and the NCCs, 
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which aid in their migration.  However, this could not be definitively proven using the 
data acquired here.  Therefore, further experimentation would be necessary to 
determine if this was, in fact, the case.   
Initial experiments would focus on lineage tracing of the NCCs, using the R26REYFP 
construct in conjunction with Wnt1cre, in whole mount and in sections.  Alternatively, 
WISH or whole mount immunohistochemistry of a NCC marker, such as Sox10 (which 
was unaffected in the transcriptional target analysis) may be used.  This would allow us 
to determine if the NCCs are halted at some point along their migratory pathway, or if 
the initial delamination of NCCs in disrupted, preventing the cells from migrating to 
their final locations.  Lineage tracing should be carried out at several stages between 
e8.5-e10.5, to determine when the migratory defect is occurring.  If the migration of 
the NCCs is disrupted in the circumpharyngeal region, it may again suggest that the 
signalling from the PSE to the NCCs is disturbed in these mutant embryos.  If this were 
the case, it would be important to examine the pathways involved in this process, and 
to determine how the signalling is disturbed.  Immunohistochemistry could be used for 
this purpose.  Examination of FGF8 and other FGF family members would be 
important, as both the qPCR and WISH data suggests that Fgf8 is a putative 
downstream target of AP-2α.  Additionally, it would also be important to examine the 
expression of the receptors of these signalling molecules within the NCCs, to 
determine if the NCCs are capable of receiving the secreted signals.  The receptors to 
be examined would be FGFR1 and FGFR3, however, other receptors and alternative 
signalling pathways may also be examined. 
If the results of the lineage tracing experiments do not suggest that NCC migration is 
being inhibited in any way, it would be possible that the NCCs are dying en route to the 
PA region, or even prior to delaminating from the neural tube.  In this instance, whole 
mount terminal deoxynucleotidyl transferase dUTP nick end labelling may be 
appropriate, to determine if the NCCs are undergoing cell death, therefore reducing 
the numbers available to migrate into the PAs.  Again, examination of various stages 
between e8.5-e10.5 would be necessary, to determine when cell death is occurring.  
Alternatively, further immunofluorescence staining using the pHH3 and caspase3 
antibodies at these stages would also be possible.  This would allow the 
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proliferation/apoptosis indices to be calculated, and would therefore allow for 
statistical examination of these processes. 
7.8.2. Downstream targets of AP-2α 
The qPCR analysis carried out has suggested two new, putative, target genes of AP-2α: 
Dlx5 and Fgf8.  However, further experimentation is required in order to validate these 
genes as downstream targets.  Although Fgf8 expression was significantly reduced at 
e9.5 in Tcfap2a-/- mutant embryos, WISH suggested that the changes in spatial 
expression of this gene is not likely to affect cardiovascular development.  However, it 
is possible that reduced expression of Fgf8  at later stages is responsible for some of 
the PAA defects observed in Tcfap2a-/- mutant embryos.  Therefore, the expression 
levels of this gene at e10.5 and e11.5 should also be examined by qPCR, and 
complemented with further WISH at these stages.  In addition, downstream targets of 
FGF8 should also be examined.  WISH should also be used to validate the results 
obtained by qPCR for Dlx6, Hand2, Tcfap2b and Tcfap2c.  It would also be interesting 
to repeat the qPCR examination at various other stages between e10.5-15.5 to identify 
any roles these genes may have in other processes during cardiovascular development. 
Following on from the qPCR analysis and subsequent validation by WISH, it would be 
important to determine if the putative targets are directly activated by AP-2α.  This 
could be confirmed using a luciferase assay, which would require the cloning of a 
region of the promoter of the gene of interest into a luciferase expression vector and 
examining the levels of promoter activation upon the addition of AP-2α.  Alternatively, 
chromatin immunoprecipitation may also be used to determine if AP-2α is capable of 
binding directly to the promoter region of a gene of interest. 
Although the Tcfap2a+/-;Dlx5+/- compound heterozygote embryos did not show any 
cardiovascular phenotypes, it is possible that more complex mutants are required in 
order to produce a phenotype.  It will therefore be important to examine embryos of 
the genotype Tcfap2a+/-;Dlx5-/- to understand if completely knocking-out Dlx5, in the 
presence of only a single Tcfap2a allele,  will result in a cardiovascular phenotype.  It is 
likely, due to the severity of the Tcfap2a-/- external phenotype, that embryos of the 
genotypes Tcfap2a-/-;Dlx5+/- and Tcfap2a-/-;Dlx5-/- will prove difficult to examine for 
either external defects or cardiovascular malformations.  However, if there are no 
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further defects in the Tcfap2a+/-;Dlx5-/- mutant embryos, then these other genotypes 
should also be examined. 
7.8.3. Craniofacial development and BOFS 
Tcfap2af/-;Foxg1cre mutant embryos on a C57BL/6J background were shown in this 
thesis to have a frontonasal defect reminiscent of the cleft lip phenotype that is often 
observed in BOFS patients. Therefore this may present an interesting model for 
understanding the causes of the craniofacial defects seen in patients.  Initial studies 
would investigate the levels of apoptosis and proliferation within the first PA, to 
determine if the failure of the maxillary component of the first PA to fuse with the 
frontonasal prominence is due to a problem in the size of the maxilla.   
In addition, ectopic placement of the thymic rudiments was also described in these 
mutant embryos.  This resembled the dermal thymus phenotype of BOFS patients, 
therefore, further suggesting that the Tcfap2af/-;Foxg1cre mutant embryos may also be 
a viable model for investigating this phenotype.  To investigate this further, it would 
first be important to confirm that the tissue thought to be ectopic thymus is in fact 
thymic tissue.  This may be possible using slide ISH with a Foxn1 probe.  This was not 
possible in the initial study as the tissue was not processed in an RNase-free 
environment.  Therefore, more embryos should be collected at e15.5 for this purpose.  
Once it is confirmed that this is in fact thymus tissue, it would be interesting to follow 
the formation of the ectopic thymus through development, from e9.5 to e15.5.  
Tcfap2af/-;Foxg1cre mutant embryos and Tcfap2a+/f;Foxg1cre control embryos would 
be examined using Foxn1 slide ISH  at each of the stages, to determine when the 
development of the thymus deviates from the normal processes, in the mutant 
embryos. Furthermore, as discussed in section 3.3.3, it is likely that the ectopic 
placement of the thymic rudiments is due to the failure of the endodermal tissue to 
separate from the pharyngeal ectoderm.  Therefore, the levels of apoptosis between 
these tissues should also be compared.  For this purpose, embryos would be collected 
at e12.5, as this is the time at which the thymic rudiments sever their connection with 
the pharynx (Manley and Blackburn, 2003), sectioned and immunohistochemistry 
using the caspase3 antibody would be performed and quantified. 
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In addition to the experiments described above, it would also be interesting to 
investigate the transcriptional changes occurring in the tissues concerned.  To 
investigate the expression changes occurring in the formation of the frontonasal 
defects, it would be possible to extract the first and second PA region from mutant 
(Tcfap2af/-;Foxg1cre) and control (Tcfap2a+/f) embryos.  The candidate genes for 
analysis would be selected by identifying mutants with similar phenotypes, or genes 
known to be involved in the formation of the craniofacial processes.  Additionally, 
depending on the results of the apoptosis study described above, genes may also be 
selected due to their involvement in basic cellular processes, such as apoptosis, 
proliferation and differentiation.  
7.8.4.   Transcriptional self-interference 
We proposed in chapter 4 that the lack of phenotype observed when using the 
Tcfap2aflox allele, compared to the Tcfap2a-null allele, was a result of transcriptional 
self-interference in the Tcfap2a-/- mutant embryos.  However, further investigations 
are required in order to confirm this hypothesis.  Initially, it will be important to 
ascertain if a protein is produced by the Tcfap2a-null allele, using western blotting.  If a 
protein product is produced, it will then be important to determine if this truncated 
protein is capable of interfering with the function of other AP-2 isoforms.  In order to 
examine this, a luciferase assay could be carried out.  This would require the 
production of a construct identical to that of the null transcript.  This construct may 
then be used in a luciferase assay to investigate the potential inhibitory effect of the 
construct on a wild type Tcfap2a construct.  A control experiment containing only the 
wild type construct would also be carried out, for comparison.  It would also be 
interesting to attempt a rescue experiment, in which higher levels of the necessary co-
activator molecules are added to the assay, in order to demonstrate that the reduced 
activity is due to the mutant protein sequestering the co-activators available within the 
cell.  Furthermore, repeating these experiments using wild type Tcfap2b and Tcfap2c 
constructs would allow us to confirm that the Tcfap2a-null allele is capable of 
inhibiting these isoforms through the process of transcriptional self-interference. 
7.9. Conclusions 
The data presented in this thesis demonstrates the importance of Tcfap2a in 
cardiovascular development.  In particular we have demonstrated a role for this gene 
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in the development of the fourth PAA.  Furthermore, we have presented data to 
suggest the possibility of redundancy between AP-2α and other AP-2 isoforms, AP-2β 
and –γ.  This work also clearly demonstrates the importance of genetic background in 
working with mouse models. 
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Appendix A.  Primer sequences and conditions for PCR 
genotyping. 
Tcfap2a alleles 
Tcfap2a wild type 
Primer name Primer Sequence Product size (bp) 
Tcfap2a wt fw1 GACTGGCCTTGAGTCCTGAG 
244 
Tcfap2a wt rev1 GAGGTTGAAGTGGGTCAAGC 
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
30 times 
3 58 30 seconds 
4 72 30 seconds 
5 72 10 minutes  
6 4 10 minutes  
 
Tcfap2a-null 
Primer name Primer Sequence Product size (bp) 
neo 3’ KO AACGCACGGGTGTTGGGTCGTTTGTTCG 
1200 
Kyko3 GGAGGGGGAGTCTTACCCAAACCTTGG 
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 36 
times 
3 66 52 seconds 
4 72 1 minute 
5 72 15 minutes  
6 4 10 minutes  
 
Tcfap2a flox 
Primer name Primer Sequence Product size (bp) 
Alflox4 CCCAAAGTGCCTGGGCTGAATTGAC wild type – 490 
floxed – 560 Alfscsq GAATCTAGCTTGGAGGCTTATGTC 
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Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
34 times 
3 58 30 seconds 
4 72 1 minute 
5 72 10 minutes  
6 4 10 minutes  
 
Tcfap2a del 
Primer name Primer Sequence Product size (bp) 
Alflox4 CCCAAAGTGCCTGGGCTGAATTGAC wild type – 490 
floxed – 560 
deleted – 185 
Alfscsq GAATCTAGCTTGGAGGCTTATGTC 
Alflp CCTGCCTTGGAACCATGACCCTCAG 
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
30 times 
3 58 30 seconds 
4 72 1 minute 
5 72 10 minutes  
6 4 10 minutes  
 
Primer concentrations: All primers used at 0.5 μM.  Water adjusted accordingly. 
 
Cre lines 
Wnt1cre 
Primer name Primer Sequence Product size (bp) 
Wnt1Cre-1 fw ACAGCAACCACAGTCGTCAG    
174 
Wnt1Cre-1 rev TCCCTGAACATGTCCATCAG    
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Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
30 times 
3 56 30 seconds 
4 72 1 minute 
5 72 10 minutes  
6 4 10 minutes  
 
Nkx2.5cre 
Primer name Primer Sequence Product size (bp) 
Nkx2-5Cre-3 fw ATACTCCCTGCCACCCCTAC    
215 
Nkx2-5Cre-3 rev ACATGTCCATCAGGTTCTTGC    
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
35 times 
3 65 35 seconds 
4 72 35 seconds 
5 72 15 minutes  
6 4 10 minutes  
 
Foxg1cre 
Primer name Primer Sequence Product size (bp) 
Foxg1Cre-2 fw GCTTTTGCTACATGCCTTGC 
250 
Foxg1Cre-2 rev TCTTGCGAACCTCATCACTC 
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
30 times 
3 58 30 seconds 
4 72 1 minute 
5 72 10 minutes  
6 4 10 minutes  
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Reporter constructs 
R26RLacZ and R262EYFP 
Primer name Primer Sequence Product size (bp) 
r1 eyfp common AAAGTCGCTCTGAGTTGTTAT 
wild type – 500 
mutant -250 
r2 mut GCGAAGAGTTTGTCCTCAACC 
r3 wt GGAGCGGGAGAAATGGATATG 
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
30 times 
3 59 30 seconds 
4 72 1 minute 
5 72 5 minutes  
6 4 10 minutes  
 
Primer concentrations per reaction: 1 μM r1, 0.5 μM r2, 0.5 μM r3.  Water adjusted 
accordingly. 
 
Dlx5 
Primer name Primer Sequence Product size 
(bp) 
S1X-A GCATAACCAGTGAAACAGCATTGCTG  
280 
S1X-B GGACATGTTCAGGGATCGCCAGGCG  
 
Conditions: 
Step Temperature (°C) Time  
1 95 2 minutes  
2 95 30 seconds Repeat 
steps 2-4 
30 times 
3 55 30 seconds 
4 72 30 seconds 
5 72 10 minutes  
6 4 10 minutes  
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Appendix B.  Genetic backgrounds of embryos examined. 
 Genetic background (%) 
Litter no. Male Female Offspring 
Tcfap2af/-Wnt1cre 
Litter 74 95.0125 93.15 94.08 
Litter 108 95.0125 93.15 94.08 
Litter 109 95.0125 93.15 94.08 
Litter 112 95.8689 93.15 94.509 
Litter 119 95.8689 93.15 94.509 
Tcfap2af/-;Wnt1cre 
Litter 272 47.846 97.078 72.46 
Litter 273 47.846 97.078 72.46 
Litter 274 47.846 97.078 72.46 
Litter 283 47.846 97.078 72.46 
Tcfap2af/-;Wnt1cre;Foxg1cre 
Litter 214 94.3156 97.078 95.6968 
Litter 220 94.3156 97.078 95.6968 
Litter 224 94.3156 97.078 95.6968 
Litter 230 94.3156 97.078 95.6968 
Tcfap2af/-;Wnt1cre;Nkx2.5cre 
Litter 239 97.078 97.668 97.373 
Litter 284 96.916 97.078 96.997 
Litter 294 96.916 97.078 96.997 
Litter 296 96.916 97.078 96.997 
Litter 303 96.916 97.078 96.997 
Tcfap2af/f;PGKcre 
Litter 335 97.391 97.078 97.2235 
Litter 337 97.391 97.078 97.2235 
Litter 346 97.391 97.078 97.2235 
Litter 348 97.391 97.078 97.2235 
Tcfap2af/-;PGKcre 
Litter 374 97.408 97.078 97.219 
Litter 375 97.408 97.078 97.219 
Litter 376 97.408 97.078 97.219 
Tcfap2af/fSox2cre 
Litter 564 98.286 97.078 97.682 
Litter 572 98.286 97.078 97.682 
Litter 578 98.286 97.078 97.682 
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 Genetic background (%) 
Litter no. Male Female Offspring 
Tcfap2aΔ/Δ 
Litter 587 98.286 98.286 98.286 
Litter 606 98.286 98.286 98.286 
Litter 610 98.286 98.286 98.286 
Litter 611 98.286 98.286 98.286 
Tcfap2a-/- (MRI, e15.5) 
Litter 41 93.45 93.45 93.45 
Litter 42 93.45 93.45 93.45 
Litter 45 93.45 96.725 95.088 
Litter 48 93.45 93.45 93.45 
Tcfap2a-/- (PECAM-1 staining) 
Litter 410 97.112 97.112 97.112 
Litter 421 97.112 97.112 97.112 
Litter 551 97.584 97.584 97.584 
Litter 393 97.112 97.112 97.112 
Litter 422 97.112 97.112 97.112 
Litter 436 98.056 98.056 98.056 
Litter 579 97.584 97.584 97.584 
Litter 586 97.584 97.584 97.584 
Litter 378 97.112 97.112 97.112 
Litter 451 97.481 98.056 97.769 
Litter 474 97.297 97.584 97.441 
Litter 481 97.297 97.584 97.441 
Tcfap2a-/- (Immunofluorescence) 
Litter 515 97.953 97.584 97.769 
Litter 524 97.953 97.584 97.769 
Litter 532 97.953 97.584 97.769 
Litter 538 97.953 97.584 97.769 
Litter 474 97.297 97.584 97.441 
Litter 486 98.741 97.584 97.663 
Tcfap2a+/-;Dlx5+/- 
Litter 597 100 97.584 98.792 
Litter 609 100 98.678 99.339 
Litter 617 100 97.584 98.792 
Litter 620 100 97.584 98.792 
Litter 627 100 97.584 98.792 
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